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Sulfonamides  are  important therapeutic  agents  and  have  a diverse  array  of biological 
functions in biology and medicine. Their means of synthesis has often involved the use 
of  unstable  sulfonyl  chloride  species;  however,  recent  research  has  established 
pentafluorophenyl (PFP) sulfonate esters as a useful stable alternative to such species.
This  thesis  describes  the  use  of PFP  vinyl  sulfonate  in  a  [3+2]  cycloaddition  with  a 
variety  of  A-methyl  nitrones,  providing  access  to  the  corresponding  4C-substituted 
isoxazolidine in a regio- and diastereoselective manner. Aminolysis of the resultant PFP 
sulfonate ester then provides functionalised sulfonamides of potential biological utility. 
In  addition,  the  [3+2]  cycloaddition  reaction  of  several  vinyl  sulfonamides  with  N- 
methyl  nitrones  is  reported.  Regiospecificity  of  the  reaction  is  poor,  nevertheless  a 
diverse  collection  of heterocyclic  sulfonamide  structures  have  been  isolated.  Further 
attempts  to  further  diversify  the  isoxazolidine  products  generated  from  [3+2] 
cycloaddition  chemistry  were  carried  out.  The  synthesis  of  isoxazoles  from 
isoxazolidines  was  explored,  and  in  the  process  a  novel  tertiary  amine  catalysed 
‘cycloaddition’ has been discovered.
The  resulting  isoxazolidine  products  were  assessed  as  potential  biological  probes 
against  various  enzymes/diseases,  and  as  a  result  a  collection  of  products  were 
submitted  for  biological  evaluation  against  the  enzymes  dimethylarginine 
dimethylamino hydrolase (DDAH) and arginine deiminase  (ADI).  Several compounds 
displayed  pM  inhibition  against  DDAH  and  ADI;  and  in  addition,  these  currently 
represent the first known inhibitors of ADI.
During the course of our investigation, it was also revealed that a small assortment of 
our heterocyclic  sulfonamides possess good anti-HIV activity at concentrations of 75- 
lOOpM.  Attempts  to  isolate  the  cellular  target,  through  modifications  to  our  drug 
candidates for the purpose of affinity chromatography have also been explored.
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xiCHAPTER 1: Introduction
This  thesis  presents  research  directed  towards  the  synthesis  of a  structurally  diverse 
range of sulfonamides through the development of new methods, and by applying this 
discovery to new biological probes and potential therapeutics.
1.1.  Introduction to sulfonamides
Sulfonamides  are  an  important  class  of  synthetic  bacteriostatic  antibiotics  still  used 
today  for  the  treatment  of  bacterial  infections  and  those  caused  by  other
microorganisms.  They  are  also  known  as  sulfa  drugs  and  were  the  main  source  of
1   2 therapy  against  bacterial  infections  before  the  introduction  of penicillin  in  1941.  ’  
Although sulfonamides have for the most part been replaced by other agents, they still 
maintain  considerable  action  in  certain  types  of infection,  for example  in  the  urinary 
tract, eye and ear, and bronchitis.3
One of the first sulfonamides identified by Domagk et al.  in  1935 was the red azo dye 
known  as Prontosil  1.  It was  active against streptococcal  infection  in  vivo,  but not in 
vitro. This observation was finally clarified when it was discovered that Prontosil 1 was 
metabolised  by  bacteria  in  the  intestines  into  sulfanilamide  2,  the  active  metabolite 
(Scheme I).1,4
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Having  determined  that  sulfanilamide  2  was  the  antibacterial  agent  this  led  to  its 
synthesis  in  1936 4 Since  then  there  have  been  many  analogues  of  sulfanilamide  2 
developed as pharmacological agents that display a wide range of biological activities 
(Figure  1).  For  example,  Glibenclamide  3  has  found  use  as  a  hypoglycaemic  agent, 
El010 4 as an anticancer agent, Amprenavir 5 is used in HIV therapy, Furosemide 6 as 
a diuretic, Acetazolamide 7 as a carbonic anhydrase inhibitor, and Sulfathiazole 8 as an 
antibacterial agent.5
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1.1.1.  Action of sulfonamides
The  majority  of  sulfonamides  prevent  bacterial  reproduction  by  acting  as  an 
antimetabolite to /?ara-aminobenzoic acid (PABA), where PABA is a vital component 
in  the  biosynthesis  of  tetrahydrofolic  acid.1,6  Competitive  inhibition  of  PABA 
processing enzymes by sulfonamides ultimately blocks the action of dihydrofolic acid 
synthetase, and therefore prevents dihydrofolic acid formation (Scheme 2). As bacteria 
are  unable  to  take  up  tetrahydrofolic  acid  from  their  surroundings,  inhibition  of 
dihydrofolic acid synthetase will starve the bacteria of thymidine and uridine. These two 
nucleosides  are  required  for DNA replication  and  transcription,  therefore  cell  growth 
and division is disrupted,  and thus provides enough time for the body’s own immune 
system to eliminate the bacterial threat.1,6
Often  sulfonamides  are  employed  in  conjunction  with  trimethoprim  which  inhibits 
dihydrofolate reductase. This approach of sequential blocking in treatment permits the 
inhibition of two enzymes in the same biosynthetic route and allows the dose of each 
drug to be reduced.6,7
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1.1.2.  Value of sulfonamides as therapeutic agents
Sulfonamides were primarily developed as antibacterial agents, with sulfanilamide 2 the 
first recognized sulfonamide antibacterial. Since then many other effective antibacterials 
derived from sulfonamides have been discovered and utilised in medicine. For example, 
other  common  sulfonamide  antibacterials  still  in  circulation  are  Sulfathiazole  8, 
Sulfaquinoxaline 9, silver Sulfadiazine (Silvadene®) 10, Sulfasalazine (Azulfidine®) 11, 
and Sulfamethoxazole (Gantanol®) 12 (Figure 2).8Sulfaquinoxaline Sulfathiazole
Silver Sulfadiazine 
10
COOH
Sulfasalazine
11 Sulfamethoxazole
12
Figure 2
Of these sulfamethoxazole 12 and sulfasalazine 11 are antibiotics utilised in alleviating 
the  symptoms  of  malaria,  urinary  tract  infections,  and  Crohn’s  disease.  Silver 
sulfadiazine  10 is used as a topical treatment for severe bums,9 and has more recently 
been  discovered  to  prevent  relapses  of  toxoplasmic  encephalitis  in  HIV-infected
patients.  10  Sulfathiazole  8  has  found  use  as  an  anti-microbial  agent,  11  and
12 sulfaquinoxaline 9 is an antiprotozoal agent used to combat coccidial infections.
The  development  of bacterial  resistance  to  some  sulfonamides  has  seen  their use  as 
antibacterials restricted in modem therapy. However, in recent years sulfonamides have 
been  identified  as  inhibitors  of  other  classes  of  enzymes  which  control  important 
physiological  processes  in  the  human  body.  Consequently,  the  effects  of  these 
sulfonamides have been extended to uncovering treatments for certain diseases, some of 
which are discussed below.
1.1.3.  Sulfonamides with anti-carbonic anhydrase activity
Sulfonamides  are  also  known  to  inhibit  the  enzyme  carbonic  anhydrase  (CA),  an 
enzyme present in red blood cells  and kidneys  that catalyses  the hydration of carbon 
dioxide  and  the  dehydration  of bicarbonate  at  physiological  pH,  (CO2  +  H2O 
HCO3'  +  H+) .13 The  formation  of  bicarbonate  is  essential  as  it  is  involved  in  the 
carboxylation  step  of  key  metabolic  pathways  in  gluconeogenesis,  lipogenesis, 
ureagenesis, as well as the biosynthesis of amino acids and pyrimidines.14 CA controls 
the release of CO2 from the body via its transfer from tissue to blood and blood to the 
lungs.  CA is also responsible for the secretion of electrolytes in tissues and organs as
4well  as  homeostasis,  and  because  of  its  ubiquitous  nature  has  been  the  target  for 
inhibitors in the clinical treatment of a variety of diseases.13,15
The discovery that sulfonamides inhibit CA has led to them being used for more than 50 
years as  agents to reduce blood pressure, in the treatment of conditions  such as heart 
failure,  glaucoma,  epilepsy,  and  now  potentially  cancer.  Acetazolamide  7, 
methazolamide  13,  ethoxzolamide  14,  and  dichlorophenamide  15,  are  four  such 
sulfonamides that have been in clinical use as systemic CA inhibitors since the  1950’s 
(Figure  3).  In  addition,  dorzolamide  16,  and brinzolamide  17,  have been  launched  as 
topically acting antiglaucoma pharmacological agents since the 1990’s (Figure 3).15,16
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In humans there are  14 different CA isozymes each with a specific cellular location or 
tissue distribution.  CA I,  II, III, and VII are found in the cytosol of cells, CA IV, IX, 
XII, and XIV are membrane bound, CA V is located in the mitochondria, and CA VI is 
secreted  in  saliva.15  Little  is  known  about  the  outstanding  CA  isozymes  and  their 
cellular locations have yet to be revealed. Each isozyme possesses a distinct biological 
function  within  the  body  and  hence  through  the  design  of  isozyme  specific  CA 
inhibitors,  any side effects that result from non-specific  inhibition  will be reduced.  In 
addition,  specific  isoform  inhibition  may  further  enhance  our  understanding  of each 
physiological and physiopathological role displayed by each CA isozyme.
It has been revealed in recent years that CA IX and CA XII are over-expressed in cancer 
cells, and that membrane bound CA IX is associated with the development of tumours 
in  kidney,  lung,  oesophagus,  breast,  colon,  and  cervical  carcinomas  by  instigating 
hypoxia.  CA IX expression is strongly related to intra-tumoural hypoxia,  as CA IX is 
thought  to  be  crucial  in  the  acidification  of extracellular  surroundings  thus  assisting
5tumour invasion. Therefore, via the selective inhibition of CA IX and/or CA XII there is 
a potential for the development of anticancer agents.15,17
This  has  led  to  the  discovery  of several  aromatic  and  heterocyclic  sulfonamides  by 
Supuran  et  al.  that  display  inhibition  against  CA  IX  in  the  region  of  14-285nM. 
However,  these  sulfonamides  are  not  completely  selective  for  CA  IX  as  inhibition 
against CA I, II, and IV was also achieved, although of the 32 sulfonamides evaluated 5 
of these (19-23) showed promising levels of CA IX selectivity over the rest (Figure 4). 
The  strongest  CA  IX  inhibitor was  the ethoxzolamide  phenol  18  with  a K\  of  14nM, 
however this lacked any selectivity. These sulfonamides on the other hand constitute the 
first sulfonamide inhibitors of CA IX studied.15
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In the search for more potent inhibitors of CA IX, Supuran et al revealed another class 
of sulfonamides  incorporating  a thiadiazole  moiety  that  exhibited  improved  levels  of 
inhibition.  Each  analogue  displayed  nM  inhibition  of between  3.2-23nM  for CA  IX, 
however  with  all  compounds  surveyed  there  was  no  selectivity  between  the  CA 
isozymes  I,  II, and IX.  In fact, inhibition levels were far greater for CA I (0.6-62nM) 
and CA II (0.5-1.7nM), a few of the most promising sulfonamides are shown in Figure 
5.17
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CA inhibitors have been utilised in the treatment of glaucoma and macular edema which 
results  from  over-activity  of two  CA  isozymes  (namely  CA  II  and  IV).  It  has  been 
shown by Maren et al. that the topical application of sulfonamides such as dorzolamide 
16 and brinzolamide  17  (Figure  3)  can  alleviate  symptoms  of glaucoma  and  macular 
edema,  by  reducing  intraocular  pressure  through  the  suppression  of  bicarbonate 
formation  and hence  aqueous  humor secretion.  Unfortunately these two  sulfonamides 
are secondary amines, and to apply them as efficient topical agents requires their usage 
as  the  hydrochloride  salt  in  order  to  achieve  water  solubility.  However,  such  a 
conversion produces problematic side effects namely stinging of the eye, blurred vision, 
and pruritus.16
Subsequently,  Scozzafava  et  al.  identified  a  solution  to  this  problem  and  set  about 
correcting  it  with  the  design  of  CA  sulfonamide  inhibitors  with  increased  water 
solubility.  They  recognized  during  their investigation  that  the  perfluoroalkyl-  or  aryl 
moiety  exhibited  good  water  solubility,  and  set  about  synthesizing  a  range  of 
sulfonamide  derivatives.  A  total  of  150  perfluoro-sulfonamides  were  produced  and 
assayed against CA  II and IV,  the isozymes  connected  to  glaucoma.  The most active 
inhibitors are shown (Figure 6 ).16
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They also examined the in vivo effect of the most effective CA sulfonamide inhibitors
on glaucomatous rabbits,  and observed  a significant drop  in intraocular pressure.  The
best result obtained saw a drop from 31.9±3.0mmHg to 6.8±0.3mmHg,  and as testing
16 1 8 was carried out under neutral pH eye irritation was avoided.  ’
CA  inhibition  has  also  generated  interest  as  a  target  for  malaria  chemotherapy,  by 
targeting  an  enzyme  fundamental  to  the  life  cycle  of  the  parasite.  Plasmodium 
falciparum is responsible for 2.5  million deaths  annually,  and  it has been established 
that infected individuals display high levels of CA in human red cells. In 2004 this CA 
was isolated and characterised as CA I by Krungkrai et al. Malarial parasites require the 
synthesis of pyrimidines for DNA/RNA replication,  and as bicarbonate is essential to 
this process, inhibition of CA I may be targeted as a means for the design of new anti- 
malarials.  19 ’20  This  revelation  has  opened  the  possibility  for  sulfonamide  based 
inhibition of CA I as a method for malarial treatment, which potentially does not suffer 
from the toxicity and drug-resistance shown by current anti-malarials.
Krungkrai et al having cloned and expressed the P. falciparum CA I (pfCAl) gene in E. 
coli,  subjected  this  to  testing  in  vitro  by  acetazolamide  7  and  sulfanilamide  2.  They 
report that it  was  possible  to achieve  a 50%  inhibition  on  P. falciparum growth  at  a 
concentration of  lOOpM.  In extension of this work Krungkrai et al  identified another 
sulfonamide 24 with an inhibition constant of 80nM (Figure 7), four times more potent 
than acetazolamide 7 (315nM).20
8H  H
Acetazolamide (7) 
pfCAl = 315nM 
IC50 = 20fiM
24
pfCAl = 80nM 
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Figure 7
Selective inhibition of the mitochondrial prevalent CA V has been investigated as a tool 
in the development of novel anti-obesity drugs based on sulfonamides. This hypothesis 
is  derived  from  the  knowledge  that  CA  V  is  responsible  for  important  biosynthetic 
pathways  namely  ureagenesis,  gluconeogenesis,  and  more  importantly  lipogenesis.  In 
lipogenesis, bicarbonate ions are required by the enzymes pyruvate carboxylase (in the 
mitochondria) and acetyl CoA carboxylase (in the cytosol) in the eventual synthesis of 
fatty  acids,  therefore  by  inhibition  of CA  V  and  CA  II  there  exists  a  possibility  to 
prevent  obesity.  This  in  fact  was  demonstrated  when  obese  epileptic  patients  were 
supplied with the anti-epileptic drug topiramate 25, which also displays a potent CA II 
and good CA V inhibitory effect.  Such patients recorded a  10-15% reduction in body
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weight, and 25 was consequently patented as an anti-obesity drug (Figure 8).
Supuran et al. explored the possibility of obtaining selective CA V inhibition over CA I, 
II, and IV using a large collection of sulfonamides with interesting results. They found 
that while all sulfonamides inhibited each CA isozyme to some degree; it was possible 
to  get  selective  nM  inhibition  of  CA  V  over  the  other  CA  isozymes  (Figure  8). 
Moreover,  the  sulfonamides  (26-28)  highlighted  by  Supuran  et al.  showed  increased 
potency for CA V over topiramate 25.2 1
26
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27
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91.1.4.  Sulfonamides with anticancer activity
Apart from the examples above where anti-tumour activity is gained by the inhibition of 
CA  (see  Section  1.1.3.),  other  structurally  related  sulfonamides  have  also  generated 
interest as potential anti-cancer agents. Chloroquinoxaline 29 is one such sulfanilamide
Chloroquinoxaline 29 inhibited the formation of solid tumours in breast, lung, ovarian, 
and  skin  cancer,  and  whilst its  mode of action  is  unclear,  it is  understood that folate 
metabolism  remains  unaffected,  hence deviating  from  the  usual  distinctive  nature  of 
sulfonamide action. However, the lack of success during phase II clinical trials in non­
small  cell  lung  cancer  meant  its  development  as  a  clinical  drug  candidate  was 
suspended.14
In 1992 Yoshino et al discovered sulfonamide 30 displays weak in vitro activity (IC50 = 
1.2pM/mL)  in  tumour-bearing  mice  (Figure  9).23 This  encouraging  result  led  to  the 
design of derivatives of sulfonamide 30 with the aim of finding improved anti-tumour 
activity.  Thus,  Yoshino  et al.  reported sulfonamide  E7010 31  as  a  suitable candidate 
which displayed pleasing levels of tumour growth inhibition  (IC50 = 0.06-0.8pM/mL) 
against 26 human tumour cell  lines  (Figure 9).  In rodent colon tumour models it was 
possible  to reach  a 60-99% inhibition of tumour growth  at a dosage of 25-100mg/kg 
daily over an eight day period. E7010 31 has been clinically assessed in phase I and II 
trials, and is currently being developed as an anti-tumour agent.14 24 Ueda et al in 1995 
developed  a  second  generation  sulfonamide  ER-34410  32  based  on  the  structure  of 
E7010  that  exhibited  double  the  potency  of the  parent  compound  (Figure  9).  It  was 
effective in vitro against human tumour cell lines, and could be administered at a lower 
dose (50mg/kg) compared with E7010 31 (400mg/kg).1 4
derivative  that  has  progressed  to  Phase  II  clinical  trials  (Figure  9).12’   22
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10More  recently,  studies  by  Ozawa  et  al.  have  disclosed  a  series  of  V-7-indolyl- 
benzenesulfonamides of which E7070 4 is revealed to be the most potent anti-tumour 
sulfonamide known (Figure 9). E7070 4 is effective in vitro (IC5o= O.llpM/mL) and in 
vivo (IC50 < 0.5pM/mL) against human colon carcinoma, and exhibited tumour growth 
suppression. This was evident in its ability to exert complete tumour regression in lung 
and colon carcinomas at a daily intravenous dose of 25mg/kg over 8 days. 14,25 E7070 4
more  commonly  known  as  indisulam  is  currently  in  phase  II  clinical  trials,  and  is
26 awaiting approval to be used as an anticancer drug.
1.1.5.  Sulfonamides with protease inhibitory activity (cysteine and HIV)
In recent years, sulfonamides have been investigated as inhibitors of cysteine protease, a 
ubiquitous  group  of enzymes  that  hold  important  roles  in  mammalian  cell  turnover, 
apoptosis,  and  the  life  cycles  of  several  parasitic  protozoa.  Therefore,  sulfonamide 
inhibitors  could  potentially  have  therapeutic  uses  in  the  treatment  of  Alzheimer’s, 
arthritis, cancer, and osteoporosis.27,28  The potential to treat such high profile diseases 
means that the synthesis of sulfonamides is highly desirable, and in an early example by 
Roush  et  al.,  work  was  directed  towards  the  synthesis  of  vinyl  sulfonates  and 
sulfonamides  which targeted  Trypanosoma  cruzi,  the parasite responsible for Chaga’s 
disease. Chaga’s disease is prevalent in South America and is the main cause of heart 
disease, to which current therapy is limited due to toxicity of drugs.  Cruzain has been 
identified as the cysteine protease of T. cruzi, and hence it was envisaged that inhibition 
of cruzain  holds  the  key  to  treatment of Chaga’s  disease.  This  was  demonstrated  by 
Bromme  et al.  and  McKerrow  et al.  through  in  vivo  experiments  with  vinyl  sulfone 
compounds  33,  & jnact  16400  s' 1   M' 1   (Figure  10);  however  these  sulfones  are  not 
especially  potent  at  therapeutic  doses  and  displays  poor  selectivity  for  cruzain  over
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other cysteine proteases.  In search of more potent inhibitors of cruzain Roush and co­
workers  examined  vinyl  sulfonamides  34  and  35.28  These  compounds  screened  were 
moderately potent 34 (kass = 9700 s"1  M'1 ) and 35 (kass = 289000 s' 1  M'1 ), however, they 
were able to further enhance potency with the synthesis of second generation inhibitors. 
Thus, by utilising the vinyl sulfone scaffold developed by Bromme et al., Roush et al. 
synthesized  the  two  V-benzyloxysulfonamides  36  and  37  which  displayed  much 
improved inhibition compared to 34 and 35 (Figure 10).30
11kass Cruzain = 9.7x103 s’1  M'1 kass Cruzain = 2.9x105 s'1  M'1
Ph Ph
O O
Ph  36 
kass Cruzain = 2.3x106 s'1  NT1
Ph  37 
kass Cruzain = 6.5x106 s'1  M'1
Figure 10
Another  benefit  derived  from  the  inhibition  of cysteine  proteases  is  in  the  potential 
treatment of P. falciparum (malaria). P. falciparum contains falcipain, a member of the 
papain family of cysteine proteases responsible for hydrolysing haemoglobin, and thus 
providing  amino  acids  for  parasite  replication.  Shenai  et  al.  using  an  SAR  based 
approach discovered that their peptidyl vinyl sulfonamides provided low nM inhibition 
against falcipain-2, and therefore demonstrating the potential for sulfonamides as anti- 
malarial cysteine protease inhibitors (Figure l l ).31
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Caspase-1 belongs to the family of cysteine proteases and is responsible for controlling 
interleukin-1  p.  Interleukin-lp  is  a  cytokine  and  therefore  responsible  for  peripheralinflammatory disorders  and apoptosis;  such diseases  that are  concerned  with  a raised 
interleukin-ip level are arthritis, Alzheimer’s disease, and septic shock. As a result the 
control of interleukin- 1(3 via the modulation of caspase-1  has been explored as a target 
for sulfonamide inhibition.32
A biphenyl ether sulfonamide 38 synthesised by Shahripour and co-workers displayed 
good  pM  inhibition  against  caspase-1,  which  also  exhibited  good  potential  against 
apoptosis  in  cell  studies  performed  in  vitro  (Figure  12).32,33  However,  the  more 
illustrious  nM  potency  was  finally  reached  through  efforts  by  Harter  et al.  in  2004, 
through their design and synthesis of rigidified sulfonamides. By examining the crystal 
structure of the enzyme, they rationalised that enhanced potency could be gained upon 
the  addition  of  rigidity  to  the  molecule  through  intramolecular  H-bonding. 
Consequently, a variety of conformationally locked sulfonamides were screened against 
caspase-1 and the best inhibitor 39 is shown in Figure 12.34
c o 2h
V
c o 2h
c o 2h
0  °w°
N  N  Ph
H  II  H 
O
OH
38, Ki = 0.11nM 39, Ki = 4nM
Figure 12
Another related class of cysteine protease enzymes known as cathepsins has also been 
the  target  for  sulfonamide  action.  Cathepsins  are  functionally  important  lysosomal 
enzymes involved in intracellular proteolysis, and have been implicated in diseases such 
as osteoporosis, cancer, muscular dystrophy, Alzheimer’s, and multiple sclerosis. There 
are eleven types of human cysteinyl cathepsin (B, C, F, H, K, L, O, S, V, W, and X), of 
which sulfonamide inhibition has been examined with two forms (K and L).35 Oballa et 
al. reported the synthesis of non-peptidic inhibitors of cathepsin K and L based on a  1  - 
cyanopyrrolidinyl  ring.  In  vitro  testing determined  sulfonamides  40  and 41  have  low 
pM levels of inhibition, and that substitution at the 3-position of the cyanopyrrolidine 
ring is essential for maintaining an inhibitory effect (Figure  13). During their studies it 
was also revealed that it was possible to gain some degree of selectivity for cathepsin K 
and  L  over  cathepsin  B,  with  sulfonamide  40  the  most  selective.  Cathepsin  K  is
13expressed  in  bone-resorbing  osteoclasts  it  is  thus  a  target  in  osteoporosis.  The  most 
potent sulfonamide 40 was tested against cathepsin K in a bone resorption assay (IC50 = 
0.75pM),  earmarking  this  as  a potential  starting-point  in  the  development  of a novel 
anti-osteoporosis drug.35,36
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Sulfonamides display a wide range of actions against cysteine proteases. However, there 
has also been literature precedent for the use of sulfonamides in the inhibition of another 
class of protease enzyme belonging to the HIV family, namely HIV protease.
Inhibitors of HIV protease are able to prevent formation of mature viral particles and 
consequently,  hinder  or  inhibit  the  infectious  process.  Since  1996  HIV  protease 
inhibitors have been used with some success in conjunction with reverse transcriptase 
inhibitors  to  treat  AIDS  patients  through  highly  active  anti-retroviral  therapy
36 (HAART).  However, the development of drug resistant strains of virus means that the 
continual development of new protease candidates is of utmost importance.
Currently  there  are  several  sulfonamide-derived  HIV  protease  inhibitors  employed 
clinically, such as amprenavir 5 and tipranavir 43 (Figure 14). Amprenavir 5 is a potent 
protease inhibitor with a K[ of 0.6nM against the wild type enzyme, whilst tipranavir 43 
exhibits a K\ <  InM. The emergence of these sulfonamide HIV protease inhibitors has 
resulted in much research into derivatizing these aforementioned clinical compounds, in 
the  search  for  more  potent  inhibitors.  For  instance  various  analogues  of amprenavir 
have been reported since its acceptance as HIV protease inhibitor.36
Amprenavir Tipranavir
Figure 14
14Fosamprenavir 44 has recently been disclosed as a bioequivalent prodrug of amprenavir 
5, has also exhibited promising results during phase I and II clinical trials. In addition, 
as the sodium salt of amprenavir it is more water soluble, and as a prodrug it provides 
the  opportunity  for  single  daily  dosing.  Other  sulfonamides  possessing  structural 
similarities to amprenavir 5 include DPC-681  45, which is undergoing phase I clinical 
trials, and also TMC-126 46 and TMC-114 47, which exhibit sub-nM inhibition and are 
being  evaluated  in  human  clinical  trials  (Figure  15).  Examples  of tipranavir  derived 
analogues  (PNU-103017  48  and  49)  with  low  nM  affinity  for HIV  protease  are  also 
shown in Figure 15.
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Hallberg et al. reported a range of sulfonamides distinct from the clinically used drugs. 
Their symmetrical cyclic sulfamides were able to inhibit HIV protease within the range 
of 3-84nM, and the most potent compound 50 exhibited a A^of 3.1nM (Figure  16).37 In 
a related study by Stranix et al., they synthesized a range of sulfonamides incorporating 
a  lysine  backbone  that  displayed  highly  potent  nM  inhibition  of the  wild  type  HIV 
protease. Compound 51 was the most active (K[ = 1.7nM) from a selection of alkyl, and 
aryl  lysine  sulfonamide  derivatives  (Figure  16);  the  authors  speculated that increased 
potency was gained from the additional ability of the dioxolane oxygens to H-bond to 
the enzyme active site.38
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1.1.6.  COX inhibition by sulfonamides
Since  1999  sulfonamides  have  been  used  extensively  as  selective  COX-II  inhibitors. 
COX  enzymes  are  responsible  for  catalysing  the  conversion  of  arachidonic  acid  to 
prostaglandins,  which  in  turn  is  responsible  for  many  biological  functions  such  as 
platelet  aggregation,  normal  renal  function,  and  vasodilation,  but  most  notably  the 
perception of pain.39,40 The COX family is further subdivided into COX-I and COX-II, 
of which COX-II is the key contributor in induced inflammatory responses. Hence, ever 
since COX-II was identified in 1991, it has become a target for inhibition as a means to 
control pain resulting from rheumatoid and osteo- arthritis. This has led to the discovery 
of aryl sulfonamides celecoxib 52 and more recently vadecoxib 53 in 2002 as selective 
COX-II inhibitors (Figure 17).40 Both are used clinically in the management of pain and 
inflammation,  and  as  selective  COX-II inhibitors  they  do  not exhibit the  side  effects 
displayed  through  non-selective  COX  inhibition  most  commonly  seen  with  non­
steroidal  anti-inflammatory  drugs  (NSAIDs)  such  as  aspirin.  In  human  whole  blood 
assays  IC50  values  for  COX-II  inhibition  was  0.65pM/L  for  valdecoxib  53,  and 
0.54pM/L for celecoxib 52.41
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Celecoxib 52 and valdecoxib 53 have also been identified as potent carbonic anhydrase 
inhibitors,  specifically  for CA  II  (IC50  21-43nM)  and  CA  IX  (IC50  16-27nM).  It hasbeen previously described that CA II is implicated in glaucoma and CA IX with various 
carcinomas;  therefore,  these  two  COX-II inhibitors  also  possess  the  potential  to  treat 
these disorders  via CA  inhibition.  Klebe et al.  showed that celecoxib  and  valdecoxib 
compared  favourably  with  other  clinically  used  CA  inhibitors  (see  Figure  3),  and 
additionally the authors report that celecoxib 52 (IC50 = 16nM) is one of the most potent 
CA IX inhibitors known to date.42
1.1.7.  Other applications for sulfonamides
Several other sulfonamides have been clinically accepted and are currently employed in 
the treatment of various diseases (Figure  18). Furosemide  6 and torsemide 54 are two 
such  sulfonamides  that  have  found  value  as  diuretics  which  relieve  hypertension  in 
patients with chronic  systolic heart failure,43 whilst glibenclamide 55 is a sulfonamide 
that is prescribed  for treatment of type  II diabetes.  Glibenclamide  55  is  a potent and 
selective  ATP-sensitive  potassium  ion  channel  blocker,  which  applies  a  glucose 
lowering effect by stimulating calcium influx and thus insulin production in the p cells 
of the  pancreas.44 Finally  amongst  the  most  topical  of current  sulfonamide  drugs  is 
sildenafil  56.  Sildenafil  was  launched  in  1998  as  an  anti-impotence  drug  and  is 
responsible for inhibiting the degradation of cyclic guanosine monophosphate (cGMP), 
as a result the effects of nitric oxide are prolonged and thus vasodilation occurs 45
In  conclusion,  it  has  been  shown  that  sulfonamides  have  a  number  of  biological 
applications  in  the  treatment  of a  wide  range  of  ailments.  Their  key  importance  as 
motifs in an array of therapeutic agents seems certain to continue.
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171.2.  Synthesis of sulfonamides
As this investigation concerns the synthesis of functionalised sulfonamides, it would be 
noteworthy here to provide a brief overview of the key methods for their synthesis.
1.2.1.  Sulfonamides from sulfonyl chlorides
Traditionally sulfonamides are synthesized by the reaction of a sulfonyl chloride with a 
primary or secondary amine. Sulfonyl chlorides in turn are most commonly synthesized 
by oxidation of the required thiol by bubbling chlorine gas into the reaction.46 Some of 
the earliest examples of sulfonamide synthesis date back to  1903 and involved utilising 
simple alkyl sulfonyl chlorides (Scheme 3) 47
Koburger (1903):
Forster (1914):
20% NaOH
Scheme 3
Yields  were  not  reported  however  Koburger  showed  that  it  was  possible  to  obtain 
reactions with the normally non-nucleophilic anilines, whilst Forster et al  provided an 
interesting example in the synthesis of a camphor-derived sulfonamide.48 
Since these early examples, the formation of sulfonamides from sulfonyl chlorides has 
often involved the use of more complex reagents containing sensitive functional groups, 
and/or  the  use  of  novel  conditions  to  generate  the  corresponding  sulfonyl  chloride 
required for aminolysis.
An  example  of sulfonamide  synthesis  from  sulfonyl  chlorides  that  are  derived  from 
thioanisoles  via  a Pummerer reaction is described by Gauthier et al.  Thioanisoles  are 
readily  available  stable  reagents  and  as  a result  were  chosen  by  Gauthier as  suitable 
precursors  to  sulfonyl  chlorides.  Their  synthetic  route  involves  the  oxidation  of the 
desired  thioanisole  57  to  the  analogous  sulfoxide  by  means  of  magnesium 
monoperoxyphthalate (MMPP). This is followed by a Pummerer reaction to provide the 
corresponding sulfide derivative 58. Chlorine oxidation furnishes the sulfonyl chloride
1859, which when treated with dimethylamine gives sulfonamide 60. Some high yielding 
examples are shown in Scheme 4.49
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Although this entails a long synthetic sequence into sulfonamides, yields throughout are 
high  and  can  tolerate  a  broad  range  of substrates  that  contain  a  variety  of common 
functional  groups.  Typical  R  groups  used  include  saturated  hydrocarbons,  halogens, 
carbonyls, alcohols, ethers, and heterocycles.49
The use of chlorine gas to affect the oxidation of thiols/sulfides to sulfonyl chlorides has 
been  widely  exploited  to  carry  out  this  transformation.  However,  the  use  of excess 
oxidant  and/or  aqueous  acid  during  reaction  conditions  could  be  potentially 
unfavourable in the case of sensitive substrates, and thus has led to the development of 
novel methods to furnish sulfonyl chlorides in preparation for sulfonamide synthesis.
Bonk  et  al.  in  2007  reported  the  synthesis  of  sulfonamides  via  a  mild  and  general 
protocol,  which  limited  the  amount  of oxidant  and  aqueous  component  used  in  the 
oxidation of thiols to sulfonyl chlorides. They recognized that it was possible to release 
a  controlled  quantity  of  chlorine  into  aprotic  organic  solvents,  by  the  addition  of 
benzyltrimethylammonium chloride to trichloroisocyanuric acid (TCCA) in acetonitrile. 
Two equivalents of water are also required to complete the oxidation and so this was 
employed in a slight excess. A selection of alkyl and aryl thiols were subjected to these 
conditions and provided sulfonamides in excellent yields, by entrapment of the ‘in-situ’ 
produced  sulfonyl  chloride  (Scheme  5).  Unsuccessful  reactions  were  observed  with 
heteroaromatic thiols of pyrimidine and benzothiazole 46
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In  addition,  Wright  et  al.  showed  that  by  using  commercial  bleach  (NaOCl)  it  was 
possible  to  produce  sulfonamides  from heteroaromatic  thiols  via  formation  of an  Hn- 
situ’ ’  sulfonyl  chloride.  Wright  et  al.  reasoned  that  bleach  was  a  safer  and  more 
convenient  reagent  to  chlorine  gas  and  allowed  control  of the  stoichiometry  of  the 
oxidant added; therefore, yields could be enhanced due to minimised decomposition of 
the sulfonyl chloride from excess oxidant. This work also highlights their success with 
mercapto-pyrimidines  which  have  been  reported  in  the  literature  as  providing  poor 
yields  or  unsuccessful  reactions.  The  unstable  sulfonyl  chloride  61  generated  is 
subsequently  trapped  with  benzylamine,  providing  in  some  cases  near  quantitative 
yields of the heteroaryl sulfonamide 62 (Scheme 6).50
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Less frequently seen is the synthesis of carbohydrate-derived sulfonamides, in which a 
phosphate linkage is replaced with a sulfonamido intemucleoside linkage. Bolanos et al. 
report  the  synthesis  of  an  N-alkyl  sugar  sulfonamide  64  from  its  sulfonyl  chloride 
precursor, by coupling with an amine under phase-transfer conditions (Scheme 7).51
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Oxidation of the 6-thiosugar to its corresponding sulfonic acid salt 63 is achieved with 
hydrogen peroxide in an 85%  yield, which is followed by chlorination to the sulfonyl 
chloride  with  sulfuryl  chloride.  Finally,  synthesis  of the  sulfonamide-linked  pseudo­
disaccharide 64 is completed in a 40% yield upon reaction with an aminosugar.51
In the development of novel  sulfonamides derived from substituted quinolines 65 and 
isoquinolines  6 6,  Lai  et  al.  explored  chlorosulfonylation  as  a  route  into  sulfonyl 
chlorides  (Scheme  8).  These  sulfonyi  chlorides  are  subsequently  converted  to 
sulfonamides in good yields, through the actions of solid phase DMAP and benzylamine 
in a process termed ‘resin-capture and release’ (Scheme 8).52
i. HSO3CI, 20°C
ii. SOCI2, DMF,80°C
65
R = Me, OMe, OH
S 02CI
37-99%
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Scheme 8
Vogel  et  al.  have  recently  reported  a  one-pot,  three  component  synthesis  of 
sulfonamides, which incorporates an ene reaction between a silyl enol ether and sulfur 
dioxide  (SO2)  as  a  key  step  into  compounds  that  can  contain  keto  p-alkoxyketone, 
allylic ether, or alkenyl ester moieties. The ene reaction of a silyl enol ether with SO2 
promoted by a Lewis acid generates sulfinate 67, which is oxidised by treatment with 
chlorine or V-chlorosuccinimide (NCS) to furnish the corresponding sulfonyl chloride
2168. This is followed by the simple addition of a primary or secondary amine to the crude 
material, thus providing the sulfonamide 69 in a good yield; an example is presented in 
Scheme 9.53
OSiMe3
Cl2 or NCS
TBSOTf (cat.) S 0 2CI
68 67
MeNHBn
NEt,
69 (75%)
Scheme 9
They also disclose a four component synthesis of sulfonamides in which an additional 
hetero-Diels-Alder reaction is added to the sequence in order to introduce another level 
of molecular diversity to the product (Scheme 10).53
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Sulfonamides have more recently been investigated as potential peptidomimetics in the 
field of drug discovery. The replacement of a peptidyl amide bond with a sulfonamido 
bond holds several advantages due to their increased resistance to metabolic catabolism, 
their structural similarity to the analogous amides in enzymatic hydrolysis, and its more 
acidic  hydrogen  giving  rise  to  the  possibility  of  a  stronger  H-bond.54 This  idea  was 
explored  by  Gennari  et  al  through  the  solid  phase  synthesis  (SPS)  of  vinylogous 
sulfonamidopeptides.  Vinylogous  amino-sulfonyl  chlorides  70a-i  were  consecutively 
coupled together to form an extended peptide chain,  which is covalently attached to a 
TentaGel-OH resin via a glycine linkage (Scheme  11). Gennari et al demonstrated the 
generality of their SPS  approach by successfully  synthesizing  a library of vinylogous 
sulfonamido-tetrapeptides 71. Cleavage from solid support was achieved by direct ester 
methanolysis  to  afford  the  corresponding  glycine  methyl  ester  derivative.54,  55  In 
addition, further functionalisation of the vinylogous sulfonamidopeptides is possible by 
V-alkylation of the sulfonamide nitrogen, or Michael addition of stabilised enolates to 
the vinyl component.55
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As  shown  previously,  the  corresponding  sulfonyl  chlorides  required  for  sulfonamide 
synthesis can be accessed from sulfonic acid species. The most common method for this 
functional  group  interconversion  is  through  the  action  of phosphorus  pentachloride, 
phosphoryl chloride, or thionyl chloride. However, these chlorinating reagents are fairly 
harsh and produce toxic and corrosive by-products; therefore, there existed a need for 
milder reagents to effect this conversion.  Kataoka et al.  reported the transformation of 
sodium  sulfonate  salts  into  sulfonyl  chlorides  under  mild  neutral  conditions.  They 
envisaged  that  triphenylphosphine  dichloride  would  be  a  suitable  chlorinating  agent, 
with the generation of neutral triphenylphosphine oxide as the by-product. A variety of 
alkyl  and  aromatic  sulfonic  acid  salts  were  subjected  to  their  conditions,  with  the 
ensuing aminolysis of sulfonyl chloride 72 to provide excellent yields of sulfonamide 
73 (Scheme 12).56
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In a related  study by Jang et al,  they developed a set of mild conditions that allows 
access  into  sulfonamides  from  sulfonic  acids  via  a  reactive  sulfonyl  chloride
23intermediate.  Having established the successful conversion of carboxylic acids to acid 
chlorides  with  PPI13  and  CI3CCN,  they  applied  this  methodology  to  the  analogous 
sulfonic acids. Accordingly, a selection of alkyl and aryl sulfonic acids were surveyed 
and gave good yields of sulfonamide 74  (Scheme  13). The scope of amines used was 
also explored,  and it was reported that primary and secondary amines,  as well as aryl
amines produced pleasing yields (71-100%).57
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1.2.2.  Sulfonamides from sulfenamides and methyl sulfones
As  the  reduced  form  of sulfonamides,  sulfenamides  may  also  be  regarded  as  useful 
intermediates towards the synthesis of sulfonamides. In 1960, Farrar was one of the first 
to apply oxidative conditions to sulfenamide 75 in order to furnish sulfonamide 76 in a
modest 36% yield (Scheme 14).
58
KMn04, acetic acid 
acetone, rt
Scheme 14
76 (36%)
Glass et al.  also investigated the oxidation of trichloromethyl-sulfenamides  as a route 
into  sulfonamides.  However,  unlike  with  Farrar’s  endeavours  with  KMnC>4,  Glass 
discovered that m-CPBA was a far better oxidant and provided aliphatic  sulfonamides 
77a-d in much improved yields (Scheme 15).59
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24In their attempts to generate potent anti-fungal agents, Tasaka and co-workers required 
the oxidation of triazole sulfenamide 79 to afford triazole sulfonamide 80. Oxidation of 
79  was preferred over aminolysis of the analogous  sulfonyl  chloride 78,  as this route 
failed  to  provide  the  desired  product  due  to  an  additional  competing  elimination 
reaction (Scheme 16).60
KMn04 oxidation  of 79 provided a 59%  isolated yield of sulfonamide 80  along with 
17% of the mono-oxygenated sulfinamide. Nevertheless, removal of this unwanted by­
product was resolved by changing the oxidant to m-CPBA, with the resultant product 80 
furnished  exclusively  in  a  71%  yield.  The  authors  report  that  other  primary  and 
secondary  amino-sulfenamides  have  been  successfully  oxidised  to  sulfonamides  and 
thus demonstrating the practicality of their protocol.60
So far oxidation  of alkane-sulfenamides has  been presented.  Revankar et al.,  in their 
pursuit of pyrimidine-4-sulfonamides as potential anticancer agents, utilise an oxidation 
protocol to achieve the synthesis of aromatic sulfonamides from aromatic sulfenamides. 
Oxidation of sulfenamide 81 with one-equivalent of m-CPBA resulted in a 48% yield of 
the corresponding sulfinamide, the desired sulfonamide 82 was eventually realised in a 
58% yield with three equivalents of m-CPBA (Scheme 17).61
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Alkenyl-sulfenamides are less well studied, with Schwan et al being one group to have 
accomplished  their  synthesis  as  well  as  studied  their  conversion  to  sulfonamides. 
Transamination of their A-(l-alkenylthio) phthalimides 83 with the desired amine was 
first conducted  to provide the necessary crude  sulfenamide  84.  m-CPBA  oxidation  is 
then performed to afford the sulfonamide 85 in variable yields (Scheme  18). Schwan et
al reported that yields were generally good except with aniline, which was explained by
•  62 observation of a sluggish transamination step.
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m-CPBA, K2CO3
R = n-Bu or (CH2)2Ph  R'NH2 = benzylamine, M-methyl benzylamine,
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Scheme 18
Other unique and atypical methods towards the synthesis of sulfonamides also deserve a 
mention.  A  one-pot  conversion  of methyl  sulfones  to  sulfonamides  was  reported  by 
Huang et al  in  1994.  They rationalised that the known formation  of ‘ate’  complexes 
from  the  treatment  of  trialkylboranes  with  lithiated  organosulfur  compounds,  could 
potentially be extended to sulfonamide synthesis via rearrangement of the ‘ate’ complex 
87  to  a  sulfinic  acid  salt  88  (Scheme  19).  A  selection  of  methyl  sulfones  86  was 
subjected  to  methylmagnesium  chloride  followed  by  tributylborane;  the  resultant 
sulfinic  acid  88 is  subsequently treated  with hydroxylamine-O-sulfonic  acid to afford 
sulfonamide 89.63
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This  protocol  although  moderately  yielding,  provides  the  opportunity  to  conduct 
multiple  reactions  on  a  readily  accessible  methyl  sulfone  as  a  ‘masked’  sulfonamide 
during  a total  synthesis,  since  they possess  the  ability  to  withstand  harsher chemical
To conclude, this literature survey has revealed that the synthesis of sulfonamides relies 
heavily on the use of sulfonyl chlorides or a sulfonyl chloride intermediate which can be 
trapped  by  an  amine.  Lesser known procedures  are  used  in  cases  where  the  sulfonyl 
chloride is not accessible; however, these are not especially high yielding, tedious, and 
often involve numerous chemical steps to obtain the sulfonamide precursor.
1.3.  Sulfonate esters as sulfonamide precursors
The  value  of  sulfonamides  in  medicine  and  chemistry  has  become  increasingly 
important  with  time,  and  so  they  are  often  in  high  demand  as  potential  therapeutic 
agents.  Their conventional  means  of synthesis has  often involved the use  of sulfonyl 
chlorides which are often unstable species which are not amenable to long term storage. 
Furthermore, the lack of availability of sulfonyl chlorides and difficulty in preparation 
adds to the disadvantages.
This  has  led  to  the  discovery  and  introduction  of pentafluorophenyl  (PFP)  sulfonate 
esters  within  the  Caddick  group,  as  a  shelf stable  alternative  to  sulfonyl  chlorides.64 
They postulated that the resultant PFP sulfonate esters would be crystalline solids and 
so provide ease of handling. In addition, due to the electron-withdrawing nature of the 
PFP group, the sulfur centre would be susceptible to nucleophilic attack especially by 
amines, to make sulfonamides (Scheme 20). Furthermore, the PFPOH regenerated upon 
exposure to an amine can easily be removed with a basic work up.
•  63 transformations over the analogous sulfonamide.
27Where R, R' = akyl or aryl groups
Scheme 20
To date work within the Caddick group has established that PFP sulfonate esters have 
the added advantage over sulfonyl chlorides of being stable to a variety of conditions, 
such as acidic and basic work-ups, column chromatography, and ability to be employed 
under  aqueous  conditions.65 They  have  identified  that  to  get  a  successful  aminolysis 
reaction a base is required, and those used include NEt3  and DBU.  Solvents typically 
used are THF, NMP, and toluene, although choice of solvent depends on how harshly 
one wants to heat the reaction. Studies have also shown that aminolysis is possible for 
primary, secondary, and a selection of sterically hindered amines. Herein the results of 
previous  group  studies  into  sulfonamide  synthesis  via  PFP  sulfonate  esters  are 
presented.
1.3.1.  PFP sulfonate esters in the synthesis of sulfonamides
In order to obtain PFP sulfonate esters, a novel method for their synthesis avoiding the 
use  of  sulfonyl  chlorides  was  desired.  By  analogy  with  the  amide  bond  formation 
through  the  coupling  of  a  carboxylic  acid  with  an  amine,  Caddick  et  al.  devised  a 
strategy  that  utilised  the  same  principle  to  make  sulfonamides  via  activation  of  a
sulfonic acid (Scheme 21).
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They rationalised that nucleophilic attack by the PFP anion to an activated intermediate 
such as 92 would be a facile process, because the generation of a strong P=0 double 
bond would provide the necessary driving force for this reaction to proceed. To make 
this  activated  intermediate  92,  triphenylphosphine  ditriflate  91  was  treated  with  asulfonic acid salt 90 (Scheme 21). The pyridine or triethylamine sulfonic acid salt were 
used in their studies principally due to their solubility in organic solvents.64 
Once  92  has  been  prepared  treatment  with  PFPOH  then  provided  the  PFP  sulfonate 
esters  93  in  good  yields,  and  these  were  carried  out  on  a  number  of alkyl,  aryl  and 
heteroaromatic intermediates,  demonstrating that a number of different functionalities 
are tolerated by this new protocol (Figure 19).
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These  PFP esters  can be treated with an  amine to  transform them into  sulfonamides. 
However,  Caddick  et  al.  also  revealed  that  intermediate  92  could  potentially  be 
converted  directly  to  the  sulfonamide  therefore  waiving  the  need  for  PFP  sulfonate 
esters.  To  test  this  theory  they  treated  92  with  a  variety  of primary  and  secondary 
amines and were happy to report successful reactions for all (Figure 20), and in general 
providing the first literature example for the transformation of a sulfonic acid or its salt 
directly into a sulfonamide.64
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Often it is more convenient to prepare the PFP sulfonate ester first and then transform it 
to sulfonamides at a later date. PFP sulfonate esters are very stable species and suitable
29for long term storage in comparison to sulfonic acid salts, which are often hygroscopic 
species and not tolerant to a range of chemistries.
Having  established  that  PFP  sulfonate  esters  react  well  with  amines  thermally  under 
refluxing conditions, the effects of microwave irradiation on the aminolysis of various 
alkyl and aryl PFP sulfonate esters were investigated.66
Alkyl  and  aryl  PFP  sulfonate esters  have been  investigated  due  to their difference  in 
reactivity with amines.  Alkyl PFP sulfonate esters require much milder conditions for 
aminolysis due to the presence of an a-sulfonyl CH2 group, which in theory provides an 
alternative elimination pathway via the reactive sulfene intermediate (Scheme 22). This 
postulation was confirmed by experimental methods in the aminolysis of PFP sulfonate 
94  with  4-methyl-benzylamine  in  the  presence  of THF-D2O.  A  trapping  of a  single 
deuterium atom at the a-sulfonyl position accordingly provides persuasive evidence for 
a sulfene intermediate (Scheme 22 (i)). To verify that the capture of deuterium was not 
occuring post-product formation, a solution of sulfonamide 95 was treated to the same 
conditions  with  no  deuterium  inclusion  being  observed  (Scheme  22  (ii)).67 Aryl  PFP 
esters do not possess  this  a-sulfonyl  CH2  group,  and  so need harsher conditions  and 
longer reaction times, as aminolysis presumably proceeds by direct displacement of the 
leaving group. The reactivity of aryl PFP esters is further governed by what functional 
groups are on the  arene ring,  with electron-withdrawing groups tending to give faster 
reaction times than those with electron-donating groups.66
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The alkyl PFP sulfonate esters  were the first to be considered.  A range possessing  an 
aryl group, a heterocycle, and a sugar derivative were subjected to optimum conditions 
of 85°C heating for up to 45 minutes, using NMP or THF as solvent, one equivalent of 
the amine and two equivalents of base (Scheme 23).66
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Each alkyl  PFP sulfonate ester 96 was treated with a variety of secondary amines  and 
successfully  produced  a  diverse  array  of  aliphatic  sulfonamides  97.  Yields  reported 
were  generally  good  for the  simple  alkyl  PFP  esters  (76-90%)  and  average  with  the 
heterocyclic and sugar-derived PFP esters (25-70%). With the sterically encumbered N-
31methyl-terr-butyl  amine  the  yields  were  low  as  a  result  of the  high  steric  demands 
forced upon the corresponding product,  especially when reacted with the heterocyclic 
and sugar-derived PFP sulfonate ester (25% and 38% respectively).66 
Aryl PFP sulfonate esters 98 were treated with an analogous series of amines; however, 
because  of the  reduced  reactivity  of aryl  PFP  sulfonate  esters,  elevated  temperatures 
were applied to drive reactions to completion (Scheme 24).66
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As expected, aminolysis with an assortment of primary and secondary amines provided 
excellent yields of the corresponding sulfonamide 99. Lower yields were again obtained 
when  the  sterically  hindered  A-methyl-terr-butyl  amine  was  employed  (41-58%), 
although this  may be due to decomposition resulting from  an  increased reaction time 
and elevated temperature.66
The difficulty in  achieving  a high yielding and fast aminolysis reaction between PFP 
sulfonate esters with a sterically demanding amine was resolved by Wilden et al  They 
envisaged that if tefra-butylammonium chloride (TBAC) was added to the reaction, an 
Hn-situ’  sulfonyl chloride would be produced which is more susceptible to nucleophilic 
attacked by an  amine.  This hypothesis  was  confirmed when TBAC  was  added to the 
reaction of an electron-rich aryl PFP sulfonate ester with a selection of bulky amines, 
and presented a marked increased rate of reaction  as  well  as  yield in  some examples 
(Table l).68
32OPFP
Amine
Time 
(no TBAC)
Time 
(1.5 eq. TBAC)
Yield 
(no TBAC)
Yield 
(1.5 eq. TBAC)
^ - nh2 > 7 days 7.5 hrs 67% 89%
45 mins 5 mins 91% 96%
0
H
55 mins 10 mins 88% 85%
Me02C  NH2
1.5 hrs 25 mins 77% 75%
OQ
H
> 7 days 13 hrs 38% 84%
Table 1
Continued  studies  on the chemistry of PFP sulfonate esters centred  around PFP-vinyl 
sulfonate 100 (Scheme 25). PFP-vinyl sulfonate was chosen because it is a bifunctional 
acceptor, and so susceptible to attack from both radical and nucleophilic species. It was 
proposed that the olefinic region of PFP-vinyl sulfonate could act as a template, upon 
which a wide range of reactions could be carried out before aminolysis to sulfonamides 
is performed.65,69
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Scheme 25
Intermolecular tin-mediated radical addition of a variety of organo-halide compounds to 
100 has been reported utilising AIBN as the radical initiator (Scheme 26). The reaction 
was  successful  with  a  variety  of primary,  secondary  and  tertiary  alkyl  halides  with 
moderate to good yields.65
330 R1-X, Bu3SnH, AIBN,
PFPO"
100
R X =  X'
85%
PhMe, 110°C
93%
OAc
AcA °co
41%  Ac°   B r
77%
71%
Scheme 26
PFPO
O  O
i t
30%
X
R1
BocHN  COjMe 
46%
The authors report that the reaction was not restricted to simple alkyl radicals or those 
that are stabilised, but that it was also possible using sugar and amino acid analogues. 
They  then  proceeded  to  test  the  aminolysis  reaction  on  a  sugar-derived  alkyl  PFP 
sulfonate ester 101 (Scheme 27). A wide variety of amines were used to give a selection 
of derivatised sulfonamides  102, and the yields reported were near quantitative except
when an amide or a bulky sugar molecule was involved.
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PFP-vinyl  sulfonate  100  was  also  examined  as  a  potential  dipolarophile  in  the  1,3- 
dipolar  cycloaddition  with  nitrones.  Cycloaddition  of  nitrones  to  monosubstituted 
alkenes  can  provide  a  mixture  of  products,  the  5C-substituted  and  4C-substituted
products (Scheme 28).
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It is  widely accepted  in  literature that the 5C  cycloadduct is  usually  given,  but when 
increasingly electron-deficient dipolarophiles are used the  ‘reversed’ 4C cycloadduct is 
formed.  This  literature  observation  was  supported  when  Caddick  et  al  reported  that 
cycloaddition of PFP-vinyl sulfonate 100 with a large assortment of C-alkyl and C-aryl- 
A-methyl nitrones proceeded with complete regio- and diastereo- control for the AC-anti 
cycloadduct 103 (Scheme 29).69
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All cycloadditions were successful and produced AC-anti isoxazolidines 103 containing 
alkyl  groups,  aryl  groups  (with  electron-withdrawing  and  electron-donating 
functionalities),  and  heteroaromatic  groups.  Yields  obtained  were  moderate  and 
dependant on  the  stability of the  nitrone under elevated temperatures.  Caddick group 
research  then  continued  with  the  facile  aminolysis  of each  of these  shelf-stable  PFP 
isoxazolidines,  and  they  report  that  aminolysis  proceeds  with  clean  retention  of 
stereochemistry (Scheme 30).69
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35Amines  explored  included  the  primary  amines  4-methylbenzylamine  and  allylamine, 
and yields reported were generally good; where the more hindered phenylalanine ethyl 
ester was employed this was reflected with a slight drop in yield. A further contributing 
factor  towards  a  decrease  in  the  isolated  yield,  results  from  the  presence  of a  polar 
functional  R'  group  (i.e. p-NC^Ph).  In  all  it  has  been  shown  that by  utilising  a  1,3- 
dipolar cycloaddition it has been possible to synthesise a diverse array of biologically 
interesting acyclic sulfonamides 104 via PFP-isoxazolidines.69
Furthermore, PFP isoxazolidines  103 synthesised within the Caddick group have been 
identified  as  intermediates  towards  the  synthesis  of  p-sultams.  p-Sultams  are  cyclic 
sulfonamides,  and  are  potential  serine  p-lactamase  inhibitors  which  have  been 
implicated in the treatment of penicillin resistance.  It was  reported that  an N-0 bond 
cleavage  of  a  PFP-isoxazolidine  103,  followed  by  an  intramolecular  nucleophilic 
displacement of pentafluorophenol provided P-sultam 105 (Scheme 31).70
This  functional  group  interconversion  was  achieved  with  Mo(CO)6  in  a  one-pot 
procedure to furnish a selection of predominantly aromatic P-sultams. Although yields 
were low this protocol represented a new route towards the synthesis of p-sultams and 
further demonstrates the synthetic utility of PFP sulfonate esters in organic chemistry.70
1.3.2.  TCP sulfonate esters in the synthesis of sulfonamides
Due  to  the  perceived  toxicity  of polyfluorinated  aromatic  compounds  and  relatively 
high cost of PFPOH, a cheaper and less-toxic alternative was sought. Trichlorophenol is 
a  known  cheap  household  antiseptic  which  fulfils  these  requirements,  and  has  been 
found  to  be  a  good  leaving  group  in  the  aminolysis  reaction.  This  supposition  has 
prompted  the  introduction  of  trichlorophenyl  (TCP)  sulfonate  esters  as  a  suitable 
replacement  for  PFP  sulfonate  esters,  and  hence  sulfonyl  chlorides  in  the  eventual 
synthesis of sulfonamides.  Present Caddick group research has focused on optimising
Mo(CO)6, MeCN PFPO
103
R = Ph, Naphthyl, 4-MeOPh, 4-Allyloxy-Ph, 4-BrPh, 
2-CIPh, 2-BrPh, 4-CIPh, 3-BrPh, cyclopropyl
105 (27-58%)
Scheme 31
36the  aminolysis  reactions  of  TCP  sulfonate  esters  with  a  variety  of  amines  and  in 
addition, radical experiments on the analogous TCP vinyl sulfonate have been explored 
(Scheme 32).7 1
Aminolysis:
° \ / °
X s i   NMP, NEt3,140°C
OTCP  +  R'NH2 -----------------------------
20 mins, MW
° \   0 
X sl  ^R'
N
R-n-  I   H  
72-94%
Intermolecular radical addition:
TCPO
P
)si  +   R“ Br
Bu3SnH, BEt3, air 
DCM, 18 hr
O ,  O
xs7   ^
TCPO^  R
20-88%
Scheme 32
Although TCP sulfonate esters are less toxic, their reactivity versus PFP sulfonate esters 
is noticeably reduced, and reactions normally require increased reaction times and more 
forcing conditions. Therefore, TCP sulfonate esters are complementary to PFP sulfonate 
esters  and  they  both  hold  great promise  as  future  intermediates  towards  sulfonamide 
formation.
In conclusion, Caddick et al. have shown from their comprehensive work that PFP and 
more recently TCP sulfonate esters, whether alkyl or aryl, are excellent alternatives to 
sulfonyl  chlorides,  and provide a new route towards  the  synthesis  of highly desirable 
sulfonamides.
37CHAPTER 2: R&D - Studies on cycloaddition 
reactions of vinyl sulfonates and sulfonamides
2.1.  Aim
The  aim  of  this  work  is  to  explore  the  scope  of  cycloaddition  reactions  of 
pentafluorophenyl (PFP) vinyl sulfonate 100 (Figure 21). It has previously been found 
that this species can act as an effective dipolarophile, and the present investigation is a 
continuation  of  work  previously  conducted  within  the  group  on  1,3-dipolar- 
cycloaddition chemistry involving nitrones and vinyl sulfonates (see Section 1.3.1.).
100
°v  P
pfpo"
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A n
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Figure 21
The [3+2] cycloaddition of 1,3-dipoles to olefins has been a widely studied topic since 
the  1880’s,  and is  still one of the best ways of synthesizing heterocyclic  compounds. 
PFP vinyl sulfonate 100 contains an extremely electron-deficient olefin making it very 
reactive,  and  therefore  can  readily participate  in  cycloaddition  reactions.  It has  been 
shown  that  cycloaddition  of  PFP-vinyl  sulfonate  100  with  nitrones  occurs  in  a 
regioselective  and  diastereoselective  manner  furnishing  isoxazolidine  products  103 
(Figure  21).  Aminolysis  of these  PFP  isoxazolidines  can  then  generate  heterocyclic 
sulfonamides.69
2.2.  Introduction
The  1,3-dipolar  cycloaddition  addition  reaction  dates  back  to  1883  when  Buchner 
performed the reaction of a diazoacetic ester with an a,p-unsaturated ester.72 It is still 
one  of  the  best  and  easiest  ways  of  synthesizing  heterocyclic  compounds,  and  the 
reaction is  highly attractive because of its use for the  synthesis  of 5-membered rings 
with multiple stereocentres in one step.
38Many  1,3-dipoles  have  been  used  in  1,3-dipolar  cycloadditions:  nitrile  ylides,  nitrile 
imines,  diazoalkanes,  nitrous  oxide,  azomethine  ylides,  azomethine  imines,  nitrones, 
and azides are just a few examples.
0o^©/R1
N
Where R \ R2, R3 = H, alkyl aryl, alkenyl
Figure 22
Nitrones  (or  azomethine  oxides)  were  first  discovered  in  the  1880’s  by  Beckmann 
(Figure 22).72,73 They are a commonly studied class of 1,3-dipole with over a thousand 
papers describing their use since their discovery.  They are mostly synthesized by two 
reported  methods;  the  first  and  most  common  method  is  the  condensation  of  a 
monosubstituted  hydroxylamine  with  an  aldehyde,  and  the  second  method  is  the 
oxidation of secondary amines by hydrogen peroxide (Scheme 33).74
(1)
O  ° O x® ,R '
R'NHOH  v n
R  H
R  H
R’
R  H
where R, R' = alkyl, aryl
Scheme 33
2.2.1.  Mechanism of 1,3-dipolar cycloaddition
The  1,3-dipolar cycloaddition reaction involves the 2n electrons of the alkene and the 
47t  electrons  of  the  nitrone.  It  was  first  proposed  to  be  a  concerted  mechanism  by 
Huisgen; this means that the three pz orbitals of the nitrone and the two pz orbitals of the 
alkene combine suprafacially in a single step to generate two stronger c bonds (Scheme 
34).72,75
Scheme 34
39However,  in  the  1960’s  Firestone challenged  this  mechanism by suggesting that  it in 
fact proceeds via a two-step spin-paired diradical intermediate (Scheme 35).72,76
©
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Scheme 35
Methods  for differentiating between  a concerted  and  a two-step reaction  involve:  (1) 
Study  of the  stereoselectivity  and  regioselectivity  observed  in  product formation,  (2) 
Exploration of the influence of solvent polarity on rate,  (3) Trapping of intermediates,
H fs
and (4) Study of substituent effects.
The  mechanism  was  eventually  confirmed  as  concerted,  by  a  study  of  the 
stereochemical  outcome  of  the  reaction  of  benzonitrile  oxide  with  trans  deuterated 
ethene.  The product obtained from this reaction was exclusively the trans isoxazoline 
106, and so thereby confirming a concerted mechanism (Scheme 36).72,77
2.2.2.  Selectivity in nitrone 1,3-dipolar cycloaddition with monosubstituted alkenes
1,3-Dipolar cycloadditions can give rise to four potential isomeric products, which can 
be grouped into two categories: the 5C-substituted isoxazolidine, or the 4C-substituted 
isoxazolidine, depending on the orientation that the nitrone approaches the double bond 
(Scheme 37).78
Ar
106
Scheme 36
40Scheme 37
In  the  past,  work  conducted  on  the  cycloaddition  of  mono-substituted  alkenes  was 
presumed to be unidirectional, furnishing only the 5C cycloadducts.79 However, through 
the early work of Houk et al. it has become clear that the 4C cycloadduct is also formed 
depending on the nature of the olefin substituents.
The application of FMO theory by Sustman has led to the categorisation of 1,3-dipolar
72  76  80 cycloaddition reactions into 3 classes (Figure 23).  ’   ’
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In type I reactions the dominant FM O  interaction is between that of the HOM Odipoie and 
the LUMOdipoiarophile,  for type III it is between the L U M O diPoie and the HOMOdipoiarophiie- 
Finally,  for  type  II  cycloaddition  reactions  the  similarity  in  energies  between  the 
H O M O   and  L U M O   of  each  dipole  and  dipolarophile,  means  that  the  HOM Odipoie- 
LUMOdipoiarophiie  and  the  LUMOdipoie-HOMOdipoiarophiie  interactions  are  both  just  as 
important in determining the regiochemistry and reactivity. In general, substituents that 
raise  the  HOMOdipoie  or  lower  the  LUMOdipoiarophile  energy  will  accelerate  Type  I 
cycloadditions;  whilst  substituents  that  raise  the  LUM O dipoie  or  raise  the 
HOMOdipoiarophiie energy will accelerate Type III cycloaddition reactions.78,80For example, comparing C-phenyl-Af-methyl nitrone with a range of dipolarophiles with
*  •  76 different substituents generates the following FMO’s (Figure 24).
ENERGY (eV)
0  o
P h.
LUMO
HOMO
-0.4
-8.58
e  Ph.
+ 1.8
-9.88
-0.4
-8.58
-0.4
-10.72
+2.0
-8.58
-9.05
P h.
0
1   © 
- N.
-0.4
NO,
-0.7
- 11.4
Figure 24
From the orbital diagrams a general pattern can be observed, electron-rich alkenes tend 
to  give  dominant  LUM O dipoie-HOMOdipoiarophiie  interactions  (Type  I),  and  electron- 
deficient alkenes give dominant HOM Odipoie-LUMOdipoiarophiie interactions (Type III). It 
was also noted that the 4C-substituted cycloadduct involves  a transition  state with  an 
interaction  between  the  HOMOdipoie-LUMOdipoiarophiie,  and  vice  versa  for  the  SC- 
substituted cycloadduct. However, it was reported that if the alkene is weakly electron- 
deficient, then regio-isomeric mixtures of the cycloadducts will be obtained.76
2.2.3.1,3-dipolar cycloaddition with electron deficient dipolarophiles
Having established that electron deficient dipolarophiles tend to give the 4C-substituted 
product, a few examples are shown. Houk and co-workers were one of the first groups 
interested  in  exploring  the  reversal  of regioselectivity  in  nitrone  cycloaddition  with 
electron-deficient dipolarophiles. The results of their investigation are shown in Table 
2.8 1
42■z
Entry Nitrone Dipolarophile Ratio 107 : 108
a R= Ph, R'= Me
/
/
0
:
\
o
/ 42 58
b R= H , R'= t-Bu
0
70 30
c R= Ph, R = Me CN 0 100
d R= H , R'= t-Bu = — CN 50 50
e R= Ph, R'= Me >^no2 0 100
f R= H , R'= t-Bu ^ ^ no2 100 0
g R= Ph, R'= Me
Ph 32 68
h R= H , R'= t-Bu
o w °
Ph 70 30
Table 2
Houk  et  al.  observed  that  cycloaddition  of  C-phenyl-A-methyl  nitrone  with  mildly 
electron-deficient dipolarophiles (entry a and g) produced a mixture of products 107 and 
108.  More  electron-deficient  dipolarophiles  such  as  cyanoacetylene  (entry  c)  and 
nitroethylene (entry e) exhibited complete regioselectivity for the 4C cycloadduct 108. 
They also investigated the effect of increasing steric bulk of the nitrone nitrogen (entries 
b, d, f, and h). Their endeavours showed that it is possible to greatly reduce the amount 
of the reverse 4C product formed no matter how electron-deficient the dipolarophile is; 
this effect was seen greatest with nitroethylene (entry f) which saw a complete switch in 
regioselectivity for the 5C-cycloadduct 107.8 1
In  1984 Padwa et al.  also explored the  1,3-dipolar cycloaddition of nitroethylene and 
methyl acrylate with C-phenyl-A-methyl nitrone, and they also reported the presence of 
the  4C-substituted  product  in  both  cases.79  Arbuzov  has  also  shown  that  vinyl 
phosphonates  and  C,N-diphenyl  nitrone  show  regioselective behaviour furnishing  the 
4C-cycloadduct exclusively.76
Brandi  et  al.  exploit  the  [3+2]  cycloaddition  reaction  involving  chiral 
acrylates/acrylamides with a cyclic nitrone, as a synthetic tool towards the synthesis ofpyrrolizidinone derivatives which are capable of imitating the two central residues of a 
(3-tum (Scheme 38).82
CHjC Ij  x
Ph
a  b  c  d  e  f
Scheme 38
The  combined  effect of an  electron  deficient dipolarophile  with  an  electron  deficient 
nitrone led to a 3:2 ratio of the 5C-cycloadducts versus the 4C-cycloadduct. However, 
there was  no  asymmetric  induction from the chiral  auxiliaries,  and the products  were 
isolated as racemates for each cycloadduct.82
Recent work on the enantioselective  1,3-dipolar cycloaddition between a nitrone and a 
dipolarophile  often  involves  the  use  of  a  transition  metal  catalyst  to  control  the 
enantioselectivity of the reaction. Not only are they able to offer control in the endolexo 
selectivity  of each  diastereoisomer but  also  the  regioselectivity.  Lewis  acid  catalysts 
exert their effect on the dipolarophile or dipole by lowering the energy of the LUMO, 
thus with a smaller energy difference between the HOMO and LUMO of the reacting 
partners, increased reactivity is achieved.83
Kanemasa et al.  was one group that explored this phenomenon in the racemic series in 
1992,  with  the  use  of  ZnCU,  TiCl(0 /-Pr)3,  or  TiCl2(0 /-Pr)2  in  the  1,3-dipolar 
cycloaddition between nitrone 109 and enone 110 (Scheme 39).72,84
catalyst
endo  bxo
Uncatalysed: 30%, endo:exo = 40:60 
Catalysed [TiCI2(OAPr)2]: 50%, endo:exo = >99:1
Scheme 39
44Although yields were moderate (35-77%) the use of these Lewis acids in stoichiometric 
amounts  did  provide  excellent  endo  selectivity,  especially  when  promoted  with 
TiCl2(Oi-Pr)2 (endo'.exo,  >99:1).  In  the  absence  of this  promoter  the  reaction  gave  a
84 product endo’ .exo ratio of 40:60.
While  Kanemasa’s  work  showed  excellent  regioselectivity  and  diastereoselectivity, 
their reactions produced a racemic mixture of products. In more recent years it has also 
been  possible  to  gain  excellent  enantioselectivities  through  transition  metal 
complexation with chiral catalysts.
CHO
Br
° ^ ® /Ph  10 mol% 111, MS, DCM, RT 
N _____________________________
U  67-100%
PhN—O 
Br  CHO
111  =
R = Ph, 4-MePh, 4-BrPh,  4-N02Ph, 
2-Furyl, 1-Naphthyl, 2-Naphthyl
Scheme 40
This was demonstrated by Kanemasa et al. in their utilisation of a DBFOX/Ph-Zn(OTf)2 
catalyst  111  in  the  cycloaddition  of a,(3-unsaturated  aldehydes  with  acyclic  nitrones 
(Scheme  40).  The  authors  report  that  this  catalyst  promotes  an  entirely  endo-4C 
selective reaction with enantioselectivities greater than 94% ee.85
Carmona and co-workers utilised a rhodium-SbF6 complex to catalyse the cycloaddition 
of C,iV-diphenyl nitrone with the mildly electron-deficient methacrolein (Scheme 41).86
4C endo  5C endo
cat. = [(Ti5-C5Me5)-Rh(/?-Prophos)(H20 )](SbF6)2
Scheme 41
45In  the  absence  of  catalyst  at  room  temperature  they  observe  exclusively  the  5C 
cycloadduct  in  a  63%  yield.  However  using  5  mol%  of  catalyst  under  various 
temperatures  (-45°C  to  5°C)  quantitative  yields  were  obtained,  with  a  switch  in 
regioselectivity in favour of the 4C cycloadduct (approx. 6:4 ratio of 4C:5C). It was also 
reported that ee’s of up to 92% were obtained and with 100% endo selectivity.86
In  2005  Desimoni  and  Faita  described  the  use  of various  transition  metals  catalysts 
based  on  (4/?)-phenyl-bis(oxazolines)  112,  as  a  way  to  obtain  either  endo  or  exo 
selective products by careful manipulation of reaction conditions. They report that their 
catalysts  provided  excellent  regio-  and  stereoselectivity  in  the  reaction  between
87 acryloyloxazolidinone and CVV-diphenyl nitrone (Table 3).
"  Ph 
Exo-114 Endo-113
Endo-115
Entry Cation Anion
Temp
(°C)
Additive
Ratio
[113+114]/[115+116]
Ratio
113:114
a Mg1 1 C104 -15 - >98:<2 95:5
b Co1 1 CIO4 -15 - 95:5 90:10
c Mn1 1 CIO4 -15 - 95:5 93:7
d NiU CIO4 -15 - >98:<2 98:2
e Zn1 1 CIO4 -15 - decomposition -
f Co1 1 CIO4 -15 4A MS >98:<2 24:76
g ZnA l CIO4 -15 4A MS >98:<2 27:73
h Mg1 1 CIO4 -15 4A MS >98:<2 70:30
i Ni1 1 CIO4 -15 4A MS 88:12 72:28
j Mn1 1 CIO4 -15 4A MS 78:22 48:52
Table 3
46It  was  reported  that  quantitative  yields  were  obtained  for  all  reactions,  with  the  4C- 
substituted  cycloadducts  113  and  114 preferentially  formed.  The  reactions  were  also 
endo- selective irrespective of the metal counterion used (entries a-d), except for Zn(II) 
(entry e)  which  failed  to  offer any  appreciable  product formation.  Surprisingly,  upon 
addition of 4A molecular sieves to the Co(II) and Zn(II) catalysts (entries f and g) exo- 
selectivity  was  favoured  with  ee’s  of  up  to  84%.  However,  this  effect  was  less 
prominent when Mg(II), Mn(II), and Ni(II) were utilised (entries h-j), due to a reported 
change in the conformation of the transition state.87
More  recently  Carretero  et  al  have  achieved  complete  regioselectivity  and 
diastereoselectivity  in  a  1,3-dipolar cycloaddition  with  the  related  azomethine  ylides. 
Catalysis  was  attributed  to  the  Cu(I)-Taniaphos  system  they employed  in  their  [3+2]
oo
cycloaddition with a variety of aryl vinyl sulfones (Scheme 42).
Cu(CH3CN)4CI04, 
Taniaphos, NEt3
PhMe, 0°C
Scheme 42
Yields  of the  single  product  obtained  were  over  70%  and  ee’s  of up  to  83%  were 
observed  where  Ar was  phenyl  or thiophenyl.  Desulfonylation  of their products  with 
Na(Hg) then transformed their products into enantiopure 2,5-disubstituted pyrrolidines, 
which are synthetically useful building blocks for many natural products.88
Much less well studied are cycloaddition reactions of vinyl sulfonates. Unfortunately, it 
appears that there is very little precedent in the literature on  1,3-dipolar cycloadditions 
to  vinyl  sulfonates,  with  only  Chan  and  co-workers  having  explored  its  potential.89 
[4+2]  Diels-Alder cycloaddition  with  vinyl  sulfonates  is  more commonly  seen,  and  a 
few examples are shown in Scheme 43.90,9 1
47Intermolecular
,  . 
s  - ^   *  \  //
70°C, 4 days
PhO
Intramolecular
48%, exo/endo = 5:1
Tolene, 110°C
8 8%, exo/endo = 1:2.3
Scheme 43
S 03Ph
S03Ph
SO- SO
Chan  and  co-workers,  having  already  shown  that  vinyl  sulfonates  are  effective 
dienophiles  in  Diels-Alder  reactions,  also  demonstrated  its  ability  to  act  as  a  useful 
dipolarophile (Scheme 44).89
Bn
PhMe, 120°C
24 hrs 
62-86%
R = Et, f-Bu, Ph,  c x y 1*
Scheme 44
They tried a variety of simple and bulky nitrones and the yields obtained were moderate 
to  good,  affording  a  reaction  that  is  diastereo-  and  regioselective  for  only  the  4C- 
substituted product.89
In  addition,  Caddick  group  research  into  the  [3+2]  cycloaddition  between  PFP-vinyl 
sulfonate 100 with a selection of TV-methyl nitrones has been reported (Scheme 45, see
Section 1.3.1.).
69
PhMe, 2 hrs 
110°C
100 103
Scheme 45
Various alkyl,  aromatic,  and heterocyclic R groups were utilised, with yields between 
44-77%.  Moreover,  with  this  electron  deficient  dipolarophile  it  was  reported  that
48regioselectivity and complete diastereoselectivity for the 4C am/-cycloadduct 103 was 
obtained.69
Vessiere et al. has shown that a related dipolarophile akin to that of PFP-vinyl sulfonate 
100,  the  very  electron-deficient  vinyl  sulfone  117  underwent  a  regioselective  [3+2] 
cycloaddition with 2 different nitrones to furnish only the 4C-substituted isoxazolidine 
118 exclusively in gratifying yields, although the stereochemistry of the final product is 
not reported (Scheme 46).92
°x ,°
117
0^©„R N
Ph"
Benzene, reflux 
24 hrs
R = Me 6 8% 
Ph 69%
118
Scheme 46
In conclusion, it has been possible to show through pioneering work by Houk et al. that 
electron-deficient  olefins  exhibit  a  preference  in  regiochemistry  for  the  4C 
cycloadducts.  Therefore  through  this,  it  is  possible  to  predict  that  the  [3+2] 
cycloaddition between the extremely electron poor PFP-vinyl  sulfonate  and  a nitrone 
should  furnish  solely  the  4C-substituted  product,  and  this  was  confirmed  through 
previous work in the group.  However,  whilst the literature displays numerous nitrone 
cycloadditions  with  a  variety  of electron-deficient  olefins,  few  reported  cases  with  a 
vinyl  sulfonate  are  known.  While  the  aforementioned  examples  show  excellent 
regioselectivity,  a current limitation on nitrone cycloadditions with vinyl  sulfonates is 
that little is known about the diastereoselectivity of the reaction. Through the following 
work  it  is  hoped  a  better  understanding  of cycloadditions  with  vinyl  sulfonates  and 
related  dipolarophiles  will  be  gained.  The  use  of  microwave  chemistry  in  organic 
synthesis has risen in the past 10 years, and so the effect of microwave heating will also 
be explored. Furthermore, as the transformation of PFP sulfonate esters to sulfonamides 
is known, further studies were proposed, involving the application of any methodology 
to the synthesis of sulfonamides, containing a diverse array of functional groups.
492.3.  Studies  on  [3+2]  cycloaddition  reactions  of vinyl  sulfonates  and 
related dipolarophiles
2.3.1.  Synthesis of PFP vinyl sulfonate (100)
To initiate the study, work commenced with the synthesis of PFP vinyl sulfonate  100,
Commercially  available  2-chloroethane-l-sulfonyl  chloride  was  treated  with  a 
suspension of pentafluorophenol and NEt3 (Scheme 47).
The reaction is particularly temperature sensitive and requires that the internal reaction 
temperature  is  maintained  below  -10°C  to  avoid  significant  decomposition. 
Nevertheless, the reaction proceeds in high yields and was reproducible on up to a 20g 
scale.
2.3.2.  Synthesis of nitrones
Nitrones can be easily prepared from the condensation reaction of an aldehyde with an 
TV-substituted hydroxylamine (Scheme 48).69 R and R' can be aryl or alkyl groups, but 
our initial studies utilised R' = Me with variations in the aldehyde component. R groups 
included  alkyl,  cyclic,  heterocyclic,  and  aryl  groups  (incorporating  electron- 
withdrawing, electron-donating, and halogen substituents) (Table 4).
93 through  a  slight  modification  to  Distler’s  procedure  for  vinyl  sulfonate  synthesis.
OH
c PFPO
100 F
Scheme 47
o o  ©   R’ 
DCM, NaHC03  f+
+
OH  Cl  reflux, 2 hrs R
119 (a-v)
Scheme 48
50Entry (119) R Yield (%)
a Ph 74
b p-MeOPh 93
c p-Allyloxy-Ph 88
d p-N02Ph 56
e p-ClPh 91
f p-BrPh 96
g m-ClPh 96
h m-BrPh 99
i o-FPh 96
j o-ClPh 97
k o-BrPh 83
1 Naphthyl 99
m Terephthyl 17
n Furyl 98
0 2-Br-furyl 98
P Cyclopropyl 99
q Cyclohexyl 95
r Valeryl (C5Hn) 61
s 2,6-Dimethylphenyl 85
t Pentamethylphenyl 59
u o-IPh 98
V m-IPh 89
Table 4
The reactions proceed very smoothly to give product  119 in good to excellent yields. 
Often  the reaction proceeds  sufficiently well  such that the product is  isolated in high 
purity without the  need  for purification.  If necessary,  recrystallisation  can be used to 
give the product as readily handled crystalline solids. However, yields for entries d and 
m are appreciably lower because they contained polar substituents which made isolation 
of the product non-trivial due to its insolubility in organic solvents. The reaction time 
was generally 2 hours; however, entries s-v required a prolonged reflux presumably due 
to the extra bulk of its substituents.
512.3.3.  Formation of PFP isoxazolidines
Previous work within the group has presented us with a procedure for carrying out the
1,3-dipolar  cycloaddition  of  nitrones  with  PFP  vinyl  sulfonate  100  in  a  regio-  and 
diastereoselective  manner  by  refluxing  in  toluene.69,94 This  protocol  was  followed  to 
synthesize  a  library  of  isoxazolidines  with  varied  R  groups  (Table  5).  In  addition, 
microwave heating was also investigated and it was found that this enabled us to carry 
out the reactions with a significantly reduced reaction time (Table 5).
o  o ^  \\//
P v °   N  A: PhMe, reflux, 1-5 hrs  PFPO  19
S  ^   +  \ \    *-  1   P
PFPO  R  B: PhMe, MW, 140°C,5 mins  N
100  119 (a-v)  .
v   '  103 (a-v)
Entry (103) R Yield A (%) Yield B(%)
a Ph 65 74
b p-MeOPh 71 64
c /7-Allyloxy-Ph 81 78
d /?-N02Ph 43 73
e p-C lPh 77 83
f /?-BrPh 73 79
g m-ClPh 65 76
h ra-BrPh 66 79
i o-FPh 47 60
j o-ClPh 56 59
k o-BrPh 51 53
1 Naphthyl 72 80
m Terephthyl 35 -
n 2-Furyl 70 74
0 2-Br-furyl 44 69
P Cyclopropyl 62 44
q Cyclohexyl 53 46
r Valery  1  (C5Hn) 18 -
s 2,6-Dimethylphenyl 61 -
t Pentamethylphenyl 57 -
u 0-IPh - 33
V m-IPh - 36
Table 5
52Apart  from  the  benefits  of reduced  reaction  times  microwave  heating  also  generally 
produced  higher  yields  than  using  conventional  heating.  There  is  no  obvious  general 
trend between the nitrone used and the yield obtained. However, some aryl groups with 
electron-donating  substituents  seem  to  give  excellent  yields  (entries  c  and  1),  while 
hydrophilic nitrones (entries d and m) are less efficiently converted into isoxazolidines 
103d  and  103m  respectively.  Aryl  groups  with  halogen  functionality  tended  to  give 
moderate to good yields, but when microwave assisted gave enhanced yields. Aromatic 
groups  with  very  bulky  substituents  also  required  a  longer  reaction  time  of 5  hours 
(entries s and t) for reaction completion.
Most of the  yields  reported employing conditions  A compared favourably with those 
obtained previously within the group.  One particularly pleasing result was the success 
of the p-halogeno  aryl  nitrones  (entries  e  and  f),  since  these  have  been  reported  as 
giving unsuccessful reactions in the past.94 In these cases it was found that the product 
and PFP-vinyl sulfonate 100 exhibited the same R/, and so it became clear why previous 
attempts were mistaken for an unsuccessful reaction. For all examples the presence of 
exclusively  the  4C  anti  cycloadduct  was  confirmed  by  NMR  comparisons  with 
literature examples.69
2.3.4.  Aminolysis of PFP isoxazolidine cycloadducts
Now  in  possession  of a  selection  of isoxazolidines,  the  aminolysis  reaction  of these 
products was attempted (Scheme 49).
PFPO
Scheme 49
It  has  been  reported  that  aminolysis  of  these  substrates  proceed  with  no  loss  of 
stereochemistry  during  the  transformation.69,  94  Accordingly,  a  selection  of  simple 
amines was subjected to aminolysis conditions (Table 6).
53PFPO
°x P
xs7
R  \  
103 (a-v)
R'NH2 (3 eq), DBU (1  eq)
R'HN
THF, reflux
O ,  O
xs7
&   R   \ 
120
R'HN
°x P
xs7
121
Entry
(120/121)
R R'NH2 Time
Product ratio 
(120 : 121)
Yield
(%)
a Ph 30 mins 4:  1 70
b Ph 1  hr 3 :  1 84
c Ph
" l E t02C ^ ^ N H 2
2 hrs 1   :  1* 65
d /7-MeOPh 1  hr 3 :  1* 63
e 2-Br-furyl H2N 1  hr 4:  1 78
f p-N02Ph 1  hr 3 :  1 63
g Cyclopropyl h2n ^ ^ ' ^ 30 mins 3 :  1* 92
* = products not separated  Table 6
It soon became clear by TLC analysis that, in general, the reactions were generating a 
mixture  of  products,  which  were  difficult  to  separate  by  column  chromatography. 
Fortunately, separation of each product (entries a, b, e, and f) was achieved and NMR 
analysis  confirmed  that  both  the  anti  and  syn  diastereoisomers  were  synthesized. 
Further NMR  analyses,  including NOE analysis,  combined with  molecular modelling 
have  confirmed  that  the  major  product  is  the  anti  cycloadduct  120,  and  the  minor 
product the syn cycloadduct 121. An example of this is shown in Figure 25. There are 
marked  differences  between  the  two  NMR  spectrum  of 120a  and  121a,  which  is 
evident  by  comparing  the  positions  of protons  1   and  2,  and  how  clearly  the  peak 
resolves.  In particular,  the  amino  proton  1   of the  4C  anti cycloadduct  120a  shows  a 
clear triplet at 4.75 ppm; however, in the 4C syn cycloadduct 121a this proton shifts up- 
field  and its  multiplicity less  well  defined.  In addition,  molecular modelling  suggests 
that the dihedral angle between protons 2 and 3 in 120a is approximately  145°, whilst 
that for 121a is 23°. These dihedral angles correspond to calculated coupling constants 
of approximately 7Hz and 8Hz respectively, and this agrees favourably with measured 
coupling constants of 7.3Hz (120a) and 8.4Hz  (121a).  NOE was also used to confirm 
that  sulfonamides  120a  and  121a  were  indeed  the  anti  and  syn  diastereoisomers 
respectively.  In the anti diastereoisomer no apparent NOE between protons 2 and 3 is 
visible,  whilst  an  NOE  is  clearly  evident between  that  of proton  2  and  those  of the 
phenyl ring of 4. In stark contrast to the syn diastereoisomer, an obvious NOE signal is
54visible between protons 2 and 3, whilst that of protons 2 and 4 is absent (Supplementary 
data  graphs  1   and  2).  Using  these  guidelines  the  syn  and  anti  products  for  the  other 
aminolysis reactions were identified accordingly.
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Figure 25
After numerous  attempts  at  the  aminolysis  reaction,  it  was  possible  to  conclude  that 
aminolysis does not proceed with exclusive retention of stereochemistry, but is in fact a
55diastereoselective  reaction.  A  possible  mechanistic  explanation  is  that  aminolysis 
proceeds through a ‘sulfene’ intermediate (Scheme 50).
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Scheme 50
After deprotonation  of the  a  hydrogen  by  DBU  a  ‘sulfene’  intermediate  is  generated. 
This  sulfene  intermediate  is  planar  and  so  after  nucleophilic  attack  by  the  amine, 
protonation can be from A the top face, or B the bottom face, and thus giving rise to two 
possible diastereomeric products.
In  order  to  try  and  overcome  this  problem,  we  decided  to  run  the  reaction  using  a 
weaker  base  in  order  to  avoid  a-H  deprotonation.  Pyridine  and  2,6-lutidine  were 
selected  for  this  purpose,  and  after  12  hours  reflux  starting  material  was  recovered 
accompanied by unknown decomposition by-products.
Previous work has shown that aminolysis in the presence of nucleophilic catalysts such 
as  tetra-butylammonium chloride (TBAC)  greatly enhance  the rate of reaction.68 So it 
was predicted that if TBAC was used then the rate of direct nucleophilic displacement 
might be greater than that of a-H deprotonation, and as a result circumvent the need for 
the reaction to proceed via the  ‘sulfene’  intermediate. It was envisaged that the reaction 
would proceed via a direct displacement of an  *in situ  formed sulfonyl chloride, which 
would  be  rapidly  trapped  by  the  desired  amine  with  retention  of  stereochemistry 
(Scheme 51).
56Scheme 51
To test this hypothesis isoxazolidine 103d was treated with allylamine and DBU, with  1  
eq. of TBAC included. Although the reaction displayed a shorter reaction time, as with 
previous attempts the anti and syn cycloadducts were still generated in a 58% yield and 
with a product ratio of 3:2 (anti:syn). It was then predicted that if an insoluble source of 
base was  utilised (NaHCCb)  along with TBAC, this  may further slow  the rate  of a-H 
deprotonation.  In  practise  although  a  better  yield  was  observed  (78%)  both 
diastereoisomers  were  still  generated  (5:2  anti:syn),  therefore  suggesting  aminolysis
possibly prefers to proceed via the ‘sulfene’ intermediate.
By this stage, it became clear that we were not going to easily be able  to  suppress this
undesirable isomerisation, and we therefore sought a new solution.
2.3.5.1,3-Dipolar cycloaddition of vinyl sulfonamides
Having  established  that  cycloaddition  is  both  regio-  and  diastereospecific,  it  was 
decided  to  change  the  synthetic  sequence.  For  example,  if  aminolysis  is  carried  out 
before  1,3-dipolar cycloaddition we felt that it might be possible to isolate the products 
with improved diastereoselectivity (Scheme 52).
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An additional  advantage was that vinyl  sulfonamides can be synthesized directly from 
2-chloroethane-l-sulfonyl chloride using an existing protocol (Scheme 53).69,93o  o
rv s ci
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Scheme 53
1,3-Dipolar  cycloaddition  of  nitrones  to  vinyl  sulfonamides  is  not  well  described  in 
literature,  with  Vessiere  et al.  and  Chan  and  co-workers  being  two  groups  who  have 
reported  brief  studies.  An  early  example  from  Vessiere  in  1987  reported  the 
regioselective  [3+2]  cycloaddition between  a  mono-substituted  vinyl  sulfonamide  122 
with  two  nitrones  (Scheme  54).  The  authors  also  report  that  the  reaction  is
92 diastereoselective, however the stereochemical outcome was not reported.  "
o  o
0   0   O  ©^R
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Scheme 54
Chan’s  reported  examples  are  shown  in  Scheme  55.  Although  they  utilise  a  di­
substituted olefin they do not report formation of the 5C-substituted cycloadduct, so the 
reaction appears to be proceed with excellent regioselectivity (Scheme 55 (i)).95 Further 
work  from  this  group  described  a double  asymmetric  induction between  a chiral  06,(3- 
unsaturated-y-sultam  with  a  chiral  nitrone  (Scheme  55  (ii)).  The  reaction  was 
regioselective  with  respect  to  the  4C-substituted  cycloadduct,  and  a  diastereomeric 
excess of 76% was obtained.83
PhMe
PhMe
m ajo r
Scheme 55
58Despite these two studies, very little is known about the regio- or diastereoselectivity of 
the reaction. Indeed the problem that now exists is that the sulfonamide group does not 
exhibit as  strong an electron withdrawing effect  as the PFP  group,  and  consequently 
might have an effect on the reactivity of the double bond. It has been mentioned earlier 
that  if  a  dipolarophile  is  weakly  electron-deficient  then  a  regioisomeric  mixture  of 
cycloadducts will be obtained.
In  order  to  perform  a  study  into  the  reactivity  of vinyl  sulfonamides,  a  range  were 
synthesized using a variety of primary and secondary amines (Table 7).
DCM, NEt3  0   0
------------------- /Si ^
Cl  RNH2,-10°C  r h n
123 (a-g)
Entry (123) Amine Yield (% )
a 65
b 76
c
EIOjC  NH2
56
d H2 N— 55
e h2 n - ^ - 64
f e r r 67
g
tb d m so^ nh2 65
Table 7
All the reactions were non-trivial and required purification by flash chromatography to 
furnish the vinyl sulfonamides 123a-g in modest yields. Ethanolamine was protected as 
the TBDMS ether (entry g) before undergoing transformation to the vinyl sulfonate to 
improve handling.
With  a  small  selection  of  vinyl  sulfonamides  available,  optimisation  of  their  [3+2] 
cycloaddition  with  nitrones  was  attempted  in  a  CEM  microwave.  Previous  studies 
within the group have established toluene as the solvent of choice for the reaction of 
nitrone [3+2] cycloadditions with a reaction temperature of 140°C. Cycloaddition was 
attempted between  vinyl  sulfonamide  123b  (1  eq.)  and  C-(4-bromophenyl)-A-methyl 
nitrone (1.5 eq.) 119f initially (Table 8, entry 1) for 10 minutes; however the presence
59of vinyl peaks  in the  *H NMR suggested the reaction was incomplete after this time. 
Reaction times of 30 and 60 minutes (entry 2 and 3) produced a similar result. Rather 
than increase the reaction time it was  suggested that degradation of the nitrone under 
intense  MW  heating  was  responsible  for  the  inability  of the  reaction  to  proceed  to 
completion.  Hence,  the  amount  of  nitrone  used  was  increased  (3  eq.)  to  drive  the 
reaction to completion.  Accordingly, various reaction times were screened and the  *H 
NMR of the crude material recorded to determine the extent of conversion (entries 4- 
13). Optimum conditions were eventually found to be 3 eq.  of nitrone with a reaction 
time of 30 minutes (entry 11).
PhMe, MW
140°C
Entry Nitrone Time (mins) Outcome
1 1.5 eq. 10 Approximately 40% conversion
2 1.5 eq. 30 Approximately 70% conversion
3 1.5 eq. 60 Approximately 85% conversion
4 3 eq. 1 Approximately 10% conversion
5 3 eq. 2 Approximately 15% conversion
6 3 eq. 5 Approximately 40% conversion
7 3 eq. 10 Approximately 65% conversion
8 3 eq. 15 Approximately 75% conversion
9 3 eq. 20 Approximately 80% conversion
10 3 eq. 25 Approximately 95% conversion
11 3 eq. 30 100% conversion
12 3 eq. 40 100% conversion
13 3 eq. 50 100% conversion
Table 8
This new protocol was repeated on vinyl sulfonamide 123b and nitrone 119f (Table 9, 
entry a); however upon purification it was observed that there was no regiocontrol, and 
that  the  5C-substituted  isoxazolidines  (125a  and  126a)  were  also  produced.  No 
evidence for the formation of the 4C syn diastereoisomer was observed, and the 4C anti
60124a could be easily separated from the 5C diastereoisomers.  The remaining nitrones 
were also examined and the results shown (Table 9).
'V /   ^   PhMe, MW
+   fj  ----------------
H  FT  140°C,30mins
123b  119
Entry R
Product ratio 
(124: [125/126])
Product ratio 
125 : 126
Overall 
Yield (%)
a p-BrPh 3 :2 3 :  1 72
b o-ClPh 2:3 2:  1 78
c Ph 5 :  1 2:  1 81
d o-BrPh 2:3 2:  1 83
e oFPh 6:7 5 : 2 89
f p-MeOPh 7 : 3 2:  1 73
g p-N02Ph 7 :2 2 :5 67
h p-ClPh 5:2 3 :  1 78
i Naphthyl 5:2 2:  1 57
j ra-BrPh 5:  1 1  : 0 57
k m-ClPh 3 :  1 1  : 0 62
1 2-Br-furyl 1  : 0 - 20
m 2-Furyl 4 :9 6 :3 63
n p-Allyloxy-Ph 1  : 0 - 24
0 0-IPh 2:  1 0:  1 32
P m-IPh 5 :2 1  :0 61
124
125 = 5C anti
126 = 5C syn
Table 9
As with entry a,  the majority of other nitrones  also furnished mixtures of the 4C anti 
diastereoisomer  124,  as  well  as  the  5C  diastereoisomers  125  and  126  often  as  an 
inseparable mixture.  Yields were generally good,  however for the less  stable nitrones 
(entries 1  and o) poor yields were obtained and this was visible by a severe darkening of 
the reaction vial after MW irradiation. A poor yield for entry n can also be explained by
61possible  complications  resulting  from  the  presence  of  another  olefin  on  the  nitrone 
available for cycloaddition. An unexpected result from this study was the disappearance 
of the 5C syn cycloadduct 126 when meta-substituted phenyl nitrones (entries j, k, and 
p) were used, although it is not obvious how this phenomenon occurs.
Although there was not perfect regiocontrol in nitrone [3+2]  cycloadditions with vinyl 
sulfonamides,  the ease with which the 5C-substituted products  can be  separated from 
the desired 4C  anti diastereoisomer was  advantageous.  Overall  this  may be preferred 
over the  approach utilising  aminolysis  of PFP isoxazolidines  103a-v  (Section  2.3.4.). 
Furthermore, as there is little known about the  1,3-dipolar cycloaddition between vinyl 
sulfonamides and nitrones, this study does provide some useful information about such 
cycloaddition  reactions.  We  therefore  utilised  this  route  to  prepare  a  selection  of 
heterocyclic  sulfonamides  from  vinyl  sulfonamides  123e  and  123g,  and  the  results 
shown in Tables 10 and 11.
PhMe, MW
140°C, 30 mins
129 = 5C syn
Entry R Product ratio 
(127 : [128/129])
Product ratio 
128 :129
Overall 
Yield (%)
a p-BrPh 10:3 2: 1 59
b <?-ClPh 1 :  1 3 : 2 58
c Ph 3 :  1 2:  1 55
d 6>-BrPh 2:  1 3 : 2 43
e o-FPh 7 : 6 4 :2 57
f p-MeOPh 5 :  1 3 : 2 39
g p-N02Ph 8 :  1 1   : 0 47
h p-ClPh 13:4 2 :  2 59
i Naphthyl 7 :  1 1   :  1 49
j m-BrPh 2:  1 2:  1 57
k m-ClPh 12:3 2: 1 52
1 2-Br-furyl 1  : 0 - 37
m 2-Furyl 2:3 2:  1 72
n Cyclopropyl 3:7 9 :5 43
Table 10
62TBDMSO.
°x yO
.  5* N  
H
123g
TBDMSO
0
N   &   r  
H   O
R
119
PhMe, MW 130
J   N
140°C, 30 mins
O   O
TBDMSO/ / N /S ^
”  O-N 
131 = 5C anti  \
Entry R
Product ratio 
(130 : [131/132])
Product ratio 
131 : 132
Overall 
Yield (%)
a /7-BrPh 5 :  1 4:  1 70
b o-ClPh 1   :  1 5 : 3 82
c Ph 3 :  1 3 :2 55
d o-BrPh 1  :  1 3 : 2 57
e o-FPh 1   :  1 1   :  1 76
f p-MeOPh 11 : 3 1   : 2 66
g p-N02Ph 11  : 2 2 :0 60
h p-C  lPh 11 : 2 2 :0 62
i Naphthyl 3 :  1 3 : 2 75
j m-BrPh 6:  1 1  : 0 63
k m-ClPh 5 :  1 1  : 0 66
1 2-Br-furyl 1 : 0 - 12
m 2-Furyl 5 :6 4 :2 71
n p-Allyloxy-Ph 6:5 3 :2 58
0 Cyclopropyl 6:21 13 :  9 64
Table 11
With vinyl  sulfonamide  123e,  the yields were not as encouraging as those previously 
described  in  Table  9,  although  better  yields  were  obtained  with  the  less  sterically 
congested vinyl sulfonamide 123g. It was interesting to note that there was normally a 
greater preference for the 4C anti cycloadduct over the 5C cycloadducts irrespective of 
the nature of the vinyl sulfonamide. A few exceptions arose when furyl or cyclopropyl 
nitrone was used  (Tables 9-11),  and in these cases we observed a reversal in product 
selectivity,  although  additional  work  would  be  required  to  investigate  this 
inconsistency.
63Likewise when 2-bromofuryl nitrone was used, yields were consistently low with only 
the 4C substituted diastereoisomer obtained from a mixture of decomposition products 
(Tables 9-11, entry 1). A pattern that also re-emerges is the loss of the 5C syn products 
when meta-substituted phenyl nitrones were used (Table  11, entries j  and k), however 
this  outcome  was  not  observed  in  cycloadditions  with  123e,  thus  adding  further 
confusion  over  how  to  predict  the  diastereoselectivity  of the  5C  regioisomers  when 
raeta-substituted phenyl nitrones are involved.
The  simple  and  clean  removal  of the  TBDMS  protecting  group  from  isoxazolidines 
130a-n was achieved in excellent yields after purification (Table  12) to provide another 
collection of interesting sulfonamides which, as can be seen later, have some potential 
application in chemical biology (see Chapter 3).
0N   0 \\//
T B D M S a ^ //\  /S  
H
R
130a-n
1M TBAF, THF
0°C, 15 mins
HO N
H
133a-n
Entry (133) R Yield (% )
a p-BrPh 86
b o-ClPh 91
c Ph 92
d oBrPh 85
e o-FPh 78
f /7-MeOPh 83
g p-N02Ph 50
h p-ClPh 85
i Naphthyl 97
j m-BrPh 82
k m-ClPh 70
1 2-Br-furyl 70
m 2-Furyl 69
n p-Allyloxy-Ph 92
Table 12
642.4.  Isoxazole synthesis from vinyl sulfonates
We  were  interested  in  developing  the  cycloaddition  chemistry  further  such  that  we 
could apply this to the synthesis of isoxazoles. The most obvious way to achieve this is 
by  utilising  PFP-alkynylsulfonate;  however,  previous  researchers  in  the  group  had 
shown that this was a difficult compound to prepare. In this section we describe a range 
of attempts to find a means towards synthesizing isoxazole species.
Common literature preparations for the synthesis of isoxazoles often involve the use of 
an alkyne (l),96 an alkyne equivalent (2),97 or a 1,3-dicarbonyl (3)98 as shown in Scheme 
56.
(1)
EtOH, NaOEt
O
Scheme 56
There is, however, much less precedent for the direct oxidation of isoxazolidines as a 
route into isoxazoles; hence work will be focused on this particular pathway.
A  literature  search  reveals  a  limited  number  of  examples  for  the  oxidation  of 
isoxazolidine rings (Scheme 57). Puranik and Zhao both utilise DDQ as the oxidant of 
choice to carry out an A-deprotection followed by oxidation,  and while Puranik et al 
obtained  the  aromatic  product  with  their protocol  Zhao  et al,  obtained  the  partially 
oxidised isoxazoline 99,100 Whilst it may be difficult to predict how our 4C-substituted 
isoxazolidines  may  preferentially  oxidise,  there  is  also  literature  precedent  as 
demonstrated by Shin et al  that the oxidation of oxazolines to oxazoles is available as 
an option should our 4C-cycloadducts fail to aromatise (Scheme 57).10 1
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2.4.1.  Oxidation of isoxazolidines
The initial focus of this work was to develop the key reaction where an isoxazolidine 
possessing a PFP  sulfonate group might be fully oxidised  to  the  analogous  isoxazole 
with preservation of the PFP functionality (Scheme 58). It was anticipated that the PMB 
group  could  be  removed  and  then  the  free  isoxazolidine  subjected  to  oxidation 
conditions to give the desired isoxazole (Scheme 58).
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For the initial optimisation study, a phenyl-substituted isoxazolidine was selected as a 
suitable substrate, with an iV-PMB substituent. As with previous cycloaddition strategies 
we have examined, it would be possible to vary the R group in the initial cycloaddition 
for the purposes of introduction of diversity. Hence, nitrone  136a was synthesized via 
the following route (Scheme 59).
NaBHjCN
1.25M HCI/MeOH 
2 days 
99%
DCM, NaH C03, 
reflux, overnight 
96%
Scheme 59
66Using  known  literature  procedures  the  required  nitrone  136a  was  easily  prepared  in 
excellent  yield  through  a  series  of simple  reactions.  Condensation  of hydroxylamine
i n?
with anisaldehyde provided oxime 134 in a 94% yield.  Compound 134 was reduced 
with NaBtUCN in a near quantitative yield, and a final condensation of hydroxylamine 
135 with benzaldehyde produced the required nitrone in a yield of 96%.69,102,103 1,3- 
Dipolar  cycloaddition  with  PFP  vinyl  sulfonate  100  subsequently  furnished  the  PFP 
isoxazolidine 137 in a entirely regioselective and diastereoselective manner (see Section 
2.3.3), in an 85% yield (Scheme 60).
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¥
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PhMe, reflux, 9 hrs  PFPO^
85%
136a 
Scheme 60
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The  cyclohexyl-substituted  variant  138  was  also  prepared  in  a  slightly  more  modest 
55% yield via the condensation of hydroxylamine 135 with cyclohexanecarbaldehyde, 
followed by a [3+2] cycloaddition of the resulting nitrone 136e with PFP vinyl sulfonate 
100 (Scheme 61).
PFPO PFPO
DCM, NaHC03, 
reflux, overnight 
95%
PhMe, reflux, 9 hrs 
55%
Scheme 61
With the N-protected isoxazolidines in hand, removal of the PMB group was attempted 
using various typical literature conditions. The results of these trials are shown in Table 
13.
67°v  0
x s7
PFPO-  Y ^ O
99
PMB
x s7
pfpo'   r ^ Q
/   NH R
139
Entry Conditions R Yield (%)
a Pd/H2, RT, MeOH, 24 hrs Cyclohexyl Failed
b Pd/H2, reflux, MeOH, 7 hrs Cyclohexyl 34%
c Pd/H2, reflux, EtOAc, 16 hrs Cyclohexyl Failed
d 1-chloroethylchloroformate, reflux Phenyl Failed
e DDQ, DCM/H20, RT, 16 hrs Phenyl Failed
f DDQ, DCM/H20, reflux, 16 hrs Phenyl Failed
g DDQ, dioxane, reflux, 6 hrs Phenyl Failed
Table 13
With the more common hydrogenation conditions the reaction was unsuccessful at room 
temperature,104 no reaction  was  taking place  and instead recovery  of starting material 
was obtained as the major result (entry a). Heat was applied to the reaction with some 
degree of success (entry b), however the product 139 generated proved to be difficult to 
isolate  via  silica  gel  chromatography.  Nevertheless,  the  problem  associated  with  this 
protocol  was  the  generation  of PFPOH,  and  consequently  suggesting  degradation  of 
starting material 138 or the resultant product. Changing the solvent from MeOH to the 
less  polar  EtOAc  stopped  the  reaction  altogether  (entry  c),  as  starting  material  was 
recovered.  1-Chloroethyl  chloroformate  was  attempted  as  a  means  of  trapping  the 
product isoxazolidine as the HC1 salt (entry d);105 however, failure of this method was 
again verified by the recovery of starting material. Endeavours with DDQ (entries e-f) 
led  to  the  decomposition  of starting  material  or  product,  although  this  was  possibly 
down  to  hydrolysis  of  the  PFP  group  by  water.106, 107 Removal  of  water  (entry  g) 
provided no appreciable product formation so studies were directed elsewhere.
Due to the labile nature of the PFPOH group it was decided that aminolysis should be 
carried out first to make a more stable S-N bond, which would also be more likely to 
survive the harsher deprotection and oxidation conditions (Table 14).
68\y/
PFPO
Prf
PMB
137
RNH2, DBU, THF 
reflux, 1 hr
PMB
140
Ph
PMB
141
Entry Amine Yield (%) Product ratio (140 :141)
a 4-methylbenzylamine 95 7:2*
b 4-methylbenzylamine 90 3 :  1
c /ert-butylamine 85 2:  1
* = separated  Table 14
4-Methylbenzylamine  and  ter/-butylamine  sulfonamides  140/141a-c  were  prepared  in 
excellent yield;  however,  as with previous  attempts  at aminolysis  (see  Section  2.3.4.) 
the reactions proceeded with little diastereocontrol (Table  14).  This was not a concern 
however,  as upon  oxidation to the isoxazole both diastereoisomers  should furnish the 
same final product.  Therefore,  after the first reaction  with 4-methylbenzyl  amine,  we 
did not attempt to separate the product isomers, but simply continued using the mixture 
of products (entries b and c).
Due to the difficulties  associated with the isolation of the free  isoxazolidine  139,  the 
one-step  deprotection-oxidation  process  reported  by  Puranik  et al.  (Scheme  57)  was 
examined, as this would remove the need for a separate PMB deprotection step (and the 
resulting necessary purification).99 This process utilised DDQ to carry out an ‘m situ’ N- 
deprotection followed by isoxazolidine oxidation to the isoxazole. Investigation of this 
procedure met with limited success (Scheme 62).
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140/141
DDQ, Benzene 
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142a: R = 4-Mebenzyl, 20% 
142b: R = f-butyl, 69%
Scheme 62
With  4-methylbenzylamine  the  reaction  was  not  trivial,  and  the  only  characterisable 
product obtained from a complex mixture of decomposition products was the partially 
oxidised isoxazoline  142a  in  a  12-20%  yield.  In  addition,  the  reaction  was  left for a 
longer period of 48  hours to determine whether complete  conversion  to the  aromatic
69isoxazole  could  be  achieved.  However,  disappointingly  the  product  was  reluctant  to 
undergo aromatisation and degradation is observed which further diminished the poor 
yield. Further attempts at optimisation were unsuccessful. As it was envisaged that there 
was  a possibility that the DDQ could  also be reacting  with  the 4-methylbenzylamine 
moiety, this was subsequently exchanged for tert-butylamine (Table 14, entry c).
The DDQ deprotection/oxidation reaction was repeated on the tert-butylamine analogue 
140/141c  furnishing  the  isoxazoline  142b  in  a  gratifying  69%  yield  (Scheme  62). 
Repeated  attempts  produced  similar  yields  and  consequently  demonstrated  that  the 
choice of amine was an important factor.  Again it was noticeable that the isoxazoline 
142b was resistant to aromatisation as there was no evidence of the isoxazole, even with 
prolonged heating.
2.4.2.  Cycloaddition studies on a-bromo-PFP-vinyl sulfonate
Following these  difficulties  in  the preparation of the isoxazole,  a modification to the 
synthetic route was  sought.  Due  to  the lack of success  in  mediating  aromatisation of 
isoxazolidines, it was envisaged a PFP-alkynyl-sulfonate equivalent might enable us to 
circumvent these problems. Hence, it was decided to study the reactions of a novel  1,3- 
dipolarophile, a-bromo-PFP-vinyl sulfonate 143.
The use of a-bromo-PFP-vinyl sulfonate 143 as an alkyne equivalent is well established 
within  the  group,  thus  it  was  conceived  that  as  a  direct  replacement  for  PFP-vinyl 
sulfonate  100 in the previously described cycloaddition chemistry (see Section 2.3.3.) 
aromatisation  could  be  accomplished  later  in  the  synthesis.  Accordingly,  a  new 
synthetic plan is shown, Scheme 63.
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Scheme 63
Following  a  known  procedure  a-bromo-PFP-vinyl  sulfonate  143  was  synthesised  in 
75% yield through a radical mediated process (Scheme 64).108
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Scheme 64
A [3+2] cycloaddition with 143 as the dipolarophile was first performed using a simple 
model  nitrone  119f,  to  determine  optimal  conditions  for  this  novel  transformation 
(Scheme 65).
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However, when subjected to the previously optimised cycloaddition conditions (1.5 eq. 
nitrone and  1  eq. of dipolarophile in refluxing toluene), no product was visible after 20 
hours,  instead  partial  recovery  of  a-bromo-PFP-vinyl  sulfonate  143  was  the  main 
outcome. Similarly no product was obtained when the reaction mixture was heated in a 
microwave oven at 140°C for 2 hours. It was assumed that the olefin was too hindered 
and  even  prolonged  heating  at  an  elevated  temperature  was  insufficient  to  drive  the 
reaction  forward.  It  was  noticed  that  under  MW  heating  PFPOH  was  liberated, 
indicative of degradation of the a-bromo-PFP-vinyl sulfonate prior to cycloaddition.
It was then decided to examine the potential beneficial effect of base in the reaction. It 
was  conceived  that  if a base  was  added to  the  reaction,  ‘in  situ’  elimination  of HBr 
could be effected and the nitrone could then undergo cycloaddition, with the much less 
sterically encumbered alkyne. Hence, the reaction was repeated with 1.5 eq. of NEt3 and 
after  purification  3  products  were  obtained  (Scheme  66).  Surprisingly  none  of  the 
expected eliminated cycloadduct 144 was obtained. However, more remarkable was the 
presence of the brominated cycloadduct 145/146 as the major product. Also eluted from 
the column  were  the  de-brominated product  148  and  the  other regioisomer  147  as  a 
minor product. Additionally,  145/146 was obtained as a diastereomeric mixture of the 
4C regioisomer, whilst 148 and 147 were furnished as single diastereoisomers.
7168%
Scheme 66
Isoxazolidine  145/146  could  be  the  result  of  several  different  reaction  pathways. 
Previous  work  from  the  group  had  shown  that  amines  tend  to  undergo  conjugate 
addition to PFP-vinyl  sulfonate.94 Hence it is possible that apparent cycloaddition is in 
fact proceeding  via  a  stepwise  process  bearing  some  similarity  to  the  Baylis-Hillman 
reaction. Thus under such a scheme, triethylamine undergoes conjugate addition to the 
vinyl sulfonate, the resulting anion 149 undergoes addition to the nitrone, and finally a 
cyclisation leads to the product (Scheme 67).
: N Et,
o o f
X Q /
PFPO
143  Br
\M  Br  z'-*' S  /<© N E tg PFPO PFPO
Br
O
Br
149 Br
Scheme 67
The  Baylis-Hillman  reaction  is  an  atom  economic  reaction  that  involves  the 
condensation  of an  electron-deficient  olefin  with  an  aldehyde  catalysed  by  a  tertiary 
amine or phosphine, to produce an a-methylene-P-hydroxy-carbonyl (Scheme 68).109
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PFPO
145/146The Baylis-Hillman reaction has evolved greatly since  1998, and recent advancements 
involve  achieving  an  asymmetric  version  of  this  reaction  by  means  of  a  chiral 
multifunctional organocatalyst.110 A few literature examples are described.
Barrett  et  al.  in  1998  reported  that  it  was  possible  to  obtain  moderate  levels  of 
asymmetric  induction  (up  to  72%  ee)  with  their chiral  pyrrolizidine base  150,  in  the 
Baylis-Hillman reaction between ethyl vinyl ketone and various aryl aldehydes (Scheme
69).109’1 1 1
Et
0
1  
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150 (10 mol%), -40°C 
NaBF4, MeCN
150 OH
OH  O 
Ar  Et
17-93% yield 
21-72% ee
Ar= 2-N02Ph, 2-FPh, 2-CIPh, 
2-BrPh, 3-N02Ph, 4-N02Ph, 
2-Pyridyl, 3-Pyridyl
Scheme 69
Since the formation of the /^-configuration of the alcohol was observed it was postulated 
that the aldol step proceeded via the least sterically hindered intermediate 151 (Scheme
70). In addition, rate enhancement was explained by the ability of the hydroxyl group of 
the catalyst to tether to the aldehyde through a metal-oxygen bond thus increasing the 
susceptibility of the aldehyde to nucleophilic attack.1 1 1
Favoured:  Unfavoured:
n o 2
151
@ N -
O j
OH N02
Ar
Scheme 70
In  1999,  work  by  Hatakeyama  et  al  produced  one  of  the  first  examples  of  an 
enantioselective Baylis-Hillman reaction catalysed by a rigid tricyclic chiral amine 152 
derived from the Cinchona alkaloids (Scheme 71).110,112
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Scheme 71
The  reaction  of  1,1,1,3,3,3-hexafluoroisopropyl  acrylate  153  with  a  selection  of 
aromatic  and  aliphatic  aldehydes  provided  moderate  yields  of  the  corresponding  a- 
methylene-P-hydroxy  esters  154,  albeit  with  excellent  enantioselectivity  (>91%  ee). 
The  modest  yields  obtained  were  as  a  consequence  of the  formation  of a  secondary
product, the dioxanone 155, which is formed via the addition of a second molecule of
112 aldehyde to the zwitterionic species 156 (Scheme 72).
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Interestingly  upon  exchanging  the  hexafluoroisopropyl  moiety  for  a  methyl  group 
enantioselectivity  is  lost  (8%  ee)  along  with  reaction  rate  enhancement  (14  hours 
compared to 1 hour).  Therefore, Hatakeyama concluded that not only did their catalyst 
control  enantioselectivity  and  rate  of reaction,  but  these  were  also  dependent  on  the
119 nature of their activated alkene.
This brief survey of the literature has shown that while tertiary amines are widely used 
to mediate reactions involving a conjugate addition step, there are few instances of an 
amine promoted/catalysed  [3+2]  cycloaddition reaction.  Consequently,  a search of the 
literature  reveals  that  although  amines  have  been  used  to  mediate  1,3-dipolar 
cycloadditions, this has been limited to secondary amines and there does not currently
74appear to  be  a  [3+2]  cycloaddition  mediated  by  a tertiary  amine.83  Secondary  amine 
activation of [3+2] cycloadditions has been intensely explored by MacMillan et al. and 
involves  a  LUMO-lowering  activation  of a,p-unsaturated  aldehydes  (Scheme  73).113 
Iminium ion formation is reversible  and utilises  no more than  20  mol%  of the chiral 
imidazolidinones 157 to provide improved enantioselectivities of up to 93% ee for the 
endo cycloadduct.  Overall the amine catalyses the process by generating a covalently 
bound  and  activated  iminium  species  and  this  approach  has  become  known  as 
organocatalysis.113
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More recently in 2007, Nevalainen et al have developed a prolinol catalyst 158 which 
was  employed  for  [3+2]  cycloaddition  with  mono-substituted  and  di-substituted  a,p- 
unsaturated  aldehydes,  giving  comparable  statistics  to  MacMillan’s  catalyst  (Scheme 
74).  The  advantage  of  this  catalyst  over  Macmillan’s  catalyst  was  that  it  was 
synthesized  in  one  step  from  commercially  available  diphenyl-(S)-prolinol,  whereas 
MacMillan’s catalyst requires multiple steps from phenylalanine methyl ester.114
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75Karlsson et al have also studied an enantioselective [3+2] cycloaddition between cyclic 
a,p-unsaturated  aldehydes  and  nitrones  using  their  chiral  pyrrolidinium  salt  159  as 
catalyst,  providing  the  ^^-isoxazolidine  as  the  major product  in  high  diastereo-  and 
enantioselectivity (Scheme 75).115
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Scheme 75
Given  that  there  appears  at  present  no  precedent  for  tertiary  amine-catalysed  [3+2] 
cycloadditions, further investigation into this area is necessary to understand more about 
this promising reaction.
As it appeared that NEt3 was promoting the previously unsuccessful reaction, it became 
desirable  to  optimise  conditions  and  to  try  to  eliminate/minimise  the  two  other 
undesirable  side  products.  It  is  logical  to  assume  that  if the  reaction  does  proceed 
through  a  Baylis-Hillman  type  pathway  then  the  reaction  should  also  work  with 
catalytic NEt3. This was examined (Table  15), and it was pleasing to observe that the 
reaction works with a sub-stoichiometric amount (10%) of NEt3 in a 76% yield, and also 
that the amount of de-brominated product 148 was also reduced (Table  15, entry 2). It 
was then desirable to test the reaction at room temperature and it was repeated with both 
1.5 eq. of NEt3  (entry 3) or catalytic quantities  (0.1  eq.) of NEt3 (entry 4).  The yields 
obtained  were  excellent  and  it  was  evident  that  performing  the  reaction  at  room 
temperature leads to an approximately 10% increase in the yield of 145/146. As a result 
it was decided that further investigation should be carried out at room temperature.
Entry Temp. NEt3 Nitrone Time Yield/Ratio 
(145/146 : 148 : 147)
1 110°C 1.5 eq. 1.5 eq. 1  hour 68% / 6 : 2.5 :  1
2 110°C 0.1 eq. 1.5 eq. 1  hour 76% 16: 1   :  1
3 RT 1.5 eq. 1.5 eq. 3 days 79% / 14 :  1   :  1
4 RT 0.1 eq. 3 eq. 3 days 92% / 20 : 2 :  1
Table 15
76Due  to  the  impractical  length  of  the  reaction  (3  days),  other  base/catalysts  were 
explored.  It  is  well  known  that  DABCO  has  been  used  in  Baylis-Hillman  reactions, 
therefore this was examined as an alternative to NEt3 (Table 16, entry 1  and 2). With 1.5 
eq.  of DABCO the a-bromo-PFP-vinyl  sulfonate  143 underwent slow decomposition, 
but when a catalytic amount was used the reaction worked extremely well, and provided 
the desired product 145/146 in an excellent yield with a significantly reduced reaction 
time. The other regioisomer 147 was still obtained as a minor product, but even more 
pleasing was the disappearance of the de-brominated isoxazolidine 148. In addition, one 
could  also  use  2,6-lutidine  as  the  base  in  catalytic  amounts,  however  DABCO  was 
preferred as it was an easy-to-handle solid and provided a slightly better product ratio.
Entry Base/Catalyst Time Temp. Yield
Product ratio 
(145/146 :148 :147)
1 DABCO (1.5 eq.) 3 days RT - -
2 DABCO (0.1 eq.) 18 hours RT 89% 23:0:1
3 2,6-Lutidine (0.1 eq.) 18 hours RT 93% 19:0:1
Table 16
Although a larger variety of tertiary amines ought to have been screened, we felt it was 
more beneficial to further explore the scope with efforts concentrated on synthesizing a 
range of isoxazoles. Work continued with the synthesis of a larger selection of PMB- 
nitrones,  all  in  excellent  yields,  through  the  simple  condensation  reaction  of 
hydroxylamine 135 with the desired aldehyde (Table 17).
DCM, NaHCOs, reflux
overnight
Entry
(136) R Yield (%)
a Phenyl 96
b 4-Bromophenyl 80
c 4-Methoxyphenyl 92
d 4-Chlorophenyl 90
e Cyclohexyl 95
f Naphthyl 92
Table 17
77Having established a set of optimum conditions of 1   eq. alkene,  3 eq. nitrone, and 0.1 
eq. of DABCO in toluene at RT, this protocol was employed in the formal  1,3-dipolar 
cycloaddition to synthesize substituted isoxazolidines (Table 18).
O v  ,o
PFPO
Br
143 (1 eq.)
PMB
PhMe, RT
DABCO (0.1  eq.)
PFPO
VB r S
PFPO
\\//  Br
136a-f 
(3 eq.)
PMB PMB
160/161 162
Entry R Time Yield (%) Product ratio 
160/161:162
Product ratio 
160/161
a Ph 18 hours 84 34:  1 2:  1
b 4-Methoxyphenyl 18 hours 94 65 :  1 4:  1
c 4-Chlorophenyl 48 hours * 74 18 :  1 3 :  1
d 4-Bromophenyl 48 hours * 57 11  :  1 5 :2
e Naphthyl 48 hours * 85 19:  1 2:  1
f Cyclohexyl 18 hours 68 4:  1 -
* = DCM added after 24 hours  Table 18
The reaction worked very well and furnished two isolable regioisomeric products which 
significantly  favoured  formation  of  160/161  over  162,  in  particular entry  b.  The  4C 
cycloadduct is  obtained  as  an inseparable mixture of diastereoisomers,  whilst the  5C 
cycloadduct  is  formed  solely  one  diastereomer.  The  only  exception  was  when 
cyclohexyl nitrone 136e (entry f) was employed in the reaction; rather peculiarly the 4C 
cycloadduct  was  obtained  as  a  single  diastereoisomer.  It  is  not  understood  how  this 
happens,  but further investigation is needed in order to establish  whether this pattern 
occurs with other alkyl R groups.  Yields in general were good but it can be seen that 
electron-donating  aryl  groups  furnished  slightly  higher  yields.  A  slightly  prolonged 
reaction  time  was  required  for  entries  c,  d,  and  e;  this  was  presumably  due  to  the 
reluctance  of those particular nitrones to dissolve  in  toluene  at room  temperature,  so 
DCM was added to aid dissolution.  Consequently,  this suggests that the reaction time 
reported  is  not  a  true  reflection  of rate  of reaction  and  so  more  work  is  needed  in 
screening for a more suitable solvent in the future.
Meanwhile aminolysis was attempted on isoxazolidine 160/161a. It was anticipated that 
the reaction would require a greater length of time as aminolysis would not be occurring 
via the  ‘sulfene’  intermediate, but instead through the direct displacement of a leaving
78group. Nevertheless, each attempt has failed to yield the desired sulfonamide 163, as the 
reaction  generates  a  complex  mixture  of  products  which  do  not  correspond  to 
sulfonamide 163 (Scheme 76). The use of TBAC to aid the reaction through formation
It appeared that the  very bulky Br substituent was hindering the  aminolysis reaction, 
and so DBU was added to remove HBr and install the first double bond of the isoxazole. 
However, rapid decomposition of starting material resulted on addition of DBU to the 
isoxazole.
As there  does  not  seem to be  a way of accessing the  sulfonamide  163  for oxidation 
studies  at  present,  oxidation  was  attempted  on  isoxazolidine  160/161a.  Hence, 
isoxazolidine 160/161a was refluxed with DDQ in benzene," and upon NMR analysis 
of the recovered product it was evident that isoxazoline 164 was generated along with 
a-bromo-PFP-vinyl  sulfonate  143  through  cycloreversion  of the  starting  material.  To 
minimise the cycloreversion a room temperature protocol was followed; this produced 
very similar results although we noted a slight improvement in the yield of isoxazoline 
164 after purification (Scheme 77).
68 of an ‘m situ’ sulfonyl chloride was also unsuccessful.
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792.5. Conclusion on Chapter 2
This  study  has  established  that  PFP  vinyl  sulfonate  is  indeed  a  good  dipolarophile 
towards  1,3-dipoles such as nitrones, which was shown by the relative ease by which a 
library of PFP isoxazolidines could be synthesized.
Aminolysis of these isoxazolidines, however, has been troublesome and progress in this 
area has been slow. The realisation that aminolysis proceeds with loss of stereochemical 
integrity at the a-sulfonyl carbon to give two often inseparable diastereoisomers has led 
to  a  new  approach,  which  has  so  far proved  to  be  quite  successful  in  acquiring  the 
required 4C anti cycloadduct. However, this new synthetic route also produces the 5C 
cycloadducts, and though this doesn’t interfere with isolation of the 4C anti product, the 
yield will never be especially high because of these unwanted products.  So after all, it 
seems  the  real  solution  is  still  to  accomplish  aminolysis  of PFP  isoxazolidines  with 
retention of stereochemistry. Therefore, further work is required in this area. 
Nonetheless, it has been demonstrated that this approach can be used to rapidly produce 
interesting functionalised isoxazolidine compounds.
More recently studies directed towards the synthesis of isoxazoles has met with limited 
success.  Direct  oxidation  studies  were  generally  unsuccessful  since  the  isoxazoline 
obtained  was  reluctant  to  aromatise.  When  a  leaving  group  (Br)  is  attached  to  the 
isoxazolidine  ring  to  aid  aromatisation,  it  appears  not  only  to  hinder  the  aminolysis 
reaction but also makes it more difficult to oxidise. Although this new route seems more 
promising,  it  does  require  further  work  on  identifying  conditions  for  effective 
aminolysis of the resultant PFP isoxazolidines.
Our  investigation  did,  however,  uncover  a  novel  tertiary  amine  catalysed  [3+2] 
cycloaddition  which  still  requires  further  investigation.  Solvents,  catalysts  and 
mechanistic studies need to be explored, to further provide optimal conditions and fully 
understand how this reaction works. General applicability of this methodology to other 
electron-deficient olefins also remains to be explored. Overall the reaction remains in its 
infancy and has the potential to be an asset to the field of organocatalysis.
80CHAPTER 3: R&D - Development of new small 
molecule inhibitors of DDAH, ADI, and HIV
The use of small molecules to probe a range of diseases by means of high-throughput 
screening is a concept widely used today in the identification of a lead-compound. Once 
a hit/target  has  been  identified,  further  SAR  is  carried  out  in  an  attempt  to  improve 
activity and hence the effectiveness of the tools, through the design of compounds with 
enhanced  molecular  interactions  and/or  biological  activity.  This  field  of  organic 
chemistry has  been  utilised  efficiently  in  dissecting biological  mechanisms  of action, 
and of course underpins medicinal chemistry. Moreover, the small molecule approach 
has much merit because, where appropriate, it can provide a basis for the development 
of small  molecule  therapeutics.  In  this  chapter our efforts  toward  developing  generic 
small molecule tools for biological studies are presented.
3.1.  Aim
Our investigations have thus far been directed towards the [3+2] cycloaddition of vinyl 
sulfonates and sulfonamides with nitrones (see Section 2.3.). This comprehensive study 
has been used to  synthesise a range of heavily functionalised and  structurally diverse 
small molecules, many of which may possibly possess biological activity (Figure 26).
PFPO
103  124  127  133
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Figure 26
In order to explore their potential in chemical biology these small molecules need to be 
screened against a multitude of enzymes. The main focus of this chapter in which we 
intend  to  apply  to:  (a)  the  arginine  processing  enzymes;  dimethylarginine
dimethylamino  hydrolase  (DDAH)  and  arginine  deiminase  (ADI),  and  (b)  HIV- 
inhibition, in the hope of uncovering a novel series of small molecule inhibitors.
81Dimethylarginine  dimethylamino  hydrolase  (DDAH)  and  arginine  deiminase  (ADI) 
have  a  similar  catalytic  triad  in  their  active  sites  as  cysteine  protease  (see  Section
3.2.5.),116 and  there  has  been  some  literature  precedent  on  the  inhibition  of cysteine
28  30 protease with sulfonates and sulfonamides by Roush et al (Figure 27).  ’
Cbz
X = O, NH
O   O
X = O, NMe
Figure 27
Given  this  precedent  it  was  believed  that  there  was  some  merit  in  screening  some 
sulfonates  and  sulfonamides  against  these  arginine  processing  enzymes.  There  are 
currently  very  few  known  inhibitors  of  DDAH  and  those  are  based  primarily  on 
analogues of arginine (see Section 3.2.3.). Moreover, there are no known inhibitors of 
ADI.
Amprenavir Tipranavir
(43)
Figure 28
In addition, sulfonamide structures have found use in HIV therapy (Figure 28), in which 
for  example  amprenavir  5  and  tipranavir  43  display  an  inhibitory  effect  on  HIV
36 protease.  Furthermore, HIV protease has been the target in the design of more potent 
sulfonamide  inhibitors  through  the  efforts  of Hallberg  et  al,  and  Stranix  et al  (see
•  37  38  m Section  1.1.5.).  ’   Therefore, through a collaborative effort our compounds will also 
be evaluated against HIV, and herein the results of this investigation are presented.
823.2.  Introduction: Control of arginine processing enzymes
DDAH  and  ADI  are  both  important  biological  enzymes  which  are  involved  in 
processing arginine or arginine analogues into citrulline.  Furthermore,  citrulline plays 
an  essential  role  in  the  nitric  oxide  (NO)  cycle  and  in  the  production  of adenosine 
triphosphate  (ATP).117, 118 Thus,  it  would  be  appropriate  here  to  discuss  the  roles  of 
DDAH  and  ADI  in  these  biological  processes  (NO  synthesis  and  ATP  production 
respectively).
3.2.1 NO synthesis and control
Nitric  oxide  (NO)  is  an  important  biological  messenger  that  is  involved  in 
cardiovascular,  gastrointestinal,  respiratory,  and  nervous  system  signalling.  It  is  also 
known  to  regulate  a  variety  of  physiological  processes  such  as  vascular  tone  and 
immune  system  response.  NO  is  biosynthesised  endogenously  from  L-arginine  via  a 
family of enzymes known as nitric oxide synthase (NOS).119 The reaction requires the 
action  of several  co-factors,  specifically nicotinamide adenine dinucleotide phosphate 
(NADPH),  flavin  adenine  dinucleotide  (FAD),  flavin  mononucleotide  (FMN), 
calmodulin,  tetrahydrobiopterin  (BH4)  and  oxygen  to  catalyse  the  formation  of  NO 
along with citrulline through the intermediate TV-hydroxyl-L-arginine (Figure 29).120,1 2 1
NADPH Arginine + 0 2
reductase oxygenase
FMN FAD Fe (haem 
component)
NADP+ + H+  Citrulline + NO
Figure 29
There are two main isoforms of NOS, an inducible Ca2+/calmodulin-independent form 
(iNOS)  and  a  constitutive  Ca2+/calmodulin-dependent  type  (cNOS),  which  can  be 
further sub-divided  into  endothelial  (eNOS)  and  neuronal  (nNOS)  isoforms.  iNOS  is 
present in  activated macrophages  and is  only induced  as  a response  to  inflammatory 
mediators and bacterial endotoxins. eNOS is found in vascular endothelial cells and is 
responsible  for  smooth  muscle  relaxation,  blood  pressure,  and  platelet  aggregation, 
whilst nNOS is located in neural tissue and plays a key role in neurotransmission. All 3
83isoforms share a 50% sequence homology but display differences in their structure, their 
mode  of action,  and  regulatory  aspects.125,122 Associated  with  all  isoforms  is  a  Ca2+ 
binding  protein  (calmodulin),  and  when  Ca2+  levels  are  high  the  Ca2+/calmodulin 
complex  binds  to  and  activates  eNOS/nNOS,  which  in  turn  initiates  NO  synthesis. 
iNOS  is  insensitive  to  Ca2+  levels  as  it  already  contains  a  Ca2+/calmodulin  complex 
bound to the enzyme, and as a result enables it to produce large quantities of NO when 
‘induced’.1 2 1
The  formation  of  NO  starts  with  the  binding  of  acetylcholine  to  receptors  on  the 
endothelial cell membrane, which in turn opens a Ca2+ channel  allowing extracellular 
Ca2+ to enter the cell (Figure 30). As Ca2+ levels rise, NO is produced through arginine 
by activation of NOS, and since NO is a gas it can permeate the plasma membrane and 
rapidly diffuse into neighbouring cells. NO’s mechanism of action involves binding to 
the heme moiety of the enzyme soluble guanylate cyclase (sGC) and stimulating cyclic 
guanosine  monophosphate  (cGMP)  synthesis.  As  cGMP  levels  rise,  a  cascade  of 
reactions subsequently leads to muscle relaxation and therefore increased blood flow.121,
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Although NO synthesis  is important in biological  systems,  overproduction of NO has 
been linked to various diseases and conditions. Specifically, overproduction of NO by
84iNOS  is  connected  to  septic  shock,  nociception,  arthritis,  asthma,  ischaemia,  and 
cerebral  inflammation.  nNOS  over-activity  is  related  to  neurodegeneration  during 
stroke,  migraines,  Parkinson’s  and  Alzheimer’s  disease,  while  increased  activity  of
•  123 eNOS  is  associated  with  acute  inflammation  in  various  tissues  and  diabetes. 
Therefore, there is an obvious advantage for preventing or minimising NO production 
through the inhibition of NOS. Moreover, as each isoform of NOS possesses a different 
regulatory role, selective inhibition of each isoform is highly desirable.
The first NOS inhibitor identified was monomethylated L-arginine (L-NMMA)  165, a 
naturally occurring amino acid that is present in cell cytosol, tissue, and plasma. Two 
other  analogues  of L-NMMA  that  are  also  present  in  submicromolar  concentrations 
were  named  asymmetric  dimethylated  L-arginine  (ADMA)  166  and  symmetric 
dimethylated L-arginine (SDMA) 167 (Figure 31).124,125
COOH COOH COOH
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Figure 31
All 3 methylated arginine derivatives are synthesised endogenously by the action of the 
enzyme protein arginine methyltransferases (PRMTs) on arginine residues in proteins. 
The number of methyl groups that are transferred to the guanidine nitrogens of arginine, 
determines  whether an  asymmetric  (type  1)  or symmetric  (type  2)  methyl  arginine is 
formed.124,125 However, only L-NMMA and ADMA are competitive inhibitors of NOS 
whilst SDMA is inactive; and furthermore, as mammalian concentrations of ADMA are 
ten  times  higher  than  L-NMMA,  it  is  presumed  this  plays  a  greater  role  in  NOS 
inhibition. Although since L-NMMA and ADMA inhibit all 3 isoforms of NOS, there is 
a greater need for inhibitors which are able to discriminate between each isoform.125 A 
few examples  of other NOS  inhibitors that have been  evaluated  are  shown in Figure 
32.123
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The substrate based inhibitor 1400W has shown great selectivity for iNOS over eNOS 
(10000 fold), and iNOS over nNOS  (30 fold); however due to toxicity problems it has 
not been developed as a drug candidate. Toxicity of GW273629, GW274150, and the 
fo's-isothiourea  1,4-PBITU  also  prevented  their  development  as  selective  NOS 
inhibitors.  Clotrimidazole does  not exhibit toxicity,  but there  are issues  with its NOS 
isoform selectivity in vivo, hence limiting its therapeutic potential.123 
As  there  appear to be  very few potent  and  selective  clinically  viable  NOS  inhibitors 
available, new strategies for NO inhibition need to be investigated.  Recently it has been 
discovered  that  control  of  NO  levels  could  be  possible  through  regulation  of  the 
endogenous methylarginines L-NMMA and ADMA.124
3.2.2.  Control of NO via the ADMA/DDAH pathway
It is well known that NO generation can be competitively inhibited by the endogenous 
methyl arginines L-NMMA and ADMA. Therefore, control of L-NMMA and ADMA 
levels could provide an indirect route for the modulation of NO levels. L-NMMA and 
ADMA  concentrations  are  further  governed  by  the  enzyme  dimethylarginine 
dimethylamino hydrolase (DDAH), which catalyses their catabolism into citrulline and 
monomethyl or dimethylamine respectively (Figure 33). SDMA is unaffected by DDAH 
and is cleared from our system by urinary excretion.123'125
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As a result, through the inhibition of DDAH the resultant rise in ADMA and L-NMMA 
levels will exert a negative effect on NOS.  Hence, pathological levels  of NO will be 
reduced,  alleviating  the  symptoms  of NO overproduction.  Leiper et al  discovered in 
1999 that there are two isoforms of mammalian DDAH:  DDAH  1  and DDAH 2.  The 
authors report that DDAH  1   shares 62% homology with DDAH 2 through their amino 
acid sequence, and both isoforms inhibit L-NMMA and ADMA but not SDMA. DDAH 
1  is present primarily in the brain, liver, kidney, skeletal muscle, and pancreas, organs 
which  are  generally  associated  with  nNOS.  DDAH  2  is  expressed  predominantly  in 
highly vascularised tissues  such as the heart, placenta,  and kidney,  indicative of cells 
governed by eNOS.126,127 ’128  Hence,  it could be  assumed  that through  the  selective 
inhibition of one isoform of DDAH over the other,  selective inhibition between NOS 
isoforms could also be achieved. This indirect method for controlling excess NO levels 
over  a  more  direct  NOS  inhibitor  also  offers  an  added  advantage  whereby  NO 
production will not be completely blocked, as it is generally accepted that ADMA and 
L-NMMA inhibition of NOS is not likely to exceed 30%.123 The danger associated with 
complete NO inhibition is that decreased levels of NO are also linked to renal failure, 
cardiovascular and neurological  diseases.125 Thus,  a controlled level of NO inhibition 
without disrupting NO-mediated processes is highly desirable and this is more likely via 
DDAH inhibition.3.2.3.  Inhibitors of DDAH
Apart  from  the  endogenous  inhibitors  of  DDAH  which  comprise  L-citrulline,  L- 
homocysteine, S-nitroso-L-homocysteine, and Zn2+, there are very few known literature 
examples of synthetic inhibitors for DDAH (Figure 34).128 Vallance et al.  discovered 
the  first  selective  but  non-potent  inhibitor,  4124W,  with  an  IC50 of  1.5mM  in  1996 
(Figure 34).125
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4124W,  a  chain  shortened  L-NMMA  analogue,  was  able  to  inhibit  DDAH  with  no 
direct  affect  on  NOS.  However,  this  substrate  was  not  capable  of  discriminating 
between  each  isoform  of DDAH,  and  this,  coupled  with  its  low  potency,  limited  its 
usage as an indirect NO inhibitor. Conversely, it did provide a good lead molecule from
125  129 which further substrate based inhibitors could be designed.  ’
More  recently  in  2005,  Rossiter  et al.  developed  secondary  analogues  of 4124W  as 
more potent inhibitors for DDAH. It was from their library of compounds synthesized 
that 3 good inhibitors of DDAH with IC50 values < 30pM were identified (Figure 35).
129
NH2
168, IC50 27fiM  L-257 (169), R = H, IC50 22^M
L-291 (170), R = Me, IC50 20^M
Figure 35
Common  to  all  three  inhibitors  was  the  presence  of a  2-methoxyethyl  group  on  the 
terminal guanidine nitrogen. However, whilst ex vivo testing reveals that all 3 inhibitors 
are selective for DDAH over each NOS isoform, these compounds lack DDAH isoform 
specificity.  Hence,  it  has  not  been  possible  to  establish  the  relative  importance  of 
DDAH  1   and 2 in the regulation of L-NMMA and ADMA levels.129 Nonetheless, the 
most promising inhibitors identified (169 and 170), were used to determine if DDAH 
inhibition was retained in vivo.130
-citrulline  L-homocysteine  S-nitroso-L-homocysteine  4124W
Figure 34
88As  inhibition  of  DDAH  should  give  rise  to  an  elevated  concentration  of  ADMA,  a 
preliminary  study  was  conducted  and  involved  giving  rats  a  60mg/kg  intravenous 
injection of each inhibitor. The efficiency of DDAH activity after 4 hours (i.e. the mean 
ADMA/SDMA  ratio)  was  recorded  and  in  comparison  to  saline  treated  rats,  it  was 
shown  that  both  inhibitors  were  well  tolerated  and  gave  rise  to  raised  blood  ADMA 
levels (Table  19). A more in-depth time course study was conducted with inhibitor 170, 
and  revealed  that  after  a  60mg/kg  intravenous  dose  of  170  the  ADMA  concentration 
was significantly raised after 30 mins peaking at around 2 hours (approx.  1.5pM), this 
was  followed  by  a  steady  decrease  in  ADMA  concentration  (approx.  1.1 pM  at  5 
hours).129’130
4
Control  L-257 (169)  L-291  (170)
Treatment (60 mg/kg)
Experiment 
(4 hours)
[ADMA], pM [SDMA], pM Mean
[ADMA]/[SDMA]
Control 0.665 ± 0.023 0.350 + 0.026 1.93
L-257 (169) 1.292 + 0.124 0.374 ± 0.036 3.50
L-291  (170) 0.870 + 0.092 0.318 + 0.013 2.73
Table 19
Having shown that inhibition of DDAH occurred in vivo and that it was a key regulator 
of ADMA concentrations, the functional relevance of DDAH in vivo  was probed  with 
methyl ester 170 (Figure 36).  As  DDAH is an indirect modulator of NO synthesis and 
effectively  vasodilation  and  vasoconstriction,  the  effect  of  lOOpM  L-291  (170)  on 
mouse  aortic  rings  was  examined  in  the presence  of phenylephrine  and  acetylcholine
89(Figure 36 i and ii). The authors report that the respective blood vessel contraction and 
relaxation  in  response  to  increased  concentrations  of stimuli  is  indicative  of reduced
130 levels of endogenous endothelial NO.
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In addition, the hemodynamic effects resulting from chemical DDAH inhibition in vivo 
was explored (Figure 36 iii and iv). A 30mg/kg injection of 170 was administered to 
rats, and after 2.5 hours a resulting rise in systemic vascular resistance and mean arterial 
blood pressure, and decreased heart rate and cardiac output was observed. Finally, when 
iNOS  expression  was  induced  in  rats,  the  rapid  onset  of hypotension  brought  about
90through increased NO production, was directly alleviated upon treatment with a DDAH 
inhibitor 170  (Figure  36 v).  Therefore,  as a result of these in vivo studies the authors 
have been able to demonstrate, that a loss in DDAH activity or raised ADMA level is
130 associated with an increased cardiovascular risk and endothelial dysfunction.
In  2005  Stone  and  co-workers  developed  an  irreversible  small  molecule  inhibitor  of 
DDAH  (Figure  37).  2-Chloroacetamidine  171  was  reported  to  exhibit  a  K\ of 3.1  ± 
0.8mM, however activity was not limited to DDAH, as peptidylarginine deiminase was 
also  inactivated  (Kx   =  20  ±  5mM).131  More  recently,  virtual  screening  has  been 
employed  by  Selwood  et  al.  as  an  investigative  tool  in  the  discovery  of  DDAH 
inhibitors  without  the  need  for  high  throughput  screening.  By  utilising  the  crystal 
structure  of  DDAH,  a  series  of  computer  aided  processes  were  applied  (namely 
physicochemical filtering, virtual screening, and hit analysis) to a database of 308,000 
compounds.132 Compounds with the indolylthiobarbituric acid skeleton were identified 
as potential inhibitors, and subsequently a variety of commercially available analogues 
were tested for activity. Of these, 172 and 173 displayed good activity against DDAH, 
with 173 the most potent DDAH inhibitor known to date (Figure 37). The authors also 
reported that synthesis of the most active compounds 172 and 173 was carried out, and 
that they maintained biological activity, and thus confirming their results.132
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3.2.4. ADI
ADI belongs to the amidotransferase family of enzymes  and is ultimately responsible 
for  the  irreversible  catabolism  of arginine  to  citrulline  and  ammonia.132,133 This  key 
reaction is the first step of the arginine dihydrolase pathway, which plays a fundamental 
role in the generation of ATP under anaerobic conditions  (Scheme 78).  The citrulline 
by-product from  arginine hydrolysis undergoes further degradation into  ornithine  and 
carbamoyl phosphate, in a reaction catalysed by ornithine transcarbamylase (OTC). The
91final  step  involved  in  ATP  production  is  the  carbamate  kinase  (CK)  catalysed 
phosphorylation of adenosine diphosphate (ADP) by carbamoyl phosphate.134
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ADI is found only in prokaryotes and the primitive eukaryote Giardia intestinalis, thus 
is largely responsible for supplying these organisms with a source of energy (ATP).135 
For  this  reason,  inhibition  of  ADI  presents  itself  as  a  possible  antibacterial/anti­
protozoal  drug  target  for treatment  against various  pathogens.  Giardia  intestinalis  in 
particular  is  a  prevalent  intestinal  pathogen  that  causes  symptoms  of  giardiasis, 
vomiting,  and  diarrhoea.  The  rising  emergence  in  drug  resistant  strains  of  Giardia 
intestinalis means that current treatments are of limited expediency,  and consequently 
ADI represents an attractive target for chemotherapeutic intervention in the treatment of 
giardial infection.135 More recently it has been reported that ADI may also play a part in 
apoptosis,136 angiogenesis,137 and act as a tumour growth inhibitor.138 In addition, ADI 
processing of intestinal arginine can have a negative effect on NO production, due to 
competition for endogenous arginine between ADI and NOS. Therefore, the action of 
NOS and NO mediated processes may be blocked, and Thomas et al. suggested that this 
can be advantageous in neutralising the toxic effects of tumour necrosis factor-a (TNF- 
a) and endotoxins.133,139
92Although inhibition/control of ADI exhibits the potential to be of enormous benefit in 
the  treatment  of  various  diseases,  there  are  currently  no  known  inhibitors  of  ADI. 
Therefore, there exists a pressing need for the development of ADI inhibitors,  so that 
the role of ADI (and consequently arginine catabolism) in various disease states could 
be better understood.
3.2.5.  Structural and mechanistic insight into DDAH and ADI
DDAH and ADI are both very similar enzymes that catalyse the hydrolysis of arginine 
by the breaking of the same equivalent guanidino C-N bond. Leiper et al identified that 
there were considerable  similarities between the protein sequences  of DDAH I/II and 
ADI.  They report that ADI derived from Pseudomonas putida  shared 48%  homology 
with human DDAH  I and 31%  to DDAH II.  Additionally,  a 70%  level  of homology 
with each DDAH isoform could be observed by considering a 72-residue domain within 
the protein sequence (residues 123-194 DDAH I and 121-192 DDAH II).126
Comparisons  of  the  X-ray  crystal  structures  of  both  enzymes  reveal  that  there  are 
further  similarities  between  DDAH  and  ADI.  The  crystal  structure  of  DDAH  from 
Pseudomonas aeruginosa (Pa) was first elucidated by McDonald et al. in 2001;140 those 
of  ADI  from  Pseudomonas  aeruginosa  and  Mycoplasma  arginine  followed 
simultaneously in 2004 by Herzberg et al.134 and Das et a/.133 respectively (Figure 38).
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Figure 38
From these crystal  structures it was revealed that the core structure of both enzymes is 
made up of 5 repeats of a (3pa(3 motif, presenting a barrel-shaped structure that encloses 
the  active  site.  Furthermore,  it has  been  revealed  that the  active  site of both enzymes 
contains  a  similar catalytic  triad  comprising  a  cysteine-histidine-glutamine/asparagine 
unit, which can be seen by superimposition of their active site residues (Figure 39 B).125’
133, 134,140
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It  has  been  reported  that  due  to  the  structural  similarities  between  DDAH  and  ADI,
128 these  enzymes  share  a  common  enzymatic  reaction  mechanism.  "  In  the  substrate 
binding pocket of DDAH and ADI there exists a small  pore which allows entry of the 
substrate  (i.e.  ADMA,  L-NMMA,  and  arginine).  A  series  of H-bonds,  covalent  links, 
and  hydrophobic  interactions  are  able  to  stabilise  the  substrate,  which  upon  binding 
causes  a conformational  change in  the enzyme and closure of the pore.  Hydrolysis of 
the  substrate  intermediate produces  citrulline  and  other by-products  which  are  able  to 
diffuse away. Finally, it is believed that citrulline is expelled from the active site upon 
another conformational change of the enzyme from a closed to an open state.125,133
DDAH: ADI:
Asp271
Glu65 His162
Glu114
O
Cys398
Asp161
I  ^ 2
H— (©•n
N -H
oy
H  N
His269
Asp66
O N-H
Glu213
NH3
Cys249
O ©
Figure 40
95A more detailed mechanism was proposed by Vallance et al. and Das et al., whereby all 
three residues of the catalytic triad are involved (Figure 40).  In both DDAH and ADI, 
the initial step involves nucleophilic attack of the cysteine thiol on the carbon centre of 
the guanidino moiety.133, 140 A tetrahedral transition state is generated which collapses to 
provide  thiouronium  174  with  release  of ammonia  or  alkylamine  (Scheme  79).  The 
second  step  entails  another nucleophilic  attack,  this  time by  water  to  form  a second 
tetrahedral intermediate. Citrulline is formed upon cleavage of the covalent C-S cysteine 
link, thus freeing the enzyme for further catalysis.125,141,142
Citrulline
R = (CH2)3CH(NH3+)COO-
R' = H or Me  174
Scheme 79
More recently,  the crystal  structures  of the DDAH inhibitor L-257  169  and citrulline 
bound to active site of DDAH-1 have been resolved by McDonald et al.  (Figure 41).130 
Diagram  A represents  the experimental  electron  density that  169  occupies  inside  the 
human DDAH-1  active site, and also reveals that a water molecule is co-bound within 
the  cavity.  Diagram  B  highlights  the  ability of both  L-257  169  (cyan)  and  citrulline 
(yellow)  to  anchor to  the DDAH  active by an  H-bonding  interaction  with Asp78.  In 
addition,  it  shows  that  the  aliphatic  backbones  of  both  compounds  are  in  close 
proximity to Phe75, and that an additional H-bonding interaction is present between the 
amino-nitrogens to Asp72 and the oxygen atom of residue 29.  A notable difference is 
the  inhibitor  induced  change  within  the  active  site,  as  shown  by  the  change  in 
disposition of the His 172 and Argl44 side chains. This creates a small pocket within the 
binding site which allows the extra bulk of the ether moiety to be accommodated, thus 
preventing hydrolysis of the substrate.130
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It  has  been  reported  that  cysteine  proteases,  such  as  those  belonging  to  the  papain 
family, contain a three residue catalytic triad in their active sites comprising of cysteine- 
histidine-asparagine.125,143 ’144 This  displays  analogy  with  the  catalytic  triad  observed 
with  DDAH  and ADI (cysteine-histidine-glutamine/asparagine),  which  means cysteine 
protease could potentially exhibit a comparable enzymatic reaction mechanism. In fact, 
it is known that cysteine proteases catalyse the hydrolysis of peptide (amide, ester and 
thiol  ester)  bonds  via  the  action  of  a  nucleophilic  cysteine  thiolate.  Two  tetrahedral 
transition  states  are  generated en  route to the product with concomitant release of the 
enzyme, which suggest that this mechanistic pathway is much akin to that displayed by 
ADI and DDAH.144
As  sulfonates  and  sulfonamides have been  successfully utilised by Roush  et al.  in  the 
inhibition of cysteine protease (see Section  1.1.5.),28,30 it was envisaged that the related 
sulfonates and sulfonamides synthesised previously (see Section 2.3.3. and 2.3.5.) could 
be of potential interest as DDAH/ADI inhibitors. Accordingly, a range of products was 
biologically  evaluated  against  the  aforementioned  enzymes  and  the  results  of  these 
endeavours presented.
973.3.  Biological results for DDAH/ADI
Further to our synthetic investigations the following biological assays were conducted 
on  our  compounds  by  Leiper  and  co-workers,  and  the  biological  results  that  were 
obtained presented and analysed in this chapter.
3.3.1.  Testing on PFP sulfonate esters
A  selection  of PFP  sulfonate  esters  were  evaluated  and  initially  assayed  against  the 
isolated bacterial DDAH and ADI expressed from Pseudomonas aeruginosa (Pa)  at a 
concentration of 500 pM, in order to establish whether or not the compounds displayed 
any activity.
The assays run by Leiper et al  were performed by incubating our compounds with the 
required enzyme for a period of 5 minutes, thus allowing sufficient time for the inhibitor 
to bind to the enzyme.  The substrate  (ADMA for DDAH  and L-arginine for ADI)  is 
then added, and a measure of their conversion into citrulline is recorded with the aid of 
colour developers  (see Supplementary data).  If the compound is  a good inhibitor less 
citrulline is produced,  and as a result the intensity of the colour displayed is reduced. 
The  colour  displayed  is  then  compared  against  that  of a  control  experiment  (i.e.  no 
inhibitor) and recorded as a percentage.
It was pleasing to see that at a concentration of 500 pM all compounds showed greater 
than  40%  inhibition,  with  a  small  selection  reaching  90%.  The  compounds  were 
subjected to further testing at a much lower concentration of 50 pM and the results are 
shown in Table 20.
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%  inhibition at 50 pM
Entry R DDAH ADI
1 Ph 30 14
2 p-N02Ph 76 35
3 /7-Allyloxy-Ph 44 14
4 /?-MeOPh 19 -
5 o-FPh 10 -
6 m-ClPh 36 -
7 p-ClPh 28 -
8 <9-BrPh 1 9
9 ra-BrPh 58 27
10 Naphthyl 56 33
11 2-Furyl 63 27
12 2-Br-Furyl 65 38
13 Cyclohexyl 40 26
14 Cyclopropyl 41 15
- = compounds not tested  T able 20
It was encouraging to see that a handful of PFP sulfonate esters retained a good level of 
inhibition,  with  a  greater effect  seen  against  DDAH  over  ADI  at this  concentration. 
There is no clear SAR, although it was noticed that ortho substituted aromatics (entries 
5 and 8) gave poor results while furyl R groups (entries  11  and  12) showed good levels 
of inhibition. The most active compounds, entries 2, 9,  10,  11, and  12 were taken and 
further evaluated to provide IC50 values (Table 21).
Entry R IC50 |iM (DDAH) IC50 pM (ADI)
2 p-N02Ph 21 74
9 m-BrPh 58 -
10 Naphthyl 32 167
11 2-Furyl 34 246
12 2-Br-Furyl 16 103
Table 21
99IC50 values  show  that  entries  2,  9,  10,  11,  and  12  still  retained  good  activity  against 
DDAH,  while entries  2  and  12  show  moderate  activity  against  ADI.  However,  as  the 
first inhibitors of ADI identified, this will provide a platform on which further design of 
more potent small molecule inhibitors of ADI will be based.
3.3.2.  Testing on sulfonamides
Having  revealed  that  PFP  sulfonate  esters  exhibit  an  inhibitory  effect  on  DDAH  and 
ADI,  an  analogous  study  on  sulfonamides  was  conducted.  As  previously,  all 
compounds’  inhibitory  effects  were  initially  evaluated  at  500  pM  and  then  further 
scrutinised at 50 pM.  It soon became apparent that sulfonamides showed a comparable 
level of inhibition at 500 pM with PFP sulfonate esters. However, the level of inhibition 
at 50 pM was not maintained, except for in a few examples (Table 22 and 23).
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R Entry DDAH Entry DDAH Entry DDAH
Ph 1 46 14 15 27 23
p-N 02Ph 2 16 15 21 28 50
p-MeOPh 3 14 16 0 29 21
o-FPh 4 15 17 1 30 33
o-ClPh 5 7 18 12 31 -
ra-ClPh 6 18 19 0 32 -
p-ClPh 7 10 20 1 33 23
o-BrPh 8 3 21 9 34 38
m-BrPh 9 18 22 21 35 25
/7-BrPh 10 2 23 25 36 -
Naphthyl 11 22 24 - 37 -
2-Furyl 12 26 25 - 38 -
2-Br-furyl 13 38 26 32 39 -
- = compounds not tested  Table 22
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R Entry ADI Entry ADI Entry ADI
Ph 1 24 14 10 27 9
p-NCbPh 2 8 15 9 28 23
p-MeOPh 3 5 16 0 29 10
o-FPh 4 26 17 10 30 22
0-ClPh 5 0 18 15 31 -
m-ClPh 6 35 19 13 32 -
p-ClPh 7 28 20 9 33 2
o-BrPh 8 9 21 0 34 35
m-BrPh 9 62 22 23 35 13
p-BrPh 10 16 23 0 36 -
Naphthyl 11 65 24 - 37 -
2-Furyl 12 9 25 - 38 -
2-Br-furyl 13 6 26 17 39 -
- = compounds not tested  Table 23
Overall,  it  seemed  that  while  PFP  sulfonate  esters  produced  better  results  against 
DDAH,  sulfonamides  showed  better  promise  against  ADI.  Additional  patterns  did 
emerge from  within the 3  sets of sulfonamides tested, in that sulfonamides possessing 
the 4-methylbenzylamine moiety provided better results  with  ADI especially entries  9 
and  11  (Table 23), while sulfonamides processing the ethanolamine moiety gave better 
inhibition against DDAH, entries 28 and 34 (Table 22). Furthermore, sulfonamides with 
the  tert-butyl  amine  moiety  were  generally  poor  for  both  ADI  and  DDAH,  possibly 
resulting from the restricted conformation of the compound due to the bulk of ten-butyl 
group; thus suggesting that this group would not be suitable in further inhibitor design. 
Other general patterns that could be spotted were the poor levels of inhibition observed 
for the 4-methylbenzyl  and  te/7-butyl  sulfonamides  containing ortho  functionalised  R 
groups.  Interestingly, this effect was not observed with the ethanolamine sulfonamides. 
The p-MeOPh, p-ClPh, and p-BrPh groups also exhibited very modest inhibitory effects 
regardless  of the  amine  moiety present,  and therefore  would  be  excluded  from  future 
SAR studies.
IC50 values  were  determined  for  some  of the  most  active  sulfonamides,  with  entry  2 
showing the greatest potency against DDAH and entry 1  with ADI (Table 24).
101IC50 |JM (ADI) IC50 |iM (DDAH) Entry
Table 24
Through examination of the IC50 values  (Table 21  and 24), it is possible to infer that 
retention of the 2-bromofuryl and p-NC^Ph R groups might be appropriate for the future 
design of inhibitors for DDAH. This conclusion is drawn from the observation that both 
PFP  sulfonate  esters  and  sulfonamides  which  incorporate  these  two  groups  have  the 
shown the most promising IC50 values of < 35jiM.
3.3.3.  Nature of DDAH inhibition
Having identified  a novel  series  of active PFP sulfonate esters  and  sulfonamides,  the 
nature of the inhibition against DDAH was investigated by considering the reversibility 
and time-dependence.
In supplementary experiments it was shown that the inhibitory effect of PFP sulfonate 
ester 103o could be somewhat reversed upon increasing the concentration of ADMA, 
and  therefore  indicating  that  our  compounds  exert  their  effect  through  competitive 
inhibition (Figure 42 A). The great excess needed to reverse inhibition suggests that the 
inhibitor  has  a  greater  binding  affinity  for  the  active  site  than  ADMA.  In  a  time- 
dependent experiment, isoxazolidine 103d maintained a near constant level of inhibition 
over a period of 80 minutes at a concentration of lOpM (Figure 42 B). This confirms 
that these inhibitors do not bind irreversibly to the active site via a covalent interaction, 
as  an  increase  in  the  time-dependent  inhibition  is  normally  seen  as  the  inhibitor 
becomes increasingly irreversibly bound over time.
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In conclusion,  a new class of small  molecule inhibitors of DDAH and ADI have been 
revealed which bind reversibly to the  active site.  However,  there  still  remains  a lot to 
discover about their mode of action, and how these compounds sit in the enzyme active 
site. Therefore, future work involves identifying compounds with increased potency via 
a combination of SAR, molecular modelling and X-ray crystallography.
Biological  investigations of our PFP sulfonate esters and sulfonamides were continued 
with their evaluation against HIV.
1033.4.  Introduction: HIV
Human immunodeficiency virus (HIV) is a prevalent retrovirus that leads to failure of 
the immune system,  and eventually a condition known  as acquired immunodeficiency 
syndrome (AIDS). It was first discovered in late 1970s when the patients displaying the 
signs  of  suffering  from  lymphadenopathy,  opportunistic  infections  (i.e.  retinitis, 
meningitis),  and  a  range  of  unusual  cancers  (non-Hodgkin’s  lymphoma)  appeared. 
However, it wasn’t till  1983 that Montagnier and colleagues isolated a retrovirus from 
the  lymph  nodes  of  a  patient  suffering  from  lymphadenopathy,  which  was  later 
identified and named HIV-1. A second immunologically distinct human retrovirus was 
isolated in 1986 and labelled HIV-2.'45’146
HIV  infection  is  a  global  pandemic,  and  up  until  January  2006  it  has  claimed  an 
estimated  25  million  lives  since  it  was  first  discovered.  HIV  exerts  its  detrimental 
effects on its human host by primarily reducing immune system levels of helper T cells 
(in particular CD4+),  macrophages,  and dendritic cells.  As  host immunity is  lowered 
this  leave  the  body  open  to  opportunistic  infections  and  ultimately  AIDS.  It  is 
understood that HIV reduces CD4+ antigen levels through three mechanistic pathways: 
(1) direct viral killing of infected cells, (2) increasing rates of apoptosis in infected cells, 
and (3) killing of CD4+ cells by the cytotoxic CD8 antigens.147,148
3.4.1.  Classification and structure of HIV
HIV is a retrovirus belonging to the Lentivirus genus, which is characterised by a slow 
unremitting  disease  that  targets  hematopoietic  cells  (lymphocytes  and  macrophages). 
Lentiviruses  are  RNA-containing  viruses  that  convert  its  RNA  into  doubly  stranded 
DNA by means of a virally-encoded reverse transcriptase enzyme after infection. This 
enables the viral genome to become integrated into the hosts DNA and replicated by the 
host, spreading the infection to healthy cells. It is also possible that following infection 
the virus remains in a latent state,  and normal  cellular function is  maintained until  it 
becomes active.146,148
There  are  two  known  types of HIV  infection,  HIV-1  and  HIV-2.  HIV-1  is  the  more 
virulent form with a higher rate of transmissibility, whilst HIV-2 displays a lower level 
of virulence. In addition, HIV-2 causes a slower decline in CD4+ T-lymphocyte levels 
compared to HIV-1, and exhibits a prolonged period of asymptomatic infection with a 
considerably lower mortality rate.145
104The structure of HIV is approximately  120nm in diameter and is generally spherical  in 
nature  (Figure  43).  It  comprises  a  viral  protein  core  surrounded  by  a  matrix  whose 
purpose  is  to  maintain  the  integrity of the  viral  particle.  This  is  all  encased  in  a  viral 
envelope constructed from two phospholipid layers, and embedded in this is a series of 
proteins  known  as envelope glycoproteins  (env).  These env glycoproteins exist on  the 
particle surface as gp41/gpl20 trimers,  which form complexes that enable binding and 
attachment of the virion particle to the target cell.147,149
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The viral protein core is composed of a shell of capsid protein which encompasses two 
single  strands  of RNA  in  close  association  with  nucleocapsid  proteins  and  a  string  of 
viral-encoded  enzymes  (reverse  transcriptase,  integrase,  protease,  and  ribonuclease). 
The  RNA  genome  is  responsible  for  coding  the  HIV’s  nine  genes  required  for 
infectivity.147 Of these nine genes, three of these HIV encoded proteins include pol, and 
the  two  structural  proteins  gag,  and  env.  Pol  is  responsible  for  coding  the  enzymes 
reverse transcriptase, integrase, and protease; while Gag codes for the polyproteins that 
form the matrix, capsid and nucleocapsid. The Env gene codes for gpl60, a protein that 
is eventually broken down to give gpl20 and gp41, the glycoproteins that comprise the 
envelope polyproteins.  In addition, there remain  six other genes that collectively make 
up the accessory proteins,  and these are tat, rev, nef, vif, vpr,  and vpu (vpx in  HIV-2). 
These  regulatory  proteins  are  responsible  for  promoting  the  HIV  infection  of  cells, 
facilitating replication, and the ability to cause disease.145,147
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The rise in HIV research over the last 25 years has led to a better understanding of the 
HIV-1  life cycle. Although there still remains a lot to discover about each fundamental 
process involved in HIV-1 replication, its mode of action can be divided into 3 distinct 
stages:  (1)  binding  and  entry  into  cell,  (2)  replication  and  transcription,  and  (3)
157 assembly and release (Figure 44).
The life cycle of HIV-1  begins with adsorption of the virus particle to the surface of a 
target  cell  (macrophages  and  CD4+  cells).  Retroviral  entry then  involves  a  series  of 
intricate  multi-step  mechanisms,  which  commence with envelope  glycoprotein  gpl20 
recognition of the primary receptor CD4+ (Figure 44).150 This high-affinity interaction 
brings about a structural change which allows a second interaction between gpl20 and a 
P-chemokine  co-receptor  (either  CCR5  or  CXCR4).15 1  An  additional  conformational 
change results  in  exposure and  activation of the gp41  glycoprotein.  The  gp41  fusion 
peptide is able to penetrate the cellular plasma membrane of the target cell triggering 
fusion with the viral envelope, and the subsequent delivery of the viral capsid into the 
cytoplasm.149,152
Release of the HIV capsid into the cytoplasm initiates a process known as uncoating, 
whereby  the  viral  core  undergoes  a  partial  and  progressive  disassembly  generating 
reverse-transcription complexes (RTCs). It is here that the enzyme reverse transcriptase 
catalyses the formation of a reverse transcribed doubly stranded viral DNA intermediate 
(vDNA). This vDNA in close association with the viral proteins:  reverse transcriptase 
(RT),  matrix  protein  (MA),  integrase  (IN),  and  viral  protein  R  (Vpr)  form  a  pre­
integration complex (PIC) that travels across the cytoplasm to the cell nucleus.149' 153
The mechanism of PIC  nuclear import or how it is regulated  is not well  understood; 
however, there have been several postulations which involve the viral proteins MA, IN, 
and  Vpr.  The  most  widely  accepted  mechanism  however,  is  that  the  PIC  and  its 
components are karyophilic, recruiting the necessary cellular transport proteins required 
to cross the nuclear pore. It is believed MA, IN, and Vpr all contain nuclear localisation 
signals  (NLS)  that  interact  with  importin,  an  important  nucleocytoplasmic  shuttling 
receptor that has been implicated in HIV-1 PIC nuclear import.149,154
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107An additional distinguishing feature of HIV is its remarkable ability to replicate in non­
dividing cells. Most retroviruses (i.e. gamma-retroviruses) gain entry into the nucleus of 
proliferating  cells  during  mitosis  when  the  nuclear  membrane  breaks  and  divides. 
However, HIV can also utilise an active nuclear translocation mechanism to gain access 
to the nucleus of non-proliferating cells. Given that only a small number of T-cells in 
the  human  body  divide,  this  characteristic  of  HIV  may  explain  why  it  has  a  high 
replication  rate,  thus  ultimately,  maintaining  viral  transmission  and  disease 
pathogenesis.155
Inside  the  nucleus  the  viral  DNA  is  integrated  into  the  chromosomal  DNA  of  the 
infected  cell  generating  a  pro  virus.  This  process  is  mediated  by  the  viral  enzyme 
integrase (IN), and the resulting provirus can now remain in a dormant stage or go on 
actively  promoting  HIV  infection.149, 153 In  the  presence  of the  cellular  transcription 
factor NF-kB,  the integrated copies  of HIV DNA are transcribed to mRNA by RNA 
polymerise II. This mRNA may remain unspliced or alternatively be spliced to provide 
smaller  strands  of  RNA,  that  are  eventually  translated  in  the  cytoplasm  into  the 
structural protein env and the accessory proteins tat, rev, nef, vif, vpr, and vpu. As rev 
levels  accumulate  mRNA  splicing  is  inhibited,  and  furthermore  mediates  mRNA 
transport from the nucleus to the cytoplasm.145,156
Here in the cytoplasm the endoplasmic reticulum processes the env polyprotein (gpl60) 
into  the  two  envelope  glycoproteins  gp41  and  gpl20,  while  the  gag  and  gag-pol 
polyproteins  are  synthesised on free cytoplasmic  ribosomes.  These  glycoproteins  and 
polyproteins are transported to the inner surface of the plasma membrane along with the 
viral  RNA,  where  the  progeny  virus  particle  begins  to  ‘bud’  from  the  host  cell. 
Complete  ‘budding’  from the host cell  leads to the formation of an immature virion, 
containing the gag and gag-pol polyproteins. Proteolytic processing of these enclosed 
polyproteins  by  HIV  protease  into  functional  HIV  proteins  and  enzymes  creates  a 
mature HIV virion, which is now able to instigate a new cycle of infection.145,147
3.4.3.  Treatment of HIV with anti-retroviral drugs
Considerable progress has been made in the treatment of HIV infection in the last ten 
years,  however  there  remains  at  present  no  cure  or  vaccine  for  HIV.  Current  HIV 
chemotherapy known as highly active anti-retroviral therapy (HAART) involves using 
anti-retrovirals agents to delay the onset of HIV by suppressing/inhibiting its replication
108cycle.147,157 However, treatment needs to be continued life-long, and once treatment is 
interrupted  viral  replication restarts  and the  symptoms  of HIV  infection  resume.  The 
problems  associated  with  current  anti-retroviral  drugs  are  the  toxic  side  effects  they 
exhibit  from  long-term  usage;  for  example  rash,  nausea,  and  severe  suppression  of 
hematopoesis.158 Furthermore, due to its extremely high mutation rate, the ability of the 
virus to develop drug resistance to these agents is a major issue,  and  additionally the 
virus is able to penetrate the brain, a site not readily accessible to drugs.159 Therefore, 
there is a continual need for the improvement and development of new highly specific 
non-toxic anti-retroviral drugs.
Potential biological  targets  for therapeutic  intervention during  key  stages  of the  HIV 
replication  cycle  comprise  inhibition  of  virus  fusion,  the  co-receptor  (CXCR4  or 
CCR5),  reverse  transcriptase,  integrase,  and  protease.  However,  it  is  primarily  a 
combination  of  reverse  transcriptase  inhibitors  (nucleoside  reverse-transcriptase 
inhibitor  (NRTI)  and  non-nucleoside  reverse-transcriptase  inhibitor  (NNRTI))  and 
protease inhibitors that form the basis  of HAART.157,160 The recommended course of 
therapy  includes  a  minimum  of  three  active  drugs,  which  constitute  two  NRTIs  in 
combination with either a NNRTI or a protease inhibitor. Its ultimate goal is to suppress 
viral genome replication at the earliest point of its life cycle, by using a combination of 
as  many  antiviral  drugs  as  a patient can tolerate,  ideally  targeting different stages  of 
viral replication. This strategy’s success is based on the idea that if a mutation were to 
occur  and  rendering  one  drug  ineffective,  then  the  other  two  will  still  be  able  to 
suppress replication. HAART was first introduced in  1996, and its success has seen a 
massive decline in the morbidity and mortality of HIV-infected patients.157,161,162
The first anti-HIV drugs developed were reverse transcriptase inhibitors, of which two 
different classes exist; the nucleoside reverse-transcriptase inhibitors (NRTIs) and non­
nucleoside reverse-transcriptase inhibitor (NNRTIs).163
The NRTIs inhibit transcription of viral RNA into DNA by preventing chain elongation 
of viral DNA, and therefore no viral DNA is inserted into the host cell DNA and virus 
replication  stops  (Figure  45).157  To  successfully  synthesise  viral  DNA  the  naturally 
occurring  deoxynucleoside  building  blocks  must  first  be  converted  into  their  active 
metabolite deoxynucleotide triphosphate (dNTP), via three consecutive phosphorylation 
reactions.  These  phosphorylated  metabolites  are  then  incorporated  into  DNA by  RT, 
and  subsequently  chain  elongation  is  permitted  upon  the  addition  of  further  dNTP
109metabolites.145,157 NRTIs are essentially nucleotide mimetics that lack the necessary 3’- 
OH  group,  which  is  required  to  synthesise  a 5’-3’  phosphodiester bond  with  the  next 
deoxynucleotide  in  order  for  DNA  chain  elongation  to  continue.  They  act  as 
competitive  inhibitors  for  the  natural  substrate  dNTP  which  once  incorporated  into 
DNA, ultimately leads to chain termination and inhibition of viral DNA synthesis.157,164
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There  are  currently  seven  such  NRTIs  that  have  been  effectively  employed  in  the 
treatment of HIV (zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, 
and emtricitabine); a few of these are shown in Figure 46.16 1
NNRTIs were first discovered in  1990 and are classified as non-competitive inhibitors. 
They inhibit DNA polymerisation by binding to a hydrophobic allosteric binding pocket 
near the RT active site, and inducing a conformational change in the enzyme that blocks 
DNA synthesis.  There  are  at present 3  such  NNRTIs  that have been  approved for the 
treatment of HIV: nevirapine, delavirdine, and efavirenz (Figure 46).157,165
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Although newer more potent RT inhibitors are currently in clinical development, drug 
resistance  to  RT  inhibitors  is  a  common  problem  as  mutant  strains  of  RT  develop. 
Resistance  to  NRTIs  transpires  in  two  ways:  (1)  resistant  RT  acquires  the  ability  to 
selectively incorporate natural dNTP over NRTI,  and (2)  mutant RT incorporates the 
NRTI but is able to expel it from the terminated primer. Resistance to NNRTIs occur 
when mutations in RT impede binding of the inhibitor to its allosteric active site.145,162
The other constituent of highly active anti-retroviral therapy (HAART) involves the use 
of HIV protease inhibitors. These agents attack HIV later in its life cycle, by targeting a 
protease used by HIV  to proteolytically cleave polyproteins  into  smaller structural  or 
functional  viral  proteins,  which  mature  and  assemble  into  new  infectious  virions.  In 
particular,  gag  and gag-pol polyproteins  are cleaved to  produce  the  structural  capsid 
proteins, nucleocapsid, and the retroviral enzymes (RT, protease, and IN).157,166 
In total there are ten different protease inhibitors currently available for the treatment of 
HIV  (saquinavir,  indinavir,  ritonavir,  nelfinavir,  amprenavir,  lopinavir,  atazanavir, 
fosamprenavir,  tipranavir,  and  darunavir),  and  of  these  all  are  considered 
peptidomimetics except for tipranavir (examples shown in Figure 47). This is because 
within the structure of each protease inhibitor is a non-scissile hydroxyethylene moiety, 
which is able to mimic the readily hydrolysable peptide bond cleaved by HIV protease. 
Thus, the inhibitor competes with the gag-pol polyproteins for the protease active site, 
and  as  a  result  of  its  binding  renders  the  enzyme  inactive,  thereby  preventing  the 
maturation and assembly of infectious viral particles.157,166
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HIV cell entry has also been considered as a prime target for HIV inhibition, especially 
at the stages of cell fusion and co-receptor binding. The recently registered HIV fusion 
inhibitor enfuvirtide,  is  a  38  amino  acid  peptide  that binds  to  and  inhibits  gp41,  the 
glycoprotein  responsible  for  mediating  fusion  of the  viral  envelope  with  the  plasma 
membrane.164,  167  Additionally,  in  2007  a  drug  candidate  that  targeted  the  CCR5 
chemokine  co-receptor  was  also  approved.  Maraviroc  was  launched  as  a  selective 
antagonist  that  bound  to  CCR5  preventing  the  HIV  infection  of target  cells  (Figure 
48).157,16 1  These cell entry inhibitors, while not the basis of first-line therapy, provided 
additional benefits when supplemented with HAART, especially in patients developing 
drug resistance to existing anti-retrovirals.
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112Integration of viral DNA into the host genome is another fundamental process during 
the HIV replication cycle, which has drawn much interest in recent years as an attractive 
target for HIV chemotherapy. Consequently, the integrase enzyme that mediates such a 
process has been explored as a novel target for inhibition.  Accordingly,  as a result of 
drug  discovery  and  development  this  has  seen  the  advent  of  two  HIV  integrase 
inhibitors, raltegravir and elvitegravir (Figure 48).157,168
In conclusion HIV is a deadly and lethal infection which was previously thought of as 
untreatable,  but  through  a  better  understanding  of  the  viral  life  cycle  and  the 
introduction of HAART, HIV can now be regarded as a chronic infection that can be 
carefully controlled. Although a vaccine is considered the most promising cure for HIV 
it still remains elusive,  and the continual design and development of more potent less 
toxic HIV inhibitors is essential for the incessant management of HIV infection. Having 
revealed that sulfonamides play a role in HIV chemotherapy (see Section 1.1.5.), it is of 
interest  to  see  if  our  sulfonamides  and  their  PFP  sulfonate  precursors  display  any 
biological activity against HIV.
3.5.  Biological results for HIV
3.5.1.  Testing on PFP sulfonate esters and sulfonamides
Through  a collaborative  study with Fassati  et al.  a small  collection of PFP sulfonate 
esters  and  sulfonamides  were  randomly  selected  and  evaluated  against  HIV,  using  a 
screening  protocol  based  on  the infection  of human  T-cell  lines  with  HIV-1  vectors. 
Their biological evaluation of our compounds has led to the discovery of a previously 
uncharacterised family of small molecules that show anti-HIV activity.
In  order  to  determine  whether  our  compounds  were  able  to  reduce  HIV  infection; 
Fassati  et  al  incubated  lymphocytic  T-cells  with  our  PFP  sulfonate  esters  and 
sulfonamides for 6 hours, and then infected them with HIV-1. After 24 hours a measure 
of the HIV-1  infection reduction displayed against untreated HIV-1  cells was recorded 
as a percentage, by detecting GFP (green fluorescent protein) expression with the aid of 
fluorescent activated cell sorting (FACS) analysis. The higher the percentage exhibited 
by each compound the better its ability to act as an antiviral. Their preliminary results
113are  shown  in  Figure  49.  A  total  of 24  compounds  were  screened  against  the  HIV-1 
vector pCSGW at an initial concentration of 250pM.
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Their initial screen highlighted 5 potential inhibitors which exhibited almost complete 
reduction in infection at pM concentrations (103a,  103n,  103o,  120/121c,  and  124b). 
Several  PFP  sulfonate  esters  did  show  antiviral  activity,  however,  there  were  a  few 
examples where the compounds were ineffective because of the toxic effect they exerted
114on the cells. The sulfonamides were essentially non-toxic, and generally better tolerated 
by the T-cells, with only two out of twelve sulfonamides displaying no antiviral activity. 
The 5  most promising compounds were identified  (Figure 49)  and  it was  decided that 
these  would  be  the  focus for further testing.  Compound  120f was  also  identified  as  a 
suitable negative control to use during testing as it exhibited essentially no activity and 
was fundamentally non-toxic.
Re-evaluation of the compounds (Figure 50) by examining the % reduction in infection 
with respect to cells infected with the HIV-1  vector pCSGW (chart 2), established that 
124b  provided  the  best  result.  It  showed  close  to  complete  reduction  of  infection  at 
150|liM.  For example,  124b reduces HIV infection  from 4.53%  to 0.41%,  close to the 
percentage  seen  for  non-infected  T-cells  (chart  1,  0.16%).  Another  sulfonamide 
(120/121c) showed a similar degree of activity at a higher concentration (200pM).  It is 
noticeable that PFP  sulfonate esters were  not as effective  as  sulfonamides,  and higher 
concentrations  (250pM)  were  needed  to  provide  good  antiviral  activity  (103n  and 
103o). The role of 120f as  the  negative control  was  also confirmed by its  inability to 
reduce infection in HIV infected cells
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115With the 5 most encouraging compounds identified, toxicity tests at the working dose in 
the presence of SupTl  cells were performed by Fassati et al., to determine whether they 
displayed any toxicity to the cells (Figure 51). In SupTl  it could be seen that 97.48% of 
cells present are  alive, but when treated  with digitonin  (a membrane  solubilising  non­
ionic  detergent)  98.8%  of all  cells  died.  The  live/dead  cell  assay determined  that our 
compounds showed low toxicity, as greater than 94% of cells survived incubation  with 
the  each  candidate,  except  with  103a.  Nonetheless,  at  least  4  compounds  remain 
suitable for continual testing.
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Figure 51
At this stage a blind test of a random selection of compounds including the 5 promising 
ones were run as  a precaution.  It was pleasing to note that from this the 5  most active 
compounds  were  identified,  and  confirmed  that  antiviral  activity  was  certainly 
reproducible.
Having identified sulfonamide 124b as the most promising target to conduct additional 
studies, further structural changes were introduced to see if potency could be improved. 
A  survey of a range of orr/io-functionalised  aromatic  rings  quickly establishes  that  an 
increase  in  bulk  at the ortho position  greatly influences  the  anti-viral  potency  (Figure
11652).  With  an  increase  in  potency  it  was  also  possible  to  lower  the  dose  down  from 
150|iM  to  75pM,  especially  with  the  iodo  analogue  124o  which  resulted  in  a  >80% 
reduction in  HIV  infection.  Whilst an anti-viral concentration of 75pJVl  is  an  excellent 
start point, it is  still  relatively high  and further SAR  is  required  to  lower the  working 
dose into the more desirable nM region.
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Other positions for halogen substituents on the phenyl ring were investigated (meta and 
para  chlorophenyl,  and  bromophenyl),  and  although  they  too  displayed  anti-viral 
activity,  the  results  were  not  as  good  or  consistent  to  those  obtained  with  ortho 
substituents.
In  separate tests by Fassati  et al., the ability to inhibit replication  of a primary  HIV-1 
isolate  in  lymphocytes  obtained  from  healthy  human  donors  was  also  assessed  with 
interesting results (Figure 53).  Donor 2 was not sensitive to any of the  3  drugs  (103o, 
103n, and 124b), while donors  1   and 3 responded well  to  103o.  Rather pleasing to see 
was the potent inhibition displayed by 124d in all three donors.
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For future  work,  there  is  a pressing  need  for a more  potent  anti-viral possessing nM 
inhibition.  However,  there  currently exists  an  even  greater desire  for identifying  the 
cellular targets on which these compounds are acting.  It was envisaged that we could 
use  a  modified  version  of one  of our  existing  inhibitors  to  carry  out  a  ‘pull-down’ 
experiment using affinity chromatography.
3.5.2.  Affinity chromatography
Affinity  chromatography  is  a  technique  commonly  used  to  capture  proteins  from 
complex biological mixtures, due to a tight but reversible interaction (& D  ideally  lO^M
Q
to  10'  M)  of a  target  molecule  for  a  specific  ligand  coupled  to  a  chromatography 
matrix.  This  interaction  is either an electrostatic,  hydrophobic,  van der Waal’s,  or H- 
bonding  interaction.  The  target  is  then  released  from  the  affinity  matrix,  often  by 
changing the pH, polarity, ionic strength, or by addition of a competitive ligand so that 
the reversible interaction is broken.169 Mass spectrometric evaluation is then applied to 
identify  the  protein/s  which  was  bound  to  the  immobilised  candidate,  in  an  overall 
process  known  as  chemical  proteomics  (Scheme  80).  Chemical  proteomics  is  a  well 
established practice that can aid in the discovery of (1) unknown protein functions, (2) 
identifying the molecular mechanisms of drug action, and (3) help in the optimisation of 
lead  compounds.  However,  for  this  process  to  be  viable  the  protein  must  bind 
specifically to the target molecule, and this can often be difficult to predict if chemical 
modifications have been made to the target molecule in order to accommodate ligand 
attachment/binding.170
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A few examples of small molecules tethered to affinity beads and used to  ‘pull-down’ 
biological targets will be discussed. Most commonly affinity chromatography is carried 
out by biotinylation of a target molecule, or via direct attachment of the target molecule 
to solid supported beads (i.e. Sepharose).
Immobilisation  of a  drug  candidate  onto  chromatographic  beads  intended  for  affinity 
chromatography  has  been  commonly  used  to  determine  the  selectivity  of synthesised 
protein  kinase  inhibitors. 1 7 1   The  design  of  selective  protein  kinase  inhibitors  is 
complicated  due  to  the  relatively  well  conserved  ATP-binding  site  amongst  protein 
kinases, meaning cross-over inhibition is frequently observed. In an example by Daub et 
al.  they  immobilised  the  anti-inflammatory  drug  SB  203580  (175),  a  pyridinyl 
imidazole  which  was  designed  as  a  mitogen-activated  protein  kinase  p38  inhibitor 
(Figure 54).  Initially, in vitro assays of SB 203580 against a variety of protein kinases 
deemed  it  to  be  relatively  selective  for  p38  kinase.  However,  as  there  are  over  500 
human protein kinases and other protein targets to consider (i.e. other cellular enzymes), 
the knowledge of SB  203580’s true  selectivity for p38  kinase  is  not entirely  accurate. 
Thus,  a proteome-wide  assessment of SB  203580  selectivity is  required,  and  this  was 
reported by Daub and co-workers.172
119Investigations began by modification of a suitable functional  group on  SB  203580 so 
that it could be coupled to a chromatography resin. By considering the crystal structure 
of SB  203580  in  complex  with  p38,  Daub  concluded  that  the  best  possible  site  for 
modification  was  the  sulfoxide moiety.  Thus,  methyl  sulfoxide  was  substituted  for a 
primary  amine  which  could  be  coupled  to  epoxy-activated  Sepharose.  However,  to 
confirm  that  amine  176  bound  to  Sepharose  would  maintain  biological  activity,  a 
comparative study on pegylated amine 177 was conducted due to its structure similarity 
to the Sepharose bound product 178 (Figure 54).171,172
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Consequently,  176  and  177  were  biologically  evaluated  against  p38  kinase,  and 
displayed IC50 values of 4nM and 40nM respectively. Although pegylation reduced the 
inhibitory potency of 176 its IC50 value compared favourably with 175 (IC50 * 40nM); 
therefore, Daub et al. deduced that 178 should still retain activity and was subjected to 
affinity  chromatography.  The  binding  and  separation  of  p38  inhibitor  targets  was 
successfully performed, with gel electrophoresis and mass spectral analysis confirming 
that  in  addition  to  p38,  a variety  of other previously  unknown  protein  kinases  were 
identified. These unknown protein kinases also potently inhibited by SB  203580 were
120identified  as  Rip-like  interacting  caspase-like  apoptosis-regulatory  protein  kinase 
(RICK), cyclin G-associated kinase (GAK), and casein kinase  1   (CK1). As a result of 
this work by Daub et a l, it was shown that SB 203580 is not as selective for p38 kinase 
as  previously  reported.  This  suggests  that  SB  203580  possesses  a  more  complicated 
mechanism of action,  and has potentially provided further insight into the role of p38
172 kinases in cellular signal transduction and as anti-inflammatory drugs.
Additionally,  affinity  chromatography  has  been  employed  to  discover  the  primary 
targets  of clinically-used  drugs  whose  mode  of action  has  not been  established.  The 
amino-quinolines  (Chloroquine and Primaquine)  and the quinolinemethanols  (Quinine 
and Mefloquine) are used primarily in the treatment of malaria (Figure 55); however, 
there  is  no  known  mechanism  and  its  mode  of  action  is  unclear.  The  accepted 
hypothesis for their mode of action, as suggested by Foley and Tilley is that these anti- 
malarials  exert  their  therapeutic  effect  by  interfering  with  red  blood  cell  heme 
detoxification.173
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In order to better understand the precise mechanism of these quinoline drugs, Graves et 
al used displacement affinity chromatography to first identify all quinoline-interacting 
proteins  in  a  cell.  They  hypothesised  that  the  structurally  related  ATP  may  be 
immobilised onto sepharose and used to capture quinoline binding proteomes from cell 
lysates. The bound proteins are then displaced from the affinity matrix with one of the 
quinoline drugs, eluted and identified by mass spectrometry. Graves et al. successfully 
performed  displacement  affinity  chromatography  with  chloroquine,  primaquine,  and 
mefloquine  to  identify  the  two  proteins:  aldehyde  dehydrogenase  1  (ALDH1)  and 
quinone  reductase  2  (QR2).  To  confirm  their  findings  hydroxychloroquine  and 
primaquine were immobilised onto sepharose for  ‘pull-down’  studies,  and the authors 
report  that  isolation  of  ALDH1  and  QR2  was  observed.  Consequently,  in  good 
agreement  with  their  displacement  affinity  chromatography  work,  Graves  and  co-
121workers effectively identified the cellular targets  of the quinoline drugs  (ALDH1  and
173 QR2), thus providing additional information on their mode of action.
Whereas drug candidates can be directly coupled to the chromatography matrix in the 
case of sepharose, they may also be indirectly coupled via a biotin-streptavidin system. 
This provides an alternative technique for affinity chromatography which first involves 
the covalent attachment of candidates to biotin, for which then exhibits  an extremely 
strong binding affinity for the streptavidin matrix.
In  studies  by  Honda  et  al,  they  wanted  to  identify  the  protein  targets  of  their 
synthesised  anti-inflammatory/anti-carcinogenic  agent  2-cyano-3,12-dioxooleana- 
1,9(1 l)-dien-28-oic acid (CDDO) 179 and its analogues. CDDO 179 and its analogues 
(CDDO-Me  180  and  CDDO-Im  181)  displayed  inhibitory  activity  against  NO 
production, and were also able to inhibit proliferation of leukaemia and carcinoma cell 
lines (Figure 56).174
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However, its mechanism of action remains unexplored, and clarification of this may aid 
in  its  eventual  development  as  a valuable  clinical  candidate.  To  facilitate  this  study, 
Honda et al. set out to use the well established biotin-streptavidin methodology in order 
to  capture  cellular  proteins.  Biotinylation  was  achieved  to  provide  3  functionalised 
CDDO analogues, with a suitable spacer to avoid steric hindrance between protein and 
bead. Two analogues of CDDO were biotinylated at C-17 whilst the remaining analogue 
was  derivatised  at  C-23  (Figure  57).  To  confirm  that  these  biotinylated  conjugates 
retained  biological  activity,  they  were  evaluated  against  the  proliferation  of MCF-7 
breast  cancer  cells.  The  authors  report  that  reduced  potency  of  182,  183,  and  184 
compared  to  CDDO  179  and  CDDO-Me  180  (IC50  =  0.16pM  and  0.056pM 
respectively) was seen (Figure 57).174 However, with their most active compound (184) 
they were able to carry out successful affinity chromatography, identifying IkB kinase p 
as  the biological  target  of CDDO  and  its  analogues.  IkB  kinase  P  is  responsible for
122regulating  nuclear  factor-KB,  a  transcription  factor  that  is  activated  in  num erous 
carcinomas.
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Hence, having established CDDO and its analogue directly inhibit IkB kinase [3, this has 
led to their progression into phase I clinical trials for the treatment of leukaemia and 
solid tumours.175
3.5.3.  Preparation of immobilised inhibitors/ligands for pull down experiments
3.5.3.I.  Synthesis of modified sulfonates and sulfonamides for immobilisation onto 
an affinity matrix
Through  the  testing  of  PFP  sulfonate  esters  and  sulfonamides  against  HIV;  PFP 
sulfonate ester 103n and sulfonamides 124b and 124d have been identified as the most 
suitable  candidates  for  affinity  chromatography  (Figure  58).  For  affinity 
chromatography to work a segment of our inhibitor will have to be modified so that it 
can  be  covalently  attached  to  a  ligand,  or  directly  to  a  polymer  support  or  affinity 
matrix. In this study the commonly used biotin-streptavidin system will be used for the 
detection  of  biomolecules.  The  biotin-streptavidin  system  was  chosen  due  to  the 
extremely strong interaction between these two species (A'a-  1014  M'1), and also from 
the ease at which biotin may be attached to the inhibitor.176 Biotin is a vitamin from the 
vitamin B complex and contains a carboxylic acid unit to which drug molecules can be 
coupled (Figure 58).177
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We  considered  that  the  best  position  for  attachment  of  biotin  would  be  the  amino 
portion of the sulfonamide or on the PFP group of the PFP sulfonate ester (Scheme 81).
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3.S.3.2.  Modification of the amine component
A  simple  retrosynthetic  analysis  of  both  target  molecules  established  the  two 
dipolarophiles 185 and 186 as good [3+2] cycloaddition precursors (Figure 59).
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The proposed synthesis of 185 (Scheme 82) would start with the mono-protection of p- 
xylylenediamine,  followed by vinyl sulfonamide synthesis using existing procedures 
(see Section 2.3.5.).
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185  was  eventually  synthesized  with  excellent  yields  and  then  subjected  to  a  [3+2] 
cycloaddition with the required nitrone. As conditions had already been set up for this 
type  of  cycloaddition  (see  Section  2.3.5.),  these  were  employed  here  with  a  small 
collection of nitrones (Table 25).
BocHN
PhMe, MW, 140°C
BocHN
\
189 = 5C anti
190 = 5C syn
Entry R Yield (%) Product ratio 
(188: [189/190])
Product ratio 
189 : 190
a o-FPh 67 5:6* 2  :  1
b o-ClPh 53 1:1* 3  :  2
c o-BrPh 46 5:4* 1  :  1
d p-C  lP h 7 9 3:2 3  :  2
e p-BrPh 67 3 :  1 1   :  1
* = 5C isomers separated  Table 25
Previously  cycloadditions  with  vinyl  sulfonamides  furnished  the  desired  4C  anti 
diastereoisomer,  along with the 5C syn and anti diastereoisomer usually as  a mixture 
(see Section 2.3.5.). In all examples shown in Table 25 the same results were observed 
with  moderate  to  good  yields.  It  was  disappointing  to  see  that  the  desired  pre- 
biotinylation precursors (entries b and c) required for testing showed the lowest yields. 
As a result, aminolysis of PFP sulfonate ester 103j with 187 was examined as a way to 
improve the yield (Scheme 83).
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Although the reaction does indeed provide a much improved yield of 90%, separation of 
the  diastereomeric  mixture  {anti:syn  =  5:2)  proved  a  lot  more  troublesome  and  time 
consuming  so  this  alternative  route  was  avoided.  With  two  of three  pre-biotinylated 
testing precursors  synthesized (188b and  188c);  the TFP  sulfonate ester was  the next 
endeavour.
Synthesis of 186 involved a similar synthetic sequence to that used for the synthesis of 
185 (Scheme  82), but with an additional EDC coupling step of Boc-ethylene diamine 
192 to 2,3,5,6-tetrafluoro-4-hydroxybenzoic acid 193 (Scheme 84).
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Mono-protection  of ethylene  diamine  furnished  a  78%  yield  of  the  desired  product 
192,179 which  was  then  utilized  for  amide  coupling  to  give  194,180 and  finally  vinyl 
sulfonamide  186  synthesis  was  achieved  in  a  modest  yield  of  52%.  The  [3+2] 
cycloaddition with  2-furyl  nitrone  119n was performed  to  give  cycloadduct  195  in  a 
regioselective and diastereoselective fashion, albeit in a poor yield, 38% (Scheme 85).
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F 186With our more valuable biotin containing precursors synthesized it was considered more 
appropriate to first test the coupling reaction of biotin with a standard amine using a set
of conditions obtained from literature. Thus, L-phenylalanine ethyl ester.HCl in DMF
1 8 1 was  coupled  to  biotin  using  a  procedure  set  out  by  Kim  et  al  (Scheme  86).  The 
reaction worked extremely well furnishing a 64% yield of the desired product 196.
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Having established that the reaction was successful, the amine was finally liberated as 
the TFA or HC1 salt and then subjected to Kim’s conditions for coupling (Scheme 87). 
Disappointingly the isolated  yields of 197 and 198 obtained were poor,  but furnished 
sufficient material for biological testing. Accordingly, if encouraging biological results 
are obtained then further optimisation will be required to improve these disappointing 
yields.
i. TFA/DCM or 4M HCI/dioxane
ii. Biotin, EDC.HCI, DMAP 
DMF, 5-6 hrs
BiotinHN
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Scheme 87
With the two biotinylated inhibitors synthesized it was now vitally important that these 
molecules retained activity against HIV for affinity chromatography to be successful. 
However, preliminary tests deemed these biotinylated compounds to be devoid of any 
activity. To determine whether biotin was the problem the non-biotinylated precursors 
188b and 188c were also tested as the free amine and Boc protected species; however, 
evaluation of these also displayed no antiviral activity.
To  check  the  importance  of the  amine  moiety,  sulfonamide  124g  was  also  assayed 
against  HIV,  and  effectively  this  revealed  that  the  4-methylbenzylamine  region  is 
essential and not suitable for modification. In support of this, Fassati et al. noted that the 
allyl  sulfonamide  120f  exhibited  no  anti-viral  activity  but  the  4-methylbenzylamine 
sulfonamide 124g possessed a good level of inhibition at 100 |iiM (Figure 60). This loss
127of activity associated with biotinylation, along with the known problem associated with
1  7  1  89
protein purification when associated with biotin,  ’  led to the development of a new 
strategy.
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3.5.3.3.  Modification of the iV-terminus
We  needed  to  determine  an  appropriate  position  for  attachment  of  the  tag,  and  the 
options were limited by the requirement to retain the amine moiety and R group of the 
isoxazolidine ring for anti-viral activity. It was therefore decided that the nitrogen of the 
isoxazolidine ring  would be utilised  as  a point of attachment.  Hence,  a new  synthetic 
plan was devised in which a hydroxyl group would provide a suitable linker at the end 
of isoxazolidine 202, and to which a suitable tag for affinity chromatography would be 
appended (Scheme 88).
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128As biotin also raised some potential problems in protein purification it was decided to 
modify the approach so that the ligand would be attached to the affinity matrix, not by 
biotin,  but  via  epoxy-activated  Sepharose  6B  (Scheme  89).  The  advantage  of using 
epoxy-Sepharose is that it contains a long spacer arm which should help minimise any 
obstruction  to  binding  between  the  ligand  and  target  molecule.169  However,  before 
sepharose  is covalently attached to the modified inhibitor,  it must first be shown that 
such modification does still lead to a compound which retains an inhibitory affect.
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The synthesis began with the mono-silylation of ethylene glycol to give a 91% yield of 
203.183 Swem oxidation furnished aldehyde 204 in a 95% yield184 which was condensed 
with hydroxylamine to give oxime 205 (95%) as a mixture of geometrical isomers. 
Finally, reduction with NaBHsCN provided hydroxylamine 199 in a 92% yield.186 All 4 
steps, although simple and tedious, were near quantitative and set up nitrone formation 
(Scheme 90).
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In this case the modified hydroxylamine produced very poor yields of the nitrone 200a- 
c.  The reaction remains  incomplete  after 2 days  and  furnishes  a crude nitrone  which 
requires purification by column chromatography. Longer reaction times do not improve
129the isolated yield, so it was suspected that the low yields observed are as a result of the 
polar nitrone adhering to or decomposing on silica during purification.
However despite this, it is possible to prepare sufficient quantities of material for further 
studies  and  the  [3+2]  cycloaddition  with  vinyl  sulfonamide  123b  was  attempted. 
Reagents were heated in a microwave at  140°C for 45 minutes, but disappointingly no 
appreciable  amount  of  product  was  generated  (Scheme  91).  The  reaction  was  very 
messy and TLC analysis showed decomposition of nitrone as the major result.
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Scheme 91
Therefore, as the alternative route available, it was decided to proceed through the PFP 
sulfonate ester pathway (Scheme 92).
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Accordingly, PFP vinyl sulfonate 100 and nitrones 200a-c were heated together, to give 
isoxazolidines  210a-c.  As  with  all  previous  [3+2]  cycloaddition  with  PFP  vinyl 
sulfonate, the reactions produced the anti diastereoisomer cleanly and with satisfactory 
yields (see Section 2.3.3.). Isoxazolidines 210a-c were unfortunately rapidly epimerised 
upon aminolysis with 4-methylbenzylamine (Table 26).
130PFPO
OTBDPS
210a-c
4-Me benzylamine 
THF, DBU, reflux, 1  hr
OTBDPS
206= 4C anti
207 = 4C syn
Entry X Yield (%) Product ratio 
[206 : 207]
a Cl 78 10:3
b Br 69 7 :  3
c I 63 5 :  2
Table 26
Repeated  column  chromatography  of  the  diastereomeric  mixture  was  eventually 
successful in enabling the separation of both the syn and anti diastereoisomers with a 
minor reduction in yield. Yet again the preferred anti diastereoisomer 206 was produced 
in a greater quantity, and this was taken and subjected to desilylation using  1  M TBAF 
in  THF187 to  deliver  near  quantitative  yields  of  the  alcohols  211a-c  for  biological 
screening in a HIV assay (Scheme 93).
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Our 3 compounds are currently being assayed against HIV to assess if anti-viral activity 
has been retained. Preliminary screening has revealed that alcohols 211a-c have no anti- 
HIV  activity,  however further in-depth  testing  is  required  to  corroborate  these  initial 
results.  This  did  lead  to  further  uncertainty  as  to  whether  the  V-position  of  the 
isoxazolidine ring is also not suitable for modification, and or whether the free OH is 
complicating  testing.  There  is  a  possibility  of  an  internal  H-bond  between  the  free 
alcohol and the O of the isoxazolidine ring causing a small conformational change in 
the structure, and therefore changing the activity of the candidate. As a test, the silylated 
alcohol 206b was also examined by Fassati et al., but initial tests suggest this compound 
is toxic at the working doses, and at present does not possess anti-viral activity.
1313.6. Conclusion on Chapter 3
In conclusion a new class of small molecule inhibitors for the enzymes  DDAH,  ADI 
and HIV has been discovered, demonstrating the general role of our sulfonamides and 
PFP  sulfonate  esters  as  potential  chemical  agents  to  aid  in  biological  and  potentially 
medicinal studies.
In the DDAH/ADI study a selection of PFP sulfonate  esters  and  sulfonamides  tested 
showed  encouraging  levels  of  inhibition  at  a  concentration  of  50pM,  and  a  more 
accurate determination of their potency has been carried out.  Generally PFP sulfonate 
esters exhibited greater levels of inhibition against DDAH, whilst sulfonamides showed 
most  promise  against  ADI.  It  was  also  evident  that  isoxazolidines  containing  the 
naphthyl,  2-bromofuryl,  p-NC^Ph,  or  m-bromoaryl  groups  tended  to  give  good 
inhibition against ADI and DDAH, irrespective of whether they are PFP sulfonate esters 
or sulfonamides  (Tables  20,  22  and  23).  Pleasingly this  study has  identified the  first 
known  inhibitor of ADI,  and  moreover revealed  the first example  of a non-substrate 
based inhibitor for DDAH.  Inhibition has provided promising levels of activity in the 
pM range; however, further SAR is required to obtain a potent inhibitor displaying nM 
inhibition,  which  will be important for fundamental biological  studies  and/or clinical 
studies.  Future  work  also  entails  a  more  detailed  investigation  into  the  molecular 
interactions of our active compounds within the DDAH and ADI binding pocket. Once 
this has been achieved the next objective would then be to design inhibitors with DDAH 
isoform selectivity.
In the HIV study, a selection of PFP sulfonate esters and sulfonamides that exhibit anti- 
HIV activity have been identified, and through further evaluation it has been possible to 
identify inhibitors with anti-viral activity at around 75-100pM. Although nM activity is 
more desirable we have established an excellent foundation on which further SAR and 
drug design will be used to target this.
Attempts to identify the cellular component which our compounds are acting on were 
unsuccessful,  due  to  loss  of  anti-viral  activity  from  modifications  to  our  active 
compounds for tag attachment. It was discovered that a change to the amine component 
of our sulfonamide  was  detrimental  to  anti-HIV  activity,  and  so  a  new  position  was 
investigated. However, tag attachment to the nitrogen of the isoxazolidine ring has also 
given negative preliminary results and additional tests are currently being investigated.
132Conceptually  isoxazolidine  N-tagging  still  offers  the  most  robust  position  for  drug 
modification, so future work would entail exploring alternative linkers and spacers that 
could  be  used  in  biological  evaluation.  If  biological  results  ultimately  suggest  that 
isoxazolidine iV-tagging removes anti-viral activity, then future work entails exploring 
another  position  on  the  sulfonamide  motif  for  tag  attachment.  The  most  feasible 
remaining position for this is the CH2 of the isoxazolidine ring, and this would ideally 
be the next endeavour.
Finally, it is also notable that biological activity of the PFP group is totally unexplored, 
so could be potentially valuable in the future identification of other enzyme inhibitors. 
Consequently, screening against a wider range of enzymes would also be desirable.
133CHAPTER 4: Experimental section
4.1.  General methods and experimentation
All  the  starting  materials  including  solvents  were  used  as  received  without  further 
purification, unless otherwise stated. Where necessary, reactions were carried out under 
argon  unless  otherwise  stated.  Specially  dried  (anhydrous)  solvents  were  used  when 
necessary. Reactions were monitored by TLC analysis carried out on SIL G/UV254 silica 
plates purchased from VWR, and were visualised under a UV lamp operating at short 
and long wavelength ranges. Visualisation was aided by dipping plates into an alkaline 
potassium permanganate solution. Flash column chromatography was carried out with 
Kieselgel 60M 0.04/0.063mm (230-400 mesh) silica gel. All yields quoted are isolated 
yields,  and  when  multiple products  are obtained  data are presented  in  terms  of order 
isolated.
Microwave  reactions  utilized  a  CEM  Discover  instrument.  JH  NMR  spectra  were 
recorded  on  a  Bruker  AMX  300  (300  MHz)  instrument  operating  at  ambient  probe 
temperature, unless otherwise stated. Deuterated chloroform CDCI3, CD3OD, D2O, and 
DMSO were used as the deuterated solvents for all the spectra run.  Peaks are reported 
as  singlet  (s),  doublet  (d),  triplet  (t),  quartet  (q),  broad  (br),  appears  (app),  some 
combinations  of these,  or multiplet (m).  All  chemical  shifts  are reported  in parts  per 
million  (ppm)  relative  to  residual  protiated  signals  of  the  solvent,  and  coupling 
constants  (/)  in hertz  (Hz).  13C NMR spectra were recorded  at 75  MHz  on  a Bruker 
AMX 300 unless otherwise stated. Standard abbreviations used were singlet (s), doublet 
(d), triplet (t), and quartet (q). C-F aromatic peaks not observed due to 19F coupling. 
Mass spectra were obtained from a VG70-SE or a MAT 900 XP spectrometer, and infra 
red spectra were run on a Shimadzu FTIR 8700 spectrophotometer using KBr discs or 
using a Perkin Elmer Spectrum 100. IR’s were run as thin films using DCM as a solvent 
or neat. Melting points were measured, where appropriate, with a Gallenkamp apparatus 
and are uncorrected. Elemental analysis was performed at the Department of Chemistry, 
University College London.
1344.2.  Nitrone procedures
General protocol 69,94
To A-methylhydroxylamine hydrochloride  (1.2  eq.)  in  dry DCM  (50  mL)  was  added 
aldehyde (10 g,  1   eq.) and NaHCC>3 (3 eq.). The mixture was heated at reflux (40 °C) 
for 2 hours, then the resulting suspension was filtered and the remaining residue washed 
thoroughly with DCM (4 x 40 mL). The combined organic fractions were concentrated 
in  vacuo  to  yield  a  solid  that  was  recrystallised  (hexane/EtOAc)  to  give  the  title 
compound.
C-(Phenyl)-A-methyl nitrone (119a)69’94
General  protocol  was  followed  using  3.2  g  of benzaldehyde.  Recrystallisation  from 
hexane/EtOAc, gave the product as white crystals (3.0 g, 74%).
Rf 0.26  (9:1  DCM/MeOH);  mp  89-91  °C;  um ax  (film)/cm''  3410,  3003,  1591,  1416, 
1163, 937;  8h (300 MHz, CDC13) 8.17-8.23  (m, 2 H, Ar//), 7.37-7.44 (m, 3 H, Ar//), 
7.35  (s,  1   H, C//N),  3.85  (s, 3  H,  NC//3);  8c (75  MHz, CDCI3)  135.2  (d),  130.5  (s),
130.4  (d), 128.5 (d),  128.4 (d), 54.4 (q); m/z (El) 271 (24),  135 (M+, 99),  134 (100), 118 
(57), 107 (42), 89 (57); HRMS (El): calcd for C8H9NO (M+) 135.0684, found 135.0682.
C-(4-Metlio\yphenyl I-iV-niethvl nitrone (119b)69,94
MeO
General protocol was followed using 10 g of 4-methoxybenzaldehyde. Recrystallisation 
from hexane/EtOAc, gave the product as white crystals (11.3 g, 93%).
Rf 0.40  (9:1  DCM/MeOH);  mp  80-82  °C;  t>m ax  (film)/crn'  3389,  3051,  2976,  1601, 
1506,  1456,  1418,  1167,  1030, 945;  8h (300 MHz, CDCI3)  8.20  (d, J = 9.0 Hz, 2 H, 
Ar//), 7.29  (s,  1   H,  C//N), 6.93  (d, J = 9.0 Hz,  2 H,  Ar//),  3.84  (s,  6  H,  OC//3  and 
NC/Z3);  8c (75 MHz, CDCI3)  161.1  (s),  134.9 (d),  130.4 (d),  123.5 (s),  113.8 (d), 55.3 
(q), 53.9 (q); m/z (El)  165 (M+,  100),  135  (51); HRMS (El): calcd for C9HnN02 (M+) 
165.0790, found 165.0791.
135C-(4-Allyloxy  phenyl)-iV-methyl nitrone (119c)69,94
General protocol was followed using 1.9 g of 4-allyloxybenzaldehyde. Recrystallisation 
from hexane/EtOAc, gave the product as light yellow crystals (2.0 g, 88%).
Rf 0.37  (9:1  DCM/MeOH);  mp  89-91  °C;  t)m ax  (filmVcm1   3404,  3084,  2986,  1655, 
1564,  1502,  1418,  1308,  1252,  1163, 991; SH  (300 MHz, CDC13) 8.17 (d, J = 9.0 Hz, 2 
H, Ar//), 7.26 (s,  1 H, C//N), 6.91  (d, J = 9.0 Hz, 2 H, Ar//), 6.02 (ddt, /  =  17.2,  10.5,
5.3  Hz,  1  H, OCH2C//CH2), 5.38 (app. dq, J= 17.3,  1.5 Hz,  1   H, CHC//H), 5.27 (app. 
dq, J = 10.5, 1.5 Hz, 1 H, CHCH//), 4.54 (app. dt, J = 5.3,  1.5 Hz, 2 H, OC//2), 3.81 (s, 
3  H, C//3);  5C  (75  MHz,  CDC13)  160.0 (s),  134.8  (d),  132.7  (d),  130.4 (d),  123.6  (s),
118.0  (t), 114.6 (d), 68.8 (t), 54.0 (q); m/z (El) 191 (M+, 100), 150 (29) 122 (18); HRMS 
(El): calcd for Ci,H13N02 (M+) 191.0946, found 191.0947.
C-(4-Nitrophenyl)-A-methyl nitrone (119d)69,94
o2 n
General  protocol  was  followed  using  10  g  of 4-nitrobenzaldehyde.  Recrystallisation 
from EtOAc gave the product as orange-yellow crystals (6.7 g, 56%).
Rf 0.48  (9:1  DCM/MeOH); mp 218-220 °C; o w  (filmVcrn1 3055,  2986,  1597,  1518, 
1423, 1342, 1175, 897; 5H  (300 MHz, CDCI3) 8.44 (d, /=  9.1 Hz, 2 H, Ar//), 8.27 (d, J 
= 9.1 Hz, 2 H, Ar//), 8.10 (s, 1 H, C/7N), 3.85 (s, 3 H, C//3); 5C  (75 MHz, CDC13) 146.9 
(s),  136.7  (s),  132.7  (d),  128.3  (d),  123.7  (d),  54.7  (q);  m/z  (El)  180  (M+,  100),  179 
(100),  163  (21),  133  (97),  105  (63),  89  (33);  HRMS  (El):  calcd  for CgHg^Os  (M+) 
180.0535, found 180.0526.
C-(4-ChlorophenyI)-A-methyl nitrone (119e) 188,189
ci
General  protocol  was  followed  using  5  g  of 4-chlorobenzaldehyde.  Recrystallisation 
from hexane/EtOAc, gave the required product as white crystals (5.5 g, 91%).
136Rf 0.44 (9:1  DCM/MeOH);  mp  135-136 °C; om ax (film)/cm'‘  3007,  2951,  1558,  1423, 
1310,  1173, 947, 854, 739; 8H  (300 MHz, CDCI3) 8.16 (d, J = 8.7 Hz, 2 H, Ar//), 7.37 
(d, J = 8.7 Hz, 2 H, Ar//), 7.34 (s, 1 H, C//N), 3.86 (s, 3 H, C//3); 8c (75 MHz, CDCI3)
135.8  (s),  134.1  (d),  129.6 (d),  128.9 (s),  128.8  (d), 54.5  (q);  m/z (El)  171  (M+,  37C1, 
100),  170(100),  169 (M+, 35C1, 99), 168 (98), 152 (34),  139 (75),  125 (31),  111  (43), 99 
(32), 89 (93); HRMS (El): calcd for C8H835C1N0 (M+) 169.0294, found 169.0296.
C-(4-Bromophenyl)-,V-methvl nitrone (1191) 2
General protocol  was followed using  10 g of 4-bromobenzaldehyde.  Recrystallisation 
from hexane/EtOAc, gave the product as white crystals (11.2 g, 96%).
Rf 0.46 (9:1  DCM/MeOH);  mp  130-131  °C; Om ax (film)/cm'' 3427,  3078,  3003,  1551, 
1423,  1310,  1171, 945, 821; 8h (300 MHz, CDC13) 8.07 (d, J = 8.8 Hz, 2 H, Ar//), 7.51 
(d, J = 8.8 Hz, 2 H, Ar//), 7.31  (s,  1  H, C//N), 3.84 (s, 3 H, C//3); 8c (75 MHz, CDC13)
134.1  (d), 131.7 (d), 129.7 (d), 129.3 (s), 124.2 (s), 54.6 (q); m/z (El) 215 (M+, 8lBr, 88), 
214  (100),  213  (M+,  79Br,  89),  212  (99),  185  (23),  89  (37);  HRMS  (El):  calcd  for 
C8H879BrNO (M+) 212.9789, found 212.9784.
C-(3-Chlorophenyl)-lV-methyl nitrone (119g)69'94
ci
General protocol  was  followed using  10 g of 3-chlorobenzaldehyde.  Recrystallisation 
from hexane/EtOAc provided the product as a white solid (11.6 g, 96%).
Rf 0.33  (9:1  DCM/MeOH);  mp  57-58  °C;  t>m ax  (film)/cm'‘  3410,  3096,  1560,  1470, 
1418,  1273, 1171, 1090, 947, 787; 8h (300 MHz, CDC13) 8.33 (s,  1  H, ArH) 7.89 (d, J =
7.1  Hz,  1  H, Ar//), 7.26-7.33 (m, 3 H, C//N and Ar//), 3.82 (s, 3 H, C//3); 8c (75 MHz, 
CDCI3)  134.4 (s),  133.9 (d),  132.0 (s),  130.3 (d),  129.7 (d),  127.8 (d),  126.5 (d), 54.6 
(q); m/z (El) 171 (M+, 37C1,32), 170 (42), 169 (M+, 35C1, 100), 168 (96), 89 (53); HRMS 
(El): calcd for C8H835ClNO (M+) 169.0294, found 169.0297.
137C-(3-Bromophenyl)-A-methyl nitrone (119h)69,94
ov + N
Br
General protocol  was followed using  10 g of 3-bromobenzaldehyde.  Recrystallisation 
from hexane/EtOAc, gave the product as a white solid (11.5 g, 99%).
Rf 0.36  (9:1  DCM/MeOH);  mp  59-60  °C;  o w   (film)/cm_1 3418,  3053,  2986,  1636, 
1589,  1420,  1173,  1076, 991, 894, 748; 5h (300 MHz, CDC13) 8.47 (s,  1  H, Ar//), 8.04 
(d, J = 8.0 Hz, 1  H, Ar//), 7.52 (d, J = 8.0 Hz, 1  H, Ar//), 7.32 (s,  1  H, C//N), 7.24-7.30 
(m, 1  H, Ar//), 3.88 (s, 3 H, C//3); 6C  (75 MHz, CDC13)  133.7 (d),  133.2 (d),  132.3 (s),
130.7  (d),  129.9 (d),  126.9 (d),  122.6 (s), 54.6 (q); m/z (El)  215  (M+,  81Br,  100), 214
(99), 213  (M+,  79Br, 95), 212 (90),  196 (100),  185  (88),  171  (33),  157  (43),  134 (87), 
119 (78), 106 (95); HRMS (El): calcd for C8H879BrNO (M+) 212.9789, found 212.9790.
C-(2-Fluorophenyl)-A-methyl nitrone (119i)69,94
General  protocol  was  followed  using  5  g  of 2-fluorobenzaldehyde.  Recrystallisation 
from hexane/EtOAc, gave the product as a light orange solid (5.9 g, 96%).
Rf 0.70  (9:1  DCM/MeOH);  mp  58-59  °C;  Pm ax  (film)/cm'‘  3412,  3111,  2941,  1643, 
1597,  1410,  1308,  1167,  1103,  1031, 947, 772; §H  (300 MHz, CDC13) 9.20 (app. t, J =
7.7  Hz, 1  H, Ar//), 7.65 (s, 1  H, C//N), 7.34-7.44 (m, 1 H, Ar//), 7.20 (app t, i  = 7.6 Hz, 
1  H, Ar//), 7.02-7.09 (m,  1 H, Ar//), 3.89 (s, 3 H, C//3); 5c (75 MHz, CDC13)  159.8 (s, 
J cf = 252.8 Hz),  131.6 (d, JCF = 8.7 Hz),  128.6 (d, Jcf =  1.1  Hz),  127.4 (d, iCF = 8.8 
Hz),  124.3 (d, Jcf = 3.7 Hz),  118.9 (s, J C f  = 8.9 Hz),  114.6 (d, i CF = 21.2 Hz), 54.9 (q); 
m/z  (El)  153  (M+,  100),  123  (49),  107  (18);  HRMS  (El):  calcd  for  CgHgFNO  (M+) 
153.0590, found 153.0597.
C'-(2-Chloropheny])-A'-methyl nitrone (119j)
138General  protocol  was  followed using  10 g of 2-chlorobenzaldehyde.  Recrystallisation 
from hexane/EtOAc gave the product as a white solid (11.7 g, 97%).
Rf 0.34  (9:1  DCM/MeOH);  mp  79-81  °C;  a)™,  (film)/cm''  3418,  3055,  2986,  1583, 
1423,  1265, 1175, 1043, 897, 745; 6H  (300 MHz, CDC13) 9.26 (dd, J = 7.2, 2.7 Hz,  1  H, 
Ar//), 7.82 (s,  1   H, CHH), 7.24-7.38 (m, 3 H, Ar//),  3.89 (s, 3  H, C//3);  8c (75 MHz, 
CDC13)  132.7  (s),  131.0 (d),  129.4 (d),  129.0 (d),  128.1  (s),  127.1  (d),  113.0 (d), 55.3 
(q); m/z (El)  171  (M+,  37C1, 47),  170 (100),  169 (M+, 35C1, 50),  152 (22),  107 (33), 89 
(27); HRMS (El): calcd for C8H835ClNO (M+) 169.0294, found 169.0295.
C-(2-Bromophenyl)-A-methyl nitrone (119k)
General protocol  was  followed using  10  g of 2-bromobenzaldehyde.  Recrystallisation 
from hexane/EtOAc, gave the product as white crystals (9.6 g, 83%).
Rf 0.49  (9:1  DCM/MeOH);  mp  88-89  °C;  t)m ax  (film)/cm''  3412,  3090,  2937,  1636, 
1578,  1420,  1171,  1096,  1018, 947, 754;  8h (300 MHz, CDCI3) 9.26 (dd, J = 8.0,  1.9 
Hz, 1  H, Ar//), 7.82 (s, 1 H, CZ/N), 7.59 (dd, J = 8.0, 1.3 Hz,  1 H, Ar//), 7.37 (app. dt, J 
= 7.8,  1.3 Hz,  1   H, Ar//), 7.22 (app. dt, J = 7.8,  1.9 Hz,  1   H, Ar//), 3.91  (s, 3 H, C//,); 
8c  (75  MHz,  CDCI3)  133.6 (d),  132.8  (d),  131.4  (d),  129.5  (s),  129.3  (d),  127.7  (d),
123.1  (s), 55.3 (q); m/z (El) 215 (M+, 81Br, 82), 213 (M+, 79Br, 85),  183 (16),  134 (100), 
119 (78),  107 (95), 91  (58); HRMS  (El): calcd for C8H879BrNO (M+) 212.9789, found 
212.9791.
C-(Naphthyl)-,V-inethyl nitrone (1191)69'94
General protocol was followed using  10 g of 2-Naphthaldehyde. Recrystallisation from 
hexane/EtOAc provided the product as cream crystals (11.8 g, 99%).
Rf 0.11  (20:1  Et20/AcOH);  mp  126-128  °C; um ax (film)/cm 1  3416,  3090, 2941,  1574, 
1415,  1366, 1128, 957, 842; 8 h   (300 MHz, CDC13) 9.18 (s,  1  H, C//N), 7.79-7.93 (m, 4 
H, Ar//), 7.48-7.52 (m, 3 H, Ar//), 3.90 (s, 3 H, C//3); 8c (75 MHz, CDC13) 135.3 (d),
134.1  (s), 133.1 (s),  129.2(d),  128.4(d),  128.0(d), 127.8 (s),  127.6(d),  127.4(d), 126.5
139(d),  125.7 (d), 54.5 (q); m/z (El)  185 (M+,  100),  184 (57),  139 (20),  127 (16),  115 (36);
HRMS (El): calcd for C^HnNO (M+) 185.0841, found 185.0844.
/V,jV-Dimethyl-/;-phenylene dinitrone (119m)190
General  protocol  was  followed  using  5  g  of terephthaldehyde,  gave  the  product  as 
yellow crystals (1.2 g, 17%).
Rf 0.29  (9:1  DCM/MeOH);  mp 248-250 °C; Dm ax (filmVcm' 1  3319,  3055,  2986,  1580, 
1416,  1310,  1265,  1169, 937;  8H  (300 MHz, CDC13)  8.24 (s, 4 H, ArH), 7.40 (s, 2 H, 
CAN), 3.88 (s, 6 H, C//3); 8C  (75 MHz, DMSO) 133.4 (d),  131.8 (s), 127.5 (d), 54.1 (q); 
m/z (El) 219  (70),  192  (M+, 57),  184 (54),  175  (22),  155  (24),  136 (24),  115  (23), 91 
(55), 85 (46); HRMS (El): calcd for CioH12N202 (M+) 192.0899, found 192.0894.
C-(2-Furyl)-/V-methyl nitrone (119n)69,94
o
General  protocol  was  followed  using  10  g  of  2-furaldehyde.  Recrystallisation  from 
hexane/EtOAc, gave the product as orange crystals (12.8 g, 98%).
Rf 0.36  (9:1  DCM/MeOH);  mp  96-98  °C;  \)m ax  (film)/cin 1   3369,  3105,  1678,  1612, 
1479,  1402,  1229,  1146,  1011, 939;  8r (300 MHz,  CDC13) 7.69  (d, J = 3.5  Hz,  1  H, 
CHO), 7.50 (s, 1 H, C//N), 7.42 (d, J = 1.4 Hz, 1  H, C//CO), 6.49 (ddd, J = 3.5, 1.8, 0.6 
Hz,  1   H, OCHC//CH),  3.77  (s, 3  H,  Ctf3);  8C  (75 MHz,  CDC13)  146.7  (s),  143.6 (d),
123.6  (d),  115.2 (d),  112.3 (d), 52.7 (q); m/z (El)  126 (98),  125 (M+, 98),  125 (98),  124 
(24), 108 (100); HRMS (El): calcd for C6H7N02 (M+) 125.0477, found 125.0479.
C-(5-Bromofuryl)-A-methyl nitrone (119o)69,94
0
General  protocol  was  followed using 5  g of 5-bromo-2-furaldehyde.  Recrystallisation 
from hexane/EtOAc, gave the product as off white crystals (5.7 g, 98%).
Rf 0.40 (9:1  DCM/MeOH); mp  142-143  °C; t>m ax (film)/cirf'  3396,  3053, 2984,  1599, 
1479,  1396,  1225,  1136,  1009, 912;  8h (300 MHz, CDC13) 7.64 (d, J = 3.5  Hz,  1  H,
140CHCO), 7.46 (s,  1   H, CHN), 6.42 (d, J = 3.5 Hz,  1   H, CHCBr), 3.77 (s, 3 H, CH3); 8c 
(75 MHz, CDCI3)  148.7 (s),  125.2 (d),  124.2 (s),  117.3 (d),  114.1  (d), 52.8 (q); m/z (El) 
205  (M+,  slBr, 98), 203  (M+, 79Br,  100), 79 (97);  HRMS (El):  calcd for C6H679BrN02 
(M+) 202.9582, found 202.9589.
f-( Cyclop ropy  I )-Y-methyl nitrone (119p)69,94
General protocol was followed using 5  g of cyclopropane carboxaldehyde, to give the 
product as a yellow oil (7.0 g, 99%).
Rf 0.24 (9:1  DCM/MeOH); 0)m ax (neat)/cnf‘ 3387, 3005, 2945,  1616,  1408,  1319,  1227, 
1138, 970; 5h (300 MHz, CDC13) 6.07 (d, J = 8.5 Hz,  1   H, CHN), 3.56 (s, 3 H, CH3), 
2.18-2.30  (m,  1   H,  CH(CH2)2),  0.92-0.99  (m,  2  H,  CH2CH),  0.57-0.60  (m,  2  H, 
CH2CH);  8 c   (75 MHz, CDC13)  143.2 (d), 51.8 (q), 9.3  (d),  6.9  ( t),  6.6 (t); m/z (El) 99 
(M+,  68),  86  (34),  84  (100);  HRMS  (El);  calcd  for  C5H9NO  (M+)  99.0684,  found 
99.0690.
C-(Cyclohexyl)-:Y-niethyl nitrone (119q)69,94
General  protocol  was  followed  using  5  g  of  cyclohexancarboxaldehyde.  Gave  the 
product as a white solid (6.0 g, 95%).
Rf 0.49  (9:1  DCM/MeOH);  mp  51-52  °C;  t)m ax  (film)/cm'‘  3395,  2928,  2855,  1616, 
1447, 1356, 1171, 972, 941, 889; 8H  (300 MHz, CDClj) 6.42 (d, 7 = 7.5 Hz, 1 H, CHN),
3.57  (s, 3 H, CH3), 2.85-2.93 (m,  1   H, CH2CHCH2),  1.76-1.81 (m, 2 H, CH2),  1.60-1.65 
(m, 3 H, CH2 and C(H)HCH2),  1.23-1.31  (m,  2 H, CH2),  1.01-1.14 (m, 3  H, CH2 and 
C(H)HCH2);  8c (75 MHz, CDClj)  144.2 (d), 52.6 (q), 44.2 (d),  28.7 (t),  25.8 (t), 25.1 
(t); m/z (El)  141  (M+, 97),  124 (25),  111  (29), 95 (100), 83 (45); HRMS (El): calcd for 
C8H,5NO (M+) 141.1154, found 141.1160.
C-(Pentyl)-fV-methyl nitrone (119r)
69,94
141General  protocol  was  followed  using  10  g  of  valeraldehyde.  Purified  by  flash 
chromatography (98:2 DCM/MeOH), to give the product as a light yellow solid (8.1  g, 
61%).
Rf 0.34  (9:1  DCM/MeOH);  mp  62-64  °C;  -om ax  (film)/cm''  3246,  2955,  2864,  1636, 
1456,  1375,  1126,  1086, 947;  8H  (300 MHz, CDC13) 6.61  (t, J = 5.9 Hz,  1   H, CHN), 
3.61  (s,  3  H,  NCHi),  2.40  (app.  q,  J =  7.0  Hz,  2  H,  C//2CHN),  1.24-1.48  (m,  4  H, 
CH3(C//2)2CH2),  0.85  (t, J = 7.2  Hz,  3  H, CH2C//3);  8c  (75  MHz,  CDC13)  140.5  (d),
52.3  (q),  27.5  (t),  26.5  (t),  22.5  (t),  13.7  (q);  m/z (El)  115  (M+,  100),  86 (18); HRMS 
(El): calcd for C6Hi3NO (M+) 115.0997, found 115.0997.
C-(2,6-I)imethylphenvll-,V-methyl nitrone (119s)1 9 1
General protocol was followed using 4 g of 2,6-dimethylbenzaldehyde, and refluxed for 
18 hours.  Recrystallisation from hexane/EtOAc provided the product as white crystals 
(4.1 g, 85%).
Rf 0.41  (9:1  DCM/MeOH); mp  156-159 °C; v w  (neat)/cm_1 3040,  2913,  1590,  1460, 
1431,  1395,  1176,  1042, 954; 8h (300 MHz, CDC13) 7.56 (br s,  1  H, CHN), 7.19 (dd, J 
= 8.0,7.2 Hz,  1 H, ArH), 7.05 (d, J = 7.8 Hz, 2 H, Ar//), 3.90 (s, 3 H, NC//3), 2.29 (s, 6 
H, ArC//3);  8c (75  MHz,  CDC13)  137.6 (s),  137.2 (s),  135.4  (d),  129.5  (d),  128.5  (s),
128.1  (d),  127.6 (d), 53.4 (q),  19.9 (q); m/z (Cl)  164 (MH+,100); HRMS (Cl): calcd for 
Ci0H14NO (MH+) 164.1075, found 164.1068.
C-(2,3,4,5,6-lVntamethylphenyl)-A-methyl nitrone (119t)191
General protocol was followed using 2 g of pentamethylbenzaldehyde, and refluxed for 
18 hours.  Recrystallisation from hexane/EtOAc provided the product as white crystals 
(1.4 g, 59%).
Rf 0.44 (9:1  DCM/MeOH);  mp 206-209  °C;  t)m ax  (neat)/cm‘‘ 3037,  2916,  1585,  1417, 
1389,  1182, 952; 8H  (500 MHz, CDC13) 7.61  (s,  1  H, CHN), 3.90 (s, 3 H, NC//3), 2.23 
(s,  3  H,  Ar(CH,h),  2.20  (s,  6  H,  Ar(CH3)s),  2.18  (s,  6  H,  Ar(CH3)5);  8C   (125  MHz,
142CDC13)  137.2 (d),  136.8 (s),  132.9 (s),  132.3 (s),  126.5 (s), 53.0 (q),  17.3 (q),  17.0 (q),
16.4  (q); m/z (El) 205  (M+, 26),  190 (97),  175  (100),  159 (34),  149 (18); HRMS  (El): 
calcd for C13H19NO (M+) 205.1461, found 205.1470.
C-(2-Iodophenyl)-,/V-methyl nitrone (119u)
General protocol was followed using 0.5 g of 2-iodobenzaldehyde, and refluxed for 18 
hours.  Recrystallised  from  hexane/EtOAc,  gave  the  product  as  white  crystals  (0.6  g, 
98%).
Rf 0.59  (9:1  DCM/MeOH); mp  122-124 °C;  0)m ax (neat)/cm_1  3086,  2924,  1573,  1405, 
1164, 1011, 946; 6H  (300 MHz, CDC13) 9.18 (dd, J= 8.0, 1.6 Hz,  1  H, Ar//), 7.89 (dd, J 
= 8.0,  1.3 Hz,  1   H, Ar//), 7.70 (s,  1  H, CHN), 7.38-7.44 (m,  1  H, Ar//), 7.06 (app. dt, J 
= 7.8,  1.6 Hz,  1   H, Ar//),  3.91  (s, 3 H, NC//3);  6C  (75 MHz, CDCI3)  139.7 (d),  138.6 
(d),  132.3 (s),  131.6 (d),  129.2 (d),  128.5 (d), 99.0 (s), 55.2 (q); m/z (El) 261  (M+,  100), 
245 (33),  134 (52),  119 (49),  107 (99), 89 (66), 77 (98), 63 (64); HRMS (El): calcd for 
C8H8INO (M+) 260.9645, found 260.9635.
C-(3-Iodophenyl)-A-methyl nitrone (119v)
General protocol was followed using 0.5 g of 3-iodobenzaldehyde, and refluxed for 18 
hours.  Recrystallised  from  hexane/EtOAc,  gave  the  product  as  white  crystals  (0.5  g, 
89%).
R f 0.58  (9:1  DCM/MeOH);  mp  110-113  °C; om ax (neatj/cm' 1   3078,  1575,  1468,  1392, 
1159,  1064, 948; 5H  (300 MHz, CDCI3) 8.60 (s,  1   H, Ar//),  8.11  (d, J = 7.8 Hz,  1  H, 
Ar//), 7.71  (d, i  = 8.0 Hz,  1 H, Ar//), 7.28 (s,  1   H, C//N), 7.12 (app. t, J = 8.0 Hz,  1  H, 
Ar//), 3.86 (s, 3 H, NC//3); Sc (75 MHz, CDCI3)  139.2 (d),  136.7 (d),  133.6 (d),  132.3 
(s),  130.1  (d),  127.4 (d), 94.2 (s), 54.7 (q); m/z (El) 261  (M+,  100); HRMS  (El): calcd 
for CgHgINO (M+) 260.9645, found 260.9645.
1434.3.  Cycloaddition with pentafluorophenyl-vinyl sulfonate procedures
Method A:
To pentafluorophenyl vinyl sulfonate 100 (1 eq.) in dry toluene was added nitrone (1.2- 
2  eq.),  and  the  mixture  was  heated  at  reflux  for  1-5  hours.  The  reaction  was 
concentrated  in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography 
(starting 16:1 petroleum ether 40-60°C /Et2 0) to give the title compound.
Method B:
To pentafluorophenyl vinyl sulfonate 100 (1 eq.) in dry toluene was added nitrone (1.5 
eq.),  and  the  mixture  was  heated  in  a CEM  microwave  at  140  °C  for  10  mins.  The 
reaction  was  concentrated  in  vacuo  and  the  crude  residue  was  purified  by  flash 
chromatography (starting 9:1 petroleum ether 40-60°C/Et20) to give the title compound
Pentafluorophenyl-vinyl sulfonate (100)69,94
o,  o \x//  /
PFPO  ^
NEt3  (11.2  g,  110.4  mmol)  was  carefully  added  to a  stirring  suspension  of
pentafluorophenol  (8.1  g,  44.2 mmol)  in  DCM  (20  mL).  2-Chloroethane-l-sulfonyl
chloride  (6.0  g,  36.8  mmol)  in DCM  (60 mL)  was  then  treated  slowly  with  the PFP 
solution while stirring in an ice-MeOH bath, keeping the internal temperature below  10 
°C.  The reaction was allowed to stir for a further 10 minutes after addition, warmed up 
to  RT,  and  then  diluted  with DCM  (ca.  50  mL).  The DCM  layer  was  washed
consecutively with 2M  HC1 (3 x  50 mL), sat. NaHCC>3  (3 x  50 mL), H2O (1 x 50 mL),
dried with MgSCL, and filtered.  The filtrate was concentrated in vacuo to leave a crude 
oil, which was purified by flash chromatography (9:1 hexane/Et2 0) to give a grey solid 
(8.5 g, 84%).
Rf 0.45  (1:1  hexane/Et20);  mp  24-26  °C;  \> m ax  (neatycm1   3123,  3080,  1649,  1522, 
1393,  1144, 997;  6H  (300 MHz, CDC13) 6.80 (dd, J =  16.5, 9.8 Hz,  1  H, CHCH2), 6.54 
(d,  J =  16.5  Hz,  1   H,  CHC/TH),  6.34  (d,  J =  9.8  Hz,  1   H,  CHCHtf);  6C   (75  MHz, 
CDCI3)  133.2 (t),  131.8 (d); m/z (El) 274 (M+, 54), 211  (49),  184 (100),  155 (63),  136 
(37),  117  (28),  91  (79);  HRMS  (El):  calcd  for  C8H3F5 03S  (M+)  273.9723,  found 
273.9727.
144(35*, 45*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic acid pentafluorophenyl ester
(103a)69'94
\y/
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (5.0 g,  18.2 mmol) in dry 
toluene (50 mL) was added C-phenyl-iV-methyl nitrone 119a (6.2 g, 45.6 mmol) and the 
mixture was heated at reflux for 2 hours. The reaction was concentrated in vacuo and 
the crude residue was purified by flash chromatography (starting  16:1  hexane/Et2 0) to 
give the title compound (4.9 g, 65%) as a grey white solid.
Rf 0.28 (3:1 hexane/Et20); mp 69-71 °C; t w  (filmVcm'12970, 2880,  1522,  1464, 1391, 
1142, 997, 746; 8H  (300 MHz, CDC13) 7.36-7.49 (m, 5 H, Ar//), 4.61  (dd, J =  10.2, 3.2 
Hz,  1 H, SCHC//H), 4.49 (dd, J =  10.2, 8.0 Hz,  1   H, SCHCH//), 4.33 (app. td, J = 7.1,
3.2  Hz,  1   H, SC//), 4.06 (d, J = 7.1  Hz,  1  H, NC//), 2.70 (s, 3 H, NC//3); Sc (75 MHz, 
CDC13)  135.6 (s),  129.2 (d),  129.1  (d),  128.0 (d), 74.1  (d), 73.9 (d),  66.8 (t), 42.7  (q); 
m/z (El) 410 (100), 409  (M+,  100), 332  (33),  183  (76),  161  (100),  119  (100);  HRMS 
(El):  calcd  for  C16H12F5NO4S  (M+)  409.0407,  found  409.0418;  Anal,  calcd  for 
C16H12F5NO4S: C 46.95, H 2.95, N 3.42, found C 46.87, H 2.92, N 3.27.
(35*, 45*)-3-(4-Methoxyphenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103b)69,94
PFPO
MeO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (4.4 g,  16.1  mmol) in dry 
toluene (50 mL)  was  added  C-(4-methoxyphenyl)-A-methyl nitrone  119b (4.0 g,  24.2 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/Et2 0) to give the title compound (5.0 g, 71%) as a yellow solid.
Rf 0.22 (2:1 petroleum ether 40-60°C/Et20); mp 79-81  °C; \)m ax (filmVcm1  2934,  1612, 
1520,  1466,  1389,  1252,  1182,  995;  8H  (300 MHz,  CDC13)  7.37  (d, J =  8.7  Hz,  2 H, 
Ar//), 6.90 (d, J = 8.7 Hz, 2 H, Ar//), 4.58 (dd, J =  10.2, 3.1 Hz,  1  H, SCHC//H), 4.47 
(dd, J = 10.2, 8.1 Hz, 1 H, SCHCH//), 4.29 (app. td, 7= 7.8, 3.1 Hz, 1  H, SC//), 3.99 (d,
145J = 7.1  Hz,  1   H, NCH), 3.80 (s, 3 H, OC//3), 2.67 (s, 3 H, NC//3); 8C  (75 MHz, CDC13)
160.2  (s),  129.2 (d),  127.2 (s),  114.5 (d), 73.7 (d), 66.7 (t), 55.3 (q), 42.5 (q),  1   x d not 
observed; m/z (El) 439 (M+, 57),  184 (19),  165  (100),  147  (55),  86 (55); HRMS  (El): 
calcd  for  CnH^FsNOsS  (M+)  439.0513,  found  439.0501;  Anal,  calcd  for 
ChHmFsNOsS: C 46.47, H 3.21, N 3.19, found C 46.40, H 3.11, N 3.16.
(3S*, 4S*)-3-(4-AlIyloxyphenyl)-2-methylisoxazolidine-4-suIfonic acid 
pentafluorophenyl ester (103c)69,94
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate  100 (4.0 g,  14.6 mmol) in dry 
toluene  (50  mL)  was  added  C-(4-allyloxyphenyl)-A-methyl  nitrone  119c  (3.5  g,  18.2 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
petroleum  ether 40-60°C/Et20)  to  give  the  title  compound  (5.5  g,  81%)  as  a  yellow 
solid.
Rf 0.38 (2:1 petroleum ether 40-60°C/Et20); mp 58-60 °C; Dm ax (filmVcm"1  2970, 2878, 
1611,  1520,  1429,  1389,  1246,  1144, 997, 932, 777; 5h (300 MHz, CDC13) 7.37 (d, J =
8.8  Hz, 2 H, Ar//), 6.92 (d, J = 8.8 Hz, 2 H, Ar//), 6.04 (ddt, J = 17.2, 10.5, 5.3 Hz, 1  H, 
OCH2C//CH2), 5.41  (app. dq, J = 17.2,  1.5 Hz,  1  H, OCH2CHC//H), 5.29 (app dq, J =
10.5,  1.5 Hz,  1  H,  OCH2CHCH//), 4.58  (dd, J =  10.2,  3.2 Hz,  1   H,  SCHC//H),  4.53 
(app.  dt,  J  =  5.3,  1.5  Hz,  2  H,  OC//2CHCH2),  4.46  (dd,  J  =  10.2,  8.0  Hz,  1   H, 
SCHC//H), 4.29 (app. td, J = 7.6, 3.2 Hz,  1   H, SC//), 3.99 (d, J = 7.2 Hz,  1   H, NC//), 
2.63  (s,  3  H,  NC//3);  6C   (75  MHz,  CDC13)  159.2  (s),  133.0  (d),  129.2  (d),  127.4  (s),
117.9  (t), 115.2 (d), 73.8 (d), 68.8 (t), 66.7 (t), 42.6 (q); m/z (El) 465 (M+, 71), 218 (25), 
191  (100),  136  (37);  HRMS  (El):  calcd  for  C19H16F5NO5S  (M+)  465.0669,  found 
465.0665.
146(35*, 4S*)-2-Methyl-3-(4-nitro-phenyl)isoxazolidine-4-sulfonic acid
pentafluorophenyl ester (103d)69,94
PFPO O
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (5.0 g,  18.2 mmol) in dry 
toluene  (50  mL)  was  added  C-(4-nitrophenyl)-A-methyl  nitrone  119d  (4.9  g,  27.4 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
petroleum ether 40-60°C/Et20) to give the title compound (3.6 g, 43%) as a white solid. 
R f  0.35  (2:1  petroleum  ether 40-60°C/Et20);  mp  127-129  °C;  (film)/cm-1 3078, 
2856, 1601, 1518,  1389,  1105, 993, 779; 5h (300 MHz, CDC13) 8.26 (d, J = 8.8 Hz, 2 H, 
Ar//), 7.70 (d, J = 8.8 Hz, 2 H, Ar//), 4.62 (dd, J = 10.2, 3.2 Hz,  1   H, SCHC/m), 4.50 
(dd, J = 10.2, 7.8 Hz, 1  H, SCHCH//), 4.27 (app. td, /=  7.2, 3.2 Hz, 1  H, SC//), 4.20 (d, 
/=  7.0 Hz,  1   H, NC//), 2.73 (s, 3 H, NC//3); 5C  (75 MHz, CDC13)  148.4 (s),  143.1  (s),
129.0  (d),  124.3  (d),  73.8  (d), 72.9  (d), 66.9  (t),  42.9  (q); m/z (El) 454  (M+,  97),  207 
(67),  191  (88),  164  (45),  131  (24),  116  (100);  HRMS  (El):  calcd for C^HnFsNzOeS 
(M+) 454.0258,  found 454.0265;  Anal,  calcd for C16H11F5N2O6S:  C 42.30,  H 2.44,  N 
6.17, found C 42.41, H 2.43, N 6.05.
(3S*, 4S*)-3-(4-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103e)
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (3.2 g,  11.8 mmol) in dry 
toluene  (30  mL)  was  added  C-(4-chlorophenyl)-A-methyl  nitrone  119e  (3.0  g,  17.7 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/Et2 0) to give the title compound (4.0 g, 77%) as light yellow solid.
Rf 0.46  (2:1  hexane/Et2 0);  mp  99-102  °C;  X > m ax  (filmVcm-1 2968,  2882,  1522,  1466, 
1389,  1184,  1096, 997, 777; 5h (300 MHz, CDC13) 7.42 (d, J = 8.6 Hz, 2 H, Ar//), 7.36 
(d, J =  8.6 Hz, 2 H, Ar//), 4.59 (dd, J =  10.2,  3.1  Hz,  1   H, SCHC//H), 4.47  (dd, J =
PFPO
Ox   ,0
Cl
14710.2, 8.1  Hz,  1  H, SCHCH//), 4.26 (app. td, J = 7.4, 3.1  Hz,  1   H, SC//), 4.03 (d, J = 7.1 
Hz,  1   H, NC//), 2.69 (s, 3 H, NC//3); Sc (75 MHz, CDC13)  135.2 (s),  134.1  (s),  129.4 
(d), 129.3 (d), 73.8 (d), 73.4 (d), 66.8 (t), 42.7 (q); m/z (El) 445 (M+, 37C1, 26), 443 (M+, 
35C1,  100),  196  (72),  151  (80),  115  (66),  89  (24);  HRMS  (El):  calcd  for 
Ci6Hn35ClFsN04S (M+) 443.0018, found 443.0019; Anal, calcd for CiaHnClFsNC^S: C
43.30,  H 2.50, N 3.16, found C 43.40, H 2.47, N 2.97.
(3S*, 45*)-3-(4-Bromophenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103f)
PFPO
Br
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (3.0 g,  10.9 mmol) in dry 
toluene  (30  mL)  was  added  C-(4-bromophenyl)-A-methyl  nitrone  119f  (3.5  g,  16.4 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
petroleum  ether 40-60°C/Et20)  to  give  the  title  compound  (5.9  g,  66%)  as  a  yellow 
solid.
R f  0.33  (2:1  petroleum  ether  40-60°C/Et20);  mp  112-114  °C;  \)m ax  (filmVcm1  2885, 
1589, 1518, 1477, 1379, 1171, 993, 783; 6r (300 MHz, CDC13) 7.52 (d, J= 8.6 Hz, 2 H, 
Ar//), 7.35 (d, J = 8.6 Hz, 2 H, Ar//), 4.59 (dd, J = 10.2, 3.2 Hz,  1 H, SCHC//H), 4.46 
(dd, J = 10.2, 8.0 Hz,  1  H, SCHCH//), 4.25 (app. td, J = 7.4, 3.2 Hz, 1  H, SC/7), 4.02 (d, 
J = 7.2 Hz,  1   H, NC/7), 2.69 (s, 3 H, NC//3); 5C  (75 MHz, CDC13)  134.7 (s),  132.3 (d),
129.6  (d),  123.3  (s), 73.8 (d), 73.4 (d),  66.8  (t), 42.7  (q); m/z (El) 489  (M+, slBr, 50), 
487  (M+,  79Br,  48),  240  (28),  213  (22),  197  (18),  116  (100);  HRMS  (El):  calcd  for 
Ci6Hn79BrF5N0 4S  (M+) 486.9512, found 486.9506;  Anal,  calcd for CigHnBrFsNC^S: 
C 39.36, H 2.27, N 2.87, found C 39.40, H 2.22, N 2.75.
(3S*, 4S*)-3-(3-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103g)69,94
PFPO
C l
148Using Method A. To pentafluorophenyl vinyl  sulfonate 100 (5.0 g,  18.2 mmol) in dry 
toluene  (50  mL)  was  added  C-(3-chlorophenyl)-A-methyl  nitrone  119g  (4.6  g,  27.4 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/Et2 0) to give the title compound (5.3 g, 65%) as a yellow solid.
Rf 0.37 (3:1 hexane/Et20); mp 78-81 °C; t)m „ (neat)/cm'‘ 3080, 2970,  1576,  1516, 1472, 
1394,  1267,  1142, 993, 791; 5H  (300 MHz, CDC13) 7.49 (s,  1   H, Ar//), 7.29-7.38 (m, 3 
H, Ar//), 4.59 (dd, J =  10.2, 3.2 Hz,  1   H, SCHC//H), 4.47 (dd, J =  10.2, 8.0 Hz,  1   H, 
SCHCH//), 4.28 (app. td, J = 7.2, 3.2 Hz,  1   H, SC//), 4.04 (d, J = 7.0 Hz,  1   H, NC//), 
2.71  (s,  3  H,  NC//3);  8c (75  MHz, CDC13)  137.8  (s),  135.0  (s),  130.4  (d),  129.4  (d),
127.9  (d),  126.4 (d), 73.8  (d), 73.3  (d),  66.8 (t), 42.7  (q); m/z (El) 445  (M+, 37C1, 26), 
443  (M+,  35C1,  72),  196  (32),  151  (34),  101  (100);  HRMS  (El):  calcd  for 
C,6H,i35C1F5N04S (M+) 443.0018, found 443.0019; Anal, calcd for C|6H| 1CIF5NO4S: C
43.30,  H 2.50, N 3.16, found C 43.66, H 2.41, N 3.10.
(3S*, 4S*)-3-(3-Bromophenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103h)69’94
\y/
PFPO
Br
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (5.0 g,  18.2 mmol) in dry 
toluene  (50  mL)  was  added  C-(3-bromophenyl)-A-methyl  nitrone  119h  (5.9  g,  27.4 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/Et2 0) to give the title compound (5.9 g, 6 6%) as a light brown solid.
R f 0.26 (3:1 hexane/Et2 0); mp 86-88 °C; u max (filmVcm' 1  3090, 2968, 2881, 1570, 1522, 
1431,  1391,  1267,  1142, 997, 791; SH  (300 MHz, CDC13) 7.65 (s,  1  H, Ar//), 7.48-7.52 
(m,  1   H Ar//), 7.40 (br d, J = 7.7 Hz,  1   H, Ar//), 7.26 (app. t, J = 7.7 Hz,  1   H, Ar//), 
4.59 (dd, J = 10.2, 3.2 Hz, 1 H, SCHC//H), 4.46 (dd, J = 10.2, 8.0 Hz,  1  H, SCHCH//), 
4.28 (app. td, J = 7.1, 3.2 Hz,  1 H, SC//), 4.02 (d, J = 7.0 Hz,  1 H, NC//), 2.71  (s, 3 H, 
NCZ/3); 8c (75 MHz, CDC13)  138.1  (s),  132.4 (d),  130.7 (d),  130.6 (d),  126.9 (d),  123.2 
(s), 73.8 (d), 73.2 (d), 66.8 (t), 42.8 (q); m/z (El) 488 (M+, 8lBr, 64), 486 (M \ 79Br, 63), 
332  (54),  274  (20),  241  (73),  155  (72),  117  (68),  89  (100);  HRMS  (El):  calcd  for
149C|6Hn 79BrF5N0 4 S  (M+) 486.9512, found 486.9506;  Anal,  calcd for C|6H, iBrF5N0 4S:
C 39.36, H 2.27, N 2.87, found C 39.09, H 2.24, N 2.64.
(35*, 45*)-3-(2-FIuorophenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103i)69,94
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate  100 (4.0 g,  14.6 mmol) in dry 
toluene  (50  mL)  was  added  C-(2-fluorophenyl)-A-methyl  nitrone  1191  (3.4  g,  21.9 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/Et2 0) to give the title compound (2.9 g, 47%) as a yellow oil.
Rf 0.28 (2:1  hexane/Et20); Dm ax (neat)/cm ‘2970, 2883,  1618,  1587,  1522,  1462,  1394, 
1184,  1105, 995, 779; 5h (300 MHz, CDCI3) 7.47 (ddd, J = 9.0, 7.4,  1.5 Hz,  1 H, Ar//), 
7.34-7.41  (m,  1   H,  Ar//),  7.09-7.23  (m,  2  H, Ar//),  4.63  (dd, J =  14.1,  7.4 Hz,  1  H, 
SCHC//H), 4.49-4.56 (m, 2 H, SCH and SCHCH//), 4.33 (br d, J = 4.8 Hz,  1  H, NC//), 
2.70 (s, 3 H, NC//3); 8c (75 MHz, CDCI3)  161.2 (s, Jcf = 248.4 Hz),  131.0 (d, Jcf = 8.6 
Hz),  129.9 (d, Jcf = 3.3 Hz), 124.9 (d, J C f  = 3.6 Hz),  122.1  (s, 7CF = 11.6 Hz), 116.3 (d, 
7 c f   = 21.6 Hz), 72.3  (d),  68.6 (d), 66.9 (t), 42.8 (q); m/z (El) 427 (M+,  100),  180 (99), 
133 (98); HRMS  (El): calcd for C16HnF6N04S (M+) 427.0313, found 427.0335; Anal, 
calcd for C^HnFeNC^S: C 44.97, H 2.59, N 3.28, found C 45.48, H 2.71, N 2.88.
(35*, 45*)-3-(2-Chlorophenyl)-2-methylisoxazoIidine-4-suIfonic acid 
pentafluorophenyl ester (103j)
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (3.0 g,  10.9 mmol) in dry 
toluene  (30  mL)  was  added  C-(2-chlorophenyl)-A-methyl  nitrone  119j  (2.8  g,  16.4 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/Et2 0) to give the title compound (2.7 g, 56%) as an orange solid.
150R f 0.23 (2:1  petroleum ether 40-60°C/Et20); mp 72-73 °C; t)m ax (filmj/cm1  2968, 2883, 
1580,  1522,  1472,  1393,  1186,  998,  783;  8H   (300  MHz,  CDC13)  7.52-7.56  (m,  1   H, 
Ar//), 7.41-7.44 (m,  1   H, Ar//), 7.30-7.35  (m, 2 H, Ar//), 4.71  (br d, J = 6.9 Hz,  1   H, 
NC//),  4.65  (dd, J =  10.1, 3.2  Hz,  1   H, SCHC/7H),  4.56  (dd,  J =  10.1, 7.9 Hz,  1   H, 
SCHCH//), 4.45 (app. td, 7 = 7.3, 3.2 Hz, 1  H, SC//), 2.70 (s, 3 H, NC//3); 8c (75 MHz, 
CDCI3)  134.6 (s),  132.7 (s),  130.4 (d),  130.3 (d),  129.8 (d),  127.6 (d), 73.0 (d), 70.1  (d),
67.1  (t), 42.6 (q); m/z (El) 445  (M+, 37C1, 38), 443 (M+, 35C1,  100),  196 (88),  151  (63), 
134  (66),  115  (44);  HRMS  (El):  calcd  for  Ci6H, IC1F5N04S  (M+)  443.0018,  found 
443.0023; Anal, calcd for C16Hn35ClF5N0 4S: C 43.30, H 2.50, N 3.16, found C 43.45, 
H 2.57, N 2.87.
(3S*, 4S*)-3-(2-BromophenyI)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103k)
PFPO
Using Method A. To pentafluorophenyl vinyl  sulfonate 100 (3.5  g,  12.8 mmol) in dry 
toluene  (40  mL)  was  added  C-(2-bromophenyl)-/V-methyl  nitrone  119k  (4.1  g,  19.2 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/EtjO) to give the title compound (3.2 g, 51%) as a light brown solid.
Rf0.26 (2:1  petroleum ether 40-60°C/Et20); mp 76-78 °C; t)m ax (filmVcm' 1  2967, 2919, 
1515,  1475, 1386,  1179, 992, 778; 8H  (300 MHz, CDC13) 7.61  (dd,7=8.0, 1.3 Hz,  1  H, 
Ar//), 7.52 (dd, 7 = 7.8,  1.6 Hz,  1   H, Ar//), 7.34 (app. dt, 7 = 7.5,  1.3 Hz,  1   H, Ar//), 
7.23 (app. dt, 7 = 7.8,  1.9 Hz,  1  H, Ar//), 4.75 (br d, 7 = 6.8 Hz,  1   H, NC//), 4.64 (dd, 7 
= 10.2, 3.3 Hz,  1   H, SCHC/ZH), 4.55 (dd, 7 =  10.2, 7.9 Hz,  1   H, SCHCH//), 4.42 (app. 
td, 7 = 7.6,  3.3  Hz,  1  H,  SC//),  2.71  (s, 3 H, NC//,);  8c  (75  MHz, CDCI3)  134.4 (s),
133.7  (d),  130.5 (d),  129.9 (d),  128.2 (d),  124.8 (s), 73.2 (d), 72.1  (d), 67.2 (t), 42.5 (q); 
m/z (El) 489 (M+, 81Br, 20), 487 (M+, 79Br, 20), 244 (70), 240 (43),  198 (16),  183 (23), 
155 (24), 134 (57),  116 (100); HRMS (El): calcd for Ci6H1179BrF5N04S (M+) 486.9507, 
found 486.9499.
151(35*, 45*)-2-Methyl-3-naphthalen-2-yIisoxazolidine-4-siilfonic acid
pentafluorophenyl ester (1031)69,94
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (4.0 g,  14.6 mmol) in dry 
toluene (50 mL)  was  added  C-(2-naphthyl)-A-methyl nitrone  1191  (4.1  g, 21.9 mmol) 
and  the  mixture  was  heated  at  reflux  for  2  hours.  The  reaction  was  concentrated  in 
vacuo  and  the  crude  residue  was  purified  by  flash  column  chromatography  (starting 
16:1 hexane/Et2 0) to give the title compound (4.8 g, 72%) as a yellow solid.
Rf 0.27  (3:1  hexane/Et20);  mp  111-114  °C; v w   (film)/cm'‘ 3059,  2968,  2880,  1520, 
1466,  1389,  1184, 995, 822, 746; SH  (300 MHz, CDC13) 7.96 (s,  1  H,  Ar//), 7.84-7.91 
(m, 3 H, Ar//), 7.58 (dd, J = 8.5,  1.5 Hz,  1  H, Ar//), 7.50-7.55 (m, 2 H, Ar//), 4.67 (dd, 
J = 10.2, 3.1 Hz, 1 H, SCHC/ZH), 4.56 (dd, J = 10.2, 7.9 Hz, 1  H, SCHCH//), 4.44 (app. 
td, J = 7.3, 3.1  Hz,  1   H, SC//), 4.14 (d, J = 7.4 Hz,  1  H, NC//), 2.75 (s, 3 H, NC//3); 8c 
(75 MHz, CDCI3)  133.6 (s),  133.2 (s),  132.9 (s),  129.2 (d),  128.1  (d),  128.0 (d),  127.8 
(d),  126.8  (d),  126.7  (d),  124.7  (d), 74.3  (d), 73.4 (d),  67.0 (t), 42.8  (q); m/z (El) 459 
(M+, 35),  185 (26),  167 (100),  152 (41),  128 (34); HRMS (El): calcd for C20H14F5NO4S 
(M+) 459.0564,  found 459.0572;  Anal,  calcd  for C20H14F5NO4S:  C  52.29,  H  3.07,  N
3.05,  found C 52.11, H 2.98, N 2.96.
(35*, 45*)-Terephthyl PFP bis-isoxazolidine (103m)
PFPO
OPFP
Using Method A with  1.4 eq. of 100. To pentafluorophenyl vinyl sulfonate 100 (1.0 g, 
3.7 mmol) in dry toluene (10 mL) was added C-(terephthyl)-A-methyl bis nitrone 119m 
(0.5 g, 2.7 mmol) and the mixture was heated at reflux for 2 hours.  The reaction was 
concentrated  in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography 
(starting 16:1 petroleum ether 40-60°C/Et20) to give the title compound (0.9 g, 35%) as 
a white solid.
152R f 0.09 (2:1  petroleum ether 40-60°C/Et20); mp 66-68 °C; \)m ax (filmVcm1  2882,  1522, 
1466,  1389,  1184, 997; 8H  (300 MHz, CDC13) 7.51  (br s, 4 H, Ar//), 4.59 (dd, J = 10.2,
2.9 Hz, 2 H, SCHC//H), 4.47 (app. t, J = 9.1 Hz, 2 H, SCHCH//), 4.29 (app. td, J = 7.5,
2.9 Hz, 2 H, SC//), 4.08 (app. t, J = 6.4 Hz, 2 H, NC//), 2.70 (s,  6 H, NC//3);  8C  (75 
MHz, CDC13)  136.9 (s),  136.8 (s),  128.7 (d),  128.2 (d), 73.9 (d), 73.8 (d), 73.5 (d), 66.9 
(t), 66.8 (t), 42.9 (q), 42.7 (q); m/z (FAB+) 740 (MH+, 7), 307 (19),  154 (100); HRMS 
(FAB+):  calcd for C26H19F10N2O8S2 (MH+) 741.0423, found 741.0410; Anal, calcd for 
C26H,8FioN208S2: C 42.17, H 2.45, N 3.78, found C 42.40, H 2.49, N 3.62.
(3S*,  4S*)-3-Furan-2-yl-2-methylisoxazolidine-4-sulfonic  acid  pentafluorophenyl 
ester (103n)69,94
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (5.0 g,  18.2 mmol) in dry 
toluene (50 mL) was added C-(2-furyl)-A-methyl nitrone 119n (4.6 g, 36.5 mmol) and 
the mixture was heated at reflux for 2 hours.  The reaction was concentrated in vacuo 
and the crude residue was purified by flash chromatography (starting 16:1 hexane/Et2 0) 
to give the title compound (5.1 g, 70%) as a brown oil.
Rf 0.28 (2:1 hexane/Et20); um „ (neat)/cm'‘ 3126, 2972, 2883,  1520,  1468,  1344,  1246, 
1145, 1107, 999, 750; §h (300 MHz, CDCI3) 7.46-7.48 (m,  1 H, OC//CHCH), 6.48 (d, J 
= 3.2 Hz,  1   H, OCC//CH), 6.38 (dd, 7= 3.2,  1.9 Hz,  1   H, OCHC//CH), 4.69 (app. td, J 
= 7.8, 3.2 Hz,  1   H, SCH), 4.59 (dd, J =  10.3, 3.2 Hz,  1  H, SCHC//H), 4.45-4.51  (m,  1  
H, SCHCH//), 4.17 (br s,  1   H, NC//), 2.76 (s, 3 H, NC//3); §c (75 MHz, CDCI3)  146.7 
(s),  144.0 (d),  111.1  (d),  110.8 (d), 69.7  (d),  67.5  (d), 66.7  (t), 42.8  (q); m/z (El) 399 
(M+,  100); HRMS (El): calcd for ChHioFsNOsS (M+) 399.0200, found 399.0185.
(3S*, 4S*)-3-(5-Bromofuran-2-yl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103o)69,94
PFPO
153Using Method A. To pentafluorophenyl vinyl sulfonate  100 (5.6 g, 20.4 mmol) in dry 
toluene  (50  mL)  was  added  C-(5-bromo-2-furyl)-A-methyl  nitrone  119o  (5.0  g,  24.5 
mmol) and the mixture was heated at reflux for 2 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
petroleum ether 40-60°C/Et20) to give the title compound (4.3 g, 44%) as a yellow oil. 
R f 0.59  (1:1  petroleum ether 40-60°C/Et20); \)m ax (neatycm1  3138,  2972,  1649,  1520, 
1468,  1321,  1184,  1130,  997,  791;  8H   (300 MHz,  CDC13)  6.47  (d,  J =  3.3  Hz,  1   H, 
C//CO), 6.31  (d, J = 3.3 Hz,  1  H, CHCBr), 4.66 (app. td, J = 7.3, 3.0 Hz,  1   H, SC//),
4.57  (dd, J =  10.2, 3.0 Hz,  1  H, SCHC//H), 4.47 (dd, J = 10.2, 8.2 Hz,  1   H, SCHCH//), 
4.11  (br s,  1   H, NC//), 2.75 (s, 3 H, NC//3); 5C  (75 MHz, CDC13)  148.7 (s),  123.8 (s),
113.8  (d),  112.6 (d), 69.6 (d), 67.5  (d), 66.7 (t), 42.9 (q); m/z (El) 479 (M+,  81Br, 67), 
All (M+, 79Br, 63), 433 (37), 230 (25), 205 (100),  159 (41),  106 (42); HRMS (El): calcd 
for Ci4H979BrF5N0 5S (M+) 476.9305, found 476.9307; Anal, calcd for Ci4H9BrF5N0 5S: 
C 35.16, H 1.90, N 2.93, found C 34.90, H 1.89, N 2.53.
(3S*, 4S*)-3-Cyclopropyl-2-methylisoxazolidine-4-sulfonic acid pentafluorophenyl 
ester (103p)69,94
\y/
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (4.0 g,  14.6 mmol) in dry 
toluene (50 mL) was added C-(cyclopropyl)-A-methyl nitrone 119p (1.8 g,  18.2 mmol) 
and  the  mixture  was  heated  at reflux  for  2  hours.  The  reaction  was  concentrated  in 
vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/Et2 0) to give the title compound (3.4 g, 62%) as an orange/yellow solid.
Rf 0.16 (2:1 hexane/Et20); mp 60-62 °C; um ax (film)/cm'' 3088, 2930, 2880, 1522, 1468, 
1387,  1184, 1144, 997, 910, 773, 715; 8H  (300 MHz, CDC13) 4.46 (app. d, J = 7.0 Hz, 1  
H, SCHC//H), 4.22-4.32 (m, 2 H, SCH and SCHCH//), 2.83 (s, 3 H, NC//3), 2.49 (br s, 
1   H, NC//), 0.94-1.06 (m,  1   H, CH2CH2C//), 0.54-0.76 (m, 3 H, (C//2)2CH), 0.37-0.45 
(m,  1  H, (C//2)2CH); 5c (75 MHz, CDC13) 74.1  (d), 71.7 (d), 66.4 (t), 43.9 (q),  12.8 (d), 
4.6 (t),  1.9 (t); m/z (El) 373 (M+,  100), 332 (100),  183 (89),  155 (90),  124 (93); HRMS 
(El):  calcd  for  Ci3H12F5N04S  (M+)  373.0407,  found  373.0423;  Anal,  calcd  for 
C13Hi2F5N04S: C 41.83, H 3.24, N 3.75, found C 41.14, H 3.25, N 3.72.
154(35*, 45*)-3-CyclohexyI-2-methylisoxazolidine-4-sulfonic acid pentafluorophenyl 
ester (103q)6994
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (5.0 g,  18.2 mmol) in dry 
toluene (50 mL) was added C-(cyclohexyl)-A-methyl nitrone  119q (5.2 g,  36.5  mmol) 
and  the  mixture  was  heated  at  reflux  for  2  hours.  The  reaction  was  concentrated  in 
vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  16:1 
hexane/Et2 0) to give the title compound (4.0 g, 53%) as a yellow oil.
Rf 0.40 (2:1  hexane/Et20); um ax (neat)/cm‘' 2930, 2858,  1672,  1521,  1450,  1387,  1142, 
997, 721; SH  (300 MHz, CDCI3) 4.57 (dd, J = 9.6, 4.9 Hz,  1   H, SCHC77H), 4.18-4.31 
(m,  2  H,  SCH and  SCHCH//),  3.21  (dd, J = 5.8,  4.2  Hz,  1   H, NC//),  2.81  (s, 3  H, 
NC//3),  1.48-1.86  (m,  6 H,  cyclohexyl-//),  1.01-1.31  (m,  5  H,  cyclohexyl-//);  8c  (75 
MHz, CDCI3) 73.8 (d), 68.7 (d), 66.5 (t), 44.9 (q), 41.6 (d), 29.6 (t), 29.3  (t), 26.2 (t),
26.0  (2 x t); m/z (El) 416 (34), 415 (M+, 31), 332 (68),  142 (30), 85 (100); HRMS (El): 
calcd for C^H^FsNC^S (M+) 415.0877, found 415.0882.
(3S*,  45*)-3-Butyl-2-methylisoxazolidine-4-sulfonic  acid  pentafluorophenyl  ester 
(103r)69,94
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (4.0 g,  14.6 mmol) in dry 
toluene (40 mL)  was added C-(pentyl)-A-methyl nitrone  119r (2.5  g, 21.9 mmol) and 
the mixture was heated at reflux for 2 hours.  The reaction was concentrated in vacuo 
and the crude residue  was purified by flash chromatography  (starting  16:1  petroleum 
ether 40-60°C/Et20) to give the title compound (1.0 g, 18%) as a brown oil.
R f 0.11  (2:1  petroleum ether 40-60°C/Et20); Dm ax  (neatycm' 1  2961,  2870,  1647,  1522, 
1466,  1389,  1142,  997,  754;  SH   (300 MHz,  CDC13)  4.50  (dd,  J =  10.2, 4.4 Hz,  1  H, 
SCHC/m), 4.27 (dd, J = 10.2, 8.0 Hz,  1 H, SCHCH//), 4.04-4.10 (m,  1  H, SC//), 3.27 
(br s,  1 H, NC//), 2.79 (s, 3 H, NC//3),  1.62-1.82 (m, 2 H, NCHC//2CH2), 1.32-1.47 (m, 
4 H, CH2(C//2)2CH3), 0.92 (t, J = 7.0 Hz, 3 H, (CH2)3C//3); 5C  (75 MHz, CDC13) 70.8 
(d), 69.3 (d), 66.1 (t), 43.7 (q), 32.6 (t), 27.6 (t), 22.6 (t), 13.8 (q); m/z (El) 390 (42), 389
155(M+, 32), 332 (100),  184 (45),  155 (58),  142 (72); HRMS (El): calcd for CuH^sNCUS
(M+)  389.0720,  found  389.0722;  Anal,  calcd  for C14H16F5NO4S:  C  43.19,  H 4.14,  N
3.60, found C 44.73, H 4.57, N 2.77.
(3S*, 4S*)-3-(2,6-Dimethylphenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103s)
PFPO
Using Method A. To pentafluorophenyl vinyl sulfonate 100 (4.0 g,  14.6 mmol) in dry 
toluene (40 mL) was added C-(2,6-dimethylphenyl)-iV-methyl nitrone 119s (3.6 g, 21.9 
mmol) and the mixture was heated at reflux for 4 hours. The reaction was concentrated 
in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  8:1 
petroleum ether 40-60°C/Et20) to give the title compound (3.9 g, 61%) as a white solid. 
Rf  0.51  (2:1  petroleum  ether 40-60°C/Et20);  mp  114-117  °C;  \)m ax  (neatVcm' 1   2929, 
1515, 1467,  1366, 1169, 990, 776;  (300 MHz, CDCI3) 7.14 (app. dd, /=  8.0, 6.7 Hz,
1  H,  ArH),  7.04  (d,  J = 7.5  Hz,  2 H,  ArH),  4.52-4.68  (m,  4 H,  SCH,  SCHCH2,  and 
NCH), 2.66 (s, 3 H, NCH3), 2.53 (br s, 6 H, Ar(073)2; §c (75 MHz, CDC13)  129.5 (s),
128.8  (d), 70.2 (d), 69.7 (d), 66.9 (t), 42.8 (q), 21.1 (q), 1  x s and 1  x d not observed; m/z 
(El) 437 (M+, 47), 244 (100), 190 (40), 183 (21),  155 (20),  148 (91),  130 (34),  115 (39), 
105  (17),  91  (24);  HRMS  (El):  calcd  for  Ci8Hi6F5N04S  (M+)  437.0715,  found 
437.0707.
(3S*, 4S*)-2-Methyl-3-pentamethylphenylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103t)
PFPO
Using Method A.  To pentafluorophenyl vinyl  sulfonate  100  (1.0  g,  3.7  mmol)  in dry 
toluene  (10  mL)  was  added  C-(2,3,4,5,6-pentamethylphenyl)-A-methyl  nitrone  119t 
(1.1  g, 5.5  mmol) and the mixture was heated at reflux for 5  hours.  The reaction was 
concentrated  in  vacuo  and  the  crude  residue  was  purified  by  flash  chromatography
156(starting 16:1 petroleum ether 40-60°C/Et20) to give the title compound (1.0 g, 57%) as 
a white solid.
Rf  0.66  (2:1  petroleum  ether 40-60°C/Et20);  mp  153-155  °C;  vm ax  (neat)/cm' 1  2962, 
1520,  1472,  1391,  1187, 994, 778; SH  (300 MHz, CDC13) 4.76 (d, J = 8.0, 4.0 Hz,  1   H, 
SCHC//H), 4.62-4.69 (m, 3 H, SCH, SCHCH[//, and NC//), 2.69 (s, 3 H, NC//3), 2.50 
(br s, 3 H, ArC//3), 2.42 (br s, 3 H, ArC//3), 2.25 (s, 3 H, ArC//3), 2.23 (s, 6 H, ArC//3); 
8c (75 MHz, CDC13) 136.2 (s), 134.3 (s), 133.0 (s), 126.6 (s), 71.1 (d), 70.2 (d), 67.1 (t),
42.9  (q),  17.4 (q),  16.9 (q),  16.7 (q); m/z (FAB+) 479 (MH+, 4), 307 (28), 289 (16),  154
(100); HRMS (FAB+): calcd for C2iH23F5N0 4S (MH+) 480.1268, found 480.1278.
(3S*, 4S*)-3-(2-Iodophenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (103u)
PFPO
Using Method B. To pentafluorophenyl vinyl sulfonate 100 (100 mg, 0.43 mmol) in dry 
toluene  (4  mL)  was  added  C-(2-iodophenyl)-A-methyl  nitrone  119u  (170  mg,  0.65 
mmol)  and the mixture was heated in a CEM microwave at  140 °C  for  10 mins. The 
reaction  was  concentrated  in  vacuo  and  the  crude  residue  was  purified  by  flash 
chromatography (starting 9:1 petroleum ether 40-60°C/Et20) to give the title compound 
(75 mg, 33%) as a brown oil.
R f 0.57  (1:1  petroleum ether 40-60°C/Et20);  \)max  (neatycm' 1  2927,  2882,  1516,  1471, 
1392,  1181, 991, 779, 720; 8H  (300 MHz, CDC13) 7.89 (d, J = 8.0 Hz,  1   H, Ar//), 7.46 
(dd, J = 8.0,  1.9 Hz,  1 H, Ar//), 7.39-7.44 (m,  1  H, Ar//), 7.06 (app. dt, /=  8.0,  1.9 Hz, 
1   H, Ar//), 4.62-4.66 (m, 2 H, SCHC//H, and NC//), 4.55  (dd, J =  10.2,  8.0 Hz,  1   H, 
SCHCH//), 4.35 (app. td, J= 7.5, 3.2 Hz, 1  H, SC//), 2.71  (s, 3 H, NC//3); 8C  (75 MHz, 
CDC13) 140.4 (d),  137.5 (s), 130.8 (d),  129.5 (d),  129.1  (d),  100.5 (s), 76.3 (d), 73.6 (d),
67.3  (t), 42.3  (q); m/z (El) 535  (M+,  100), 286 (16),  183  (53),  155  (48),  134 (61),  116 
(74),  102  (24),  77  (36);  HRMS  (El):  calcd for CieHnFsINC^S  (M+)  534.9368,  found 
534.9377.
157(35*, 4S*)-3-(3-Iodophenyl)-2-methylisoxazolidine-4-sulfonic acid
pentafluorophenyl ester (103v)
PFPO
I
Using Method B. To pentafluorophenyl vinyl sulfonate 100 (100 mg, 0.43 mmol) in dry 
toluene  (4  mL)  was  added  C-(3-iodophenyl)-iV-methyl  nitrone  119v  (170  mg,  0.65 
mmol)  and the mixture was heated in a CEM microwave at  140 °C  for  10 mins.  The 
reaction  was  concentrated  in  vacuo  and  the  crude  residue  was  purified  by  flash 
chromatography  (starting  10:1  petroleum  ether  40-60°C/Et20)  to  give  the  title 
compound (82 mg, 36%) as a brown oil.
R f 0.58  (1:1  petroleum ether 40-60°C/Et20);  \)max  (neatycm1  2925,  2882,  1516,  1472, 
1381, 1182, 991, 790, 716; 6H  (300 MHz, CDC13) 7.84 (s, 1 H, Ar//), 7.69-7.72 (m, 1  H, 
Ar//), 7.43 (app. dt, J = 7.8, 1.1 Hz,  1  H, Ar//), 7.12 (app. t, J = 7.8 Hz,  1  H, Ar//), 4.59 
(dd, J = 10.2, 3.2 Hz,  1 H, SCHC//H), 4.46 (dd, J = 10.2, 8.0 Hz,  1  H, SCHCH//), 4.27 
(app.  td, J =  8.0,  3.2 Hz,  1   H,  SC//),  3.99  (d, J = 7.0 Hz,  1  H,  NC//),  2.70  (s,  3  H, 
NC//3);  6C  (75 MHz, CDC13)  138.3 (d),  138.1  (s),  136.6 (d),  130.8 (d),  127.6 (d), 94.8 
(s), 73.8 (d), 73.1 (d), 66.8 (t), 42.8 (q); m/z (El) 535 (M+,  100), 288 (23), 260 (33), 207 
(38),  184  (26),  155  (22),  116  (64);  HRMS  (El):  calcd  for  C16H11F5INO4S  (M+) 
534.9368, found 534.9353.
1584.4.  Isoxazolidine sulfonamides (thermal procedures)
(35*,  4S*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic  acid  allylamide  (120a),  and 
(35*, 4/?*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic acid allylamide (121a)69,94
120a  121a
To  a  stirring  solution  of  (35*,  45*)-2-methyl-3-phenylisoxazolidine-4-sulfonic  acid 
pentafluorophenyl ester 103a (300 mg, 0.73 mmol) in dry THF (5 mL), was added allyl 
amine (130 mg, 2.20 mmol) followed by DBU (170 mg,  1.10 mmol).  The mixture was 
refluxed for 30 minutes. The reaction was diluted with DCM (20 mL) and washed with 
2M HC1 (2 x 20 mL), sat. NaHCC>3 (2 x 20 mL), and water (1  x 20 mL). The organic 
phase  was  separated,  dried  (MgS04),  filtered,  and  the  filtrate  concentrated  in vacuo. 
The crude residue was purified by flash chromatography (starting  10:1  petroleum ether 
40-60°C/EtOAc) to give the anti product 120a (115 mg, 56%) as a white solid and the 
syn product 121a (30 mg, 14%) as a yellow oil- overall yield (70%, 120a:121a = 4:1). 
Data  for  120a:  Rf  0.17  (2:1  petroleum  ether  40-60°C/EtOAc);  mp  88-91  °C;  vm ax 
(filmVcm-1 3281, 3047, 2926,  1636,  1597,  1454,  1313,  1150,  1040, 986;  8H  (300 MHz, 
CDC13) 7.34-7.47 (m, 5 H, Ar//), 5.49 (ddt, 7= 17.1,  10.4, 5.9 Hz,  1 H, CH2=C//), 5.05 
(app.  dq,  J =  17.1,  1.3  Hz,  1  H,  C//H=CH),  5.04  (app.  dq,  J =  10.3,  1.2  Hz,  1   H, 
CHZ/=CH),  4.75  (t,  J  =  6.7  Hz,  1   H,  CH2N//),  4.39  (dd,  J  =  9.8,  4.2  Hz,  1   H, 
SCHC//H), 4.33 (dd, J = 9.8, 8.1 Hz,  1  H, SCHCHH), 4.03 (app. td, J = 7.7, 4.2 Hz,  1  
H, SC//), 3.81 (d, J= 13 Hz, 1  H, NC//), 3.52-3.62 (m,  1  H, NHC/7H), 3.31-3.41 (m, 1  
H, NHCHZ/), 2.62 (s, 3 H, NC//3); 8C  (75 MHz, CDC13)  136.8 (s),  133.0 (d),  129.0 (d),
128.9  (d), 128.3 (d),  118.1 (t), 74.6 (d), 73.3 (d), 66.8 (t), 45.8 (t), 42.8 (q); m/z (El) 282 
(M+, 38),  161  (100),  134 (57),  117 (88),  103 (18); HRMS (El):  calcd for C,3Hi8N20 3S 
(M+) 282.1038, found 282.1035.
Data for  121a:  Rf 0.12  (2:1  petroleum  ether 40-60°C/EtOAc);  t)m ax  (neatycm1  3309, 
2923, 1455, 1329, 1150, 997; 5h (300 MHz, CDC13) 7.51-7.54 (m, 2 H, Ar//), 7.37-7.43 
(m, 3  H.  Ar//),  5.61  (ddt, J =  16.5,  10.6, 6.0 Hz,  1   H,  CH2=C//),  5.04-5.12 (m, 2 H, 
CH2=CH), 4.44 (app. d, J = 8.0 Hz, 2 H, SCHCH2), 4.25 (app. q, J = 8.3 Hz, 1 H, SC/0, 
3.78  (d,  J =  8.4  Hz,  1  H,  NC//),  3.48-3.58  (m,  1  H,  NHC//H),  3.31-3.41  (m,  1   H, 
NHCH/0, 2.93 (t, J = 5.8 Hz,  1  H, N//CH2), 2.65 (s, 3 H, NC//3); 6C  (75 MHz, CDC13)
159133.0 (s and d),  129.3  (d),  129.1  (d),  128.6 (d),  117.9  (t),  74.3  (d),  68.2 (d), 66.6 (t),
45.7  (t), 43.3  (q);  m/z (El) 282  (M+,  32),  160 (20),  146  (17),  134  (100),  117  (74), 91
(37); HRMS (El): calcd for C,3Hi8N20 3S (M+) 282.1038, found 282.1040.
(3S*,  4S*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic  acid  4-methyIbenzylamide 
(120b),  and  (3  S*9   4/?*)-2-Methyl-3-phenylisoxazoIidine-4-sulfonic  acid  4- 
methylbenzylamide (121b) 69,94
121b 120b
To  a  stirring  solution  of  (3S*,  4S*)-2-methyl-3-phenylisoxazolidine-4-sulfonic  acid 
pentafluorophenyl ester 103a (300 mg, 0.73 mmol) in dry THF (10 mL), was added 4- 
methyl-benzyl  amine  (270  mg,  2.20 mmol)  followed  by  DBU  (170  mg,  1.10 mmol). 
The mixture was refluxed for 1   hour. The reaction was diluted with DCM (20 mL) and 
washed with 2M HC1 (2 x 20 mL), sat. NaHC03 (2 x 20 mL), and water (1  x 20 mL). 
The organic phase was separated, dried (MgSCL), filtered, and the filtrate concentrated 
in  vacuo.  The  crude  residue  was  purified  by  flash  chromatography  (starting  10:1 
petroleum  ether 40-60°C/EtOAc)  to  give  the  anti  product  120b  (159  mg,  63%)  as  a 
yellow solid and the syn product 121b (53 mg, 21%) as a yellow oil- overall yield (84%, 
120b:121b = 3:1).
Data for 120b: Rf0.34 (2:1 hexane/EtOAc); mp 84-86 °C; vm ax (filmVcm'1  3290, 3034, 
2924,  1611,  1448,  1323,  1146,  1043; 5H  (300 MHz, CDC13) 7.36-7.44 (m, 5 H, Ar//),
7.05  (d, J = 8.0 Hz, 2 H, Ar//), 6.93 (d, J = 8.0 Hz, 2 H, Ar//), 4.89 (app. t, J = 5.8 Hz, 1  
H, CH2N//), 4.34 (dd, J = 9.8, 3.8 Hz,  1   H, SCHC//H), 4.23 (dd, J = 9.8, 8.4 Hz,  1 H, 
SCHCH//), 4.08 (dd, J =  13.7, 6.4 Hz,  1  H, NHC//H), 3.93 (app. td, J = 8.0, 3.8 Hz,  1  
H,  SC//),  3.80-3.86  (m,  2 H, NCH and NHCH//),  2.58  (s,  3  H,  NC//3),  2.31  (s,  3  H, 
ArCZ/3); 6C  (75 MHz, CDC13)  137.8 (s),  136.8 (s),  133.2 (s),  129.4 (d),  129.0 (d),  128.8 
(d),  128.3 (d),  128.0 (d), 74.5 (d), 73.2 (d), 66.9 (t), 47.0 (t), 42.7 (q), 21.1  (q); m/z (El) 
346 (M+,  10),  160 (100),  105 (83); HRMS (El): calcd for Ci8H22N20 3S (M+) 346.1351, 
found 346.1359; Anal, calcd for Ci8H22N20 3S: C 62.40, H 6.40, N 8.09, found C 61.94, 
H 6.47, N 7.71.
Data for 121b:  Rf0.29  (2:1  hexane/EtOAc);  \)m ax  (filmVcm' 1  3296,  2923,  2876,  1506, 
1448, 1327, 1150, 1051, 833; 8h (300 MHz, CDC13) 7.39-7.48 (m, 2 H, Ar//), 7.30-7.35 
(m, 3 H, Ar//), 7.12 (d, J = 8.0 Hz, 2 H, Ar//), 7.02 (d, J= 8.0 Hz, 2 H, Ar//), 4.36-4.47
160(m, 2 H, SCHC//2), 4.10-4.23 (m, 1 H, SC//), 4.03 (dd, J = 13.8, 6.9 Hz,  1 H, NHC//H),
3.89  (dd, J =  13.8, 5.3 Hz,  1   H, NHCH//), 3.71  (d, J = 8.4 Hz,  1   H, NC//), 3.28 (app. t, 
J =  8.7  Hz,  1   H,  CH2N//),  2.62 (s, 3  H,  NC//3),  2.34  (s,  3  H,  ArC//,);  8C   (75  MHz, 
CDCI3)  137.9 (s),  133.4 (s),  133.2 (s),  129.4 (d),  129.3 (d),  129.0 (d),  128.8 (d),  128.5 
(d), 128.3 (d),  128.0 (d), 74.2 (d), 68.5 (d), 66.7 (t), 46.9 (t), 43.3 (q), 21.1 (q); m/z (El) 
346 (M+,  14),  134 (100),  120 (72); HRMS (El): calcd for C18H22N2O3S (M+) 346.1351, 
found 346.1367.
(3S*,  4S*)  and  (3S*,  4/J*)-2-(2-Methyl-3-phenylisoxazolidine-4-sulfonylamino)-3- 
phenylpropionic acid ethyl ester (120/121c)69'
Ph
120/121c  \\
To  a  stirring  solution  of  (3S*,  4S'*)-2-methyl-3-phenylisoxazolidine-4-sulfonic  acid 
pentafluorophenyl ester 103a (200 mg, 0.49 mmol) in dry toluene (10 mL), was added 
phenylalanine ethyl ester (280 mg,  1.47 mmol) followed by DBU (110 mg, 0.73 mmol). 
The mixture was refluxed for 2 hours. The reaction was diluted with DCM (30 mL) and 
washed with 2M HC1 (2 x 20 mL), sat. NaHCOs (2 x 20 mL), and water (1  x 20 mL). 
The organic phase was separated, dried (MgSOzO, filtered, and the filtrate concentrated 
in  vacuo.  The  crude  residue  was  purified  by  flash  chromatography  (starting  10:1 
petroleum ether 40-60°C/EtOAc) to give the product (145  mg,  71%,  120c and 121c = 
1:1 majonminor) as a mixture of diastereoisomers.
Rf 0.24 (2:1 petroleum ether 40-60°C/EtOAc); \)max (neatycm' 1  3277, 3031, 2927,  1734, 
1496,  1455,  1334,  1215,  1149,  1031, 948, 853; 5H  (300 MHz, CDC13) 7.22-7.46 (m,  8
H, Ar//), 7.02-7.11  (m,  2 H, Ar//), 4.92 (d, 7 = 9.1  Hz,  1   Hmin0r, N//), 4.84 (d, 7 = 9.6 
Hz,  1   Hm aj0r, N//), 4.08-4.29 (m, 4 H, C 02C //2CH3, NHCH, and SCHC//H), 3.83-3.93 
(m,  3  H,  NC//minor,  SC//m ajor,  and SCHCH//),  3.74 (br d, 7 = 7.0 Hz,  1  Hm ajor, NC//),
3.37  (app.  td,  7 =  7.8,  3.5  Hz,  1   Hm inor,  SCH),  3.06  (dd,  7 =  13.9,  5.1  Hz,  1  Hm inor, 
CZ/HPh), 2.87-2.98 (m, 2 H, CH2 Ph), 2.83 (dd, 7= 13.9, 8.0 Hz,  1 Hmin0r, CH//Ph), 2.62 
(s, 3 Hminor, NC//3), 2.58 (s, 3 Hm ajor, NC//3),  1.23 (t, 7 = 7.2 Hz, 3 Hm ajor, C 02CH2C//3),
I.18 (t, 7 = 1.2 Hz,  3 Hm inor, C02CH2C//3);  5C  (75  MHz,  CDC13)  171.3  (s),  171.1  (s),
137.2  (s),  137.0 (s),  135.7 (s), 135.0 (s), 129.9 (d),  129.5 (d),  129.3 (d),  128.9 (d),  128.8 
(d),  128.7 (d),  128.6 (d),  128.5 (d),  128.2 (d),  128.1  (d),  127.5  (d),  127.4 (d), 74.3 (d),
74.1  (d), 74.0 (d), 73.8 (d), 67.2 (t), 67.1  (t), 62.0 (t), 61.9  (t), 57.6 (d), 57.2 (d), 43.2
161(q), 42.7 (q), 39.5 (t), 39.4 (t),  14.0 (q), 33 out of 34 expected signals observed; m/z (El) 
418 (M+, 22),  160 (100),  115 (100), 91  (98); HRMS (El):  calcd for C21H26N2O5S (M+) 
418.1562, found 418.1570.
(3S*,  4S'*)  and  (3S*,  4/?*)-3-(4-Methoxyphenyl)-2-methylisoxazolidine-4-sulfonic 
acid allylamide (120/121d)69,94
MeO
120/121 d
To  a  stirring  solution  of  (35*,  45*)-3-(4-methoxyphenyl)-2-methylisoxazolidine-4- 
sulfonic acid pentafluorophenyl ester 103b (500 mg,  1.14 mmol) in dry THF (10 mL), 
was added allyl amine (190 mg, 3.41  mmol) followed by DBU (260 mg,  1.71  mmol). 
The mixture was refluxed for 1  hour. The reaction was diluted with DCM (30 mL) and 
washed with 2M HC1 (2 x 20 mL), sat. NaHCC>3 (2 x 20 mL), and water (1  x 20 mL). 
The organic phase was separated, dried (MgS0 4), filtered, and the filtrate concentrated 
in  vacuo.  The  crude  residue  was  purified  by  flash  chromatography  (starting  10:1 
petroleum ether 40-60°C/EtOAc) to give anti product 120d (35  mg,  10%) as a yellow 
solid, and the remaining as a mixture of diastereoisomers (191  mg, 53%)- overall yield 
(63%, 120d and 121d = 3:1 majonminor).
Data  for  120d:  Rf 0.32  (1:1  petroleum  ether  40-60°C/EtOAc);  mp  85-87  °C;  Dm ax 
(filmVcm' 1 3292, 3082, 2924,  1612,  1514,  1439,  1319,  1250,  1146,  1034, 839;  6H  (300 
MHz, CDCI3) 7.36 (d, J = 8.7 Hz, 2 H, ArH), 6.89 (d, J = 8.7 Hz, 2 H, ArH), 5.52 (ddt, 
/=  17.1, 10.4, 5.9 Hz, 1  H, CH2=CH), 5.03-5.11 (m, 2 H, CH2=CH), 4.76 (t, J = 6.0 Hz, 
1  H, CH2NH), 4.28-4.39 (m, 2 H, SCHC//2), 3.99 (app. td, J = 7.7, 4.2 Hz,  1 H, SCH),
3.80  (s, 3 H, OC//3), 3.74 (br d, J = 7.1  Hz,  1   H, NC//), 3.52-3.62 (m,  1   H, NHC//H), 
3.32-3.41  (m,  1  H, NHCHH) 2.59 (s, 3 H, NC//3); 6C  (75 MHz, CDC13)  160.0 (s), 133.1 
(d),  129.4 (d),  128.4 (s),  118.0 (t),  114.4 (d), 74.1  (d), 73.1  (d), 66.7 (t), 55.3 (q), 45.8 
(t), 42.6 (q); m/z (El) 312 (M+,  18),  190 (100),  165  (75),  147 (100),  121  (43), 91  (89); 
HRMS (El): calcd for C14H2oN20 3S (M+) 312.1144, found 312.1138.
Data  for  120d/121d:  Rf 0.30  (1:1  petroleum  ether  40-60°C/EtOAc);  §h  (300  MHz, 
CDCI3) 7.42 (d, J = 8.6 Hz, 2 Hm ajor, Ar//), 7.35 (d, J = 8.6 Hz, 2 Hm inor, Ar//), 6.90 (d, J 
=  8.6  Hz,  2  Hm ajor,  Ar//),  6.89  (d,  J =  8.6  Hz,  2  Hm lnor,  Ar//),  5.45-5.69  (m,  1  H, 
C//=CH2), 5.02-5.13 (m, 2 H, CH=C//2), 4.77 (br t, 7 = 6.2 Hz, 1 Hm ajor, N//), 4.39 (app.
f
162d, 7 = 8.3 Hz, 2 H maj0r,  SCHC//2), 4.33 (dd, 7 = 9.6, 5.4 Hz,  1   H minor,  SCHC//H), 4.30 
(dd, 7 = 9.6, 8.0 Hz,  1   H min0r, SCHCHH), 4.16-4.25 (m,  1   H min0r,  SC//), 3.98 (app. td, 7 
= 7.8, 4.0 Hz,  1   H maj0r,  SC//), 3.79 (s, 3 H ,  OC//3), 3.72 (br d, 7 = 8.3 Hz,  1   H, NC//), 
3.47-3.61  (m,  1   H,  NHC//H),  3.32-3.44 (m,  1   H, NHCHZ/),  3.26  (br t, 7 = 5.9 Hz,  1  
Hm inor*  N//),  2.60  (s,  3  H m a j o r ,   NC//3),  2,59 (s,  3  H m i n o r ,   NC//3);  8C   (75  MHz,  CDCI3)
160.0  (s),  159.9 (s),  133.2 (d),  130.5 (d),  129.4 (d),  128.5 (s),  124.7 (s),  117.9 (t), 117.8 
(t),  114.4 (d),  114.0 (d), 74.1 (d), 73.7 (d), 73.1  (d), 67.9 (d), 66.7 (t), 66.6 (t), 55.3 (q),
55.2  (q), 45.7 (t), 45.6 (t), 43.2 (q), 42.6 (q), 23 out of 24 expected signals observed.
(3S*, 4S*)-3-(5-Bromofuran-2-yl)-2-methylisoxazolidine-4-sulfonic acid allylamide 
(120e), and (3S*, 4J?*)-3-(5-Bromofuran-2-yl)-2-methylisoxazolidine-4-sulfonic acid 
allylamide (121e)69,94
\y/
121e Br Br 120e
To  a  stirring  solution  of  (35*,  45*)-3-(5-bromofuran-2-yl)-2-methylisoxazolidine-4- 
sulfonic acid pentafluorophenyl ester 103o (500 mg,  1.05 mmol) in dry THF (10 mL), 
was added allyl amine (180 mg, 3.14 mmol) followed by DBU (240 mg,  1.57 mmol). 
The mixture was refluxed for 1 hour. The reaction was diluted with DCM (30 mL) and 
washed with 2M HC1 (2 x 20 mL), sat. NaHCC>3 (2 x 20 mL), and water (1  x 20 mL). 
The organic phase was separated, dried (MgS0 4), filtered, and the filtrate concentrated 
in  vacuo.  The  crude  residue  was  purified  by  flash  chromatography  (starting  10:1 
petroleum ether 40-60°C/EtOAc) to give the anti product as  a brown solid  120e (226 
mg, 62%) and the syn product 121e (60 mg,  16%) as a brown oil- overall yield (78%, 
120e:121e = 4:1).
Data  for  120e:  Rf  0.14  (2:1  petroleum  ether  40-60°C/EtOAc);  mp  88-90  °C;  Dmax 
(filmycm1  3292, 3134, 2930,  1672,  1636,  1502,  1423,  1306,  1142,  1067, 930;  8H  (500 
MHz, CDC13) 6.38 (d, 7 = 3.3 Hz, 1 H, C//CO), 6.26 (d, 7 = 3.3 Hz,  1 H, C//CBr), 5.66 
(ddt, 7 =  17.1,  10.6, 5.7 Hz,  1   H, CH2=CH), 5.10-5.19 (m, 2 H, CH2=CH), 4.77 (t, 7 =
5.7  Hz,  1  H, CH2N//), 4.21-4.32 (m, 3 H, SCH and SCHCH2), 3.94 (br s,  1   H, NC//), 
3.55-3.65  (m,  2  H,  C//2NH),  2.65  (s,  3  H,  NC//3);  5C   (300  MHz,  CDC13)  150.6  (s),
133.1  (d),  122.9 (s),  118.2 (t),  113.1  (d),  112.6 (d), 69.3 (d), 67.5 (d),  66.8 (t), 45.8 (t),
42.9  (q); m/z (El) 352 (M+, 81Br, 24), 350 (M+, 79Br, 23), 230 (100), 203 (44),  187 (50),
163159  (20),  106  (18);  HRMS  (El):  calcd  for  C,|Hl579BrN2C > 4S  (M+)  349.9936,  found 
349.9928.
Data  for  121e:  Rf0.09  (2:1  petroleum  ether 40-60°C/EtOAc);  t>m ax  (neat)/cm"'  3306, 
3138,2926, 2883, 1636, 1499,  1433, 1325, 1148, 1049, 928; SH  (500 MHz, CDC13) 6.48 
(d, 7 = 3.3 Hz, 1   H, CHCO), 6.34 (d, 7 = 3.3 Hz, 1   H, CHCBr), 5.79 (ddt, 7 = 17.1, 10.3,
5.9  Hz,  1   H, CH2=CH), 5.24 (app. dq, 7 = 17.1, 1.3 Hz,  1  H, C//H=CH), 5.18 (app. dq, 
7 =  10.3,  1.3 Hz,  1   H, CH//=CH), 4.29-4.38 (m, 2 H, SCHCH2), 4.24 (app. q, 7 = 8.1 
Hz,  1   H, SCH),  3.92 (br d, 7 = 13  Hz,  1   H, NC//), 3.84 (br t, J = 5.4 Hz,  1   H, NH), 
3.65-3.69 (m, 2 H, NHC//2), 2.65 (s, 3 H, NC//3); 8C  (75 MHz, CDCI3)  149.0 (s), 133.3 
(d),  122.0 (s),  118.2 (t),  113.5  (d),  113.0 (d), 67.7  (d), 67.3  (d), 66.7  (t), 45.9 (t), 43.8 
(q); m/z (El) 352 (M+, 8lBr, 26), 350 (M+, 79Br, 25), 230 (100), 203 (68),  185 (59),  159 
(25), 106 (28); HRMS (El): calcd forCnHi579BrN20 4S (M+) 349.9936, found 349.9928.
(3  S*,  4S*)-2-Methyl-3-(4-nitrophenyl)isoxazolidine-4-sulfonic  acid  allylamide 
(120f),  and  (3S*,  4/?*)-2-Methyl-3-(4-nitrophenyl)isoxazolidine-4-sulfonic  acid 
allylamide (121f)  69 94
120f
V
o2 n 121 f
To a stirring solution of (3S*, 4S*)-2-methyl-3-(4-nitrophenyl)isoxazolidine-4-sulfonic 
acid  pentafluorophenyl  ester  103d  (500  mg,  1.10  mmol)  in  dry  THF  (10  mL),  was 
added allyl amine (190 mg, 3.30 mmol) followed by DBU (250 mg,  1.65 mmol). The 
mixture  was  refluxed  for  1   hour.  The  reaction  was  diluted  with  DCM  (30  mL)  and 
washed with 2M HC1 (2 x 20 mL), sat. NaHCOs (2 x 20 mL), and water (1  x 20 mL). 
The organic phase was separated, dried (MgS04), filtered, and the filtrate concentrated 
in  vacuo.  The  crude  residue  was  purified  by  flash  chromatography  (starting  10:1 
petroleum ether 40-60°C/EtOAc) to give the anti product as  a yellow solid 120f (166 
mg,  46%)  and  the  syn  product  121f (61  mg,  17%)  as  an  orange  solid-  overall  yield 
(63%, 120f:121f = 3:1).
Data  for  120f:  Rf0.13  (2:1  petroleum  ether  40-60°C/EtOAc);  mp  159-162  °C;  0)m ax 
(film)/cm‘‘ 3263, 3055, 2986,  1620,  1522,  1423,  1265,  1150,  1038, 893; SH  (400 MHz, 
DMSO) 8.20 (d, J = 8.8 Hz, 2 H, ArH), 7.75 (d, J = 8.8 Hz, 2 H, ArH), 7.39 (t, J = 5.7 
Hz,  1  H, NH), 5.70 (ddt, 7= 17.2, 10.3, 5.7 Hz,  1 H, CH2=C/7), 5.16 (app. dq, 7= 17.2,
1.6  Hz,  1   H, C//H=CH), 5.05 (app. dq, 7 =  10.3,  1.6 Hz,  1   H, CH//=CH), 4.27 (d, 7 =
1646.4  Hz, 2 H, SCHCH2), 4.17 (app.td, J = 6.5, 5.9 Hz,  1  H, SCH), 4.08 (d, J = 6.6 Hz,  1  
H, NCH),  3.49-3.63  (m,  2  H,  NHCH2),  2.59  (s,  3  H,  NCH3);  5c  (100 MHz,  DMSO)
147.1  (s), 145.4 (s),  134.2 (d),  129.0 (d),  122.9 (d),  115.9 (t), 72.3 (d), 71.8 (d), 66.2 (t),
44.3  (t),  42.0  (q);  m/z  (El)  327  (M+,  7),  205  (100),  116  (55);  HRMS  (El):  calcd  for 
C13H17N3O5S (M+) 327.0889, found 327.0885.
Data  for  121f:  Rf 0.06  (2:1  petroleum  ether 40-60°C/EtOAc);  mp  119-122  °C;  um ax 
(fllmycm1 3265, 3082, 2922,  1601,  1518,  1429,  1339,  1153,  1047, 924;  6H  (300 MHz, 
CDC13) 8.21  (d, J = 8.8 Hz, 2 H, Ar//), 7.69 (d, J =  8.8 Hz, 2 H, Ar//), 5.72 (ddt, J =
17.1,  10.1, 5.9 Hz,  1   H, CH2=C//), 5.16-5.22 (m,  2 H, C//2=CH), 4.31-4.47  (m, 3  H, 
SCHC/ / 2 and SC//), 3.92-3.99 (m, 2 H, NCH and NZ/CH2), 3.58 (app. t, J = 6.0 Hz, 2 
H, NHCH2), 2.64 (s, 3 H, NC//3);  8C  (75 MHz, CDC13)  148.0 (s),  141.2 (s),  133.2 (d),
130.7  (d), 123.2 (d),  118.2 (t), 73.1 (d), 69.3 (d), 67.2 (t), 45.7 (t), 43.3 (q); m/z (El) 327 
(M+, 34),  179 (100),  163 (36),  133 (56),  116 (85); HRMS (El):  calcd for C13H17N3O5S 
(M+) 327.0889, found 327.0883.
(3S*,  4S*)  and  (3S*,  4/?*)-3-Cyclopropyl-2-methyIisoxazolidine-4-sulfonic  acid 
allylamide (120/121g)69 94
120/121 g
To  a  stirring  solution  of  (3S*,  4S,*)-3-cyclopropyl-2-methylisoxazolidine-4-sulfonic 
acid pentafluorophenyl ester 103p (300 mg, 0.80 mmol) in dry THF (5 mL), was added 
allyl amine (180 pL, 2.41 mmol) followed by DBU (180 pL,  1.21  mmol). The mixture 
was refluxed for 30 minutes then diluted with DCM (30 mL) and washed with 2M HC1 
(2 x 20 mL), sat. NaHC03 (2 x 20 mL), and water (1 x 20 mL). The organic phase was 
separated,  dried  (MgS0 4),  filtered,  and  the  filtrate  concentrated  in  vacuo.  The  crude 
residue  was  purified  by  flash  chromatography  (starting  3:1  petroleum  ether  40- 
60°C/EtOAc) to give the product as a mixture of diastereoisomers (182 mg, 92%, 120g 
and 121g = 3:1 major:minor).
Rf 0.17 (1:1 petroleum ether 40-60°C/EtOAc); Dm ax (neat)/cm_1 3584, 3289, 2874,  1437, 
1315,  1144,  1046, 921, 830; 5h (300 MHz, CDC13) 5.82 (ddt, J =  16.1,  10.2, 5.9 Hz,  1  
H, C//=CH2), 5.21-5.29 (m,  1  H, CH=C//H), 5.13-5.19 (m,  1   H, CH=CH//), 5.12 (br t, 
J —  5.9  Hz,  1   Hm ajor,  NH),  5.00  (br t, J = 6.2  Hz,  1   Hm inor,  NH),  3.97-4.23  (m,  3  H, 
SCHCH2 and SCHm inor),’3.82-3.89 (m, 1  Hm ajor, SCH), 3.71-3.77 (m, 2 H, NHCH2), 2.74
165(s, 3  H major,  N C //3),  2.69 (s, 3  H minor,  N C //3),  2.33  (br s,  1  H major,  N C //),  1.84 (br s,  1  
Hminor,  N C //),  1.15-1.29 (m,  1   Hminor,  N C H C //),  0.86-0.99 (m,  1   H major,  N C HCH), 0.71 
(dd, J = 8.0,  1.1 Hz,  1   Hminor, cyclopropyl-//), 0.49-0.63 (m, 2 H  +   lH major, cyclopropyl- 
H), 0.24-0.38 (m, 2 H, cyclopropyl-//); 6C  (75 MHz, CDC13)  133.7 (d),  117.9 (t),  117.8 
(t), 73.5 (d), 71.9 (d), 67.3 (d), 66.6 (t), 66.4 (t), 46.0 (t), 45.8 (t), 44.3 (q),  13.6 (d), 5.9 
(t), 4.4 (t), 3.4 (t), 2.0 (t),  16 out of 20 expected signals observed; m/z (E l) 246 (M+, 13), 
124 (86), 99 (35), 84 (100), 68 (28), 56 (22); HRMS  (E l):  calcd for C io H ^ C ^ S   (M+) 
246.1033, found 246.1035.
*
1664.5.  Isoxazolidine sulfonamides (MW procedures)
General protocol for [3+2] MW cycloaddition (Sections 4.5.1. to 4.5.3.)
To a solution of vinyl  sulfonamide (1  eq.) in dry toluene  (5  mL),  nitrone (3  eq.) was 
added.  The reaction mixture was heated in a CEM microwave for 30 minutes at 140 °C. 
When complete the reaction mixture was concentrated in vacuo and the crude residue 
purified by flash chromatography (starting 5:1  petroleum ether 40-60°C/Et20) to give 
the desired products.
4.5.1.  Cycloadditions with ethenesulfonic acid 4-methylbenzylamide (123b) 
Ethenesulfonic acid 4-methylbenzylamide (123b)
A premixed suspension of 4-methylbenzylamine  (8.2 g, 67.5 mmol) and NEt3 (12.4 g,
122.7  mmol)  in  DCM  (25  mL)  was  added  dropwise  to  a  stirring  solution  of  2- 
chloroethane-l-sulfonyl chloride (10.0 g, 61.3 mmol) in DCM (100 mL), while keeping 
the temperature at -10 °C.  The reaction mixture was  stirred for a further 30 minutes 
after addition, and then warmed to RT.  The reaction was diluted with DCM (60 mL) 
and washed with 2M HC1 (3 x 80 mL), H20  (1  x 80 mL), dried (MgS04), and filtered. 
The  filtrate  was  collected  and  concentrated  in  vacuo  to  give  the  crude  which  was 
purified by flash chromatography (starting 3:1 petroleum ether 40-60°C/Et20) to furnish 
the desired product (11.7 g, 90%) as white crystals.
Rf 0.14 (1:1 hexane/Et20); mp 86-88 °C; Um ax (filmj/cm' 1  3227, 3036, 2835,  1510, 1421, 
1356,  1144,  1045, 976, 812; 8h (300 MHz, CDC13) 7.13-7.26 (m, 4 H, ArH), 6.46 (dd, J 
= 16.5, 9.8 Hz,  1   H, SC//CH2), 6.22 (d, J= 16.5 Hz,  1   H, SCHC(//)H), 5.90 (d, J = 9.8 
Hz,  1  H, SCHCHH), 4.83 (br s,  1  H, NH), 4.14 (d, J = 6.1 Hz, 2 H, NHCff2), 2.33 (s, 3 
H, C//3); 8c (75 MHz, CDC13) 137.8 (s), 136.1 (d),  133.5 (s),  129.4 (d), 128.0 (d), 126.7 
(t), 46.8 (t), 21.1 (q); m/z (El) 211 (M+, 33), 203 (49), 160 (35), 146 (50), 118 (100), 105 
(72), 91 (80); HRMS (El): calcd for Ci0H,3NO2S (M+) 211.0667, found 211.0663.
167(35*,  4S*)-3-(4-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide  (124a),  (3/?*,  55*)  and  (35*,  5S*)-3-(4-Bromophenyl)-2-
methylisoxazolidine-5-sulfonic acid 4-methylbenzylamide (1257126a)
124a  125/126a
General protocol was followed using  100 mg of 123b. Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20) to give 125/126a (58 mg, 
29%)  as  a  mixture,  and  124a  (85  mg,  43%)  as  a  brown  solid-  overall  yield  (72%, 
124a:125/126a = 3:2,125a and 126a = 3:1 major:minor).
Data for 125/126a: Rf 0.37 (2:1  Et20/petroleum ether 40-60°C); \)m ax (neat)/cm_ 1  2921, 
1487, 1327,  1147,  1071,  1010, 729; 8h (300 MHz, CDC13) 7.48 (d, J = 8.3 Hz, 2 H maj0r, 
ArH), 7.46 (d, J = 8.3 Hz, 2 H^nor, ArH), 7.28 (d, J = 8.3 Hz, 2 H, Ar//), 7.23 (d, J =
8.0  Hz, 2 H, Ar//), 7.16 (d, J = 8.0 Hz, 2 H, ArH), 5.00 (dd, J = 8.6, 5.6 Hz,  1  Hm inor, 
SCH), 4.94 (dd, J = 8.6, 2.4 Hz,  1   Hm ajor, SCH), 4.88 (br t, J = 5.9 Hz,  1  Hm inor, NH), 
4.77  (br t, J = 5.9 Hz,  1  H major,  NH), 4.43  (dd, J =  14.2,  6.4 Hz,  1  H minor,  NHC/ZH),
4.36-4.41  (m,  1  H min0r,  NHCHH), 4.34-4.39 (m,  1   Hm ajor, NHC//H), 4.30 (dd, J =  14.2,
5.9  Hz, 1 Hm ajor, NHCH//), 4.02 (br dd, J = 8.6, 5.9 Hz,  1 Hm ajor, NC//), 3.53 (br dd, /  =
9.6,  7.5 Hz,  1  Hminor,  NC//), 2.96-3.08 (m,  1   H ,  SCHC//H), 2.84 (ddd, J =  13.7,  10.2,
5.6  Hz,  1  Hminor, SCHCHH), 2.73 (s, 3 H major, NC//3), 2.70 (ddd, J = 13.7,  10.2, 8.6 Hz, 
1  Hmajor,  SCHCH//),  2.60  (s,  3  Hminor,  NCH3),  2.34  (s,  3  H,  A rc//3);  6C   (125  MHz, 
CDC13)  139.0 (s),  137.1  (s),  136.7 (s),  135.2 (s),  134.8 (s),  133.2 (d),  130.8 (d),  130.6 
(d),  130.4 (d),  129.8 (d),  129.1  (d),  123.7 (s),  123.4 (s), 90.2 (d), 71.3 (d), 48.7 (t), 45.4 
(q), 44.3  (q),  42.6  (t),  42.2  (t),  22.3  (q),  21  out of 28  expected  signals  observed; m/z 
(FAB+) 427 (MH+,  slBr, 21), 425 (MH+, 79Br, 22), 338  (94), 240 (37), 219 (100), 203 
(36),  163  (45);  HRMS  (FAB+):  calcd  for  Ci8H2279BrN20 3S  (MH+)  425.0534,  found 
425.0522.
Data  for  124a:  R f  0.29  (2:1  Et20/petroleum  ether  40-60°C);  mp  96-98  °C;  v m ax 
(filmycm'1  3300, 2922, 2856,  1589,  1456,  1414,  1319,  1144,  1034, 856; 6H  (300 MHz, 
CDC13) 7.48 (d, J = 8.0 Hz, 2 H, ArH), 7.27 (d, J = 8.0 Hz, 2 H, ArH), 7.08 (d, J = 7.7 
Hz, 2 H, ArH), 6.96 (d, J = 1.1 Hz, 2 H, ArH), 4.91  (br t, J =5.6 Hz,  1  H, NH), 4.29-
4.33  (m,  1  H,  SCHCHH), 4.09-4.21  (m,  2 H, SCHCHH and  NHCHH),  3.98  (dd, J =
13.9,  5.6 Hz,  1  H, NHCHH), 3.76-3.82 (m, 2 H, SCH and NCH), 2.58 (s, 3 H, NCH3),
1682.33  (s, 3 H, ArCH3);  5c  (75  MHz, CDC13)  138.0 (s),  136.1  (s),  133.1  (s),  132.1  (d),
129.8  (d),  129.5 (d),  128.0 (d),  122.8 (s), 73.6 (d), 73.5 (d), 66.9 (t), 47.1  (t), 42.7 (q),
21.2  (q); m/z (El) 426 (M+, 8lBr, 6), 424 (M+, ™Br, 8),  240 (63),  197 (28),  120 (100); 
HRMS (El): calcd for Ci8H2i79BrN203S (M+) 424.0456, found 424.0450.
(3S*,  4S*)-3-(2-ChIorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide  (124b),  (3/?*,  5S*)-3-(2-Chlorophenyl)-2-methylisoxazolidine-5-
sulfonic  acid  4-methylbenzylamide  (125b),  and  (35*,  55*)-3-(2-Chlorophenyl)-2- 
methylisoxazolidine-5-sulfonic acid 4-methylbenzylamide (126b)
o  o o  o
124b  125b  126b
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give the three separable 
products  124b  (58  mg,  32%),  125b  (55  mg,  31%),  and  126b  (27  mg,  15%)-  overall 
yield (78%, 124b:125b:126b = 2:2:1).
Data for 126b: Rf0.43 (2:1 Et20/petroleum ether 40-60°C); Dm ax (film)/cm'! 3379, 3294, 
3055, 2986,  1514,  1429, 1329, 1265,  1151, 1059, 897, 741;  6H  (300 MHz, CDC13) 7.64 
(dd, J = 7.4,  2.1  Hz,  1  H, ArH), 7.22-7.38  (m,  5  H, ArH),  7.17  (d, /  = 2.1  Hz, 2 H, 
ArH), 5.04 (dd, J = 8.7, 5.6 Hz, 1 H, SCH), 4.72 (app. t, J = 6.0 Hz,  1 H, NH), 4.43 (dd, 
J = 14.0, 6.4 Hz,  1 H, NHCHH), 4.38 (dd, J = 14.0, 6.1 Hz,  1 H, NHCHH), 4.20 (dd, J 
= 9.8, 7.4 Hz,  1  H, NCH), 3.18 (ddd, J =  13.5, 8.7, 7.4 Hz,  1  H, SCHCHH), 2.66-2.75 
(m, 4 H, SCHCHH and NCH3), 2.35 (s, 3 H, ArCH3); 5C  (75 MHz, CDC13)  137.8 (s),
134.7  (s),  134.1 (s),  133.7 (s), 129.6 (d), 129.5 (d), 129.2 (d),  128.4 (d),  128.0 (d), 127.7 
(d), 89.3  (d), 68.5  (d), 47.6 (t), 43.5 (q), 39.6 (t),  21.2 (q); m/z (El) 382 (M+,  37C1,  1), 
380 (M+, 35C1, 3), 272 (35), 270 (100), 167 (32), 149 (50), 141  (75),  125 (8), 8 6 (36), 77 
(30); HRMS (El): calcd for Ci8H2i35C1N20 3S (M+) 380.0961, found 380.0952.
Data  for  125b:  Rf 0.36  (2:1  Et20/petroleum  ether  40-60°C);  mp  70-75  °C;  X > m a x 
(filmVcm'1 3290, 3061, 2922,  1516,  1439,  1331,  1148,  1059,  847, 756;  6H  (300 MHz, 
CDC13) 7.54 (dd, J = 7.4, 2.1 Hz,  1  H, ArH), 7.38 (dd, J = 7.4,  1.9 Hz,  1 H, ArH), 7.21- 
7.26 (m, 4 H,  ArH),  7.17  (d, J = 8.1  Hz,  2 H,  ArH), 4.89  (dd, J = 8.3,  4.2 Hz,  1   H, 
SCH), 4.69 (app. t, J = 6.0 Hz, 1  H, NH), 4.60 (app. t, J = 7.4 Hz,  1  H, NCH), 4.39 (dd, 
J = 13.9, 6.1 Hz, 1 H, NHCHH), 4.34 (dd, J = 13.9, 5.9 Hz, 1 H, NHCHH), 3.28 (ddd, J
169=  13.4, 6 .6, 4.2 Hz,  1  H, SCHCHH), 2.85 (s, 3 H, NCH3), 2.62 (dt, J =  13.4, 8.3 Hz,  1  
H,  SCHCHH), 2.34 (s,  3  H, ArCHj);  5c (75  MHz,  CDC13)  137.9 (s),  135.8 (s),  133.7 
(s),  133.5  (s),  129.7 (d),  129.5 (d),  129.0 (d),  128.0 (d),  127.6 (d),  127.3 (d), 89.8 (d),
67.0  (d), 47.7 (t), 45.6 (q), 38.9 (t), 21.1  (q); m/z (El) 382 (M \ 37C1,  1), 380 (M+, 35C1,
2),  196 (17),  168  (67),  154 (48),  138 (26),  118  (38),  105  (100),  91  (52); HRMS  (El): 
calcd for C,8H2i35ClN20 3S (M+) 380.0961, found 380.0952.
Data  for  124b:  Rf 0.23  (2:1  Et20/petroleum  ether  40-60°C);  t>m ax  (neat)/cm''  3294, 
3020, 2926, 1514, 1439, 1327, 1207, 1148, 1045, 835,760; 5H  (300 MHz, CDC13) 7.28- 
7.51 (m, 4 H, ArH), 7.03 (d, J = 8.0 Hz, 2 H, ArH), 6.90 (d, J = 8.0 Hz, 2 H, ArH), 4.70 
(app. t, J = 5.6 Hz,  1  H, NH), 4.49 (br d, J = 7.6 Hz,  1   H, NCH), 4.44 (dd, J = 9.9, 3.8 
Hz,  1   H, SCHCHH), 4.34 (dd, J = 9.9, 8.4 Hz,  1   H, SCHCHH), 4.13 (dd, J =  13.6, 6.6 
Hz,  1  H, NHCHH), 3.97 (app. td, J = 7.6, 3.8 Hz, 1   H, SCH), 3.82 (dd, J = 13.6, 5.0 Hz, 
1   H, NHCHH), 2.62 (s, 3 H, NCH3), 2.31  (s, 3 H, ArCH3); 5c (75 MHz, CDC13)  137.8 
(s),  134.3 (s),  134.2 (s),  133.0 (s),  130.1  (d),  129.9 (d),  129.8 (d),  129.4 (d),  127.9 (d),
127.8  (d), 72.9 (d), 70.1  (d), 67.1  (t), 47.2 (t), 42.7 (q), 21.1  (q); m/z (El) 382 (M+, 37C1,
3), 380 (M+, 35C1, 9),  194 (100),  151 (49),  134 (23),  120 (53),  105 (71), 91 (33); HRMS 
(El): calcd for Ci8H2i35C1N20 3S (M+) 380.0961, found 380.0955.
(3S*,  4S*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic  acid  4-methylbenzylamide 
(124c), 69, 94  (3R*,  5S*)  and  (3S*,  5S*)-2-Methyl-3-phenylisoxazolidine-5-sulfonic 
acid 4-methylbenzylamide (1257126c)
124c  125/126c
General protocol was followed using  100 mg of 123b. Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 125/126c (22 mg, 
13%) as a mixture, and 124c (110 mg, 68%)- overall yield (81%, 124c:125/126c= 5:1, 
125c and 126c = 2:1 major:minor).
Data for 125/126c:  Rf 0.37  (2:1  Et20/petroleum ether 40-60°C);  Umax (neatycm1  2922, 
1455,  1327,  1147,  1037;  5h  (300 MHz, CDC13) 7.27-7.43  (m, 7 H, ArH), 1A1 (d, J =
7.8  Hz, 2 H, ArH), 5.03 (dd, J = 8.6, 5.9 Hz, 1 Hminor, SCH), 4.98 (dd, J = 8.6, 2.4 Hz, 1  
Hmajor, SC/7), 4.82 (app. t, J = 5.9 Hz,  1   Hmin0r, NH), 4.73  (app. t, J = 5.9 Hz,  1   Hm ajor, 
NH), 4.46 (dd, J =  13.9,  6.4 Hz,  1  Hm inor, NHC//H), 4.38-4.43  (m,  1  Hminor, NHCH//),
1704.35-4.40 (m,  1   Hm aj0r, NHCHH), 4.31  (dd, J =  13.9, 5.9 Hz,  1   Hm ajor, NHCHH), 4.06 
(br s,  1  Hm aj„r, NCH), 3.58 (br dd, J = 9.9, 7.8 Hz,  1   Hm i„„r, NCH), 3.07 (ddd, J =  13.7, 
6.2, 2.4 Hz,  1   H, SCHCHH), 2.77-2.99 (m,  1   H,  SCHCHH), 2.75  (s  ,  3 Hm ajor? N  C//3),
2.62  (s, 3 Hminor, NC//3), 2.35 (s, 3 H, ArC//3);  8C  (125 MHz, CDC13)  139.4 (s),  139.0 
(s),  137.9 (s),  137.5 (s),  135.3 (s),  134.9 (s),  130.9 (d),  130.5  (d),  130.4 (d),  130.0 (d),
129.8  (d), 129.5 (d),  129.1 (d), 128.7 (d), 128.5 (d), 90.3 (d), 72.0 (d),  48.7 (t), 45.5 (q),
44.3  (q), 42.6 (t), 42.3 (t), 22.3 (q), 23 out of 28 expected signals observed; m/z (El) 346 
(M+,  50),  282  (38),  236  (86),  209  (74),  162  (52),  147  (35),  134  (70),  120  (48),  105 
(100); HRMS (El): calcd for C18H22N2O3S (M+) 346.1296, found 346.1301.
Data  for  124c:  R f  0.29  (2:1  Et20/petroleum  ether  40-60°C);  mp  84-86  °C;  o w  
(filmVcm1  3290,  3034,  2924,  1611,  1448,  1323,  1146,  1043;  6H   (300  MHz,  CDC13)
7.36-7.44 (m, 5 H, Ar//), 7.05 (d, J = 8.0 Hz, 2 H, Ar//), 6.93 (d, J = 8.0 Hz, 2 H, Ar//),
4.89  (app. t, J = 5.8 Hz,  1   H, CH2N//), 4.34 (dd, J = 9.8, 3.7 Hz,  1  H, SCHC//H), 4.23 
(dd, J - 9.8, 8.4 Hz,  1   H, SCHCH//), 4.08 (dd, /  =  13.7, 6.4 Hz,  1   H, NHC//H), 3.93 
(app. td, J = 8.0, 3.7 Hz,  1   H, SC//), 3.80-3.86 (m, 2 H, SCHC//N and NHCH//), 2.58 
(s, 3 H, NC//3), 2.31  (s, 3 H, ArC//3);  6C  (75 MHz, CDC13)  137.8 (s),  136.8 (s),  133.2 
(s),  129.4 (d),  129.0 (d),  128.8 (d),  128.3 (d),  128.0 (d), 74.5 (d), 73.2 (d), 66.9 (t), 47.0 
(t), 42.7 (q), 21.1  (q); m/z (El) 346 (M+, 10),  160 (100),  105 (83); HRMS (El): calcd for 
C18H22N2O3S  (M+) 346.1351, found 346.1359; Anal, calcd for C18H22N2O3S:  C 62.40, 
H 6.40, N 8.09, found C 61.94, H 6.47, N 7.71.
(3  S*,  4S*)-3-(2-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide  (124d),  (3R*,  5S*)-3-(2-Bromophenyl)-2-methylisoxazolidine-5-
sulfonic  acid  4-methylbenzylamide  (125d),  and  (3S*,  5S*)-3-(2-Bromophenyl)-2- 
methylisoxazolidine-5-sulfonic acid 4-methylbenzylamide (126d)
o  o
Br  \   Br
124d  125d  126d
General protocol was followed using  100 mg of 123b. Crude residue purified by flash
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give the three separable 
products  124d  (61  mg,  31%),  125d  (72  mg,  36%),  and  126d  (33  mg,  16%)- overall 
yield (83%, 124d:125d:126d = 2:2:1).
Data  for  126d:  Rf 0.40  (2:1  Et20/petroleum  ether  40-60°C);  mp  107-109  °C;  \)max 
(neat)/cm‘‘ 3295, 2918,  1515,  1424,  1332,  1155,  1023, 958, 765; 8h (300 MHz, CDC13)
1717.63  (dd, J = 7.8,  1.7 Hz,  1  H, Ar//), 7.55 (dd, J = 8.0,  1.2 Hz,  1  H, Ar//), 7.28-7.34 (m, 
1  H, Ar//), 7.27 (d, J = 7.5 Hz, 2 H, Ar//), 7.13-7.18 (m, 3 H, Ar//), 5.04 (dd, J = 8.6,
5.6  Hz,  1   H, SCH), 4.80 (app. t, J = 6.0 Hz,  1   H, NH), 4.43 (dd, J =  14.2, 6.4 Hz,  1  H, 
NHC//H), 4.38  (dd, J =  14.2, 5.8 Hz,  1   H, NHCH//), 4.17  (dd, J = 9.8, 7.5  Hz,  1   H, 
NCH), 3.18 (ddd, J =  13.4, 8.6, 7.5 Hz,  1   H, SCHC//H), 2.65-2.76 (m, 4 H, SCHCHH 
and NCZ/3), 2.35  (s, 3 H, ArC//3); 5c (75 MHz, CDC13)  137.8 (s),  136.4 (s),  134.1  (s),
132.9  (d),  129.6 (d),  129.5 (d),  128.7 (d),  128.3 (d),  128.0 (d),  123.9 (s), 89.3 (d), 71.0 
(d), 47.6 (t), 43.4 (q), 39.7 (t), 21.1  (q); m/z (El) 426 (M+,  8lBr, 4), 424 (M+, 79Br, 4), 
316  (64),  244  (28),  224  (31),  222  (35),  198  (28),  180  (19),  165  (34),  149  (76),  140 
(100),  129  (26),  125  (44),  121  (89),  112  (74),  105  (56);  HRMS  (El):  calcd  for 
Ci8H2i79BrN20 3S (M+) 424.0456, found 424.0459.
Data  for  125d:  Rf 0.35  (2:1  Et20/petroleum  ether  40-60°C);  mp  89-94  °C;  Dm ax 
(neat)/cm"' 3250, 2919,  1516,  1432,  1291,  1152,  1027, 890, 756; 5H  (300 MHz, CDC13) 
7.55 (app. dt, J = 8.0,  1.3 Hz, 2 H, Ar//), 7.32 (app. dt, J = 7.8,  1.1  Hz,  1  H Ar//), 7.26- 
7.28 (m, 2 H, Ar//), 7.13-7.19 (m, 3 H, ArH), 4.88 (dd, J = 8.2, 4.2 Hz, 1  H, SCH), 4.72 
(app. t,J=  6.0 Hz,  1   H, NH), 4.57 (app. t, J = 7.2 Hz,  1   H, NCH), 4.40 (dd, J =  14.0,
6.0  Hz,  1   H, NHCHH), 4.33 (dd, J =  14.0, 5.8 Hz,  1   H, NHCHH), 3.28 (ddd, J = 13.5,
6.6,  4.2 Hz,  1  H, SCHCHH), 2.8 (s, 3 H, NCH3), 2.59 (app. dt, J =  13.5, 8.2 Hz,  1   H, 
SCHCHH), 2.34 (s, 3 H, ArCH3);  8c (75 MHz, CDC13)  137.9 (s),  137.4 (s),  133.8 (s),
133.1  (d),  129.5  (d),  129.3 (d),  128.0 (2 x d),  127.9  (d),  123.7  (s),  89.8  (d), 69.4 (d),
47.7  (t), 45.2 (q), 39.1  (t), 21.1  (q); m/z (El) 426 (M+, 8lBr, 3), 424 (M+, 79Br, 3), 314 
(66), 244 (54), 234 (20), 214 (59),  198 (77),  184 (33),  167 (54),  147 (59),  132 (65),  120 
(85),  105  (97),  92  (70),  84  (100);  HRMS  (El):  calcd  for  Ci8H2i79BrN20 3S  (M+) 
424.0456, found 424.0459.
Data for 124d: Rf0.22 (2:1 Et20/petroleum ether 40-60°C); u„,ax (neat)/cm'' 3289,2921, 
1516,  1433,  1325,  1146,  1028, 828, 749; 5h (300 MHz,  CDC13) 7.59  (dd, J = 8.0,  1.3 
Hz,  1  H, ArH), 7.48 (dd, J = 7.8,  1.3 Hz,  1 H, ArH), 7.38 (app. dt, J = 7.5,  1.3 Hz,  1  H, 
ArH), 7.21-7.27 (m,  1 H, ArH), 7.02 (d, J = 7.9 Hz, 2 H, ArH), 6.88 (d, J = 7.9 Hz, 2 H, 
ArH), 4.76 (app. t, J = 5.9 Hz,  1  H, NH), 4.51  (br d, J = 6.7 Hz,  1 H, NCH), 4.44 (dd, J 
= 9.8, 3.8 Hz,  1  H, SCHCHH), 4.34 (dd, J = 9.8, 8.4 Hz,  1   H, SCHCHH), 4.12 (dd, J =
13.7, 6.6 Hz,  1   H, NHCHH), 3.95 (app. td, J = 8.0, 3.8 Hz,  1   H, SCH), 3.79 (dd, J =
13.7, 4.8 Hz,  1  H, NHCHH), 2.63 (s, 3 H, NCH3), 2.30 (s, 3 H, ArCH3); 5c (75 MHz, 
CDC13)  137.8 (s),  136.0 (s),  133.3 (s),  133.0 (d),  130.1  (d),  130.0 (d),  129.4 (d),  128.4 
(d),  127.9 (d),  124.8 (s), 73.1  (d), 72.3 (d), 67.2 (t), 47.2 (t), 42.6 (q), 21.1  (q); m/z (El) 
426 (M+, slBr, 9), 424 (M+, ^Br, 9), 240 (88),  197 (54),  134 (26),  120 (87),  116 (70),
172105  (79),  97  (47),  91  (38),  84  (100);  HRMS  (El):  calcd  for  Ci8H2i79BrN20 3S  (M+) 
424.0456, found 424.0450.
(35*,  4S*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide  (124e), 69  94  (3R*,  5S*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-5- 
sulfonic  acid  4-methylbenzylamide  (125e),  and  (35*,  55*)-3-(2-Fluorophenyl)-2- 
methylisoxazolidine-5-sulfonic acid 4-methylbenzylamide (126e)
W  \  F
125e  126e
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give the three separable 
products 124e (73 mg, 43%), 125e (56 mg, 33%), and 126e (23 mg,  13%)- overall yield 
(89%, 124e:125e:126e = 6:5:2).
Data  for  126e:  Rf  0.45  (2:1  Et20/petroleum  ether  40-60°C);  mp  96-99  °C;  0)m ax 
(neat)/cm‘‘ 3276,  2920,  1489,  1453,  1319,  1232,  1155,  1053,  956, 764; 6H  (300 MHz, 
CDCI3) 7.57 (app. dt, J = 7.5,  1.6 Hz,  1  H, ArH), 7.26-7.30 (m,  3 H, ArH), 7.13-7.18 
(m, 3 H, ArH), 7.05 (ddd, J = 10.3, 8.2, 1.2 Hz,  1  H, ArH), 5.05 (dd, J = 8.6, 5.6 Hz,  1  
H, SCH), 4.74 (app. t, J = 5.9 Hz, 1  H, NH), 4.45 (dd, J = 13.9, 6.2 Hz,  1  H, NHCHH), 
4.38  (dd, J =  13.9, 5.7 Hz,  1  H, NHCHH), 4.01  (br dd, J =  10.0, 7.6 Hz,  1   H, NCH),
3.07 (ddd, J = 13.5, 8.6, 7.6 Hz, 1 H, SCHCHH), 2.85 (ddd, J =  13.5,  10.0, 5.6 Hz, 1  H, 
SCHCHH), 2.67 (s, 3 H, NCH3), 2.35 (s, 3 H, ArCH3);  6c (75  MHz, CDC13)  160.9 (s, 
J c f  = 247.1 Hz),  137.8 (s),  134.1  (s), 129.8 (d, Jcf  = 8.5 Hz),  128.0 (d),  128.7 (d, JCp =
3.8 Hz), 128.0 (d), 124.9 (d, Jcf = 3.5 Hz), 123.5 (s, 7Cf =  11.4 Hz),  115.6 (d, iCr = 21.7 
Hz), 89.4 (d), 65.1  (d), 47.6 (t), 43.4 (q), 39.6 (t), 21.1  (q); m/z (FAB+) 365 (MH+, 3), 
307  (35),  289  (16),  154  (100);  HRMS  (FAB+):  calcd  for  CiglfeF^CfjS  (MH+) 
365.1335, found 365.1324.
Data  for  125e:  Rf 0.35  (2:1  Et20/petroleum  ether  40-60°C);  mp  112-115  °C;  t)m ax 
(neat)/cm'' 3269,  2920,  1596,  1490,  1312,  1218,  1134,  1082,  1053,  892, 763; 8H  (300 
MHz, CDC13) 7.25-7.41  (m, 4 H, ArH), 7.03-7.17 (m, 4 H, ArH), 4.93 (dd, J = 8.4, 3.4 
Hz, 1  H, SCH), 4.85 (br t, J = 5.8 Hz, 1  H, NH), 4.43-4.46 (m,  1 H, NCH), 4.38 (dd, J = 
14.1, 6.1  Hz,  1   H, NHCHH), 4.31  (dd, J =  14.1, 6.1  Hz,  1   H, NHCHH), 3.13 (ddd, 7 = 
13.5, 6.5, 3.4 Hz,  1  H, SCHCHH), 2.67-2.79 (m, 4 H, NCH3and SCHCHH), 2.33 (s, 3
173H, ArC//3); 5c (75 MHz, CDCI3)  160.8 (s, 7CF = 247.7 Hz),  137.9 (s),  133.8 (s),  129.6 
(d, 7CF = 8.5 Hz),  129.5 (d), 128.2 (d), 128.0 (d), 124.5 (d, 7CF = 3.5 Hz),  115.7 (d, i CF =
21.7  Hz), 89.7 (d), 63.9 (d), 47.6 (t), 44.9 (q), 39.1  (t), 21.1  (q),  1  x s not observed; m/z 
(El) 364 (M+, 2), 254 (32),  152 (100),  137 (44),  120 (22),  109 (16),  105  (55), 91  (19); 
HRMS (El): calcd for C18H21FN2O3S (M+) 364.1251, found 364.1238.
Data for 124e:  Rf0.22 (2:1 Et20/petroleum ether 40-60°C); om ax (neat)/cm'' 3280, 2918, 
1494,  1456,  1327,  1234,  1146,  1037, 804, 759; 5H  (300 MHz, CDCI3) 7.35-7.45 (m, 2 
H, Ar//), 7.19 (app. t, J = 7.5 Hz,  1   H, Ar//), 7.03-7.11  (m, 3 H, Ar//), 6.95 (d, 7 = 7.9 
Hz,  2  H,  Ar//),  4.79  (app.  t,  7 =  5.4  Hz,  1   H,  N//),  4.39  (dd,  7 = 9.8,  3.5  Hz,  1   H, 
SCHC//H),  4.29  (dd,  7  =  9.8,  8.2  Hz,  1  H,  SCHCH//),  4.14  (m,  2  H,  NCH  and 
NHC//H), 4.02 (app. td, 7 = 7.7, 3.5 Hz,  1  H, SCH), 3.93  (dd, 7 =  13.8, 5.2 Hz,  1   H, 
NHCH//), 2.62 (s, 3 H, NC//3), 2.31  (s, 3 H, A1C //3); 5c (75 MHz, CDCI3) 161.0 (s, 7C F 
= 248.0 Hz),  137.9 (s),  133.2 (s),  130.4 (d, 7CF = 8.5 Hz),  129.9 (d, 7C F = 3.8 Hz), 129.5 
(d),  127.9  (d),  124.9 (d, 7CF = 3.5 Hz),  123.7  (s, 7CF =  11.4  Hz),  116.1  (d, 7CF = 22.0 
Hz), 72.2 (d), 68.0 (d), 67.0 (t), 47.2 (t), 42.8 (q), 21.1  (q); m/z (El) 364 (M+, 2),  178 
(100),  135  (44),  120  (19),  105  (19);  HRMS  (El):  calcd  for  C18H2iFN2 03S  (M+) 
364.1251, found 364.1252.
'V/
MeO 124f
(3S*,  4S*)-3-(4-Methoxyphenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide (124f),69,94 (3R*, 5S*)-3-(4-Methoxyphenyl)-2-methylisoxazolidine-5- 
sulfonic acid 4-methylbenzylamide (125f), and  (3S*, 5S*)-3-(4-Methoxyphenyl)-2- 
methyl isoxazolidine-5-sulfonic acid 4-methylbenzylamide (126f)
OMe
125f  126f
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give the three separable 
products 124f (94 mg, 53%), 125f (23 mg,  13%), and 126f (13 mg, 7%)- overall yield 
(73%, 124f:125f:126f= 7:2:1).
Data for 126f: Rf0.26 (2:1 Et20/petroleum ether 40-60°C); vm ax (neat)/cm_ 1  3289, 2921, 
1612, 1514,  1456,  1327,  1247, 1151, 1034; 8r (300 MHz, CDC13) 7.33 (d, J= 8.8 Hz, 2 
H, ArH), 7.29 (d, J = 8.0 Hz, 2 H, ArH), 7.17 (d, J = 8.0 Hz, 2 H, ArH),  6.87 (d, J = 8.8 
Hz, 2 H, ArH), 5.02 (dd, J = 8.5, 5.9 Hz, 1  H, SCH), 4.72 (app. t, J = 6.0 Hz,  1  H, NH), 
4.46 (dd, J =  13.9, 6.4 Hz,  1  h, NHCHH), 4.39 (dd, J =  13.9, 5.9 Hz,  1  H, NHCHH),
OMe
1743.80  (s,  3  H,  OC//3),  3.54  (br dd,  J =  9.6,  7.5  Hz,  1   H,  NC//),  2.84-3.05  (m,  2  H, 
SCHC//2), 2.60 (s, 3 H, NC//3), 2.35 (s, 3 H, ArC//3);  8c (75 MHz, CDCI3)  160.0 (s),
137.8 (s),  134.2 (s),  129.5 (d),  129.2 (d),  128.2 (s),  128.0 (d),  114.3  (d), 89.3 (d), 67.8 
(d), 55.3  (q), 47.6 (t), 43.4 (q), 41.4 (t), 21.1  (q); m/z (El) 376 (M+,  3), 266 (24),  192 
(71),  164 (58),  149 (100),  135  (36),  119 (25),  105 (87), 91  (41), 77  (24); HRMS (El): 
calcd for C 19H24N 2O4S (M+) 376.1451, found 376.1444.
Data  for  125f:  R f 0.21  (2:1  Et20/petroleum  ether  40-60°C);  mp  132-135  °C;  Uma* 
(neat)/cm'‘ 3295, 2918,  1613,  1458,  1421, 1326,  1243,  1145,  1063,  1022; 6H  (300 MHz, 
CDC13) 7.27 (m, 4 H, Ar//), 7.17 (d, J = 7.9 Hz, 2 H, Ar//),  6.88  (d, J = 8.7 Hz, 2 H, 
Ar//), 4.98 (dd, J = 8.6, 2.1 Hz,  1 H, SCH), 4.70 (app. t,J = 5.4 Hz,  1 H, N//), 4.38 (dd, 
J = 14.0, 6.2 Hz,  1  H, NHC/ZH), 4.31 (dd, J = 14.0, 5.7 Hz,  1   H, NHCH//), 3.99 (br s, 1  
H, NCH), 3.81  (s, 3 H, OC//3), 3.02 (ddd, J =  13.7, 6.0, 2.1  Hz,  1  H, SCHC//H), 2.72- 
2.82 (m, 4 H, SCHCH// and NC//3), 2.35 (s, 3 H, ArC//3);  8C (75 MHz, CDC13)  159.7 
(s),  137.9 (s),  133.8 (s),  129.5  (d),  128.8 (d),  128.3 (s),  128.0 (d),  114.3  (d),  89.1  (d),
67.6  (d), 55.3 (q), 47.6 (t), 44.5 (q), 41.1  (t), 21.1  (q); m/z (El) 376 (M+, 5), 264 (100), 
148  (16),  105  (47);  HRMS  (El):  calcd  for  C19H24N2O4S  (M+)  376.1402,  found 
376.1408.
Data for 124f: Rf0.16 (2:1 Et20/petroleum ether 40-60°C); om ax (neat)/cm_13332, 2959, 
1612, 1514, 1464, 1422, 1315, 1251, 1137, 1058,  1028; 8H  (300 MHz, CDCI3) 7.32 (d, /  
=  8 .8 Hz, 2 H, Ar//), 7.08 (d, J = 8.0 Hz, 2 H, ArH), 6.95  (d, J = 8.0 Hz, 2 H, ArH),
6.90  (d, J = 8 .8 Hz, 2 H, ArH), 4.85 (app. t, J = 5.7 Hz,  1 H, NH), 4.33 (dd, J = 9.9, 3.5 
Hz,  1   H, SCHC/7H), 4.23 (dd, J = 9.9, 8.3 Hz,  1  H, SCHCH//), 4.09 (dd, J = 13.7, 6.4 
Hz,  1   H,  NHC/ZH),  3.91  (app.  td,  J =  7.8,  3.5  Hz,  1   H,  SCH),  3.80-3.88  (m,  1   H, 
NHCH//), 3.82 (s, 3 H, OC//3), 3.75 (d, J = 6.4 Hz,  1   H, NCH), 2.57 (s, 3 H, NC//3), 
2.32 (s,  3  H, ArC//3);  5C  (75  MHz,  CDCI3)  160.0 (s),  137.8  (s),  133.3  (s),  129.4 (d),
128.8 (d),  128.4 (s),  128.0 (d),  114.4 (d), 74.1  (d), 73.0 (d), 66.7  (t), 55.3  (q), 47.0 (t),
42.5  (q), 21.1  (q); m/z (El) 376 (M+, 6),  216 (71),  190 (100),  174 (26),  164 (34),  147 
(93),  134 (45),  120 (46),  105 (53), 91 (42), 77 (28); HRMS (El): calcd for C 19H24N2O4S 
(M+) 376.1451, found 376.1460.
175(35*,  45*)-2-Methyl-3-(4-nitrophenyl)isoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide  (124g),  69  94  (3/?*,  5S*)-2-Methyl-3-(4-nitrophenyl)isoxazolidine-5- 
sulfonic  acid  4-methylbenzylamide  (125g),  and  (35*,  55*)-2-Methyl-3-(4- 
nitrophenyl)isoxazolidine-5-sulfonic acid 4-methylbenzylamide (126g)
V   ,=\  ^   ^  V   /=\  0 ^n °!   Y Y v>Y yn 0 ! ^   O - N   N ° " N
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General protocol was followed using  100 mg of 123b.  Crude residue purified by flash
chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three  separable 
products 124g (96 mg, 52%), 125g  (8 mg, 4%), and 126g (19 mg,  10%)- overall yield 
(67%, 124g:125g:126g = 24:2:5).
Data  for  126g:  R f 0.23  (2:1  Et20/petroleum  ether  40-60°C);  mp  135-139  °C;  o w  
(neat)/cnf1  3279, 2922,  1737,  1599,  1518,  1440,  1329,  1143,  1060, 850; 8H  (300 MHz, 
CDC13) 8.22 (d, J = 8.8 Hz, 2 H, ArH), 7.56 (d, J = 8.8 Hz, 2 H, ArH), 7.26 (d, J = 8.0 
Hz, 2 H, ArH), 7.18 (d, J = 8.0 Hz, 2 H, ArH), 4.93  (dd, J = 8.5, 2.6 Hz,  1   H, SCH),
4.70 (app. t, J = 5.9 Hz, 1 H, NH), 4.39 (dd, J = 13.9, 6.2 Hz,  1 H, NHCHH), 4.32 (dd, J 
=  13.9, 5.9 Hz,  1  H,  NHCHH), 4.22 (dd, J = 9.7, 6.3  Hz,  1   H,  NCH),  3.13  (ddd, J =
13.7,  6.3, 2.6 Hz,  1  H, SCHCHH), 2.78 (s, 3 H, NCH3), 2.68-2.77 (m,  1   H, SCHCHH),
2.35  (s,  3  H,  A1CH3);  8C  (75 MHz,  CDC13)  147.9  (s),  144.8  (s),  138.0 (s),  133.6  (s),
129.6  (d),  128.4 (d),  128.0 (d),  124.1  (d), 89.3 (d), 69.9 (d), 47.6 (t), 44.9 (q), 39.6 (t),
21.1  (q); m/z (Cl)  392 (MH+, 71), 225  (66),  207  (58),  191  (30),  177  (78),  122 (100); 
HRMS (ES+): calcd for QgH^NsOsS (MH+) 392.1275, found 392.1279.
Data for 125g: Rf0.15 (2:1 EtaO/petroleum ether 40-60°C); t>m ax (neat)/cm"' 3280,2923,
1737,  1520,  1435,  1348,  1149,  1054, 855; 8h (300 MHz, CDCI3) 8.20 (d, J = 8.8 Hz, 2 
H, ArH), 7.63 (d, J = 8.8 Hz, 2 H, ArH), 7.28 (d, J = 8.0 Hz, 2 H, ArH), 7.18 (d, J = 8.0 
Hz, 2 H, ArH), 5.02 (dd, J = 8.8, 5.4 Hz,  1  H, SCH), 4.73 (app. t, J = 5.9 Hz,  1 H, NH),
4.45  (dd, J =  14.2, 6.2 Hz,  1   H, NHCHH), 4.38 (dd, J =  14.2, 6.2 Hz,  1   H, NHCHH),
3.70 (dd, J = 9.8, 7.6 Hz,  1 H, NCH), 3.10 (ddd, J = 13.7, 8.8, 7.6 Hz,  1   H, SCHCHH),
2.87  (ddd, J =  13.7,  9.8,  5.4 Hz,  1  H, SCHCHH),  2.64  (s,  3  H,  NCH3),  2.36 (s,  3 H, 
ArCH3);  8c (125  MHz, CDC13)  148.2 (s),  144.3  (s),  138.0 (s),  133.9 (s),  129.6 (d),
129.0  (d),  128.0 (d),  124.2 (d), 89.2 (d), 72.6 (d), 47.6 (t), 43.4 (q), 41.3  (t), 21.2 (q); 
m/z (Cl) 392 (MH+, 5), 281  (27), 251  (21), 225 (34), 207 (74),  165 (80),  148 (70),  135 
(46),  120 (77),  105 (100); HRMS (Cl): calcd for C18H22N3O5S (MH+) 392.1280, found 
392.1272.
176Data  for  124g:  Rf0.19  (2:1  Et20/petroleum  ether  40-60°C);  mp  146-149  °C;  U m ax 
(neatVcm'1  3281, 2870,  1737,  1522,  1447,  1348,  1309,  1148,  1061, 861; 5H  (300 MHz, 
CDC13) 8.21  (d, J = 8.5 Hz, 2 H, ArH), 7.59 (d, J = 8.5 Hz, 2 H, Ar//), 7.07 (d, J = 8.3 
Hz, 2 H, Ar//), 7.02 (d, J = 8.3 Hz, 2 H, Ar//), 4.91  (br s,  1   H, NH), 4.32 (dd, J = 9.8,
3.9  Hz,  1 H, SCHC//H), 4.09-4.22 (m, 3 H, SCHCH// and NHC//2), 3.98 (br d, J = 6.8 
Hz,  1   H, NC//), 3.73 (ddd, J = 10.8, 7.0, 3.9 Hz,  1   H, SCH), 2.64 (s, 3 H, NC//3), 2.31 
(s, 3 H, ArC//3); 8C  (75 MHz, CDC13)  148.0 (s),  144.8  (s),  138.2 (s),  133.1  (s),  129.6 
(d),  129.0 (d),  128.0 (d),  124.0 (d), 74.1  (d), 72.9 (d),  67.2 (t), 47.3  (t), 42.9 (q), 21.1 
(q); m/z (El) 391 (M+, 2), 205 (100), 120 (56), 116 (27),  105 (44); HRMS (El): calcd for 
Ci8H2iN30 5S (M+) 391.1196, found 391.1208.
(35*,  45*)-3-(4-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide  (124h),  (3/?*,  55*)  and  (35*,  55*)-3-(4-Chlorophenyl)-2-methyl 
isoxazolidine-5-sulfonic acid 4-methylbenzylamide (125/126h)
124h 125/126h
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 125/126h (41  mg, 
23%)  as  a  mixture,  and  124h  (98  mg,  55%)  as  a  yellow  solid-  overall  yield  (78%, 
124h:125/126h = 5:2,125h and 126h = 3:1 major:minor).
Data for 125/126h: Rf0.35 (2:1  Et20/petroleum ether 40-60°C); \)m ax (neatycm'1  3274, 
2922,  1490,  1329,  1298,  1144,  1058,  807;  8H  (300 MHz,  CDC13) 7.28-7.37  (m, 4 H, 
Ar//), 7.26 (d, J = 8.0 Hz, 2 H, Ar//), 7.17 (d, J = 8.0 Hz, 2 H, ArH), 5.00 (dd, J = 8.6,
5.6  Hz,  1  Hminor?SCH), 4.95  (dd, J =  8.6, 2.4 Hz,  1  H major,  SCH), 4.83  (app. t, J = 5.9 
Hz,  1  H mjnor? NH), 4.73 (app. t, J = 5.9 Hz,  1   H major, NH), 4.44 (dd, J =  13.9, 6.2 Hz,  1  
Hm ia„r, N H C H H ), 4.37-4.42 (m,  1   Hm inor, N H C H H ), 4.36 (dd, J =  13.9, 6.2 Hz,  1   H maj0r, 
N H C H H ), 4.31  (dd, J = 13.9, 5.9 Hz,  1  Hm ajor, N H C H H ), 4.04 (br dd, J = 8.6 , 6.2 Hz,  1  
Hmajor,  N C H ), 3.55 (br dd, J = 9.9, 7.5 Hz,  1   H mi„0r,  N C H ),  3.05 (ddd, J =  13.7, 6.2, 2.4 
Hz,  1  H major» SCHCHH),  3.01  (ddd, J =  13.7,  8 .6,  7.5  Hz,  1   H mi„or,  SCHCHH),  2.85 
(ddd, J = 13.7, 9.9, 5.6 Hz,  1 Hm inor, SCHCHH), 2.73 (s, 3 Hm ajor, NCH3), 2.71  (ddd, J =
13.7,  10.2, 8 .6 Hz,  1  Hm ajor, SCHCHH), 2.60 (s, 3 H minor, NCH3), 2.35 (s, 3 H, ArCH3); 
8c (125  MHz,  CDC13)  139.0 t(s),  138.0 (s),  136.5  (s),  135.9  (s),  134.8  (s),  133.6 (s),
177130.6  (d),  130.1  (d),  129.6 (d),  129.5 (d),  129.1  (d),  129.0 (d), 90.2 (d),  89.1  (d), 71.2 
(t), 48.6 (t), 45.4 (q), 45.3 (q), 42.5 (t), 22.2 (q), 20 out of 28 expected signals observed; 
m/z (FAB+) 383 (MH+, 37C1, 10), 381 (MH+, 35C1, 22), 338 (63), 307 (96), 289 (60), 273 
(28),  196 (34),  155 (100); HRMS (FAB+): calcd for Ci8H2235C1N203S (MH+) 381.1040, 
found 381.1046.
Data  for  124h:  Rf 0.27  (2:1  Et20/petroleum  ether  40-60°C);  mp  101-105  °C;  \)m ax 
(neat)/cm‘1  3347, 2879,  1492, 1328, 1305, 1136, 1032, 750; 5H  (300 MHz, CDC13) 7.33 
(s, 4 H, Ar//), 7.07 (d, J = 8.0 Hz, 2 H, ArH), 6.96 (d, J = 8.0 Hz, 2 H, Ar//), 4.93 (app. 
t, J = 5.4 Hz,  1   H, NH), 4.30-4.34 (m,  1   H, SCHC//H), 4.16-4.23 (m,  1  H, SCHCHH), 
4.12 (dd, J =  13.9, 6.2 Hz,  1   H, NHC//H), 3.98 (dd, J =  13.9, 5.6 Hz,  1   H, NHCH//), 
3.76-3.83 (m, 2 H, SCH and NC//), 2.58 (s, 3 H, NC//3), 2.32 (s, 3 H, ArC//3); 5c (75 
MHz, CDC13)  138.0 (s),  135.5 (s),  134.6 (s),  133.1  (s),  129.6 (d),  129.5 (d),  129.2 (d),
128.0  (d), 73.5 (d), 66.9 (t), 47.1 (t), 42.7 (q), 21.1  (q),  1 x d not observed; m/z (El) 382 
(M+, 37C1, 2), 380 (M+, 35C1, 5),  196 (33),  194 (100),  120 (83);  HRMS  (El):  calcd for 
Ci8H2135C1N20 3S (M*) 380.0956, found 380.0949.
(35*,  45*)-2-Methyl-3-naphthalen-2-yl-isoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide  (124i),  (3R*,  55*)  and  (35*,  55*)-2-Methyl-3-naphthalen-2-yl- 
isoxazolidine-5-sulfonic acid 4-methylbenzylamide (125/126i)
124i  125/126i
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20) to give 125/126i (30 mg, 
16%)  as  a  mixture,  and  124i  (77  mg,  41%)  as  a  yellow  solid-  overall  yield  (57%, 
124i:125/126i = 5:2,125i and 126i = 2:1 major:minor).
Data for 125/126i:  Rf0.34  (2:1  Et20/petroleum ether 40-60°C);  mp  118-120 °C;  a)m ax 
(neatycm'1   3227,  2924,  1515,  1437,  1320,  1286,  1153,  1048,  889;  5H   (300  MHz, 
CDC13) 7.79-7.87 (m, 4 H, ArH), 7.60 (dd, J =  8.3,  1.3 Hz,  1  H, Ar//), 7.46-7.53 (m, 2 
H, ArH), 7.25-7.32 (m, 2 H, ArH), 7.17 (d, J = 8.0 Hz, 2 H, ArH), 5.08 (dd, J = 8.3, 6.2 
Hz,  1 Hm inor, SCH), 5.03 (dd, J =  8.3, 2.4 Hz,  1  Hmajor, SCH), 4.90 (app. t, J = 5.9 Hz,  1 
Hminor, N//), 4.80 (app. t, J =  5.9 Hz,  1  H m a j o r ,   NH), 4.48 (dd, J =  13.9, 6.2 Hz,  1 Hmi„0„ 
NHC/ZH),  4.41-4.46  (m,  1  Hminor,  NHCHH),  4.41  (dd,  J  =  13.9,  6.2  Hz,  1   Hmajo„
178NHCHH), 4.34  (dd, J =  13.9, 5.9 Hz,  1  H maj0r,  NHCHH),  4.25  (br s,  1   Hm ajor, NC//), 
3.75 (br dd, J = 9.4, 8.3 Hz,  1   H min0r,  NC//), 2.99-3.18 (m,  1   H ,  SCHCHH), 2.82-2.98 
(m,  1   H,  SCHCH//),  2.80 (s, 3  Hm ajor, NCZfc),  2.66  (s,  3  Hminor, NC//3),  2.35  (s, 3 H, 
A1C//3);  8C  (75 MHz, CDCI3)  137.9 (s),  134.1  (s),  133.8 (s),  133.3 (s),  129.5 (d),  129.4 
(d),  128.9 (d),  128.7 (d),  128.1  (d),  128.0 (d),  127.9 (d),  127.8 (d),  127.7 (d),  127.5 (d),
126.4 (d),  126.3 (d),  126.2 (d),  125.1 (s),  124.7 (s), 89.3 (d), 74.3 (d), 47.6 (t), 43.3 (q),
39.7  (t), 21.1  (q), 25  out of 34 expected signals observed; m/z (FAB+) 397 (MH+,  15), 
219 (100), 203 (43),  187 (22),  163 (68); HRMS (FAB+): calcd for C22H25N2O3S (MH+) 
397.1586, found 397.1591.
Data  for  124i:  Rf 0.28  (2:1  Et20/petroleum  ether  40-60°C);  mp  116-118  °C;  \)max 
(neatycm' 1  3278, 2959, 2874,  1508,  1457,  1412,  1308,  1152,  1038, 918; 5H  (300 MHz, 
CDCI3) 7.79-7.89  (m, 4 H, Ar//), 7.49-7.57  (m,  3  H,  Ar//),  6.86  (d, J = 8.0 Hz, 2 H, 
Ar//), 6.75 (d, J = 8.0 Hz, 2 H, ArH), 4.85 (app. t, J = 5.1  Hz,  1   H, NH), 4.43 (dd, J =
9.6,  3.5 Hz,  1  H, SCHCHH), 4.32 (dd, /=  9.6, 7.8 Hz,  1  H, SCHCHH), 4.01-4.09 (m, 3 
H, NCH and SCH and NHCHH), 3.81  (dd, J =  13.9, 5.4 Hz,  1   H, NHCHH), 2.64 (s, 3 
H, NC//3), 2.24 (s, 3 H, ArC//3);  8C  (75 MHz,  CDC13)  137.8  (s),  134.1  (s),  133.5  (s),
133.4 (s),  132.9 (s),  129.3 (d),  129.0 (d),  128.1  (d),  127.9 (2 x d),  127.8 (d),  126.6 (d),
126.5 (d),  125.1 (d), 74.7 (d), 73.1 (d), 67.0 (t), 47.1  (t), 42.8 (q), 21.1  (q); m/z (El) 396 
(M+, 36), 244 (43), 205  (61),  118 (57),  104 (33), 91  (45), 84 (100); HRMS (El): calcd 
for C22H24N2O3S (M+) 396.1502, found 396.1497.
(3S*,  4S*)-3-(3-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide (124j),69, 94 and (3/?*, 5S*)-3-(3-Bromophenyl)-2-methyIisoxazolidine- 
5-sulfonic acid 4-methylbenzylamide (125j)
\V/
124j Br 125j
General protocol was followed using  100 mg of 123b. Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20)  to give the two products 
124j (94 mg, 47%) and 125j (20 mg, 10%)- overall yield (57%, 124j:125j = 5:1).
Data for 125j: Rf0.43 (2:1 Et20/petroleum ether 40-60°C); 0)m ax (neatycm1  3259, 2918, 
1594,  1460,  1430,  1322,  1295,  1144,  1044, 779; 6H  (300 MHz, CDC13) 7.54 (br s,  1   H 
ArH), 7.45 (app. dt, J = 7.5,  L6 Hz,  1   H, ArH), 7.25-7.30 (m, 2 H, ArH), 7.24 (d, J =
1798.0 Hz, 2 H, ArH), 7.17 (d, 7 = 8.0 Hz, 2 H, ArH), 4.95 (dd, J = 8.6, 2.4 Hz,  1  H, SCH), 
4.69 (app. t, J = 5.9 Hz,  1  H, NH), 4.39 (dd, 7 = 13.9,6.4 Hz, 1  H, NHCHH), 4.31 (dd, 7 
=  13.9, 5.6 Hz,  1   H, NHCHH), 4.05 (br dd, 7 = 9.1, 6.2 Hz,  1   H, NCH), 3.07 (ddd, 7 =
13.7,  6.2, 2.4 Hz,  1   H, SCHCHH), 2.76 (s, 3 H, NCH3), 2.73 (ddd, 7 =  13.7,  10.2, 8.6 
Hz,  1   H, SCHCHH), 2.35  (s, 3 H, ArCH3); 8c (75 MHz,  CDC13)  139.2 (s),  138.0 (s),
133.7 (s), 131.5 (d),  130.4 (d),  129.6 (d),  128.9 (d),  128.0 (d),  126.3 (d),  123.0 (s), 89.2 
(d), 70.0 (d), 47.6 (t), 44.5  (q), 41.8 (t), 21.2 (q); m/z (FAB+) 427 (MH+, 81Br, 4), 425 
(MH+, 79Br, 4), 338 (19),  154 (100); HRMS (FAB+): calcd for Ci8H2279BrN20 3S (MH+) 
425.0534, found 425.0518.
Data  for  124j:  R f  0.35  (2:1  Et20/petroleum  ether  40-60°C);  mp  97-100  °C;  t)m ax 
(neat)/cm'‘ 3145, 2920,  1570,  1464,  1325,  1140,  1020, 817; 8H  (300 MHz, CDC13) 7.55 
(s,  1   H, ArH), 7.47-7.50 (m,  1   H, ArH), 7.34 (app. dt, J = 7.8,  1.3 Hz,  1   H, ArH), 7.22 
(d, J = 7.8 Hz,  1   H, ArH), 7.08 (d, J = 8.0 Hz,  2 H,  ArH),  6.99 (d, J = 8.0 Hz, 2 H, 
ArH), 4.95  (app.  t, J = 5.1  Hz,  1   H, NH), 4.32 (dd, J = 9.9, 3.5  Hz,  1   H, SCHCHH),
4.18  (dd, J = 9.9, 7.8 Hz,  1  H, SCHCHH), 4.13 (dd, J =  13.9, 5.9 Hz,  1   H, NHCHH),
4.00 (dd, 7= 13.9, 5.4 Hz, 1 H, NHCHH), 3.74-3.79 (m, 2 H, NCH and SCH), 2.60 (s, 3 
H, NCH3), 2.32 (s,  3 H,  ArCH3); 8c (75 MHz, CDC13)  139.5  (s),  138.0 (s),  133.1  (s),
131.8 (d),  130.9 (d),  130.5 (d),  129.6 (d),  128.0 (d),  127.1  (d),  123.0 (s), 73.6 (d), 73.4 
(d), 67.0 (t), 47.2 (t), 42.8 (q), 21.2 (q); m/z (El) 426 (M+, 81Br, 2), 424 (M+, 79Br, 2), 
240  (100),  238  (94),  120  (68),  105  (68),  91  (27);  HRMS  (El):  calcd  for 
Ci8H2i79BrN20 3S (M+) 424.0451, found 424.0432.
(3  S*,  4S*)-3-(3-ChlorophenyI)-2-methyIisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide (124k),69,94 and (3R*, 5S*)-3-(3-Chlorophenyl)-2-methylisoxazolidine 
-5-sulfonic acid 4-methylbenzylamide (125k)
124k 125k
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20)  to give the two products 
124k (84 mg, 47%) and 125k (27 mg, 15%)- overall yield (62%, 124k:125k = 3:1).
Data  for  125k:  R f  0.42  (2:1  Et20/petroleum  ether  40-60°C);  mp  72-75  °C;  \)m ax 
(neatycm13260, 2919,  1597,  1431, 1327, 1296, 1144,  1063, 782; 8h (300 MHz, CDC13)
1807.38 (s, 1  H, Ar//), 7.21-7.30 (m, 5 H, Ar//), 7.17 (d, J = 8.0 Hz, 2 H, Ar//), 4.95 (dd, J 
= 8.6, 2.7 Hz,  1 H, SCH), 4.74 (app. t, J = 5.9 Hz, 1  H, N//), 4.39 (dd, J = 13.9, 6.2 Hz, 
1  H, NHC//H), 4.31 (dd, J = 13.9,5.6 Hz, 1  H, NHCHH), 4.05 (br dd, J = 9.9,5.9 Hz, 1  
H, NC//), 3.07 (ddd, J =  13.7, 6.2, 2.7 Hz,  1   H, SCHCHH), 2.75 (s, 3 H, NCH3), 2.73 
(ddd,  J =  13.9,  10.2,  8.6  Hz,  1   H,  SCHCHH),  2.34  (s,  3  H,  ArCH3);  6c  (75  MHz, 
CDC13)  139.1  (s),  137.9 (s),  134.8 (s),  133.7 (s),  130.1  (d),  129.5  (d),  128.6 (d),  128.0 
(d), 127.6 (d),  125.8 (d), 89.2 (d), 70.3 (d), 47.6 (t), 44.6 (q), 41.2 (t), 21.1  (q); m/z (Cl) 
383  (MH+,  37C1,  6),  381  (MH+,  35C1,  16),  270  (35),  198  (31),  196  (100),  105  (46); 
HRMS (Cl): calcd for Ci8H2235C1N20 3S (MH+) 381.1034, found 381.1029.
Data  for  124k:  R f  0.34  (2:1  Et20/petroleum  ether  40-60°C);  mp  88-92  °C;  \)m ax 
(neat)/cm ‘3159, 2920,  1516,  1432,  1327,  1141,  1021,904, 791; 6H  (300 MHz, CDC13)
7.39 (s, 1 H, ArH), 7.28-7.35 (m, 3 H, ArH), 7.08 (d, J = 8.0 Hz, 2 H, ArH), 6.99 (d, J =
8.0  Hz, 2 H, ArH), 5.01  (app. t, /  = 5.4 Hz,  1  H, NH), 4.32 (dd, J =  10.2, 3.5 Hz,  1   H, 
SCHCHH), 4.18 (dd, 7=  10.2, 7.8 Hz,  1  H, SCHCHH), 4.13 (dd, J = 13.9, 5.9 Hz,  1  H, 
NHCHH),  4.00  (dd,  J =  13.9,  5.6  Hz,  1   H,  NHCHH),  3.74-3.82  (m,  2  H,  SCH and 
NCH), 2.59 (s, 3 H, NCH3), 2.32 (s, 3 H, ArCH3); 6c (75 MHz, CDC13)  139.3 (s),  138.0 
(s),  134.9 (s),  133.1  (s),  130.2 (d),  129.5 (d),  128.9 (d),  128.1  (d),  128.0 (d),  126.6 (d),
73.6  (2 x  d),  67.0  (t),  47.1  (t),  42.7  (q),  21.1  (q);  m/z (Cl)  383  (MH+,  37C1,  13),  381 
(MH+,  35C1,  31),  252  (100),  237  (28),  193  (41),  145  (18);  HRMS  (Cl):  calcd  for 
C18H2235C1N20 3S (MH+) 381.1034, found 381.1018.
(35*,  45*)-3-(5-Bromofuran-2-yl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide (1241)
\x ,7
1241  Br
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 1241 (39 mg, 20%) 
as a brown oil.
Data for 1241: Rf0.27 (2:1 Et20/petroleum ether 40-60°C); \)m ax (neatycm1  3142, 2919, 
1441, 1320, 1141, 1020, 901, 793; 5h (300 MHz, CDC13) 7.14 (d, 7= 8.0 Hz,2H, Ar//),
7.08  (d, J = 8.0 Hz, 2 H, Ar//), 6.37 (d, J = 3.5 Hz,  1 H, BrCC//), 6.31 (d, J = 3.5 Hz, 1  
H, OCCH), 4.81  (br s,  1   H, NH), 4.33 (dd, J = 9.1, 3.2 Hz,  1   H, SCHC//H), 4.05-4.24
181(m, 4 H, SCHCH// and NHCH2  and SCH), 3.89 (br s,  1  H, NCH), 2.67 (s, 3 H, NC//3),
2.34  (s,  3  H,  ArCZ/3);  5C  (75  MHz,  CDC13)  150.6 (s),  138.1  (s),  133.1  (s),  129.6 (d),
128.0  (d),  123.0 (s),  113.8 (d),  112.6 (d), 69.4 (d), 67.5 (d), 66.8 (t), 47.2 (t), 42.8 (q), 
21.2 (q); m/z (El) 416 (M+, 8,Br, 7), 414 (M+, 79Br, 7), 230 (100),  187 (52),  159 (22), 
120 (95); HRMS (El): calcd for Ci6Hi979BrN20 4S (M+) 414.0194, found 414.0206.
(3S*,  4S*)-3-Furan-2-yl-2-methylisoxazolidine-4-sulfonic  acid  4-methylbenzyI 
amide  (124m), 69, 94  (3R*9   5S*)-3-Furan-2-yI-2-methylisoxazolidine-5-sulfonic  acid
4-methylbenzylamide  (125m),  and  (3S*,  5S*)-3-Furan-2-yl-2-methylisoxazolidine-
5-sulfonic acid 4-methylbenzylamide (126m)
o  .0
.0
124m  125m  126m
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give the three products 
124m (30 mg, 19%), 125m (46 mg, 29%), and 126m (23 mg,  15%)- overall yield (63%, 
124m: 125m: 126m = 4:6:3).
Data  for  126m:  Rf 0.40  (2:1  Et20/petroleum  ether  40-60°C);  t)m ax  (neatycm' 1   3279, 
2921,  1516,  1436,  1325,  1144,  1054, 951; 8h  (300 MHz,  CDC13)  7.40-7.41  (m,  1  H, 
OC//CHCH), 7.25 (d, J = 8.0 Hz, 2 H, ArH), 7.14 (d, J = 8.0 Hz, 2 H, ArH), 6.39 (d, J 
= 3.2 Hz,  1  H, OCHCHCZ/), 6.36 (dd, J = 3.2,  1.6 Hz,  1  H, OCHCZ/CH), 5.06 (dd, J =
8.6,  5.6 Hz,  1  H, SCH), 4.76 (app. t,J = 5.9 Hz,  1  H, NH), 4.45 (dd, J = 13.9, 6.4 Hz,  1  
H, NHCHH), 4.38 (dd, J = 13.9, 5.9 Hz, 1  H, NHCHH), 3.72 (br dd, J = 10.2, 7.7 Hz, 1
H, NCH), 3.15  (ddd, J =  13.7,  10.2, 5.6 Hz,  1  H, SCHCHH), 2.97 (ddd, J =  13.7,  8.6,
7.7  Hz,  1   H,  SCHCHH),  2.74  (s,  3  H,  NCH3),  2.34  (s,  3  H,  ArCH3);  6C   (75  MHz, 
CDCI3)  148.5 (s),  143.2 (d),  137.6 (s),  134.3 (s),  129.4 (d),  128.0 (d),  110.6 (d),  109.5 
(d), 89.6 (d), 66.1  (d), 47.7 (t), 43.6 (q), 36.8 (t), 21.1  (q); m/z (FAB+) 337 (MH+, 52), 
210 (20),  165 (31),  154 (100); HRMS (FAB+): calcd for Q 6H21N2O4S (MH+) 337.1222, 
found 337.1226.
Data  for  125m:  Rf 0.36  (2:1  Et20/petroleum  ether  40-60°C);  ^Wx  (neatycm'1   3288, 
2917,  1505,  1426,  1335,  1294,  1134,  1071, 999;  8H  (300 MHz,  CDC13) 7.41  (dd, 7 =
I.9, 0.8 Hz, 1 H, OCZ/CHCH), 7.25 (d, J = 8.0 Hz, 2 H, ArH), 7.15 (d, J = 8.0 Hz, 2 H, 
ArH),  6.35  (dd,  J =  3.2,  1.9  H^,  1   H,  OCHC//CH),  6.30  (app.  d,  /  =  3.2  Hz,  1   H,
182OCHCHCH), 4.98 (br s,  1   H, SCH), 4.82 (app. t,J = 5.6 Hz,  1   H, NH), 4.37 (dd, J =
13.9,  6.4 Hz, 1   H, NHCHH), 4.30 (dd, J = 13.9, 5.9 Hz,  1   H, NHCHH), 4.17 (br s,  1  H, 
NCH), 3.00 (br s, 2 H, SCHCH2), 2.82 (br s, 3 H, NCH3), 2.34 (s, 3 H, ArCH3); 8c (75 
MHz, CDC13)  149.1  (s),  143.1  (d),  137.9 (s),  133.8 (s),  129.5 (d),  128.0 (d),  110.5 (d),
109.3  (d), 89.4 (d), 64.7 (d), 47.6 (t), 45.0 (q), 37.1  (t), 21.1  (q); m/z (Cl) 337 (MH+, 5), 
252 (20), 169 (59),  152 (100),  148 (23), 124 (42),  109 (36),  105 (41); HRMS (Cl): calcd 
for C,6H2iN20 4S (MH+) 337.1217, found 337.1220.
Data  for  124m:  Rf 0.30  (2:1  Et20/petroleum  ether  40-60°C);  Um ax  (neatycm'1   3280, 
2919,  1516,  1436,  1322,  1146,  1039; 5h (500 MHz, CDC13) 7.45 (brt, J= 1.3 Hz,  1 H, 
OCHCHCH), 7.12 (d, J= 8.0 Hz, 2 H, ArH), 7.06 (d, J = 8.0 Hz, 2 H, ArH), 6.41  (app. 
d, J =  1.3 Hz, 2 H, OCHCHCH and OCHCHCH), 4.34-4.43  (m, 2 H,  SCH and NH), 
4.25-4.31  (m, 2 H, SCHCH2), 4.18 (dd, J = 13.6, 6.5 Hz,  1  H, NHCHH), 3.98 (br dd, J 
= 13.6, 4.6 Hz,  1  H, NHCHH), 3.93 (br s,  1  H, NCH), 2.70 (br s, 3 H, NCH3), 2.33 (s, 3 
H, ArCH3); 8c (125 MHz, CDC13)  148.6 (s),  143.5  (d),  138.1  (s),  133.1  (s),  129.6 (d),
128.1  (d),  110.9 (d),  110.2 (d), 69.4 (d), 67.9 (d), 66.8  (t), 47.3  (t), 42.8 (q), 21.2 (q); 
m/z (Cl) 336 (M+, 9),  150 (100), 120 (24), 105 (22), 91 (19), 84 (93); HRMS (Cl): calcd 
for C16H20N2O4S (M+) 336.1138, found 336.1125.
(3S*9   4S*)-3-(4-Allyloxyphenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide (124n)69,94
124n
General protocol was followed using  100 mg of 123b.  Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  124n  (92  mg, 
24%) as a brown oil.
Data  for  124n:  Rf (4c anti) 0.24  (2:1  Et20/petroleum  ether  40-60°C);  vm ax  (neatycm'1  
3287,  2923,  1611,  1511,  1425,  1326,  1306,  1242,  1146,  1021;  5h  (300 MHz,  CDC13) 
7.30 (d, J = 8.7 Hz, 2 H, ArH), 7.06 (d, J = 7.9 Hz, 2 H, ArH), 6.89-6.95 (m, 4 H, ArH),
6.06  (ddt, J =  17.4,  10.4, 5.4 Hz,  1  H, CH=CH2), 5.43 (app. dq, J =  17.4,  1.6 Hz,  1   H, 
CH=C7/H), 5.31 (app. dq, J = 10.4,  1.6 Hz,  1 H, CH=CH//), 4.80 (app. t, J = 5.9 Hz,  1  
H, NH), 4.54 (app. dt, J = 5.4,  1.6 Hz, 2 H, OCH2CH=), 4.33 (dd, J = 9.6, 3.8 Hz,  1  H, 
SCHCHH), 4.23 (dd, J = 9.6, 8.3 Hz,  1   H, SCHCH//), 4.08 (dd, J =  13.7, 6.4 Hz,  1  H,
4
183NHC//H), 3.91  (app. td, 7 = 8.0, 3.8 Hz,  1   H, SC//), 3.84 (dd, 7 =  13.7, 5.1  Hz,  1   H, 
NHCHH),  3.74  (br  d,  7 =  7.2  Hz,  1  H,  NC//),  2.56  (s,  3  H,  NC/Z3),  2.31  (s,  3  H, 
ArCZ/3); 8C  (75 MHz, CDC13) 159.0 (s),  137.8 (s),  133.2 (s),  133.1  (d),  129.4 (d), 128.6 
(s), 128.0 (d),  117.9 (t), 115.2 (d), 114.7 (d), 74.1 (d), 73.0 (d), 68.9 (t), 66.7 (t), 47.0 (t),
42.6  (q), 21.1  (q); m/z (El) 402 (M+, 41), 353 (21), 217 (80),  191  (66),  173 (100),  150 
(25),  120 (60),  105  (56), 91  (36); HRMS  (El):  calcd for C21H26N2O4S  (M+) 402.1613, 
found 402.1614.
(35*,  4S*)-3-(2-Iodophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methylbenzyl 
amide  (124o),  and  (3S*,  5S*)-3-(2-Iodophenyl)-2-methylisoxazolidine-5-sulfonic 
acid 4-methylbenzylamide (126o)
\
124o  1260
General protocol was followed using  110 mg of 123b.  Crude residue purified by flash 
chromatography  (starting  9:1  petroleum  ether  40-60°C/Et20)  to  give  124o  (48  mg, 
20%) and 126o (27 mg, 11%) as a brown oils- overall yield (32%, 124o:126o = 2:1). 
Data for 126o: Rf0.56 (2:1 Et20/petroleum ether 40-60°C); t)max (neatycm1 2918, 1520, 
1495,  1319,  1234, 1142, 991, 808, 752; 5r (300 MHz, CDC13) 7.83 (dd, 7= 8.0, 1.1 Hz, 
1   H, Ar//), 7.59  (dd, J = 7.8,  1.6 Hz,  1   H, Ar//), 7.35  (app.  dt, J = 7.8,  1.1  Hz,  1   H, 
ArH), 7.27 (d, J = 7.8 Hz, 2 H, Ar//), 7.16 (d, J = 7.8 Hz, 2 H, ArH), 7.00 (app. dt, J =
7.8,  1.6 Hz,  1  H, ArH), 5.04 (dd, J = 8.8, 5.6 Hz,  1 H, SC//), 4.91  (app. t, J = 5.1 Hz, 1  
H, NH), 4.43  (dd, J =  14.5, 5.9 Hz,  1   H, NHCZ/H),  4.37  (dd, J =  14.5,  5.4 Hz,  1   H, 
NHCHH), 4.05 (dd, J = 9.9, 7.5 Hz,  1  H, NCH), 3.16-3.25 (m,  1 H, SCHC//H), 2.69 (s, 
3 H, NCH3), 2.65 (ddd, J = 13.7, 9.9, 5.6 Hz,  1  H, SCHCH//), 2.35 (s, 3 H, ArC//3); 8C  
(75 MHz, CDC13)  139.6 (d),  139.0 (s),  138.2 (s),  134.0 (s),  130.0 (d),  129.5  (d),  129.2 
(d),  128.6 (d),  127.9 (d), 93.6 (s), 89.1 (d), 76.2 (d), 47.5 (t), 43.3 (q), 39.8 (t), 21.2 (q); 
m/z (Cl) 473  (MH+,  27),  362 (100), 288  (63),  260 (27),  212  (20),  168  (26),  151  (34), 
105 (60); HRMS (Cl): calcd for Ci8H22lN20 3S (MH+) 473.0396, found 473.0386.
Data for 124o: Rf0.35 (2:1 Et20/petroleum ether 40-60°C); \)max (neatycm"1  3287, 2920, 
1516,  1469,  1432,  1324,  1145,  1038, 807, 749;  6H  (300 MHz, CDC13) 7.87 (d, J = 8.0 
Hz, 1 H, ArH), 7.38-7.42 (m, 2 H, ArH), 7.05-7.11 (m, 1 H, ArH), 7.01 (d, 7=8.0 Hz, 2 
H, ArH), 6.89 (d, 7 = 8.0 Hz, 2 H, ArH), 4.72 (app. t, 7 = 5.9 Hz,  1 H, NH), 4.45 (dd, 7 
= 9.9, 3.8 Hz,  1  H, SCHC//H), 4.38 (br d, 7 = 6.4 Hz,  1  H, NCH), 4.34 (dd, 7 = 9.9, 8.3
184Hz,  1   H,  SCHCHH), 4,13  (dd, 7 =  13.7, 6.7  Hz,  1   H,  NHCHH),  3.88-3.94 (m,  1   H, 
SCH), 3.78  (dd, 7 =  13.7, 4.8 Hz,  1   H, NHCHH),  2.64  (s,  3  H,  NCH3),  2.30 (s, 3  H, 
ArCH3); 5c (75 MHz, CDC13)  140.0 (d),  139.1  (s), 137.8 (s),  132.9 (s),  130.4 (d), 129.7 
(d),  129.4 (d),  129.2 (d),  128.0 (d),  101.1  (s), 77.3 (d), 73.4 (d), 67.2 (t), 47.2 (t), 42.5 
(q), 21.2 (q); m/z (Cl) 473 (MH+,  100), 287 (52),  151  (21),  105 (17); HRMS (Cl): calcd 
for C18H22IN20 3S (MH+) 473.0396, found 473.0388.
(3S*,  4S*)-3-(3-Iodophenyl)-2-methylisoxazolidine-4-sulfonic  acid  4-methylbenzyl 
amide  (124p),  and  (3R*,  5S*)-3-(3-Iodophenyl)-2-methylisoxazolidine-5-sulfonic 
acid 4-methylbenzylamide (125p)
V
h  r  \  /   \
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General protocol was followed using  150 mg of 123b.  Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  125p  (57  mg, 
17%)  as  a light brown  solid,  and  124p  (146 mg,  44%)  as  a yellow  oil-  overall yield 
(61%, 124p:125p = 5:2).
Data  for  125p:  R f  0.50  (2:1  Et20/petroleum  ether  40-60°C);  mp  100-102  °C;  a)m ax 
(neatycm' 1  3260,  3000, 2917,  1516,  1433,  1321,  1143,  1042,  879,  778;  8h (300 MHz, 
CDC13) 7.73 (s,  1  H, ArH), 7.65 (dd, J = 7.8,  1.1  Hz,  1   H, ArH), 7.31  (app. d, J = 7.8 
Hz,  1   H, ArH), 7.26 (d, J = 8.0 Hz, 2 H, ArH), 7.16 (d, J = 8.0 Hz, 2 H, ArH), 7.08 
(app. t, J = 7.8 Hz,  1  H, ArH), 4.93 (dd, J = 8.6, 2.4 Hz,  1  H, SCH), 4.76 (br t, J = 5.9 
Hz,  1  H, NH), 4.38 (dd, 7=  14.2, 5.9 Hz,  1  H, NHCHH), 4.30 (dd, J =  14.2, 5.9 Hz,  1  
H, NHCHH), 4.00 (app. t, J = 7.5 Hz, 1  H, NCH), 3.04 (ddd, J = 13.9, 6.2, 2.4 Hz,  1  H, 
SCHCHH),  2.65-2.76  (m,  4  H,  SCHCHH and  NCH3),  2.34  (s,  3  H,  ArCH3);  8c  (75 
MHz, CDC13)  139.4 (s),  137.9 (s),  137.5 (d),  136.4 (d),  133.7 (s),  130.6 (d),  129.5 (d),
128.0  (d),  126.9 (d), 94.7 (s), 89.2 (d), 70.2 (d), 47.6 (t), 44.6 (q), 42.1  (t), 21.2 (q); m/z 
(El) 472 (M+,  11), 562 (43), 288 (24), 260 (42), 246 (37),  149 (75),  120 (59),  105 (98), 
91 (68), 55 (100); HRMS (Cl): calcd for Ci8H21IN20 3S (M+) 472.0312, found 472.0328. 
Data  for  124p:  Rf  0.43  (2:1  Et20/petroleum  ether  40-60°C);  vm ax  (neatycm' 1   3296, 
2865,  1514,  1423,  1323,  1138,  1043,  832,  784;  8H   (300  MHz,  CDC13)  7.75  (s,  1   H, 
ArH), 7.66-7.71 (m,  1  H, ArH), 7.37 (d, 7 = 7.8 Hz, 1 H, ArH), 7.10 (d, 7= 7.8 Hz, 1  H, 
ArH), 7.08 (d, 7 = 8.0 Hz, 2 H, ArH), 6.98 (d, 7 = 8.0 Hz, 2 H, ArH), 5.09 (app. t, 7 =
124p
1855.9  Hz,  1   H,  NH),  4.27-4.34  (m,  1   H,  SCHCHH),  4.16  (dd,  J =  8.0,  4.3  Hz,  1   H, 
SCHCHH), 4.11  (dd, J =  13.9, 6.2 Hz,  1  H, NHCHH), 3.98 (dd, J =  13.9, 5.6 Hz,  1   H, 
NHCHH),  3.73-3.80  (m,  2  H,  SCH and  NCH),  2.58  (s,  3  H,  NCH3),  2.33  (s,  3  H, 
ArCH3); 8c (75 MHz, CDCI3) 139.6 (s),  137.9 (s),  137.8 (d),  136.8 (d),  133.2 (s), 130.6 
(d), 129.6 (d),  128.1 (d),  127.8 (d), 94.8 (s), 73.6 (d), 73.3 (d), 67.0 (t), 47.1 (t), 42.8 (q),
21.2  (q); m/z (Cl) 473 (MH+, 57), 287 (100),  151  (25),  120 (31),  105 (21); HRMS (Cl): 
calcd for C18H22lN203S (MH+) 473.0396, found 473.0393.
4.5.2.  Cycloadditions with ethenesulfonic acid terf-butylamide (123e)
Ethenesulfonic acid fert-butylamide (123e)
o, ,0
\X//
N   ^
H
A premixed suspension of terr-butyl amine (7.4 g,  101.2 mmol) and NEt3 (27.9 g, 276.0 
mmol) in DCM (40 mL) was added dropwise to a stirring solution of 2-chloroethane-l- 
sulfonyl chloride (15.0 g, 92.0 mmol) in DCM (150 mL) at -10 °C. The reaction mixture 
was stirred for a further 30 minutes after addition, and then warmed to RT. The reaction 
was diluted with DCM (60 mL) and washed with 2M HC1 (3 x 80 mL), H2O (80 mL), 
dried (MgS04), and filtered. The filtrate was collected and concentrated in vacuo and 
purification  by  flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20) 
furnished the desired product (9.5 g, 64%) as a yellow solid.
R f 0.16 (1:1  petroleum ether 40-60°C/Et20); mp 66-68 °C; a)m ax (neatycm1  3296, 3101, 
3053, 2980, 1618, 1468, 1425, 1377, 1313, 1136, 1011, 870; 5H  (300 MHz, CDC13) 6.59 
(dd, J = 16.6, 9.9 Hz,  1  H, SC/7), 6.20 (d, J = 16.6 Hz,  1 H, SCHC//H), 5.81 (d, J = 9.9 
Hz,  1  H, SCHCH//), 4.65 (br s,  1 H, NH),  1.32 (s, 9 H, C(C//3)3); 8C  (75 MHz, CDC13)
139.6  (d),  124.4 (t), 54.7 (s), 30.3 (q); m/z (Cl)  164 (MH+, 54),  147 (71),  135 (23),  124 
(28),  119  (40),  107  (63);  HRMS  (Cl):  calcd  for  C6Hi4N 02S  (MH+)  164.0749,  found 
164.0751.
186(35*,  4S*)-3-(4-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  terf-butyl 
amide (127a), (3/?*, 55*)-3-(4-Bromophenyl)-2-methyIisoxazolidine-5-suIfonic acid 
terf-butylamide (128a), and (35*, 55*)-3-(4-Bromophenyl)-2-methylisoxazolidine-5- 
sulfonic acid terf-butylamide (129a)
General protocol was followed using  100 mg of 123e.  Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three  separable 
products 127a (107 mg, 46%), 128a (18 mg, 8%), and 129a (11  mg, 5%)- overall yield 
(59%, 127a: 128a: 129a = 10:2:1).
Data  for  128a:  Rf0.31  (2:1  Et20/petroleum  ether  40-60°C);  mp  122-125  °C;  o w  
(neatycm' 1  3295, 2970,  1489,  1431,  1390,  1323,  1286,  1141,  1067,  1007, 971, 826;  8H  
(300 MHz, CDCI3) 7.47 (d, J = 8.4 Hz, 2 H, ArH), 7.24 (d, J = 8.4 Hz, 2 H, ArH), 4.93 
(dd, J = 8.6, 2.0 Hz,  1 H, SCH), 4.28 (br s,  1  H, NH), 4.00 (br dd, J = 9.2, 6.2 Hz, 1  H, 
NCH), 3.05 (ddd, J =  13.6, 6.2, 2.0 Hz,  1   H, SCHCHH), 2.63-2.76 (m, 4 H, SCHCHH 
and NCH3),  1.40 (s, 9 H C(CH3)3); 8c (75 MHz, CDC13)  136.9 (s),  132.0 (d), 129.2 (d),
122.2  (s), 90.2 (d), 67.7 (d), 55.1 (s), 44.7 (q), 38.1  (t), 30.6 (q); m/z (El) 378 (M+, 81Br, 
17), 376 (M+, 79Br,  17), 266 (32), 240 (77), 212 (100),  199 (57),  167 (23),  149 (60), 132 
(48), 117 (27); HRMS (El): calcd for Ci4H2i79BrN20 3S (M+) 376.0456, found 376.0459. 
Data  for  129a:  Rf 0.27  (2:1  Et20/petroleum  ether  40-60°C);  mp  130-134  °C;  Dm ax 
(neatycm'1  3266,  2957,  1486,  1428,  1394,  1312,  1290,  1144,  1009,  956,  824;  SH  (300 
MHz, CDC13) 7.48 (d, J = 8.6 Hz, 2 H, ArH), 7.32 (d, J = 8.6 Hz, 2 H, ArH), 4.94 (dd, J 
= 8.6, 5.6 Hz,  1 H, SCH), 4.37 (br s, 1 H, NH), 3.53 (br dd, J = 9.9, 7.8 Hz,  1  H, NCH),
3.03  (ddd, J =  13.7, 8.6, 7.8 Hz,  1  H, SCHCHH), 2.88 (ddd, J =  13.4, 9.9, 5.6 Hz,  1 H, 
SCHCHH), 2.59 (s, 3 H, NCH3),  1.42 (s, 9 H C(CH3)3); 8c (75 MHz, CDC13) 136.8 (s),
132.0  (d),  129.8 (d),  122.6 (s), 90.1  (d), 67.4 (d), 55.1  (s),  43.9  (q), 37.8  (t), 30.7 (q); 
m/z (El) 378 (M+, 81Br, 21), 376 (M+, 79Br, 20), 266 (36), 240 (76), 212 (100), 197 (54), 
149  (29),  132  (38),  117  (22),  99  (97);  HRMS  (El);  calcd  for C,4H2179BrN20 3S  (M+) 
376.0456, found 376.0452.
Data  for  127a:  Rf 0.22  (2:1  Et20/petroleum  ether  40-60°C);  mp  173-178  °C;  om ax 
(neatycm' 1  3268, 2959,  2859,  1489,  1427,  1393,  1306,  1141,  1009, 837, 814; 8h (300 
MHz, CDC13) 7.51  (d, J = 8.4 Hz, 2 H, ArH), 7.36 (d, J = 8.4 Hz, 2 H, ArH), 4.81  (s,  1
o,  o
Br
187H,  N//),  4.40  (dd,  J = 9.9,  3.7  Hz,  1  H,  SCHC//H),  4.30  (dd,  J =  9.9,  8.3  Hz,  1   H, 
SCHCH//), 3.92 (app. td, J = 8.0, 3.7 Hz, 1  H, SC//), 3.77 (br d, /  = 7.3 Hz, 1  H, NC//), 
2.61  (s, 3 H, NC//3),  1.12  ( s ,  9 H C(C//3)3); 5c (75 MHz, CDC13)  136.6 (s),  132.0 (d),
130.1  (d),  122.7 (s), 75.6 (d), 74.1 (d), 67.2 (t), 55.1  (s), 42.7 (q), 30.0 (q); m/z (El) 378 
(M+,  81Br,  21),  376  (M+,  79Br,  19),  238  (93),  213  (37),  149  (35),  116  (100);  HRMS 
(ESI): calcd for C,4H2i79BrN20 3S (M+) 376.0456, found 376.0452.
(3S*,  4S*)-3-(2-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  tert-butyl 
amide (127b), (3R*, 5S*) and (3S*9  5S*)-3-(2-Chlorophenyl)-2-methylisoxazolidine- 
5-sulfonic acid ter/-butylamide (1287129b)
127b 128/129b
General protocol was followed using  100 mg of 123e.  Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 128/129b (56 mg, 
28%) as a mixture, and 127b (62 mg, 30%) as a light brown solid- overall yield (58%, 
127b:128/129b = 1:1,128b and 129b = 3:2 majonminor).
Data for 128/129b: Rf0.37 (2:1 Et20/petroleum ether 40-60°C); 'D m ax (neatycm'1  3279, 
2971,  1474, 1438,  1319, 1231, 1142, 997, 752; 5h (300 MHz, CDC13) 7.70 (dd, /  = 7.8,
1.9  Hz,  1  Hminor,  Ar//),  7.56  (dd, J = 7.8,  1.9 Hz,  1   H major,  Ar//),  7.18-7.38  (m,  3  H, 
Ar//),  4.99  (dd, J =  8 .6 ,  5.6 Hz,  1   H min0r,  SC/7),  4.88  (dd,  J =  8.3,  4.3  Hz,  1  H major, 
SC//), 4.55 (app. br t, /  = 7.5 Hz,  1  Hm ajor, NC//), 4.46 (br s,  1  H min0r, N//), 4.41 (br s, 1  
H major,  N//), 4.20 (br dd, J = 9.9, 7.5 Hz,  1  H min0r,  NC//), 3.26 (ddd, J =  13.4, 6.7, 4.3 
Hz, 1  Hm ajor, SCHCZ/H), 3.16 (ddd, /  = 13.4, 8.6 , 7.5 Hz,  1   H min0r, SCHC//H), 2.83 (s, 3 
Hm ajor, NC//3), 2.74 (ddd, J =  13.4, 9.9, 5.6 Hz,  1   Hminor, SCHCH//), 2.66 (s, 3 Hm inor, 
NC//3), 2.61 (app. dt, J = 13.4, 8.3 Hz,  1  Hm ajor, SCHCH//),  1.41  (s• >  9 Hminor, C(C  H3)3),
1.40  (s, 9 Hm aj„r, C(C//3)3); 5c (75 MHz, CDCI3)  135.9  (s),  134.8  (s),  133.6 (s),  133.5 
(s),  129.7 (d),  129.4 (d),  129.1  (d),  128.9 (d),  128.7 (d),  127.6 (d),  127.3 (d), 90.9 (d),
90.1  (d), 68.5 (d), 67.1  (d), 55.1  (s), 55.0 (s), 45.1  (q), 43.5 (q), 39.7 (t), 39.2 (t), 30.6 
(q), 29.7 (q), 23 out of 24 expected signals observed; m/z (FAB*) 335 (MH*,  37C1,  14), 
333  (MH*,  35C1,  36),  222  (27),  196  (100),  168  (59);  HRMS  (FAB*):  calcd  for 
Ci4H2235C1N20 3S (MH*) 333.1040, found 333.1036.
Data  for  127b:  Rf 0.25  (2:1  Et20/petroleum  ether  40-60°C);  mp  190-194  °C;  Dm ax 
(neatycm' 1  3287, 2962,  2920,  1478,  1439,  1306,  1201,  1137,  1036, 870, 774;  8H  (300
188MHz, CDCI3) 7.57 (dd, 7 = 7.7, 1.6 Hz, 1  H, Ar//), 7.42 (dd, 7 = 7.7,  1.6 Hz, 1  H, Ar//),
7.29-7.37 (m, 2 H, Ar//), 4.37-4.48 (m, 4 H, NH and NC// and SCHCZ/2), 4.03 (app. td, 
7 = 8.2, 3.9 Hz,  1   H, SC//), 2.62 (s, 3 H, NC//3),  1.01  (s, 9 H, C(CZ/3)3); 5C  (75 MHz, 
CDC13)  134.8 (s),  134.6 (s),  129.9 (d),  129.8 (d),  127.8 (d), 75.2 (d), 70.5 (d), 67.2 (t),
54.9  (s), 42.6 (q), 29.8 (q),  1  x d not observed; m/z (El) 334 (M+, 37C1, 7), 332 (M+, 35C1,
29),  194  (100),  148  (43)  134 (87),  115  (98);  HRMS  (El):  calcd  for Ci4H2i35C1N20 3S 
(M+) 332.0961, found 332.0968.
(3S*,  4S*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic  acid  ter/-butylamide  (127c), 
(3R*,  5S*)  and  (3S*,  5S*)-2-MethyI-3-phenylisoxazolidine-5-sulfonic  acid  tert- 
butylamide (128c/129c)
General protocol was followed using  100 mg of 123e.  Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60 °C/Et20) to give 128/129c (25 mg, 
14%)  as  a  mixture,  and  127c  (75  mg,  41%)  as  an  orange/brown  solid-  overall  yield 
(55%, 127c:128/129c = 3:1,128c and 129c = 2:1 major:minor).
Data for 128/129c:  Rf0.33  (2:1  Et20/petroleum ether 40-60°C); mp  102-104 °C; Dm ax 
(neatycm'1   3287,  2983,  2871,  1495,  1430,  1316,  1289,  1141,  866;  5H   (300  MHz, 
CDC13) 7.28-7.45  (m,  5  H ,  Ar/7), 4.94-4.99 (m,  1  H,  SC//), 4.44 (br s,  1  Hm inor, N//), 
4.32 (br s, 1  H major, N//), 4.02 (app. br t, J = 7.5 Hz,  1 H maj0r, NC//), 3.56 (br dd, J = 9.6,
7.8  Hz,  1  Hminor,  NC//),  2.97-3.11  (m,  1   H ,  SCHC//H),  2.95  (ddd, J =  13.7,  10.2, 5.9 
Hz,  1  Hminor,  SCHCH//), 2.78 (ddd, 7= 13.7, 10.2, 8.8 Hz,  1  H major, SCHCH//), 2.74 (s, 
3 H major,  NC//3), 2,60  (S,  3  Hminor, NCZ/3),  1.42 (s, 9 Hminor,  C(C//3)3),  1.41  (S,  9 H major, 
C(C//3)3);  5c  (75  MHz,  CDC13)  137.0  (s),  136.5  (s),  128.8  (d),  128.6  (d),  128.3  (d),
128.1  (d), 127.6 (d), 90.3 (d), 90.1 (d), 70.9 (d), 55.0 (s), 43.7 (q), 43.3 (q), 38.8 (t), 30.7 
(q), 30.6 (q),  16 out of 20 expected signals observed; m/z (El) 298 (M+, 27),  188 (23), 
162  (64),  134  (100),  118  (33);  HRMS  (El):  calcd  for  Ci4H22N20 3S  (M+)  298.1351, 
found 298.1354.
Data  for  127c:  Rf 0.25  (2:1  Et20/petroleum  ether  40-60°C);  mp  160-163  °C;  Dm ax 
(neatycm'1  3272, 2966, 2870,  1494,  1454,  1393,  1264,  1137,  1010, 870; 5H  (300 MHz, 
CDC13) 7.32-7.47  (m,  5  H,  Ar//), 4.60  (s,  1  H,  N//),  4.45  (dd, 7 = 9.7,  3.8  Hz,  1   H,
127c 128/129c
189SCHC//H), 4.34 (br dd, 7 = 9.7, 8.6 Hz,  1   H, SCHCH//), 4.01  (app. td, 7 = 8.0, 3.8 Hz, 
1  H,  SC//),  3.77  (br d,  7 =  7.6  Hz,  1  H,  NC//),  2.62  (s,  3  H,  NC//3),  1.05  (s,  9  H 
C(C//3)3); 5c (75 MHz, CDC13)  137.2 (s),  128.9 (d),  128.8 (d),  128.6 (d), 75.5 (d), 75.1 
(d), 67.1 (t), 55.0 (s), 42.7 (q), 29.9 (q); m/z (El) 298 (M+, 20),  160 (100),  134 (21),  117
(38), 91 (28); HRMS (El): calcd for Ci4H22N20 3S (M+) 298.1351, found 298.1352.
(3S*,  4S*)-3-(2-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  tert-butyl 
amide (127d), (3R*, SS*) and (3S*, 5S*)-3-(2-Bromophenyl)-2-methylisoxazolidine- 
5-sulfonic acid fert-butylamide (128/129d)
General protocol was followed using  100 mg of 123e. Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20) to give 128/129d (34 mg, 
15%)  as  a  mixture,  and  127d  (66  mg,  28%)  as  a  brown  solid-  overall  yield  (43%, 
127d:128/129d = 2:1,128d and 129d = 3:2 majonminor).
Data for 128/129d: Rf 0.36 (2:1  Et20/petroleum ether 40-60°C); v > m ax (neatycm"1  3279, 
2962,  1469,  1434,  1319,  1142, 997, 862, 754; 5h (300 MHz, CDC13) 7.69 (dd, 7 = 7.8,
1.6  Hz,  1   H, Ar//), 7.51-7.57 (m,  1   H, Ar//), 7.29-7.36 (m,  1  H, Ar//), 7.11-7.18 (m,  1
H, Ar//), 4.99 (dd, J = 8.6, 5.6 Hz,  1   Hm ajor, SC//), 4.88 (dd, J = 8.3, 4.1  Hz,  1   Hm inor, 
SC//), 4.53  (app. t, J = 7.5 Hz,  1   H mil,or,  NC//), 4.40 (br s,  1   H major, N//), 4.34 (br s,  1  
Hmjnor, N//), 4.18 (dd, J = 9.6, 7.5 Hz,  1 Hm ajor, NC//), 3.29 (ddd, 7= 13.4,6.7,4.1 Hz, 1  
Hminor,  SCHC//H),  3.18  (ddd,  7 =  13.4,  8.6,  7.5  Hz,  1   Hm ajor,  SCHC/ZH),  2.83  (s,  3 
Hminor,  NC//3), 2.71  (ddd, 7 =  13.4, 9.6, 5.6 Hz,  1   H major,  SCHCH//), 2.67 (s, 3  H major, 
NC//3), 2.59 (app. dt, 7= 13.4, 8.3 Hz,  1  Hm ino„ SCHCH//),  1.41 (s, 9 Hm aj„r, C(C//3)3),
I.40 (s, 9 Hminor,  C(C//3)3);  8c (75 MHz, CDC13)  137.6 (s),  136.5 (s),  133.0 (d),  132.7 
(d),  129.5 (d),  129.3 (d),  129.0 (d),  128.3 (d),  127.9 (d),  127.8 (d),  123.9 (s),  123.7 (s),
90.8  (d), 90.1  (d), 71.1  (d), 69.4 (d), 55.2 (s), 55.0 (s), 45.1  (q), 43.5 (q), 39.8 (t), 39.3 
(t), 30.7 (q), 30.4 (q); m/z (FAB+) 379 (MH+, 81Br, 50), 377 (MH+, 79Br, 52), 307 (33), 
240  (48),  154 (100);  HRMS  (El):  calcd for Ci4H2279BrN203S  (MH+)  377.0534, found 
377.0538.
Data  for  127d:  Rf 0.24  (2:1  Et20/petroleum  ether  40-60°C);  mp  202-206  °C;  Dm ax 
(neatycm'1  3282,  2920,  1595,  1474,  1435,  1323,  1302,  1135,  998,  826,  763;  SH   (300
127d 128/129d
190MHz, CDCI3) 7.61 (dd, 7 = 8.0, 1.1 Hz,  1  H, Ar//), 7.56 (dd, J = 8.0,  1.6 Hz,  1  H, Ar//),
7.40  (app. dt, 7 = 7.8, 1.1 Hz,  1  H, Ar//), 7.22 (app dt, J = 8.0,  1.6 Hz,  1  H, Ar//), 4.35-
4.48  (m, 4 H, SCHC//2 and NH and NC//), 4.01  (app. td, J = 8.2, 3.9 Hz,  1   H, SC//),
2.63  (s, 3 H, NC//3),  1.01  (s, 9 H, C(C//,)3); 5c (75 MHz, CDCI3)  136.5 (s),  133.2 (d),
130.2  (d),  130.1  (d),  128.4 (d),  125.3 (s), 75.4 (d), 72.9 (d), 67.2 (t), 54.9 (s), 42.5 (q),
30.1  (q); m/z (El) 378 (M+, 81Br, 23), 376 (M+, 79Br, 22), 240 (100),  198 (26),  160 (25),
134  (74),  116  (78);  HRMS  (El):  calcd  for  Ci4H2i79BrN203S  (M+)  376.0456,  found 
376.0459.
(35*,  45*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  tert-butyl 
amide (127e),  (3R*, 55*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-5-sulfonic acid 
terf-butylamide (128e), and (35*, 55*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-5- 
sulfonic acid terf-butylamide (129e)
General protocol was followed using  100 mg of 123e. Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three  separable 
products 127e (58 mg, 30%), 128e (35 mg,  18%), and 129e (17 mg, 9%)- overall yield 
(57%, 127e:128e:129e = 7:4:2).
Data  for  129e:  R f   0.36  (2:1  Et20/petroleum  ether  40-60°C);  mp  78-82  °C;  t)m ax 
(neaD/cm' 1 3302,  2967,  1495,  1428,  1320,  1233,  1143,  1095, 998, 760;  8H  (300 MHz, 
CDCI3) 7.65 (app. dt, J = 7.2, 1.6 Hz, 1  H, Ar//), 7.23-7.31 (m,  1  H, Ar//), 7.16 (app. dt, 
J = 7.5,  1.1  Hz,  1   H, Ar//), 7.04 (ddd, J =  10.2, 8.3,  1.1  Hz,  1  H, Ar//), 4.99 (dd, J =
8.5,  5.7 Hz,  1 H, SC//), 4.39 (br s,  1  H, N/7), 4.03 (br dd, J = 10.0, 7.8 Hz,  1  H, NC//),
3.07 (ddd, J = 13.4, 8.5, 7.8 Hz,  1  H, SCHCJ7H), 2.88 (ddd, J = 13.5, 10.0, 5.7 Hz, 1  H, 
SCHCH//) 2.65 (s, 3 H, NC//3),  1.41  (s, 9 H C(C//3)3); 5c (75 MHz, CDC13)  161.0 (s, 
Jcf = 247.1  Hz),  129.7  (d, JCf = 8.5 Hz),  128.8 (d, Jcf = 3.8 Hz),  124.9 (d, JC F  = 3.5 
Hz),  118.4 (s),  115.3 (d, 7Cf = 22.0 Hz), 90.1  (d), 64.9 (d), 55.0 (s), 43.5 (q), 39.8  (t),
30.7 (q); m/z (El) 316 (M+, 25), 206 (24),  180 (31),  152 (100),  137 (45),  122 (23),  109 
(28); HRMS (El): calcd for CI4H2,FN20 3S (M+) 316.1257, found 316.1259.
Data  for  128e:  R f   0.32  (2:1  Et20/petroleum  ether  40-60°C);  mp  115-118  °C;  t)m ax 
(neatycm' 1 3243,  2986,  2919,  1589,  1494,  1327,  1233,  1145,  1008,  868,  765;  6H  (300
127e 128e 129e
191MHz, CDCI3) 7.46 (app. t, 7 = 7.5 Hz, 1  H, Ar//), 7.24-7.32 (m, 1  H, Ar//), 7.14 (app. t, 
7 = 7.5 Hz, 1  H, Ar//), 7.05 (ddd, 7= 10.2, 8.3,  1.1 Hz,  1  H, Ar//), 4.93 (dd, 7= 8.5, 3.5 
Hz, 1  H, S C /O , 4.37-4.42 (m, 2 H, N// and NC//), 3.14 (ddd, 7 = 13.5, 6.6, 3.5 Hz, 1  H, 
SCHC//H),  2.71-2.79  (m, 4 H, SCHCH// and NC//3),  1.40  (s,  9  H  C(C/Z3)3);  5C   (75 
MHz, CDC13) 161.0 (s, 7cf = 248.0 Hz), 129.6 (d, 7CF = 8.2 Hz),  128.2 (d), 124.5 (d, 7C F 
= 3.7 Hz),  116.6 (s),  115.4 (d, 7CF = 21.6 Hz), 90.7 (d), 64.0 (d), 55.1  (s), 44.9 (q), 39.3 
(t), 30.6 (q); m/z (El) 316 (M+,  19),  180 (34),  152 (76),  137 (37), 84 (25); HRMS (El): 
calcd for Ci4H2iFN20 3S (M+) 316.1257, found 316.1261.
Data  for  127e:  Rf 0.24  (2:1  Et20/petroleum  ether  40-60°C);  mp  160-164  °C;  Dm ax 
(neatycm' 1  3275, 2872,  1590,  1493,  1453,  1305,  1230,  1138,  1042,  1005, 869, 765; 6H  
(300 MHz, CDC13) 7.50 (app. dt, 7 = 7.5,  1.6 Hz,  1  H, Ar//), 7.31-7.39 (m,  1  H, Ar//), 
7.21  (app. dt, 7 = 7.5, 0.8 Hz,  1   H, Ar//), 7.11  (ddd, 7 =  10.2, 8.0, 0.8 Hz,  1  H, Ar//), 
4.31-4.47 (m, 3 H, SCHC/ / 2 and N//), 4.05-4.10 (m, 2 H, SCH and NC//), 2.64 (s, 3 H, 
NC//3),  1.05 (s, 9 H C(CZ/3)3); 6C  (75 MHz, CDC13) 160.9 (s, 7CF = 247.7 Hz),  130.4 (d, 
7c f=8.5 Hz),  129.9 (d,7CF = 3.5 Hz),  125.0 (d,7CF = 3.5 Hz),  119.6 (s), 116.0 (d,7C F =
22.0  Hz), 74.4 (d), 68.4 (d), 67.0 (t), 54.9 (s), 42.8 (q), 29.9 (q); m/z (El) 316 (M+,  13), 
178  (100),  135  (22);  HRMS  (El):  calcd  for  Ci4H2iFN20 3S  (M+)  316.1257,  found 
316.1253.
(3  S*,  4S*)-3-(4-Methoxyphenyl)-2-methylisoxazolidine-4-suIfonic  acid  tert-
butylamide  (127f),  (3R*,  5S*)  and  (3  S*,  5S*)-3-(4-Methoxyphenyl)-2-
methylisoxazolidine-5-sulfonic acid terf-butylamide (128/129f)
127f  128/129f
General protocol was followed using  100 mg of 123e.  Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20) to give 128/129f (13 mg, 
7%) as a mixture, and 127f (65 mg, 32%) as an orange/brown solid- overall yield (39%, 
127f:128/129f =5:1, 128f and 129f = 3:2 major:minor).
Data for 128/129f:  Rf0.27  (2:1  Et20/petroleum ether 40-60°C); Um ax (neatycm1  3235, 
2971,  1612,  1514,  1427,  1327,  1244, 1140, 1006, 843; 8h (300 MHz, CDC13) 7.35 (d, 7 
= 8.8 Hz, 2 Hminor, ArH), 7.28 (d, J = 8.8 Hz, 2 Hm ajor, Ar//), 6.88 (d, J = 8.8 Hz, 2 H, 
Ar//), 4.92-4.97 (m,  1  H, SC/7), 4.40 (br s,  1  Hm inor, N//), 4.28 (br s, 1 Hm ajor, N//), 3.95
192(app. br s,  1   Hm ajor. NC//), 3.80 (s, 3 H, OC//3), 3.52 (br dd, 7 = 9.9, 7.8 Hz,  1  Hm in0r, 
NC//), 2.87-3.06 (m, 2 H, SCHC//H and SCHCH//m inor), 2.75 (ddd, 7 =  13.7, 10.4, 9.9 
Hz,  1   Hmajor,  SCHCH//), 2.71  (S,  3  Hmajor,  NC//3), 2.58  (s,  3  Hminor,  NC//3),  1.42 (S, 9 
Hminor, C (C //3)3),  1.40 (s, 9 Hmajor,  C (C //3)3);  8c (125 MHz, CDCI3)  159.9 (s), 159.7 (s),
129.3  (d),  128.9 (d),  128.7 (s),  128.3  (s),  114.4 (d),  114.3  (d), 90.2 (d), 90.1  (d), 73.4 
(d), 70.6 (d), 55.4 (q), 55.1  (s), 44.1 (q), 43.3 (q), 41.7 (t), 41.0 (t), 30.8 (q), 30.4 (q), 20 
out of 22 expected signals observed; m/z (FAB*)  329  (MH*,  31),  307  (32),  192  (63), 
154 (100); HRMS (FAB*): calcd for C15H25N2O4S (MH*) 329.1535, found 329.1543. 
Data  for  127f:  Rf 0.18  (2:1  Et20/petroleum  ether  40-60°C);  mp  133-137  °C;  t w  
(neatycm' 1 3280, 2961,  1614,  1516, 1435,  1305,  1252,  1138,  1010, 867; 6H  (300 MHz, 
CDCI3) 7.37 (d, J = 8.7 Hz, 2 H, Ar//), 6.91  (d, J = 8.7 Hz, 2 H, Ar//), 4.57 (s,  1   H, 
N//),  4.41  (dd,  J =  9.7,  3.8  Hz,  1   H,  SCHCZZH),  4.32  (dd,  J  =  9.7,  8.6  Hz,  1  H, 
SCHCH//), 3.97 (app. td, J = 8.0, 3.8 Hz, 1  H, SC//), 3.81  (s, 3 H, OC//3), 3.72 (br d, J 
= 7.5 Hz, 1  H, NC//),  2.60 (s, 3 H, NC//3),  1.08 (s, 9 H C(C//3)3); 8c (75 MHz, CDC13)
159.9  (s),  129.7 (d),  129.0 (s),  114.3 (d), 75.2 (d), 74.6 (d), 67.0 (t), 55.3 (q), 55.0 (s),
42.6  (q),  30.0 (q);  m/z (El) 328  (M*, 21),  190 (100),  147  (32); HRMS  (El):  calcd for 
C15H24N2O4S (M*) 328.1457, found 328.1449.
(35*, 4.S*)-2-Methyl-3-(4-nitrophenyl)iso\azolidine-4-sulfonic  acid fert-butylamide 
(127g), and (3R*, 5S*)-2-Methyl-3-(4-nitrophenyl)isoxazolidine-5-sulfonic acid tert- 
butylamide (128g)
\V/
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General protocol  was followed using  100 mg of 123e. Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 128g (11 mg, 5%), 
and 127g (87 mg, 42%)- overall yield (47%, 127g:128g = 8:1).
Data for 128g: Rf0.27 (2:1 Et20/petroleum ether 40-60°C); um ax (neat)/cm_ l 3281,2922, 
1601, 1520, 1463, 1325,  1141,997, 855; 8h (300 MHz, CDC13) 8.22 (d, 7 = 8.8 Hz, 2 H, 
Ar//), 7.57 (d, 7 = 8.8 Hz, 2 H, Ar//), 4.94 (dd, 7 = 8.6, 2.4 Hz, 1 H, SC//), 4.28 (br s,  1  
H, N//), 4.19 (br dd, 7 = 9.9, 6.4 Hz,  1  H, NC//), 3.14 (ddd, 7 =  13.7, 6.4, 2.4 Hz,  1   H, 
SCHCZ/H), 2.77 (s, 3 H, NC//3), 2.72 (ddd, 7= 13.7, 9.9, 8.6 Hz, 1  H, SCHCH//),  1.41 
(s, 9 H, C(C//3)3); 8c (125 MHz, CDC13) 147.8 (s),  144.7 (s),  129.5 (d),  125.2 (d), 91.4
193(d), 70.3 (d), 56.3 (s), 45.2 (q), 42.8 (t), 31.7 (q); m/z (FAB+) 344 (MH*, 69), 299 (90), 
233 (30), 219 (21), 207 (98),  179 (28),  161  (66),  149 (100); HRMS (FAB+): calcd for 
CHH22N3O5S (MH+) 344.1280, found 344.1271.
Data  for  127g:  Rf 0.19  (2:1  Et20/petroleum  ether  40-60°C);  mp  176-180  °C;  t>m ax  
(neat)/cm'' 3271, 2968, 2921,  1607,  1519,  1430,  1347,  1142,  1040,  859,  821;  5h (300 
MHz, CDCI3) 8.25 (d, J = 8.7 Hz, 2 H, MH), 7.70 (d, J = 8.7 Hz, 2 H, Ar//), 4.76 (s,  1  
H, NH), 4.41  (dd, J = 9.6, 3.9 Hz,  1   H, SCHC//H), 4.32 (br dd, J = 9.6,  8.3 Hz,  1   H, 
SCHCH//), 4.01  (d, J = 7.0 Hz,  1   H, NC//), 3.93 (app. td, J = 7.5, 3.9 Hz,  1 H, SC//), 
2.66 (s, 3 H, NC//3),  1.17 (s, 9 H C(C//3)3); 5c (75 MHz, CDCI3)  148.0 (s),  145.4 (s),
129.2  (d),  124.0 (d), 75.9 (d), 73.4 (d), 67.4 (t), 55.4 (s), 43.0 (q), 30.1 (q); m/z (El) 343 
(M+,  10),  205  (100),  116  (21);  HRMS  (El):  calcd  for  C14H21N3O5S  (M+)  343.1202, 
found 343.1202.
(3  S*,  4S*)-3-(4-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  /ert-butyl 
amide (127h), (3R*, 5S*)-3-(4-Chlorophenyl)-2-methylisoxazolidine-5-sulfonic acid 
tert-butylamide  (128h),  and  (35*,  5S*)-3-(4-Chlorophenyl)-2-methylisoxazolidine- 
5-sulfonic acid /erf-butylamide (129h)
w
127h
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General protocol was followed using  100 mg of 123e. Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three  separable 
products 127h (90 mg, 44%), 128h (15 mg,  8%), and 129h (14 mg, 7%)- overall yield 
(59%, 127h:128h:129h = 13:2:2).
Data  for  128h:  Rf 0.35  (2:1  Et20/petroleum  ether  40-60°C);  mp  122-125  °C;  U m ax 
(neatycm' 1   3295, 2972,  1491,  1431,  1389,  1323,  1286,  1141,  1087,  1001, 829; 5h (300 
MHz, CDC13) 7.32 (app. s, 4 H, Ar//), 4.93 (dd, /  = 8.6, 2.5 Hz,  1   H, SC//), 4.28 (s,  1  
H, N/7), 4.01  (br dd, J = 9.4, 6.4 Hz,  1   H, NC//), 3.05 (ddd, J = 13.6, 6.4, 2.5 Hz,  1   H, 
SCHC//H),  2.63-2.77  (m, 4  H, SCHCH// and NC//3),  1.40  (s,  9 H C(CZ/3)3);  6c (75 
MHz, CDCI3)  136.0 (s),  134.1 (s), 129.1 (d),  128.9 (d), 90.2 (d), 66.7 (d), 55.1 (s), 44.3 
(q), 38.9 (t), 30.6 (q); m/z (El) 334 (M+, 37C1, 8), 332 (M+, 35C1, 21), 222 (27),  196 (66), 
168 (100),  153  (56), 99 (29); HRMS (El):  calcd for C]4H2i35C1N20 3S  (M+) 332.0961, 
found 332.0971.
194Data  for  129h:  Rf 0.30  (2:1  Et20/petroleum  ether  40-60°C);  mp  134-137  °C;  t)m ax 
(neat)/cm‘‘ 3263,  2919,  1491,  1428,  1311,  1289,  1145,  1089,  1013, 956,  826; §h (300 
MHz, CDC13) 7.28-7.40 (m, 4 H, Ar//), 4.95 (dd, J = 8.4, 5.5 Hz,  1  H, SC//), 4.38 (s,  1
H, N//), 3.53 (br dd, J = 9.4, 7.4 Hz,  1   H, NC//), 3.03 (ddd, J =  13.5, 8.4, 7.4 Hz,  1   H, 
SCHC//H),  2.89 (ddd, J =  13.5,  10.0, 5.5  Hz,  1   H,  SCHCH//),  2.59  (s,  3  H, NC//3),
I.42 (s, 9 H C(C//3)3);  5c (75 MHz, CDCI3)  135.1  (s),  134.4 (s),  129.5 (d),  129.1  (d),
90.2  (d), 72.2 (d), 55.1  (s), 43.3 (q), 40.0 (t), 30.6 (q); m/z (El) 334 (M+, 37C1,  19), 332 
(M+, 35C1, 43), 222 (29),  196 (75),  168 (100),  153 (53),  138 (26),  103 (38); HRMS (El): 
calcd forC|4H2i35ClN2 03S (M+) 332.0961, found 332.0974.
Data  for  127h:  Rf 0.24  (2:1  Et20/petroleum  ether  40-60°C);  mp  164-168  °C;  Dm ax 
(neat)/cm'‘ 3267, 2921,  1493,  1307, 1141,  1091,  1012, 816; 5H  (300 MHz, CDC13) 7.42 
(d, J = 8.5 Hz, 2 H, Ar//), 7.36 (d, J -  8.5 Hz, 2 H, Ar//), 4.85 (s, 1 H, N//), 4.40 (dd, J 
= 9.7, 3.7 Hz, 1 H, SCHC//H), 4.31 (dd, J = 9.7, 8.3 Hz,  1  H, SCHCH//), 3.93 (app. td, 
J = 7.9, 3.7 Hz,  1   H, SC//), 3.78 (br d, /  = 7.3 Hz,  1   H, NC//),  2.61  (s, 3 H, NCH}), 
1.12 (s, 9 H C(C//3)3);  5C  (75 MHz, CDC13)  136.0 (s),  134.5  (s),  129.8 (d),  129.1  (d),
75.6  (d), 74.1  (d), 67.1  (t), 55.1  (s), 42.7 (q), 30.0 (q); m/z (El) 334 (M+, 37C1,  10), 332 
(M+,  35C1,  27),  194  (100),  174  (39),  151  (26),  115  (33);  HRMS  (El):  calcd  for 
Ci4H2i35C1N20 3S (M+) 332.0961, found 332.0976.
(3  S*,  45*)-2-Methyl-3-naphthalen-2-yl-isoxazolidine-4-suIfonic  acid  tert- 
butylamide  (127i),  (3R*,  5  S*)  and  (3S*,  5S*)-2-Methyl-3-naphthalen-2-yl- 
isoxazolidine-5-sulfonic acid terf-butylamide (128/129i)
1271 128/129i
General protocol was followed using 200 mg of 123e. Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C /Et20) to give 128/129i (26 mg, 
6%)  as  a  mixture,  and  127i  (182  mg,  43%)  as  a  brown  solid-  overall  yield  (49%, 
127i:128/129i = 7:1,128 and 129i =1:1 majonminor).
Data for 128/129i:  Rf0.38 (2:1 Et20/petroleum ether 40-60°C)  ; \)m ax (neatycm'1  2918, 
1545,  1376,  1317,  1229,  1136,  1040,  860;  8H   (500 MHz,  CDC13)  7.79-7.86  (m,  4 H, 
Ar//), 7.45-7.52 (m, 3 H, Ar//), 5.01  (br t, /  = 7.2 Hz,  1  H, SC//), 4.68 (br s,  1   Hm ajor, 
N//), 4.44 (br s,  1   Hm in0r, N/7), 4J6-4.24 (m,  1   Hm ajor, NCH), 3.74 (br t, J = 8.6 Hz,  1  
Hminor, NC//), 3.05-3.16 (m,  1   H, SCHC//H), 2.84-2.92 (m,  1   H SCHCH//), 2.79 (s,  3
195H minor?  NC//3),  2.65  (s,  3  H major?  NC//3),  1.45  (s,  9  Hminor?  C(CZ/3)3),  1.43  (S,  9  H major? 
C(C//3)3); 5c (125 MHz, CDCI3) 138.2 (s), 133.6 (s),  133.4 (3 x s),  128.9 (d), 128.8 (d),
127.9 (2 x d),  127.8 (2 x d),  127.6 (d), 127.1  (d),  126.4 (2 x d),  126.3 (d), 90.4 (d), 74.1 
(d), 55.1 (s), 43.5 (q), 41.7 (t), 41.2 (t), 30.7 (q), 23 out of 26 expected signals observed; 
m/z (FAB+) 349 (MH+, 6), 307 (26),  154 (100); HRMS (FAB+): calcd for C18H25N2O3S 
(MH+) 349.1586, found 349.1591.
Data  for  127i:  Rf 0.26  (2:1  Et20/petroleum  ether  40-60°C);  mp  147-150  °C;  a w  
(neatycm1   3303,  2990,  2867,  1506,  1422,  1311,  1137,  1044,  863;  SH   (300  MHz, 
CDCI3) 7.99  (s,  1  H, Ar//)? 7.84-7.92  (m, 3  H,  Ar//), 7.62  (dd, J = 8.5,  1.6 Hz,  1   H, 
Ar//),  7.50-7.53  (m,  2  H,  Ar//),  5.06  (s,  1  H,  N//),  4.53  (dd,  J =  9.7,  3.6  Hz,  1   H, 
SCHC//H), 4.43 (dd, J = 9.7, 8.3 Hz,  1  H, SCHCH//), 4.13 (app. td, J = 8.1, 3.6 Hz,  1  
H, SC/0, 4.02 (br d, /  = 7.4 Hz, 1  H, NC/0, 2.68 (s, 3 H, NC//3), 1.01 (s, 9 H C(C//3)3); 
5C   (75  MHz,  CDC13)  134.6  (s),  133.4  (s),  133.2  (s),  128.9  (d),  128.5  (d),  128.0  (d),
127.8  (d),  126.6 (d),  126.5 (d),  125.2 (d), 75.3 (d), 75.2 (d), 67.3 (t), 55.0 (s), 42.8 (q),
29.9 (q); m/z (El) 348 (M+, 43), 210 (100),  184 (25),  167  (38),  152 (20); HRMS  (El): 
calcd for Ci8H24N20 3S (M+) 348.1508, found 348.1498.
(3  S*,  4S*)-3-(3-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  tert-
butylamide  (127j),  (3R*,  5 S*)  and  (3S*,  5S*)-3-(3-Bromophenyl)-2-
methylisoxazolidine-5-sulfonic acid ter/-butylamide (128/129j)
o  o
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General protocol was followed using  100 mg of 123e. Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20) to give 128/129j (43 mg, 
19%) as a mixture, and 127j  (88 mg, 38%) as a light brown solid- overall yield (57%, 
127j:128/129j = 2:1,128j and 129j = 2:1 major.minor).
Data for 128j: Rf0.37 (2:1 Et20/petroleum ether 40-60°C); a w  (neatycm' 1  3274, 2919, 
1475, 1431,  1329,  1142,  1066, 863, 787; 8H  (300 MHz, CDC13) 7.55 (s, 1  H, Ar//), 7.44 
(d, J = 7.8  Hz,  1  H,  Ar//),  7.19-7.30 (m,  2 H, Ar//), 4.93  (dd, J =  8.6,  2.4 Hz,  1   H, 
SC/0, 4.28 (s,  1  H, N//), 4.00 (br dd, 7 = 9.1, 6.5 Hz,  1  H, NC//), 3.06 (ddd, J =  13.6,
6.5,  2.4 Hz,  1   H,  SCHC/m),  2.65-2.78 (m, 4 H,  SCHC//H and NC//3),  1.40 (s, 9 H, 
C(CZ/3)3);  8C   (75  MHz,  CDC13)  139.9  (s),  131.5  (d),  130.5  (d),  130.4  (d),  126.3  (d),
196122.9 (s), 90.2 (d), 67.6 (d), 55.1  (s), 44.7 (q), 41.9 (t), 30.6 (q); m/z (El) 378 (M+, 81Br, 
12), 376 (M+, 79Br,  11), 268 (30), 240 (50), 212 (100),  198 (38),  132 (36); HRMS (El): 
calcd for C,4H2i79BrN203S (M+) 376.0456, found 376.0462.
Data  for  129j:  R f   0.34  (2:1  Et20/petroleum  ether  40-60°C);  8h  (300  MHz,  CDCI3, 
picking diagnostic peaks from 128/129j mixture) 7.62 (dd, J -   1.9,  1.6 Hz,  1  H, Ar//), 
7.37-7.50 (m, 2 H, Ar//), 7.18-7.29 (m, 1  H, Ar//), 4.95 (dd, J = 8.3, 5.6 Hz, 1  H, SC//), 
4.48 (br s,  1  H, NH), 3.53 (br dd, J = 9.6, 7.5 Hz,  1  H, NC//), 3.04 (ddd, J =  13.7, 8.3, 
7.5 Hz,  1  H, SCHC//H), 2.89 (ddd, /=  13.7, 9.6, 5.6 Hz,  1 H, SCHCH//), 2.61 (s, 3 H, 
NC//3), 1.42 (s, 9 H, C(C//3)3).
Data  for  127j:  R f   0.28  (2:1  Et20/petroleum  ether  40-60°C);  mp  117-120  °C;  a)m ax 
(neatycm' 1  3319, 2963, 2849,  1477,  1419,  1390,  1313,  1132,  1039, 984, 794;  5h (300 
MHz, CDCI3) 7.64 (s,  1   H, Ar//), 7.41-7.49 (m, 2 H, Ar//), 7.23-7.29 (m,  1   H, Ar//), 
4.78 (br s,  1   H, N//), 4.41  (dd, J = 9.7, 3.8 Hz,  1  H, SCHCZ/H), 4.30 (dd, J = 9.7, 8.3 
Hz,  1  H, SCHCH//), 3.93 (app. td, /  = 8.1, 3.8 Hz,  1  H, SC//), 3.78 (br d, J = 13 Hz, 1  
H, NC//), 2.63  (s, 3 H, NC//3),  1.12 (s, 9 H C(C//3)3); 5C  (75 MHz, CDC13)  140.0 (s),
131.8 (d),  131.4 (d),  130.5 (d),  127.1  (d),  122.9 (s), 75.6 (d), 74.1 (d), 67.1  (t), 55.2 (s),
42.8 (q), 30.0 (q); m/z (El) 378 (M+, 8,Br, 21), 376 (M+, 79Br, 20), 240 (100),  116 (49); 
HRMS (El): calcd for Ci4H2i79BrN20 3S (M+) 376.0456, found 376.0459.
(3  S*,  4S*)-3-(3-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  tert-butyl 
amide (127k), (3R*, 5S*)-3-(3-Chlorophenyl)-2-methylisoxazolidine-5-sulfonic acid 
ter/-butylamide  (128k),  and  (3S*,  5S*)-3-(3-Chlorophenyl)-2-methyIisoxazolidine- 
5-sulfonic acid ter/-butylamide (129k)
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H
0 - '~ N   ^
\  Cl
128k
General protocol was followed using  100 mg of 123e. Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether 40-60°C/Et20)  to  give  three  separable 
products 127k  (84 mg, 41%),  128k (15 mg, 7%), and 129k (7 mg, 4%)- overall yield 
(52%, 127k: 128k: 129k = 12:2:1).
Data  for  128k:  R f   0.35  (2:1  Et20/petroleum  ether  40-60°C);  mp  76-80  °C;  o w  
(neatycm1  3292,  2918,  1577,  1469,  1432,  1321,  1212,  1142,  1014, 872, 784;  8h (300 
MHz, CDC13) 7.39 (br s,  1   H, ArH), 7.22-7.29 (m, 3H, Ar//), 4.93 (dd, /=  8.6, 2.5 Hz,
127k
1971  H, SC/7), 4.27 (br s, 1 H, N//), 4.01 (br dd, 7 = 9.6, 6.2 Hz,  1  H, NC//), 3.07 (ddd, 7 =
13.6,  6.2, 2.5 Hz,  1   H, SCHC//H), 2.67-2.78 (m, 4 H, SCHCH// and NC//3),  1.40 (s, 9 
H C(C//3)3); 6c (75 MHz, CDCI3)  139.1  (s),  134.8 (s),  130.1  (d),  128.5  (d),  127.6 (d),
125.8 (d), 90.2 (d), 70.8 (d), 55.1 (s), 44.6 (q), 41.8 (t), 30.6 (q); m/z (El) 334 (M+, 37C1, 
4),  332 (M+,  35C1,  8),  196 (21),  168  (100),  152  (60),  125  (27),  103  (40);  HRMS  (El): 
calcd for Ci4H2135C1N20 3S (M+) 332.0961, found 332.0971.
Data  for  129k:  Rf0.31  (2:1  Et20/petroleum  ether  40-60°C);  mp  120-133  °C;  a)m ax 
(neatycm-13300, 2975, 2918,  1578, 1479,  1426,  1318, 1207, 1143, 1094, 996, 879, 793; 
8h (300 MHz, CDC13) 7.43 (br s,  1  H, Ar//), 7.28-7.37 (m, 3 H, Ar//), 4.95 (dd, J = 8.5, 
5.5 Hz,  1  H, SC//), 4.37 (br s,  1 H, N//), 3.53 (br dd, J = 9.4, 7.8 Hz,  1  H, NC//), 3.04 
(ddd, 7 =  13.5, 8.5,  7.2 Hz,  1   H,  SCHC//H),  2.90 (ddd, J =  13.5,  10.0, 5.5  Hz,  1   H, 
SCHC(H)H), 2.61  (s, 3 H, NC//3),  1.42 (s, 9 H C(C//3)3); 6c (125 MHz, CDC13)  131.3 
(s), 129.9 (s), 129.3 (d), 127.3 (d), 91.0 (d), 74.2 (d), 52.3 (s), 44.5 (q), 42.3 (t), 31.8 (q); 
m/z (El) 334 (M+, 37C1, 6 ), 332 (M+,  35C1,  12), 222 (22),  196 (26),  168 (100),  153 (32), 
103 (32); HRMS (El): calcd for C|4H2i35C1N20 3S (M+) 332.0961, found 332.0981.
Data  for  127k:  Rf 0.27  (2:1  EtiO/petroleum  ether  40-60°C);  mp  117-119  °C;  \)m ax 
(neat)/cm-1  3322,  2963, 2873,  1575,  1479,  1426,  1316,  1133,  1040, 986,  833, 797; 8H  
(300 MHz, CDC13) 7.49 (s,  1  H, Ar//), 7.31-7.39 (m, 3 H, Ar//), 4.73 (s, 1  H, N//), 4.41 
(dd, 7 = 9.7, 3.7 Hz,  1   H, SCHC//H), 4.31  (dd, 7 = 9.7, 8.4 Hz,  1   H, SCHCH//), 3.94 
(app.  td, 7 = 8.1,  3.7 Hz,  1   H, SC//),  3.79 (d, 7 = 7.3  Hz,  1   H, NC//),  2.64 (s, 3 H, 
NC//3),  1.12  (s,  9  H  C(C//3)3);  5c  (75  MHz,  CDC13)  139.8  (s),  134.7  (s),  130.2  (d),
128.9 (d),  128.5  (d),  126.7 (d), 75.6 (d), 74.1  (d), 67.1  (t), 55.2 (s), 42.8 (q), 30.0 (q); 
m/z (El) 334 (M+, 37C1, 4), 332 (M+, 35C1,  12),  194 (100),  115  (25); HRMS (El): calcd 
for Ci4H2,35C1N20 3S (M+) 332.0961, found 332.0974.
(35*,  45*)-3-(5-Bromofuran-2-yl)-2-methylisoxazolidine-4-sulfonic  acid  tert-butyl 
amide (1271)
1271
General protocol was followed using  100 mg of 123e. Crude residue purified by flash 
chromatography  (starting 5:1  petroleum ether 40-60°C/Et20) to give  1271 as a brown 
solid (84 mg, 37%).
198Data  for  1271:  Rf 0.21  (2:1  Et20/petroleum  ether  40-60°C);  mp  104-110  °C;  t>m ax 
(neat)/cm'' 3305, 2973, 2919,  1645, 1507,  1472,  1390,  1306,  1180,  1135, 954, 784; 5H  
(300  MHz,  CDC13)  6.43  (d,  J =  3.2  Hz,  1   H,  BrCCH),  6.31  (d,  J =  3.2  Hz,  1   H, 
BrCCHC//), 4.64 (s,  1  H, N//), 4.26-4.40 (m, 3 H, SCHC/ / 2 and SC/7), 3.84 (br s,  1   H, 
NC/7),  2.65  (s,  3  H,  NC//3),  1-20  (s, 9  H CCC//,),);  5c  (75  MHz,  CDC13)  150.9  (s),
122.7  (s),  114.1  (d),  112.5  (d), 71.3  (d), 68.3  (d), 66.9  (t),  55.2 (s), 43.5  (q), 30.3  (q),
30.0  (q), 29.7 (q); m/z (El) 368 (M+, 81Br,  17), 366 (M+, 79Br,  16), 230 (100), 205 (27); 
HRMS (El): calcd for C,2H1979BrN20 4S (M+) 366.0249, found 366.0245.
o  .0
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(3  S*,  4S*)-3-Furan-2-yl-2-methyIisoxazolidine-4-sulfonic  acid  terf-butylamide 
(127m),  (3R*,  5S*)  and  (3S*,  5S*)-3-Furan-2-yl-2-methylisoxazolidine-5-sulfonic 
acid terf-butylamide (128/129m)
o o
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General protocol was followed using 200 mg of 123e.  Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether 40-60°C/Et20)  to  give  128/129m  (149 
mg, 42%) as a mixture, and 127m (106 mg, 30%) as a brown solid- overall yield (72%, 
127m:128/129m = 2:3,128m and 129m = 2:1 major.minor).
Data for  128/129m:  Rf0.21  (2:1  Et20/petroleum  ether 40-60°C);  mp  83-85  °C;  Dm ax 
(neatycm13293, 3122, 2972,  1507, 1435, 1316,  1202,  1134,  1058, 990; 5H  (300 MHz, 
CDC13)  7.37-7.39  (m,  1  H, OC//CHCH),  6.37  (d, J =  3.2  Hz,  1   Hm inor,  OCHCHC//), 
6.31  (dd, J= 3.2,  1.9 Hz,  1  H, OCHC//CH), 6.29 (d, J = 3.2 Hz,  1  Hm ajor, OCHCHC/7),
4.94  (dd, J = 8.3, 5.9 Hz,  1  H, SCH), 4.63 (br s, 1  Hm inor, N/7), 4.52 (br s, 1 Hm ajor, NH), 
4.10 (br s,  1  Hm ajor, NC//), 3.69 (br dd, J = 9.9, 7.5 Hz,  1   Hm inor, NCH), 3.16 (ddd, J = 
13.4,  10.4,  5.9  Hz,  1   Hm i„or,  SCHC//H),  2.86-3.08  (m,  2  H,  SCHC//Hm a)or  and 
SCHCH//),  2.79  (br  s,  3  Hm ajor,  Nfflj),  2.69  (s,  3  Hm inor,  NCH}),  1.37  (s,  9  Hm inor, 
C(C  7/3)3),  1.36 (s, 9 Hmajor* C(C/f3)3); 5c (75 MHz, CDC13)  149.4 (s),  148.8 (s),  143.1 
(d), 143.0 (d),  110.5 (d),  110.4 (d), 109.1 (d), 108.8 (d), 90.5 (d), 89.9 (d), 66.2 (d), 64.3 
(d),  55.1  (s),  55.0  (s),  44.7  (q),  43.7  (q),  36.7  (t),  30.6  (q),  29.7  (q),  19  out  of 20 
expected  signals  observed;  m/z  (FAB+)  307  (26),  289  (MH+,  100),  154  (77);  HRMS 
(FAB+): calcd for C12H21N2O4S (MH+) 289.1222, found 288.1228.
Data  for  127m:  Rf0.16  (2:1  Et^O/petroleum  ether  40-60°C);  mp  148-152  °C;  \)m ax 
(neatycm1   3279,  2921,  1505,  1431,  1314,  1235,  1142,  1010;  5h  (300  MHz,  CDC13)
1997.45  (dd,  J  =  1.9,  0.8  Hz,  1   H,  OC//CHCH),  6.47  (dd,  J  =  3.2,  0.8  Hz,  1   H, 
OCHCHC//), 6.38 (dd, J= 3.2,  1.9 Hz,  1  H, OCHC//CH), 4.72 (s,  1  H, N//), 4.26-4.42 
(m, 3 H, SCHCH2 and SC/7), 3.88 (br s,  1  H, NC//), 2.67 (s, 3 H, NC//3),  1.14 (s, 9 H 
C(C//3)3);  8c (75 MHz, CDCI3)  148.6 (s),  143.3  (d),  110.8  (2 x d), 71.3  (d), 68.4 (d),
66.9  (t), 55.0 (s), 42.8 (q), 29.9 (q); m/z (El) 288 (M+, 5),  151  (48),  150 (100),  118 (26), 
91 (30); HRMS (El); calcd for QjHjoNjC^S (M+) 288.1138, found 288.1131.
(3S*,  4S*)-3-Cyclopropyl-2-methylisoxazolidine-4-sulfonic  acid  tert-butylamide 
(127n),  (3R*,  5S*)-3-Cyclopropyl-2-methylisoxazolidine-5-sulfonic  acid  ferf-butyl 
amide  (128n), and  (35*. 5S*)-3-Cyclopropyl-2-methylisoxazoIidine-5-sulfonic acid 
tert-butylamide (129n)
127n  128n  129n
General protocol was followed using 200 mg of 123e. Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three  separable 
products  127n  (41  mg,  12%),  128n  (64 mg,  20%),  and  129n  (35  mg,  11%)-  overall 
yield (43%, 127n:128n:129n = 6:9:5).
Data  for  129n:  Rf 0.41  (2:1  Et20/petroleum  ether  40-60°C);  mp  113-117  °C;  t)m ax 
(neatycm'1 3304, 2983, 2918,  1474,  1427,  1316,  1232,  1141,  1056, 863; 5H  (300 MHz, 
CDC13) 4.79 (t, J = 7.2 Hz,  1  H, SCH), 4.39 (br s,  1 H, N//), 2.66-2.76 (m, 5 H, NCH3  
and SCHC//2),  1.85 (br q, J = 7.8 Hz,  1 H, NC//),  1.37 (s, 9 H C(C//3)3), 0.82-0.95 (m, 
1 H, CH2C//CH2), 0.51-0.60 (m, 2 H, cyclopropyl-//), 0.15-0.28 (m, 2 H, cyclopropyl- 
H)\ 5c (75 MHz, CDC13) 89.5 (d), 74.2 (d), 54.9 (s), 44.3 (q), 37.9 (t), 30.6 (q), 11.2 (d),
4.2  (t),  1.0 (t); m/z (El) 262 (M+, 81),  152 (100),  126 (72), 98 (54); HRMS (El): calcd 
for CiiH22N20 3S (M+) 262.1351, found 262.1352.
Data  for  128n:  Rf 0.36  (2:1  Et20/petroleum  ether  40-60°C);  mp  92-95  °C;  \)m ax 
(neatycm13288, 2969, 2921,  1459,  1429,  1316,  1289,  1142,  1067, 863; 6H  (300 MHz, 
CDC13) 4.80 (br dd, J = 6.7, 2.9 Hz, 1 H, SC/7), 4.31 (br s,  1  H, N/7), 2.76-2.89 (m, 4 H, 
NC//3 and SCHC//H), 2.52-2.60 (m,  1 H, SCHCH//), 2.25 (br s,  1  H, NC//),  1.35 (s, 9 
H C(CZ/3)3), 0.65-0.76 (m,  1 H, CH2C//CH2), 0.47-0.61  (m, 2 H, cyclopropyl-//), 0.17- 
0.30 (m, 2 H, cyclopropyl-//); 8C  (75 MHz, CDC13) 90.0 (d), 71.6 (d), 54.9 (s), 45.2 (q),
38.7  (t), 30.3 (q),  11.5 (d), 4.1 (t), 1.1 (t); m/z (El) 262 (M+, 32), 152 (100),  126 (78), 96 
(48); HRMS (El): calcd for CnH22N2 03S (M+) 262.1351, found 262.1348.
200Data  for  127n:  Rf 0.22  (2:1  Et20/petroleum  ether  40-60°C);  mp  62-66  °C;  t)m ax 
(neatycm'1   3286,  2964,  1464,  1428,  1306,  1232,  1136,  1041,  867;  8H   (300  MHz, 
CDCI3) 4.45 (s,  1  H, N//), 4.23 (br dd, J = 9.6, 4.8 Hz,  1  H, SCHC//H), 4.12 (app. br t, 
J = 8.9 Hz,  1  H, SCHCH//),  3.88  (app. td, J = 7.9,  5.6 Hz,  1  H,  SC/7), 2.79  (s,  3  H, 
NC//3),  2.41  (app.  s,  1   H,  NC//),  1.39  (s,  9  H  C(C//3)3),  0.81-1.03  (m,  1   H, 
CH2C//CH2), 0.55-0.78 (m, 3 H, cyclopropyl-//), 0.17-0.30 (m, 1 H, cyclopropyl-//); 5C  
(75 MHz, CDCI3) 74.2 (d), 73.4 (d), 66.9 (t), 55.3 (s), 43.8 (q), 30.3 (q), 13.8 (d), 4.7 (t),
2.3  (t); m/z (El) 262 (M+,  15),  124 (100), 99 (67); HRMS (El): calcd for Q 1H22N2O3S 
(M+) 262.1351, found 262.1348.
4.5.3.  Cycloadditions  with  ethenesulfonic  acid  [2-(ter/-butyldimethyl 
silanyloxy)ethyl]amide (123g)
2-(ter/-Butyldimethylsilanyloxy)ethylamine 192
Ethanolamine (5.0 g, 81.8 mmol) was dissolved in DCM (125 mL), then NEt3 (12.6 mL,
90.0  mmol)  and  TBDMSC1  (13.6  g,  90.0  mmol)  added  to  the  stirring  suspension. 
DMAP (1.0 g, 8.2 mmol) was added and the reaction allowed to stir at RT for 16 hours. 
The reaction  mixture was  washed with H2O  (2 x 40 mL),  followed by brine  (1  x 40 
mL), dried (MgSCL), and concentrated in vacuo to yield the product (13.2 g, 92%) as a 
yellow oil. Data agrees with literature.
Rf 0.20 (4:1 DCM/MeOH); 5r (300 MHz, CDC13) 3.55 (t, /=  5.3 Hz, 2 H, OC/72CH2), 
2.70 (t, J = 5.3 Hz, 2 H, CH2C//2N), 1.39 (br s, 2 H, NH2), 0.83 (s, 9 H, C(C//3)3), 0.07 
(s, 6 H, Si(C//3)2); 5C (75 MHz, CDC13) 65.3 (t), 44.3 (t), 25.8 (q), 18.3 (s), -5.0 (q).
Ethenesulfonic acid [2-(ter/-butyldimethylsilanyloxy)ethyl]amide (123g)
\x//
TBDMSO.  /S .
H
A  premixed  suspension  of  2-(terr-butyldimethylsilanyloxy)ethylamine  (11.7  g,  44.2 
mmol) and NEt3 (7.5 g, 73.6 mmol) in DCM was dropwise added to a stirring solution 
of 2-chloroethane-l-sulfonyl  chloride  (6.0  g,  36.8  mmol)  in  DCM  (100  mL),  while 
keeping the temperature at -10 °C.  The reaction mixture was left to stir for a further 3
4
hours after addition, then warmed to RT.  The reaction was diluted with DCM (60 mL)
201and washed with 2M HC1 (3 x 80 mL), H2O (80 mL), dried (MgS0 4), and filtered.  The 
filtrate was collected and concentrated in vacuo  to  give the crude residue which was 
purified by flash chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to furnish 
the desired product (6.3 g, 65%) as a white solid.
Rf 0.24 (1:1  petroleum ether 40-60°C/Et20); mp 48-50 °C; \)m ax (neatycm'1  3297, 2930, 
1472, 1327, 1254, 1152, 1084, 967, 834, 776; 6H  (300 MHz, CDC13) 6.52 (dd, /  = 16.6,
9.9  Hz,  1   H,  SCH),  6.25  (d, J =  16.6 Hz,  1   H,  SCHC//H),  5.94  (d, J = 9.9 Hz,  1   H, 
SCHCH//), 4.64 (br s,  1 H, N//), 3.71 (t, J = 5.2 Hz, 2 H, OC//2CH2N), 3.14 (app. q, J 
= 5.4  Hz,  2 H,  OCH2C//2N),  0.88  (s,  9  H,  C(C//3)3),  0.05  (s,  6  H,  Si(C//3)2;  5C   (75 
MHz, CDCI3)  136.0 (d),  126.4 (t), 61.8 (t), 45.1  (t), 26.0 (q),  18.2 (s), -5.4 (q); m/z (Cl) 
266  (MH+,  100),  250  (28),  208  (34),  134 (31);  HRMS  (Cl):  calcd  for C,oH24N03SSi 
(MH+) 266.1246, found 266.1247.
(35*,  4S*)-3-(4-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  [2-(tert- 
butyldimethylsilanyloxy)ethyl]amide  (130a),  (3R*,  55*)  and  (35*,  55*)-3-(4- 
Bromophenyl)-2-methylisoxazolidine-5-sulfonic  acid  [2-(ter/-butyl  dimethyl
silanyloxy)ethyl]amide (1317132a)
General protocol was followed using 200 mg of 123g.  Crude residue purified by flash 
chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 131/132a (40 mg, 
11%)  as  a  mixture,  and  130a  (213  mg,  59%)  as  a  brown  oil-  overall  yield  (70%, 
130a:131/132a = 5:1, 131 and 132a = 4:1 major:minor).
Data for 131/132a: Rf0.44 (2:1 Et20/petroleum ether 40-60°C); Sh (300 MHz, CDCI3)
7.48  (d, J = 8.3 Hz, 2 H , Ar//), 7.25 (d, J = 8.3 Hz, 2 H , Ar//), 5.04 (dd, J = 8.6, 5.6 Hz, 
1   H min0r, SC//), 5.01  (dd, J = 8 .6 , 2.5 Hz,  1  H maj0r, SCH), 4.87 (br t, J = 5.9 Hz,  1  H minor, 
N//), 4.79 (br t, J = 5.8 Hz,  1 Hm ajor, N//), 4.02 (br dd, /  = 9.4, 6.3 Hz,  1  Hm ajor, NCH), 
3.75  (t, J = 5.1  Hz,  2  H ,  OC//2CH2N), 3.54 (br dd, J =  10.1, 7.5 Hz,  1   H min0r,  NCH), 
3.34-3.40 (m, 2 H minor, OCH2C//2N), 3.27-3.34 (m, 2 Hm ajor, OCH2C//2N), 3.07-3.16 (m, 
1  Hm inor, SCHC//H), 3.05 (ddd, /=  13.7, 6.3, 2.5 Hz,  1 Hm ajor, SCHC/7H), 2.84 (ddd, J 
=  13.6,  10.1, 5.6 Hz,  1   Hm inor,  SCHCH//), 2.74 (ddd, J =  13.7,  10.2,  8 .6 Hz,  1  H maj0r, 
SCHCH//), 2.72 (s, 3  H major,  NCZ/3), 2.59 (s, 3  H minor,  NC//3), 0.90 (s, 9 H,  C(C//3)3), 
0.07 (s,  6 H ,  Si(CH3)2); §c (75 MHz, CDC13)  136.0 (s),  135.6 (s),  132.1  (d),  132.0 (d),
TBDMSO
TBDMSO
131/132a
o,  0
202129.7 (d),  129.2 (d),  122.6 (s),  122.3  (s),  88.8 (d), 67.6 (d), 62.5  (t), 62.2 (t), 45.9 (t),
44.6  (q), 41.9 (t), 25.9 (q), 18.3 (s), -5.4 (q), 18 out of 26 expected signals observed.
Data for 130a: Rf0.36 (2:1 Et20/petroleum ether 40-60°C); 8h (300 MHz, CDCI3) 7.49 
(d, J = 8.4 Hz, 2 H, Ar//), 7.34 (d, J = 8.4 Hz, 2 H, Ar//), 4.81  (app. t, J = 5.9 Hz,  1  H, 
N//),  4.34  (dd,  J  =  9.9,  4.2  Hz,  1   H,  SCHC//H),  4.28  (dd,  J  =  9.9,  8.0  Hz,  1   H, 
SCHCH//), 3.97 (app. td, J = 7.5, 4.2 Hz, 1  H, SC//), 3.81 (br d, J = 7.1 Hz, 1  H, NC//), 
3.48-3.60 (m, 2 H, OC//2CH2N), 3.10 (ddt, J =  12.8, 6.2, 4.4 Hz,  1   H, OCH2C//HN),
2.95  (ddt, J =  11.8, 6.0, 4.4 Hz,  1   H, OCH2CH//N), 2.62 (s, 3 H, NC//3), 0.86 (s, 9 H, 
C(C//3)3), 0.03 (s, 6 H, Si(C//3)2); 8C  (75 MHz, CDC13)  136.3 (s),  132.1  (d),  129.8 (d),
122.7 (s), 73.6 (d), 73.3 (d), 67.0 (t), 62.1  (t), 45.4 (t), 42.8 (q), 25.9 (q),  18.3 (s), -5.4 
(q).
V
TBDMSO
130b
(3S*,  4S*)-3-(2-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  [2-(terf-butyl 
dimethylsilanyloxy)ethyl]amide  (130b),  (3/?*,  5S*)-3-(2-Chlorophenyl)-2-methyl 
isoxazolidine-5-sulfonic  acid  [2-(terf-butyldimethylsilanyloxy)ethyl]amide  (131b), 
and  (3S*,  5S*)-3-(2-Chlorophenyl)-2-methylisoxazolidine-5-sulfonic  acid  [2-{tert- 
butyldimethylsilanyloxy)ethyl]amide (132b)
0 \/0   Cl  Ov O  CIN
TBDMSO^  )s L   /x   / = r\   TBDMSO.
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131b  132b
General protocol  was followed using 200 mg of 123g.  Crude residue was purified by 
flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  the  three 
separable products 130b (134 mg, 41%), 131b (85 mg, 26%), and 132b (49 mg,  15%)- 
overall yield (82%, 130b: 131b: 132b = 8:5:3).
Data for 132b: Rf0.50 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDC13) 7.66 
(d, J = 7.6 Hz,  1  H, Ar//), 7.36 (d, /  = 7.6 Hz, 1  H, Ar//), 7.19-7.31 (m, 2 H, Ar//), 5.09 
(dd, J = 8.6, 5.7 Hz,  1  H, SCH), 4.86 (br t, /  = 5.7 Hz,  1   H, N//), 4.19 (br dd, J = 9.3, 
8.0 Hz, 1  H, NC//), 3.77 (t, J = 4.9 Hz, 2 H, OC//2CH2N), 3.37 (app. q, J = 5.4 Hz, 2 H, 
OCH2C//2N), 3.14-3.24 (m,  1 H, SCHC//H), 2.67-2.80 (m, 4 H, SCHCH// and NC//3), 
0.91  (s, 9 H, C(C//3)3), 0.09 (s,  6 H, Si(CH3)2);  8C  (75 MHz, CDC13)  134.7  (s),  133.7 
(s),  129.6 (d),  129.2 (d),  128.4 (d),  127.7 (d), 88.9 (d), 68.5 (d), 62.6 (t), 46.0 (t), 43.4 
(q), 39.7 (t), 25.9 (q),  18.3 (s), -5.3 (q).
203Data for 131b: Rf0.44 (2:1 Et2 0/petroleum ether 40-60°C); 8h (300 MHz, CDCI3) 7,55 
(dd, J = 7.5,  1.8 Hz,  1 H, Ar//), 7.36 (dd, J = 7.5, 1.7 Hz,  1  H, Ar//), 7.22-7.30 (m, 2 H, 
ArH), 4.96 (dd, J = 8.4, 4.0 Hz, 1  H, SCH), 4.81  (br t, J = 5.8 Hz, 1  H, NH), 4.57 (br t, J 
=  7.2  Hz,  1   H,  NCH),  3.76  (t, J =  5.1  Hz,  2  H,  OC//2CH2N),  3.28-3.36  (m,  2  H, 
OCH2C//2N), 3.26 (ddd, J =  13.5, 6.7, 4.0 Hz,  1   H,  SCHC//H), 2.83  (s, 3  H, NC//3),
2.63  (app. dt, J =  13.5, 8.4 Hz,  1   H, SCHCH//), 0.90 (s, 9 H, C(CH})}), 0.09 (s, 6 H, 
Si(CH3)2);  5c  (75  MHz,  CDCI3)  135.8  (s),  133.5  (s),  129.7  (d),  129.0  (d),  127.6 (d),
127.3  (d), 89.5 (d), 67.0 (d), 62.3 (t), 46.0 (t), 45.1  (q), 39.0 (t), 25.9 (q),  18.3 (s), -5.4 
(q)-
Data for 130b: Rf0.28 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDC13) 7.54 
(dd, J = 7.5,  1.8 Hz, 1 H, ArH), 7.39 (dd, J = 7.7, 1.7 Hz,  1  H, ArH), 7.25-7.34 (m, 2 H, 
Ar//), 4.78 (app. t, J = 5.9 Hz,  1 H, NH), 4.48 (br d, 7  = 7.4 Hz,  1 H, NC//), 4.43 (dd, J 
= 9.9,4.6 Hz,  1  H, SCHC//H), 4.38 (dd, J = 9.9, 7.8 Hz, 1 H, SCHCH//), 4.11 (app. td, 
J =  7.8,  4.6  Hz,  1   H,  SC//),  3.39-3.56  (m,  2  H,  OC//2CH2N),  3.07-3.15  (m,  1   H, 
OCH2C//HN),  2.73-2.82  (in,  1   H,  OCH2CH//N),  2.63  (s,  3  H,  NC//3),  0.86  (s, 9  H, 
C(C//3)3), 0.02 (s,  6 H, Si(C//3)2); 5c (75 MHz, CDC13)  134.4 (s),  134.3 (s),  130.0 (d),
129.8  (d),  129.7  (d),  127.7  (d), 72.7  (d), 70.1  (d), 67.1  (t),  62.1  (t), 45.3  (t), 42.7  (q),
25.9  (q), 18.3 (s), -5.4 (q).
(3S*,  4S*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic  acid  [2-(fert-butyldimethyl 
silanyloxy)ethyl]amide  (130c),  (3R*,  5S*)  and  (3S*,  5S*)-2-Methyl-3-
phenylisoxazolidine-5-sulfonic  acid  [2-(rerf-butyldimethylsilanyloxy)ethyl]amide 
(131/132c)
TBDMSO  , S '  0   9
“   "   T C D M S 0 ^ s y > O o N
130c  131/132C  ^
General protocol  was followed using 200 mg of 123g.  Crude residue was purified by 
flash chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 131/132c (43 
mg,  14%)  as a mixture,  and  130c  (123 mg, 41%) as a brown oil- overall yield (55%, 
130c:131/132c = 3:1,131c and 132c = 3:2 major:minor).
Data for 131/132c:  Rf0.46 (2:1  Et20/petroleum ether 40-60°C);  8 h (300 MHz, CDCI3) 
7.40-7.44 (m, 2 H, ArH), 7.30-7.38 (m, 3 H, ArH), 5.07 (dd, J =  8 .6 , 5.9 Hz,  1  Hm aj0r, 
SCH), 5.01-5.05 (m,  1 Hmin0r, SCH), 4.88 (br t,J = 5.9 Hz,  1 Hmajor, NH), 4.79 (br t, J =
5.9  Hz,  1  Hminor, NT/), 4.03  (app. br s ,  1  Hminor, NC//),  3.77 (app. q, J = 5.4 Hz, 2 H,
204OC//2CH2N), 3.57 (br dd, J = 9.9, 7.5 Hz,  1   Hm ajor, NCH), 3.39 (app. q, J = 5.4 Hz, 2 
Hmajor,  OCH2C//2N),  3.28-3.36  (m,  2  Hm inor,  OCH2Ctf2N),  3.00-3.14  (m,  1   H, 
SCHC//H), 2.77-2.95 (m,  1 H, SCHCHtf), 2.73 (br s, 3 Hm inor, NC//3), 2.61 (s, 3 Hm ajor, 
NCH3), 0.91  (s, 9 H, C(C//3)3), 0.09 (s, 6 H, Si(C//3)2); 8c (75 MHz, CDClj)  136.4 (s),
128.9  (d),  128.8 (d),  128.6 (d),  128.4 (d),  128.0 (d),  127.6 (d),  88.9 (d),  88.8 (d), 73.7 
(d), 62.6 (t), 62.3 (t), 45.9 (t), 43.2 (q), 41.2 (t), 25.9 (q), 25.8 (q),  18.3 (s), -5.4 (q), 19 
out of 26 expected signals observed.
Data for 130c: Rf0.39 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDC13) 7.32-
7.45  (m, 5 H, ArH), 4.72 (br t, J = 5.7 Hz, 1 H, NH), 4.30-4.39 (m, 2 H, SCHC«2), 4.05 
(app. td, 7 = 7.5, 4.4 Hz,  1  H, SC/7), 3.82 (br d, 7 = 7.1  Hz,  1   H, NCH), 3.43-3.56 (m, 2 
H, OC/72CH2N), 3.02-3.12 (m,  1  H, OCH2C/7HN), 2.81-2.91  (m,  1  H, OCH2CH//N),
2.63  (s,  3  H,  NC/73),  0.86  (s,  9  H,  C(C//3)3),  0.02  (s,  6  H,  Si(CH3)2);  8c  (75  MHz, 
CDC13)  137.0 (s),  129.0 (d),  128.7 (d),  128.2 (d), 74.5  (d),  73.2 (d), 66.9 (t), 62.0 (t),
45.3  (t), 42.8 (q), 25.9 (q), 18.3 (s), -5.4 (q).
(3S*,  4S*)-3-(2-Bromophenyl)-2-methyIisoxazolidine-4-sulfonic  acid  [2-(/ert-butyI 
dimethylsilanyloxy)ethyl]amide  (130d),  (3R*,  5S*)-3-(2-BromophenyI)-2-methyl 
isoxazolidine-5-sulfonic  acid  [2-(terf-butyIdimethylsiIanyloxy)ethyI]amide  (131d), 
and  (3S*,  5S*)-3-(2-Bromophenyl)-2-methylisoxazolidine-5-sulfonic  acid  [2-(tert- 
butyidimethylsilanyloxy)ethyl]amide (132d)
O  O  Br,  o   o   Br,
T B D M S O ^ ^ X ^ X   > = \   T B D H B O ^ ^ nX ^   V = \
V TBDMSO
Br 130d
H  I  /   N\  J   H  I  I
N  0~-N  ^-----
131d  ^  132d  X
General protocol  was followed using 200 mg of 123g.  Crude residue was purified by
flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three 
separable products 130d (100 mg, 28%), 131d (62 mg,  17%), and 132d (43 mg,  12%)- 
overall yield (57%, 130d:131d:132d = 5:3:2).
Data for 132d: Rf0.52 (2:1 Et20/petroleum ether 40-60°C); 8H  (300 MHz, CDC13) 7.65 
(dd, J = 7.8,  1.6 Hz,  1 H, ArH), 7.54 (dd, J = 8.0, 1.1 Hz, 1  H, ArH), 7.30-7.35 (m,  1  H, 
ArH), 7.15 (ddd, J = 8.0, 7.4,  1.6 Hz,  1  H, ArH), 5.08 (dd, J = 8.6, 5.6 Hz,  1  H, SC//), 
4.87 (br t, J = 5.8 Hz,  1   H, NH), 4.16 (dd, J = 9.8, 7.4 Hz,  1   H, NC//), 3.77 (t, J = 5.1 
Hz, 2 H, OC//2CH2N), 3.37 (app. q, J = 5.4 Hz, 2 H, OCH2C//2N), 3.21 (ddd, J = 13.5,
8.6,  7.4 Hz,  1  H,  SCHC//H), 2.63-2.72 (m, 4 H,  SCHCH// and NCH3), 0.91  (s, 9 H, 
C(CH3)3), 0.09 (s, 6 H, Si(CH3)2); 5C  (75 MHz, CDC13)  136.4 (s),  132.8 (d),  129.5 (d),
205128.7  (d),  128.3  (d),  123.9 (s), 88.9 (d),  71.1  (d),  62.6  (t), 46.0 (t),  43.4 (q),  39.7  (t),
25.9 (q), 18.3 (s), -5.3 (q).
Data for 131d: Rf0.47 (2:1 Et20/petroleum ether 40-60°C); 8h (300 MHz, CDCb) 7.52- 
7.59 (m, 2 H, ArH), 7.32 (app. dt, J = 7.4, 1.1  Hz,  1   H, ArH), 7.15 (app. dt, 7 = 8.0, 1.7 
Hz,  1   H, ArH), 4.96 (dd, 7 = 8.4, 4.1  Hz,  1   H, SC/7), 4.81  (br t, 7 = 5.8 Hz,  1   H, NH), 
4.54 (app. t, 7 = 7.3 Hz,  1  H, NCH), 3.76 (t, 7 = 5.1  Hz, 2 H, OC//2CH2N), 3.24-3.36 
(m, 2 H, OCH2C//2N), 3.28 (ddd, 7  =  13.7,  6 .6 , 4.1  Hz,  1   H, SCHC//H), 2.83 (s, 3 H, 
NCtfj), 2.58-2.68 (m,  1   H, SCHCH//), 0.90 (s, 9 H, C(C//3)3), 0.07 (s, 6 H, Si(CH3)2); 
8c (75 MHz, CDCI3) 137.4 (s), 133.0 (d),  129.3 (d),  128.0 (d),  127.9 (d), 123.6 (s), 89.5 
(d), 69.4 (d), 62.3 (t), 46.0 (t), 45.1 (q), 39.2 (t), 25.9 (q), 18.3 (s), -5.4 (q).
Data for 130d: Rf0.29 (2:1 Et20/petroleum ether 40-60°C); Sh (300 MHz, CDCI3) 7.58 
(dd, 7 = 8.0,  1.2 Hz,  1  H, ArH), 7.52 (dd, 7 = 7.8,  1.7 Hz,  1   H, Ar//), 7.36 (app. dt, 7 =
7.8,  1.2 Hz,  1  H, ArH), 7.19 (app. dt, 7 = 8.0,  1.7 Hz, 1 H, ArH), 4.80 (br t, 7 = 6.0 Hz, 1  
H, N//), 4.50 (br d, 7 = 7.4 Hz,  1 H, NCH),  4.35-4.44 (m, 2 H, SCHCH2), 4.09 (app. br 
td, 7 = 7.8, 4.7  Hz,  1  H,  SC//),  3.38-3.52 (m,  2 H,  OC//2CH2N),  3.06-3.15  (m,  1  H, 
OCH2C//HN),  2.70-2.80  (m,  1  H,  OCH2CH//N),  2.64  (s,  3  H,  NC//3),  0.86  (s,  9  H, 
C(C//3)3), 0.02 (s, 6 H, Si(C//3)2); 8c (75 MHz, CDC13)  135.9 (s),  133.3 (d),  130.1  (d),
129.9 (d),  128.3  (d),  124.9 (s), 72.9  (d),  72.4 (d),  67.1  (t),  62.1  (t), 45.3  (t), 42.6 (q),
25.9 (q), 18.3 (s), -5.4 (q).
(3S*,  4S*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  [2-(/ert-butyl 
dimethylsiIanyIoxy)ethyl]amide  (130e),  (3R*,  5S*)-3-(2-Fluorophenyl)-2-methyl 
isoxazolidine-5-sulfonic  acid  [2-(fert-butyldimethylsilanyloxy)ethyl]amide  (131e), 
and  (35*,  5S*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-5-sulfonic  acid  [2-(tert- 
butyldimethy  Isilany  lo.\y)ethyl]amide (132e)
F  O  O  F,
TBDMSO,  ) = \
132e  ^
General protocol  was followed using 200 mg of 123g.  Crude residue was purified by 
flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three 
separable products 130e (113 mg, 36%), 131e (68 mg, 22%), and 132e (58 mg,  18%)- 
overall yield (76%, 130e:131e:132e = 2:1:1).
Data for 132e: Rf0.47 (2:1 Et20/petroleum ether 40-60°C); 8H  (300 MHz, CDCI3) 7.60 
(app. td, J = 7.5,  1.9 Hz,  1 H, ArH), 7.24-7.32 (m, 1  H, ArH), 7.16 (app. td, J = 7.8,  1.1 
Hz,  1  H, ArH), 7.05 (ddd, J = 10.2, 8.2,  1.1 Hz,  1  H, ArH), 5.09 (dd, J = 8.4, 5.6 Hz,  1
206
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131e 130eH, SC//), 4.88 (br t, 7 = 5.8 Hz,  1  H, NH), 4.02 (dd, 7 =  10.2, 7.4 Hz,  1   H, NC//), 3.77 
(t, 7 = 5.1 Hz, 2 H, OC//2CH2N), 3.38 (app. q, 7 = 5.4 Hz, 2 H, OCH2C//2N), 3.09 (ddd, 
7  =  13.5,  8.4,  7.4  Hz,  1   H,  SCHC//H),  2.84  (ddd,  7  =  13.5,  10.2,  5.6  Hz,  1  H, 
SCHCH//), 2.65 (s, 3 H, NC//3), 0.89 (s, 9 H, C(CZ/3)3), 0.08 (s, 6 H, Si(CH3)2); 5C  (75 
MHz, CDC13) 161.1 (s, 7Cf = 246.8 Hz), 129.7 (d, 7Cf = 8.5 Hz), 128.6 (d, 7Cf = 3.5 Hz),
124.9  (d, Jcf = 3.8 Hz), 123.5 (s, 7C F = 12.3 Hz), 115.5 (d, Jcf = 22.0 Hz), 89.0 (d), 65.0 
(d), 62.6 (t), 46.0 (t), 43.4 (q), 39.7 (t), 25.9 (q), 18.3 (s), -5.4 (q).
Data for 131e: Rf0.41  (2:1 Et20/petroleum ether 40-60°C); Sh (300 MHz, CDC13) 7.45 
(app. br t, J= 7.2 Hz, 1  H, Ar//), 7.24-7.29 (m, 1 H, ArH), 7.14 (app. td, J = 7.6, 1.1 Hz, 
1  H, ArH), 7.05 (ddd, J =  10.3, 8.2,  1.1  Hz,  1  H, ArH), 5.01  (dd, J = 8.4, 3.5 Hz,  1  H, 
SC//), 4.82 (br t, J = 5.8 Hz, 1  H, NH), 4.37-4.45 (m,  1  H, NCH), 3.75 (t, J = 5.1 Hz, 2 
H, OC//2CH2N), 3.29-3.35 (m, 2 H, OCH2CZ/2N), 3.14 (ddd, 7= 13.5, 6.5, 3.5 Hz, 1  H, 
SCHC//H), 3.72-3.83 (m, 4 H, SCHCHH and NCH3), 0.90 (s, 9 H, C(C//3)3), 0.08 (s, 6 
H, Si(CH3)2); 5C  (75 MHz, CDC13)  161.0 (s, Jcf = 247.7 Hz),  129.6 (d, 7C F = 8.5 Hz),
128.2  (d, 7 Cf  =  3.5 Hz), 124.5 (d, Jcf =  3.5 Hz), 124.4 (s), 115.7 (d, 7CF =  21.7 Hz), 89.3 
(d), 63.9 (d), 62.3 (t), 45.9 (t), 44.7 (q), 39.2 (t), 25.9 (q), 18.3 (s), -5.4 (q).
Data for 130e: Rf0.30 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDC13) 7.07-
7.46  (m, 4 H, ArH), 4.75  (br t, J = 5.9 Hz,  1   H, NH), 4.32-4.42 (m,  2 H,  SCHCH2), 
4.12-4.19  (m,  2 H,  SCH and NC//),  3.45-3.54  (m,  2  H,  OC//2CH2N),  3.11  (ddt, J =
12.7,  6.0, 4.3 Hz,  1  H, OCH2C//HN), 2.84-2.95  (m,  1  H,  OCH2CH//N), 2.63  (s, 3 H, 
NCH3), 0.86 (s, 9 H, C(CH3)3), 0.02 (s, 6 H, Si(CH3)2); 5C  (75 MHz, CDC13)  160.8 (s, 
Jcf = 248.0 Hz),  130.4 (d, 7CF = 8.5 Hz),  129.7 (d, Jcf = 3.5 Hz),  124.9 (d, 7C F = 3.5 
Hz),  123.7 (s, 7Cf = 11.7 Hz),  116.0 (d, Jcf = 22.0 Hz), 72.1  (d), 68.0 (d), 67.0 (t), 62.1 
(t), 45.4 (t), 42.8 (q), 25.8 (q), 18.3 (s), -5.4 (q).
(3  S*,  4S*)-3-(4-Methoxyphenyl)-2-methylisoxazolidine-4-sulfonic  acid  [2-(tert- 
butyldimethylsilanyloxy)ethyl]amide  (130f),  (3/?*,  5S*)-3-(4-Methoxyphenyl)-2- 
methylisoxazolidine-5-sulfonic  acid  [2-(te/7-butyldimethyIsilanyIoxy)ethyl]-amide 
(131f),  and  (3S*,  5S*)-3-(4-Methoxyphenyl)-2-methylisoxazolidine-5-sulfonic  acid 
[2-(te/7-butyldimethylsilanyloxy)ethyI]amide (132f)
TBDMSO
130f 131f
MeO
TBDMSO
OMe
132f
General protocol was followed using 200 mg of 123g. Crude residue purified by flash
207chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three  separable 
products 130f (171  mg, 53%), 131f (16 mg, 5%), and 132f (27 mg, 8%)- overall yield 
(66%, 130f:131f:132f = 11:1:2).
Data for 132f: Rf0.33 (2:1  Et20/petroleum ether 40-60°C); 5h (300 MHz, CDCI3) 7.34 
(d, J = 8.7 Hz, 2 H, ArH), 6.88 (d, J = 8.7 Hz, 2 H, ArH), 5.05 (dd, J = 8.5, 5.8 Hz, 1  H, 
SCH), 4.87 (br t, J = 5.8 Hz,  1   H, NH), 3.80 (s, 3 H, OCH3), 3.78 (t, J = 5.1  Hz, 2 H, 
OC//2CH2N), 3.52 (br dd, J = 9.6, 7.8 Hz,  1  H, NCH), 3.39 (app. q, /  = 5.3 Hz, 2 H, 
OCH2C//2N),  3.01  (ddd, J =  13.6,  8.5, 7.2 Hz,  1   H,  SCHC//H),  2.88  (ddd, J =  13.6,
10.2,  5.8 Hz, 1  H, SCHCHH), 2.58 (s, 3 H, NCH3), 0.91 (s, 9 H, C(CH3)3), 0-09 (s, 6 H, 
Si(CH3)2); 6C  (75 MHz, CDC13)  159.8 (s),  129.2 (d),  127.9 (s),  114.3 (d), 88.9 (d), 67.8 
(d), 62.6 (t), 55.3 (q), 45.9 (t), 43.1 (q), 29.7 (t), 25.9 (q), 18.3 (s), -5.4 (q).
Data for 131f: Rf0.33 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDC13) 7.28 
(d, J = 8.8 Hz, 2 H, ArH), 6.89 (d, J = 8.8 Hz, 2 H, ArH), 5.01-5.05 (m, 1 H, SC//), 4.77 
(br t, J = 5.8 Hz,  1  H, NH), 3.98 (br s,  1 H, NCH), 3.80 (s, 3 H, OCH3), 3.76 (t, J = 5.1 
Hz, 2 H, OC//2CH2N),  3.26-3.38  (m,  2 H, OCH2C//2N),  3.02 (ddd, J =  13.6, 6.0, 2.3 
Hz,  1   H,  SCHC//H), 2.78 (ddd, J =  13.6,  10.4, 8.8 Hz,  1   H, SCHCH/7), 2.71  (s, 3 H, 
NCH3), 0.91  (s, 9 H, C(CH3)3), 0.09 (s, 6 H, Si(CH3)2); 6C (75 MHz, CDC13)  159.7 (s),
129.1  (d),  127.5  (s),  114.3  (d),  89.1  (d), 67.7  (d), 62.3  (t), 55.3  (q), 45.9  (t), 43.9 (q),
29.7  (t), 25.9 (q), 18.5 (s), -5.4 (q).
Data for 130f: Rf0.27 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDC13) 7.34 
(d, J = 8.7 Hz, 2 H, ArH), 6.88 (d, J = 8.7 Hz, 2 H, ArH), 4.69 (app. t,J = 5.9 Hz,  1  H, 
NH), 4.27-4.36 (m, 2 H, SCHC//2), 4.01 (app. td, J= 7.6, 4.3 Hz,  1 H, SCH), 3.79 (s, 3 
H,  OCH3),  3.75  (br d, J = 6.9 Hz,  1   H, NC//), 3.44-3.56 (m,  2 H, OC//2CH2N),  3.06 
(ddt, J =  12.5, 6.2, 4.6 Hz,  1   H,  OCH2C//HN), 2.87  (ddt, J =  12.5, 5.5, 4.6 Hz,  1   H, 
OCH2CH//N), 2.60 (s, 3 H, NC//3), 0.86 (s, 9 H, C(CH3)3), 0.02 (s, 6 H, Si(CH3)2); 6C  
(75 MHz, CDC13)  159.9 (s),  129.3 (d),  128.6 (s),  114.3 (d), 74.1  (d), 73.0 (d), 66.8 (t),
62.1 (t), 55.2 (q), 45.3 (t), 42.6 (q), 25.9 (q), 18.3 (s), -5.4 (q).
(3S*,  4S*)-2-Methyl-3-(4-nitrophenyI)isoxazolidine-4-sulfonic  add  [2-(ter/-butyl 
dimethylsilanyloxy)ethyl]amide (130g), and (3R*, 5S*)-2-Methyl-3-(4-nitrophenyl) 
isoxazolidine-5-sulfonic add [2-(ter/-butyIdimethylsilanyloxy)ethyI]amide (131g)
\y/ TBDMSO
130g
o  o \x//
TBDMSO.  'a
'B  I  )   \\  //  N0’
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\
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208General protocol was followed using 200 mg of 123g.  Crude residue purified by flash 
chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  two  separable 
products 130g (168 mg, 50%) and 131g (31 mg,  10%)- overall yield (60%, 130g:131g = 
11:2).
Data for 131g: Rf0.35 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDCI3) 8.22 
(d, 7 = 8.8 Hz, 2 H, Ar//), 7.56 (d, 7 = 8.8 Hz, 2 H, Ar//), 5.02 (dd, 7 = 8.5, 2.6 Hz, 1  H, 
SC//), 4.82 (br t, 7 = 5.8 Hz, 1 H, NH), 4.21  (br dd, 7 = 9.9, 6.3 Hz,  1 H, NC//), 3.76 (t, 
7 = 5.1 Hz, 2 H, OC//2CH2N), 3.30-3.37 (m, 2 H, OCH2C//2N), 3.13 (ddd, 7= 13.6, 6.3,
2.6  Hz,  1  H,  SCHCZ/H),  2.72-2.80  (m,  4  H,  SCHCH//  and  NC//3),  0.90  (s,  9  H, 
C(C//3)3), 0.09 (s, 6 H, Si(CH3)2);  6C  (75 MHz, CDC13)  147.9 (s),  144.8 (s),  128.4 (d),
124.1  (d), 88.9 (d), 69.9 (d), 62.2 (t), 45.9 (t), 44.5 (q), 29.7 (t), 25.9 (q),  18.3 (s), -5.4 
(q).
Data for 130g: Rf0.29 (2:1 Et20/petroleum ether 40-60°C); 8h (300 MHz, CDCI3) 8.20 
(d, 7 = 8.7 Hz, 2 H, ArH), 7.68 (d, 7 = 8.7 Hz, 2 H, ArH), 4.92 (br t, 7 = 5.9 Hz,  1  H, 
NH),  4.35  (dd,  7  =  9.9,  4.3  Hz,  1   H,  SCHCHR),  4.30  (dd,  7  =  9.9,  7.5  Hz,  1  H, 
SCHCH//), 4.03 (d, 7 = 6.7 Hz,  1   H, NCH), 3.98 (app. td, 7 = 7.0, 4.3 Hz,  1   H, SCH), 
3.55-3.66 (m, 2 H, OC//2CH2N), 3.02-3.21 (m, 2 H, OCH2C//2N), 2.67 (s, 3 H, NC//3), 
0.85  (s, 9 H, C(C//3)3), 0.03  (s,  6 H, Si(C//3)2); 5C  (75 MHz, CDC13)  147.9 (s),  145.3 
(s),  128.9 (d),  124.0 (d), 73.7 (d), 72.9 (d), 67.2 (t), 62.2 (t), 45.6 (t), 43.1  (q), 25.8 (q),
18.3  (s), -5.4 (q).
(3S'*,  4S*)-3-(4-Chlorophenyl)-2-methylisoxazoIidine-4-suIfonic  acid  [2-(te/7-butyl 
dimethylsilanyloxy)ethyI]amide  (130h),  and  (3/?*,  5S*)-3-(4-Chlorophenyl)-2- 
methylisoxazolidine-5-sulfonic  acid  [2-(te/7-butyldimethylsiIanyloxy)ethyI]amide 
(131h)
General protocol was followed using 200 mg of 123g. Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20) to give the two products 
130h (172 mg, 53%) and 131h (31 mg, 9%)- overall yield (62%, 130h:131h = 11:2). 
Data for 131h: Rf0.49 (2:1 Et20/petroleum ether 40-60°C); 8H  (300 MHz, CDCI3) 7.30-
TBDMSO
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7.39 (m, 4 H, ArH), 5.01  (dd, 7 = 8.6, 2.3 Hz,  1   H, SCH), 4.79 (br t, 7 = 5.8 Hz,  1   H, 
NH), 4.03  (br dd, 7 = 9.8, 6.4 Hz,  1  H, NCH), 3.76 (t, 7 = 5.1  Hz, 2 H, OC//2CH2N),
2093.24-3.40 (m, 2 H, OCH2OT2N), 3.05 (ddd, 7= 13.7, 6.4, 2.3 Hz,  1   H, SCHC//H), 2.74 
(ddd,  7  =  13.7,  10.2,  8.6  Hz,  1   H,  SCHCH//),  2.71  (s,  3  H,  NC//3),  0.90  (s,  9  H, 
C(C//3)3), 0.07 (s, 6 H, Si(CH3)2); 5c (75 MHz, CDCI3)  135.5 (s),  134.2 (s),  129.1  (d),
128.9 (d), 88.8 (d), 67.3 (d), 62.2 (t), 45.9 (t), 44.5 (q), 29.7 (t), 25.9 (q),  18.3 (s), -5.4
(q)-
Data for 130h: Rf 0.40 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDCI3) 7.40 
(d, 7 = 8.5 Hz, 2 H, Ar//), 7.33 (d, 7 = 8.5 Hz, 2 H, Ar//), 4.78 (app. t, 7 = 5.9 Hz, 1  H, 
N//), 4.26-4.36 (m, 2 H, SCHC//2), 3.97 (app. td, 7 = 7.5,4.2 Hz, 1  H, SC//), 3.82 (br d, 
7 = 7.2 Hz, 1 H, NCH), 3.48-3.61 (m, 2 H, OC//2CH2N), 3.10 (ddt, 7= 12.8, 6.1,4.4 
Hz, 1  H, OCH2C//HN), 2.95 (ddt, 7 = 11.9, 6.0,4.4 Hz, 1 H, OCH2CH//N), 2.62 (s, 3 
H, NC//3), 0.87 (s, 9 H, C(C//3)3), 0.03 (s, 6 H, Si(C//3)2); 5c (75 MHz, CDC13) 135.8 
(s), 134.5 (s),  129.4 (d),  129.1 (d), 73.5 (d), 73.4 (d), 67.0 (t), 62.1 (t), 45.4 (t), 42.8 (q),
25.9 (q), 18.3 (s), -5.4 (q).
'V/ TBDMSO
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(3S*,  4.S*)-2-Methyl-3-naphthalen-2-yl-isoxazolidine-4-siilf'onic  acid  [2-(<ert-butyl 
dimethylsilanyloxy)ethyl]amide  (130i),  (3R*,  5S*)  and  (3S*,  5S*)-2-Methyl-3- 
naphthalen-2-yl-isoxazolidine-5-sulfonic  acid  [2-(/ert-butyIdimethylsilanyloxy) 
ethyl]amide (131/132i)
TBDMSO
131/132i
General protocol  was followed using 200 mg of 123g.  Crude residue was purified by 
flash chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 131/132i (60 
mg,  18%)  as a mixture,  and  130i  (192 mg, 57%) as a yellow oil- overall yield (75%, 
130i:131/132i = 3:1,131i and 132i = 3:2 major:minor).
Data for 131/132i:  Rf0.41  (2:1  Et20/petroleum ether 40-60°C); 5h (300 MHz, CDCI3) 
7.79-7.87 (m, 4 H, ArH), 7.46-7.52 (m, 3 H, ArH), 5.11  (dd, 7 = 8.3, 5.9 Hz,  1  Hm aJor, 
SCH), 5.09 (dd, 7 = 8.3, 2.1  Hz,  1   Hm inor, SCH), 4.93  (br t, 7 = 5.9 Hz,  1   Hm ajor, NH), 
4.83  (br t, 7 = 5.9 Hz,  1  Hm inor,  NH), 4.22 (br s,  1   Hm ajor,  NC//),  3.76-3.82  (m, 2 H, 
OC//2CH2N),  3.71-3.75  (m,  1   Hminor,  NC//),  3.41  (app.  q,  7  =  5.6  Hz,  2  H maj0r, 
OCH2C//2N), 3.31-3.38 (m, 2 Hm inor, OCH2C//2N), 3.04-3.17 (m,  1  H, SCHC//H), 3.02 
(ddd, 7 =   13.7,  10.2, 5.9 Hz,  1   H minor,  SCHCH//), 2.91  (ddd, 7 =   13.7,  10.2, 8.3 Hz,  1  
Hmajor,  SCHCH//), 2.78  (br s, 3 Hm inor, NC//3), 2.65  (s,  3  H maj„r,  NCH}),  0.92 (s, 9 H , 
C(CH})i), 0.11  (s, 6 H, Si(C//3)2j; 5c (125 MHz, CDClj)  135.3 (s),  134.9 (s),  134.6 (s),
210134.4  (s),  130.0  (d),  129.9  (d),  128.9  (d),  128.7  (d),  128.2  (d),  127.5  (d),  126.2  (d),
125.9 (s), 90.0 (d), 75.0 (d), 72.2 (d), 63.7 (t), 63.4 (t), 45.5  (t), 44.4 (q), 42.6 (t), 42.1 
(t), 27.2 (q), 27.0 (q), 19.4 (s), -4.2 (q), 25 out of 32 expected signals observed.
Data for 130i: Rf0.34 (2:1 Et20/petroleum ether 40-60°C); 5H  (300 MHz, CDCI3) 7.92 
(s,  1  H, ArH), 7.81-7.88 (m, 3 H, ArH), 7.57 (dd, 7 = 8.5,  1.6 Hz,  1  H, ArH), 7.47-7.54 
(m, 2 H, ArH), 4.81  (app. t, 7 = 5.9 Hz,  1   H, NH), 4.37-4.46 (m, 2 H, SCHC//2), 4.16 
(app. td, 7 = 7.5, 4.6 Hz,  1  H, SCH), 4.02 (br d, 7 = 7.2 Hz,  1 H, NCH), 3.37-3.50 (m, 2 
H, OC//2CH2N), 3.06 (ddt, 7= 12.9, 6.2, 4.4 Hz, 1 H, OCH2C//HN), 2.88 (ddt, 7= 12.2,
5.9,  4.4 Hz,  1  H, OCH2CH/7N), 2.68 (s, 3 H, NCH3), 0.82 (s, 9 H, C(CH3)3), -0.04 (s, 6 
H, Si(Ci73)2);  8C  (75 MHz, CDC13)  134.4 (s),  133.4 (s),  133.3 (s),  128.9 (d),  128.0 (d),
127.9 (d),  127.8 (d),  126.5 (d),  125.1  (d), 74.6 (d), 73.2 (d), 67.1  (t), 62.0 (t), 45.4 (t),
42.9 (q), 25.8 (q), 18.2 (s), -5.4 (q).
(3S*,  4S*)-3-(3-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  [2-(terf-butyl 
dimethylsilanyloxy)ethyl]amide  (130j),  and  (3R*,  55*)-3-(3-Bromophenyl)-2- 
methylisoxazolidine-5-sulfonic  acid  [2-(ter/-butyIdimethylsilanyIoxy)ethyI]amide 
(131j)
TBD-S^ffV)  Q
TBDMSO
130j
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\   Br
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General protocol was followed using 200 mg of 123g. Crude residue purified by flash 
chromatography (starting 5:1  petroleum ether 40-60°C/Et20) to give the two products 
130j (196 mg, 54%) and 131j (32 mg, 9%)- overall yield (63%, 130j:131j = 6:1).
Data for 131j: Rf0.51  (2:1  Et20/petroleum ether 40-60°C);  8h (300 MHz, CDCI3) 7.55 
(s,  1 H, ArH), 7.44 (app. dt, 7 = 7.8,  1.6 Hz,  1   H, ArH), 7.19-7.30 (m, 2 H, ArH), 5.01 
(dd, 7 = 8.5, 2.5 Hz,  1   H, SC//), 4.79 (br t, 7 = 5.8 Hz,  1  H, NH), 4.03 (br dd, 7 = 9.6,
6.2  Hz,  1   H,  NCH),  3.76  (t,  7  =  5.1  Hz,  2  H,  OC//2CH2N),  3.23-3.41  (m,  2  H, 
OCH2C//2N),  3.06  (ddd,  7 =  13.7,  6.2,  2.5  Hz,  1   H,  SCHC//H),  2.70-2.80  (m,  4  H, 
SCHCHH and NCH3),  0.91  (s,  9  H,  C(CH3)3),  0.09  (s,  6 H,  Si(CH3)2);  8C   (75  MHz, 
CDCI3)  139.5 (s),  131.5 (d),  130.5 (d), 130.4 (d),  126.3 (d), 123.0 (s), 88.8 (d), 70.0 (d),
62.3  (t), 45.9 (t), 41.2 (q), 29.7 (t), 25.9 (q), 18.3 (s), -5.4 (q).
Data for 130j: Rf0.46 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDCI3) 7.64 
(s, 1 H, ArH), 7.43-7.48 (m,  1 H, ArH), 7.39 (app. dt, 7 = 7.8,  1.2 Hz,  1  H, ArH), 7.20-
2117.27  (m,  1   H, ArH), 4.74 (br t, J = 5.8 Hz,  1   H, NH), 4.36 (dd, J = 9.9, 4.2 Hz,  1  H, 
SCHCHH), 4.30 (dd, J = 9.9, 7.9 Hz,  1  H, SCHCHH), 3.99 (app. td, J = 7.5, 4.2 Hz,  1  
H, SCH), 3.83 (br d, J = 7.0 Hz, 1  H, NCH), 3.56-3.60 (m, 2 H, OCH2CH2N), 3.13 (ddt, 
J  =  12.1,  5.8,  4.5  Hz,  1   H,  OCH2CHHN),  3.00  (ddt,  J  =  11.7,  5.8,  4.5  Hz,  1   H, 
OCH2CHHN), 2.66 (s, 3 H, NCH3), 0.87 (s, 9 H, C(CH3)3), 0.04 (s, 6 H, Si(CH3)2); 5C  
(75 MHz, CDC13)  139.8 (s),  131.8 (d),  130.8  (d),  130.4 (d),  126.9  (d),  123.0 (s), 73.5 
(d), 67.0 (t), 62.1 (t), 45.5 (t), 42.9 (q), 25.9 (q), 18.3 (s), -5.4 (q), 1  x d not observed.
(3S*,  4S*)-3-(3-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  [2-(tert-butyl 
dimethylsilanyloxy)ethyl]amide  (130k),  and  (3/?*,  5S*)-3-(3-Chlorophenyl)-2- 
methylisoxazolidine-5-sulfonic  acid  [2-(teH-butyldimethylsilanyloxy)ethyl]amide 
(131k)
TBDMSO
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°x  / ° \x//
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General protocol was followed using 200 mg of 123g.  Crude residue was purified by 
flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  the  two 
products 130k (179 mg, 55%) and 131k (35 mg,  11%)- overall yield (66%, 130k:131k 
= 5:1).
Data for 131k: Rf0.46 (2:1 Et20/petroleum ether 40-60°C); 8H  (300 MHz, CDC13) 7.39 
(s, 1  H, ArH), 7.21-7.33 (m, 3 H, ArH), 5.01 (dd, J = 8.8, 2.9 Hz, 1 H, SCH), 4.79 (br t, 
J = 5.8 Hz, 1 H, NH), 4.04 (br dd, J = 10.0, 6.4 Hz, 1 H, NCH), 3.76 (t, J = 5.1 Hz, 2 H, 
OC//2CH2N),  3.26-3.39 (m,  2 H, OCH2C//2N), 3.07  (ddd, J =  13.9, 6.4, 2.9 Hz,  1   H, 
SCHC//H),  2.76  (ddd, J =  13.9,  10.0,  8.8  Hz,  1   H,  SCHCHH),  2.74 (s,  3  H, NCH3), 
0.90 (s, 9 H, C(CH3)3), 0.09 (s,  6 H, Si(CH3)2);  8C  (75 MHz, CDC13)  139.2 (s),  134.8 
(s),  130.1  (d),  128.6 (d),  127.6 (d),  125.8 (d),  88.8 (d), 70.1  (d), 62.3 (t), 45.9 (t), 44.5 
(qX 41.9 (t), 25.9 (q), 18.3 (s), -5.4 (q).
Data for 130k: Rf0.39 (2:1 Et20/petroleum ether 40-60°C); 8h (300 MHz, CDC13) 7.47 
(s, 1  H, ArH), 7.27-7.36 (m, 3 H, ArH), 4.86 (app. t, J = 5.9 Hz,  1  H, NH), 4.35 (dd, J =
9.9, 4.0 Hz,  1 H, SCHCHH), 4.29 (dd, /=  9.9, 7.8 Hz,  1  H, SCHCHH), 3.99 (app. td, J 
=  7.5,  4.0  Hz,  1  H,  SCH),  3.83  (br d, J =  7.0  Hz,  1   H,  NCH),  3.50-3.61  (m,  2  H, 
OCH2CH2N), 3.12 (ddt, J =  12.2, 5.9, 4.8 Hz,  1   H, OCH2CHHN), 2.98 (ddt, J =  11.7,
5.9, 4.5 Hz,  1 H, OCH2CHHN),4 2.64 (s, 3 H, NCH3), 0.86 (s, 9 H, C(CH3)3), 0.03 (s, 6
2 1 2H, Si(C//3)2);  8c (75 MHz, CDC13)  139.6 (s),  134.8 (s),  130.2 (d),  128.8 (d),  128.0 (d),
126.5  (d), 73.5 (d), 73.4 (d), 67.0 (t), 62.1  (t), 45.5 (t), 42.9 (q), 25.9 (q),  18.3 (s), -5.4
(q).
(35*,  45*)-3-(5-Bromofuran-2-yl)-2-methylisoxazolidine-4-sulfonic  acid  [2-(tert- 
butyIdimethylsilanyloxy)ethyl]amide (1301)
General protocol was followed using 200 mg of 123g.  Crude residue was purified by 
flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  1301  as  a 
brown oil (41 mg, 12%).
Data for 1301: Rf0.31  (2:1 Et20/petroleum ether 40-60°C);  8h (300 MHz, CDCI3) 6.41
(35*,  45*)-3-Furan-2-yl-2-methylisoxazolidine-4-sulfonic  acid  [2-(ter/-butyl 
dimethylsilanyloxy)ethyl]amide  (130m),  (3R*9   55*)-3-Furan-2-yl-2-methyl
isoxazolidine-5-sulfonic  acid  [2-(ter/-butyldimethylsilanyloxy)ethyl]amide  (131m), 
and  (35*,  55*)-3-Furan-2-yl-2-methylisoxazolidine-5-sulfonic  acid  [2-(ter/-butyI 
dimethylsilanyloxy)ethyl]amide (1317132m)
General protocol  was followed using 200 mg of 123g.  Crude residue was purified by 
flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  three 
separable products 130m (99 mg, 34%), 131m (71 mg, 24%), and 132m (38 mg, 13%)- 
overall yield (71%, 130m: 131m: 132m = 5:4:2).
TBDMSO
ox  o
(d, J = 3.2 Hz, 1 H, BrCCH), 6.30 (d, J = 3.2 Hz, 1 H, BrCCHC//), 4.68 (br s, 1  H, NH),
4.29-4.38  (m,  3  H,  SCHCH2  and  SC//),  3.90  (br  s,  1   H,  NCH),  3.56-3.68  (m,  2  H, 
OC//2CH2N), 3.18 (ddt, J =  12.9, 5.9, 4.3 Hz,  1   H, OCH2C/7HN), 3.07 (ddt, J =  12.2,
5.9,  4.3 Hz,  1 H, OCH2CH//N), 2.71 (br s, 3 H, NCH3), 0.88 (s, 9 H, C(C//3)3), 0.05 (s, 
6 H, Si(CZ/3)2); 8C  (75 MHz, CDC13)  150.6 (s),  123.8 (s),  112.9 (d),  112.5 (d), 69.1 (d),
67.9  (d), 66.8 (t), 62.1 (t), 45.5 (t), 42.8 (q), 25.9 (q), 18.3 (s), -5.4 (q).
TBDMSO
TBDMSO TBDMSO
130m 132m
213Data for 132m: Rf0.38 (2:1 Et20/petroleum ether 40-60°C); 5h (300 MHz, CDCI3) 7.40 
(dd, J = 1.9, 0.8 Hz, 1 H, OC//CHCH), 6.38 (d, J = 3.2 Hz,  1  H, OCHCHCH), 6.35 (dd, 
J = 3.2,  1.9 Hz,  1  H, OCHC//CH), 5.07 (dd, J = 8 .6 , 5.7 Hz,  1  H, SC/7), 4.87 (app. t, J 
= 5.8 Hz, 1  H, NH), 3.74 (t, /  = 5.1 Hz, 2 H, OC//2CH2N), 3.69 (br dd, J = 10.0, 7.6 Hz, 
1   H, NC//), 3.37 (app. q, /  = 5.5 Hz, 2 H, OCH2C//2N), 3.13 (ddd, J =  13.7,  10.0, 5.7 
Hz,  1   H, SCHC/m),  2.96 (ddd, J =  13.7,  8 .6 ,  7.6 Hz,  1  H,  SCHCH//),  2.71  (s,  3 H, 
NC//3), 0.88 (s, 9 H, C(C//3)3), 0.06 (s, 6 H, Si(CH3)2);  6C  (75 MHz, CDC13)  148.6 (s),
143.2  (d),  110.6 (d),  109.3  (d),  89.2 (d),  66.2 (d),  62.6  (t), 46.0 (t), 43.6 (q), 36.8  (t),
25.9 (q), 18.3 (s), -5.4 (q).
Data for 131m: Rf0.33 (2:1 Et20/petroleum ether 40-60°C); 6H  (300 MHz, CDC13) 7.40 
(dd, J =  1.6, 0.8 Hz,  1  H, OCZ/CHCH), 6.34 (dd, J = 3.2,  1.6 Hz,  1   H, OCHC//CH),
6.31  (d, J = 3.2 Hz,  1 H, OCCZ/CH), 5.06 (br dd, J = 8.5, 5.8 Hz,  1 H, SCH), 4.82 (br t, 
J = 5.5 Hz, 1  H, N/f), 4.15 (app. br s, 1 H, NC//), 3.73 (t, J = 5.1 Hz, 2 H, OC//2CH2N), 
3.24-3.37 (m, 2 H, OCH2C//2N), 2.93-3.12 (m, 2 H, SCHC//2), 2.81  (br s, 3 H, NC//3), 
0.89 (s, 9 H, C(C//3)3), 0.07  (s,  6 H, Si(CH3)2); 5C (75 MHz, CDC13)  149.1  (s),  143.1 
(d),  110.4 (d),  109.2 (d), 89.1  (d), 67.4 (d), 62.3 (t), 45.9 (t), 44.9 (q), 36.8 (t), 25.9 (q),
18.3  (s), -5.4 (q).
Data for 130m: Rf0.28 (2:1 Et20/petroleum ether 40-60°C); 8h (300 MHz, CDCI3) 7.42 
(dd, J - 1.8, 0.8 Hz, 1 H, OCZ/CHCH), 6.41 (d, J = 3.2 Hz,  1 H, OCHCHC//), 6.36 (dd, 
J = 3.2,  1.8 Hz,  1 H, OCHCZ/CH), 4.78 (br t, J = 5.8 Hz,  1 H, N//), 4.30-4.37 (m, 3 H, 
SCHC/ / 2 and SC//), 3.92 (app. br s,  1  H, NC//), 3.49-3.63 (m, 2 H, OC//2CH2N), 3.11 
(ddt, J =  12.3, 6.3, 4.4 Hz,  1  H, OCH2C//HN), 2.90-2.99 (m,  1  H, OCH2CH//N), 2.69 
(br s, 3 H, NC//3), 0.86 (s, 9 H, C(CH3h), 0.03 (s, 6 H, Si(C//3)2); 5C  (75 MHz, CDC13)
148.5  (s),  143.4 (d),  110.8 (d),  110.1  (d), 69.0 (d), 66.7 (t), 62.1  (t), 45.3 (t), 43.9 (q),
25.9 (q), 18.3 (s), -5.4 (q).
(3S*, 4S*)-3-(4-Allyloxyphenyl)-2-methylisoxazolidine-4-sulfonic acid [2-(ter/-butyI 
dimethylsilanyloxy)ethyl]amide  (130n),  (3R*,  55*)  and  (35*,  55*)-3-(4-Allyloxy 
phenyl)-2-methylisoxazolidine-5-sulfonic  acid  [2-(ter/-butyldimethyIsilanyIoxy) 
ethyljamide (131/132n)
TBDMSO
TBDMSO
130n 131/132n
214General protocol was followed using 200 mg of 123g.  Crude residue was purified by 
flash chromatography (starting 5:1 petroleum ether 40-60°C/Et20) to give 131/132n (90 
mg, 26%) as a mixture, and 130n (109 mg, 32%) as a yellow oil- overall yield (58%, 
130n:131/132n = 6:5,131n and 132n = 3:2 majonminor).
Data for 131/132n: Rf0.40 (2:1  Et20/petroleum ether 40-60°C);  8h (300 MHz, CDCI3)
7.32  (d, J = 8 .8 Hz, 2 Hmaj0r, Ar//), 7.07 (d, J = 8 .8 Hz, 2 Hmin0r, Ar//), 6.87-6.91  (m, 2
H, Ar//), 5.97-6.11 (m, 1  H, C//=CH2), 5.40 (app. dq, J = 17.4, 1.6 Hz, 1 H, CH=C//H),
5.28  (app. dq, 7 =  10.4,  1.6 Hz,  1 H, CH=CH//), 5.01-5.07 (m,  1   H, SC/7), 4.90 (app. t, 
J = 5.9 Hz,  1  H min0r,  N/7), 4.82 (app. t, 7 = 5.9 Hz,  1  H major,  N//), 4.50-4.55  (m, 2 H, 
OC//2CH=), 4.39 (dd, 7 = 9.9, 7.8 Hz,  1  H minor,  NC/7), 4.00 (br dd, 7 = 9.9, 4.0 Hz,  1  
Hmajor,  NCH),  3.76  (app.  q,  7  =  5.4  Hz,  2  H ,  OCH2C//2N),  3.28-3.44  (m,  2  H, 
OC//2CH2N),  2.74-3.06  (m,  2  H,  SCHC//2),  2.70  (br  s,  3  H min0r,  NC//3),  2.57  (s,  3 
Hmajor,  NC//3),  0.90 (s,  9 H,  C(C//3)3),  0.08  (s,  6 H,  Si(C//3)2);  8C   (75  MHz, CDC13) 
158.8 (s), 158.7 (s), 133.2 (d), 133.1 (d), 131.9 (d), 128.8 (d), 128.7 (d), 128.3 (s),  117.8 
(t),  115.1  (d),  115.0 (d),  88.8 (d), 88.7 (d), 74.6 (d), 68.8 (t), 62.6 (t), 62.3 (t), 45.9 (t),
43.1  (q), 42.8  (q), 40.9 (t), 40.6 (t), 25.9 (q),  18.3  (s),  -5.4 (q),  25  out of 32 expected 
signals observed.
Data for 130n: Rf0.29 (2:1 Et20/petroleum ether 40-60°C);  8h (300 MHz, CDCI3) 7.34 
(d, 7 = 8 .8 Hz, 2 H, Ar//), 6.90 (d, 7 = 8 .8 Hz, 2 Hf Ar//), 6.03 (ddt, 7 = 17.4, 10.7, 5.3 
Hz,  1 H C//=CH2), 5.40 (app. dq, 7 =  17.4,  1.6 Hz,  1 H, CH=C//H), 5.28 (app. dq, 7 =
10.7,  1.6 Hz,  1 H, CH=CHZ/), 4.68 (app. t, 7 = 5.9 Hz,  1 H, N/7), 4.52 (app. dt, 7 = 5.3,
I.6 Hz, 2 H, OC//2CH=), 4.29-4.38 (m, 2 H, SCHC//2), 4.01 (app. td, 7 = 7.8, 4.6 Hz,  1  
H, SCH), 3.76 (br d, 7 = 7.0 Hz, 1  H, NC//), 3.43-3.57 (m, 2 H, OC//2CH2N), 3.07 (ddt, 
7  =  12.6,  5.9,  4.3  Hz,  1   H,  OCH2C//HN),  2.87  (ddt,  7  =  12.1,  5.9,  4.3  Hz,  1   H, 
OCH2CH//N), 2.61  (s, 3 H, NC//3), 0.85 (s, 9 H, C(C//3)3), 0.02 (s, 6 H, Si(C//3)2); 6C  
(75 MHz, CDCI3) 158.9 (s), 133.0 (d), 129.3 (d), 128.8 (s),  117.8 (t),  115.1 (d), 74.1 (d),
73.0  (d), 68.8 (t), 66.8 (t), 62.1 (t), 45.3 (t), 42.6 (q), 25.9 (q), 18.3 (s), -5.4 (q).
215(3S*,  4S*)-3-Cyclopropyl-2-methylisoxazolidine-4-sulfonic  acid  [2-(ter/-butyl 
dimethylsilanyloxy)ethyI]amide  (130o),  (3R*,  55*)-3-CyclopropyI-2-methyl
isoxazolidine-5-sulfonic  acid  [2-(ter/-butyldimethylsilanyloxy)ethyl]amide  (131o), 
and  (3S*,  5S*)-3-Cyclopropyl-2-methylisoxazolidine-5-sulfonic  acid  [2-(tert-butyl 
dimethylsilanyloxy)ethyl]amide (132o)
General protocol was followed using 200 mg of 123g.  Crude residue was purified by 
flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20)  to  give  the  three 
separable products  130o  (37 mg,  14%),  131o (80 mg, 29%), and 132o (57 mg, 21%)- 
overall yield (64%, 130o:131o:132o = 6:13:9).
Data for 132o: Rf0.26 (2:1 Et20/petroleum ether 40-60°C); 6H  (300 MHz, CDC13) 4.89 
(dd, J = 8.4, 6.0 Hz,  1   H, SC//), 4.80 (br t, J = 5.8 Hz,  1   H, N//), 3.73 (t, 7 = 5.1 Hz, 2 
H,  OC//2CH2N),  3.33  (app.  q,  7  =  5.4  Hz,  2  H,  OCH2C//2N),  2.63-2.82  (m,  5  H, 
SCHC//2 and NC/73),  1.84 (br dd, 7= 16.6, 8.6 Hz,  1  H, NCH), 0.89 (s, 9 H, C(C//3)3), 
0.82-0.89 (m,  1  H, CH2C//CH2), 0.51-0.63  (m,  2 H, C//2CHCH2), 0.16-0.28  (m,  2 H, 
CH2CHCH2), 0.07 (s, 6 H, Si(CH3)2); 6C  (75 MHz, CDC13) 88.5  (d), 74.0 (d), 62.5 (t),
45.9 (t), 44.2 (q), 38.0 (t), 25.9 (q), 18.3 (s), 11.2 (d), 4.2 (t), 0.9 (t), -5.4 (q).
Data for 131o: Rf0.17 (2:1 Et20/petroleum ether 40-60°C); 6H  (300 MHz, CDC13) 4.88 
(app. br d, 7 = 7.2 Hz, 1  H, SC//), 4.76 (br t, 7 = 5.5 Hz, 1 H, N//), 3.71 (t, 7 = 5.2 Hz, 2 
H,  OC//2CH2N),  3.19-3.33  (m,  2  H,  OCH2C//2N),  2.78-2.86  (m,  4  H,  NC/ / 3  and 
SCHC//H),  2.57-2.67  (m,  1   H,  SCHCH//),  2.23-2.32  (m,  1  H,  NC/7),  0.88  (s,  9  H, 
C(C//3)3), 0.67-0.79 (m,  1  H, CH2C//CH2), 0.50-0.62 (m, 2 H, CH2CHCH2), 0.19-0.30 
(m, 2 H, CH2CHCH2), 0.05 (s, 6 H, Si(CH3)2); 6C  (75 MHz, CDC13) 88.5 (d), 71.6 (d),
62.3  (t), 45.8 (t), 45.2 (q), 38.6 (t), 25.9 (q), 18.2 (s), 11.5 (d), 4.0 (t), 1.2 (t), -5.4 (q). 
Data for 130o: Rf0.13 (2:1 Et2 0/petroleum ether 40-60°C); 5h (300 MHz, CDC13) 4.70 
(br t, J = 5.8 Hz,  1  H, N/7), 4.21 (dd, J = 9.9, 4.2 Hz,  1  H, SCHC//H), 4.13 (dd, J = 9.9,
8.0  Hz,  1   H,  SCHCH//),  3.90-3.94  (m,  1   H,  SC//),  3.73  (t,  J  =  5.1  Hz,  2  H, 
OC//2CH2N), 3.25  (app. q, J = 5.6 Hz, 2 H, OCH2C//2N), 2.79 (s, 3 H, NC//3), 2.34- 
2.41 (m,  1 H, NC//), 0.89-1.01 (m, 1  H, CH2C//CH2), 0.89 (s, 9 H, C(C//3)3), 0.54-0.68 
(m,  3  H,  CH(CH2)2),  0.33-0.40  (m,  1  H, CH(C/72)2),  0.06  (s,  6  H,  Si(C//3)2);  6C   (75 
MHz, CDC13) 74.1  (d), 71.7 (d), 66.7 (t), 62.3 (t), 45.7 (t), 44.5  (q), 25.9 (q),  18.3  (s),
13.9 (d), 4.8 (t), 2.0 (t), -5.4 (q).
TBDMSO
TBDMSO TBDMSO
130O
2164.6. Procedures for TBAF deprotection of 130a-n
General protocol187
A solution of 130a-n (1  eq.) in THF (5 mL) was treated with TBAF (1  M solution in 
THF,  1.5 eq.) while stirring at 0 °C. The suspension was allowed to stir for a further 15 
minutes and then diluted with DCM (25 mL). The organic layer was washed with sat. 
aq. NH4CI (10 mL), brine (10 mL), dried over MgSCL and concentrated in vacuo. The 
crude  residue  was  purified  by  flash  chromatography  to  give  products  133a-n  as 
appropriate.
(35*,  45*)-3-(4-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  (2-hydroxy 
ethyl)amide (133a)
HO
Br
General protocol was followed using 210 mg of 130a. The crude residue was purified 
by flash  chromatography  (starting  2:1  petroleum ether 40-60°C/EtOAc)  to give  133a 
(138 mg, 86%) as a yellow solid.
Rf 0.24  (4:1  EtOAc/petroleum  ether  40-60°C);  mp  66-68  °C;  a)m ax  (neatycm'1   3457, 
3220, 2878,  1488,  1456,  1320,  1274,  1142,  1101,  1040, 947,  836, 751;  SH  (300 MHz, 
CDCI3) 7.49 (d, J = 8.4 Hz, 2 H, Ar//), 7.34 (d, J = 8.4 Hz, 2 H, Ar//), 5.73 (br t, J = 6.0 
Hz,  1 H, N//), 4.34 (dd, J = 10.0, 4.0 Hz,  1 H, SCHC//H), 4.29 (dd, J = 10.0, 7.6 Hz,  1  
H, SCHCH//), 4.00 (app. td, J = 7.2, 4.0 Hz,  1   H, SCH), 3.80 (br d, J = 6.0 Hz,  1   H, 
NC//), 3.51-3.62 (m, 2 H, OC//2CH2N), 2.95-3.17 (m, 3 H, OCH2C//2N and OH), 2.61 
(s, 3 H, NC//3); 5C (75 MHz, CDC13)  136.1 (s),  132.1  (d),  129.9 (d),  122.8 (s), 73.5 (d),
73.2  (d), 67.0 (t), 61.6 (t), 45.5 (t), 42.7 (q); m/z (El) 366 (M+, 8lBr, 12), 364 (M+, 79Br,
12), 240 (100),  160 (82),  116 (87),  102 (20); HRMS  (El): calcd for C12H,779BrN204S 
(M+) 364.0092, found 364.0080.
(35*,  45*)-3-(2-Chlorophenyl)-2-methylisoxazoIidine-4-suIfonic  acid  (2-hydroxy 
ethyl)amide (133b)
\y/ HO
217General protocol was followed using  134 mg of 130b. The crude residue was purified 
by flash chromatography (starting 99:1 CHCl3/MeOH) to give 133b (90 mg, 91%) as a 
light brown oil.
Rf0.28 (9:1 CHCh/MeOH); um ax (neat)/cm'‘ 3476, 3309, 2879,  1478,  1438,  1314, 1135, 
1038, 939, 749; 8h (300 MHz, CDC13) 7.53 (dd, J = 7.6,  1.6 Hz,  1 H, ArH), 7.41  (dd, J 
= 7.4,  1.9 Hz,  1   H, ArH), 7.24-7.35  (m, 2 H,  Ar//), 5.31  (br t, J = 6.0 Hz,  1  H, NH), 
4.39-4.48 (m, 3 H, NCH and SCHCH2), 4.18 (app. td, J = 7.0, 5.5 Hz,  1  H, SC//), 3.43- 
3.55 (m, 2 H, OC//2CH2N), 3.12 (ddt, J =  12.1, 6.0, 4.3 Hz,  1  H, OCH2C//HN), 2.89-
2.99  (m,  1   H, OCH2CH//N), 2.62 (s, 3 H, NC//3), 2.53  (br s,  1  H, O//);  5c (75 MHz, 
CDC13) 134.4 (s), 134.1 (s), 130.1  (d),  130.0 (d),  129.9 (d),  127.7 (d), 72.6 (d), 70.1 (d),
67.2  (t), 61.7 (t), 45.5  (t), 42.6 (q); m/z (El) 322 (M+, 37C1, 6), 320 (M+, 35C1,  16),  194 
(100),  151  (25),  134  (30);  HRMS  (El):  calcd  for  C12H,735C1N2C > 4S  (M+)  320.0598, 
found 320.0598.
(3S*,  4S*)-2-Methyl-3-phenylisoxazolidine-4-sulfonic  acid  (2-hydroxyethyl)amide 
(133c)
\y/ HO
General protocol was followed using  122 mg of 130c. The crude residue was purified 
by flash  chromatography  (starting 4:1  petroleum ether 40-60°C/EtOAc)  to  give  133c 
(79 mg, 92%) as a brown oil.
Rf0.15 (2:1 EtOAc/petroleum ether 40-60°C); Dm ax (neat)/cm_1 3480, 3279, 2921,  1456, 
1311,  1144, 1039, 934, 887; 8h (300 MHz, CDC13) 7.33-7.47 (m, 5 H, Ar//), 5.53 (t, /  =
6.2  Hz, 1 H, NH), 4.38 (dd, J= 9.9, 4.3 Hz, 1  H, SCHC//H), 4.43 (dd, /=  9.9, 7.8 Hz, 1  
H, SCHCH//), 4.08  (app. td, J = 7.4, 4.3 Hz,  1   H, SC//), 3.82 (br d, J = 6.4 Hz,  1   H, 
NC//),  3.43-3.56  (m,  2  H,  OC//2CH2N),  3.08  (ddt,  J  =  12.6,  6.2,  3.9  Hz,  1   H, 
OCH2C//HN),  2.84-2.96  (m,  1  H,  OCH2CH//N),  2.69  (br s,  1   H,  OH),  2.62  (s,  3  H, 
NC//3);  5c (75 MHz, CDC13)  136.8  (s),  129.0 (d),  128.8  (d),  128.3  (d), 74.4 (d), 73.1 
(d),  67.0  (t),  61.6  (t),  45.4  (t), 42.7  (q);  m/z (El)  286  (M+,  11),  160  (100),  117  (48); 
HRMS (El): calcd for Ci2Hi8N20 4S (M+) 286.0987, found 286.0981.
218(3S*,  4S*)-3-(2-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  (2-hydroxy
ethyl)-amide (133d)
V HO
Br
General protocol was followed using  100 mg of 130d. The crude residue was purified 
by flash chromatography (starting 99:1  CHCls/MeOH) to give 133d (65 mg, 85%) as a 
light brown solid.
Rf 0.26  (9:1  CHCh/MeOH);  mp 98-100 °C;  t w   (neat)/cin 1 3403,  3308,  2876,  1473, 
1431, 1301, 1132,  1038, 938, 826,748; SH  (300 MHz, CDC13) 7.60 (dd, J = 8.0, 1.3 Hz, 
1   H, Ar//), 7.53 (d, J = 7.8 Hz,  1   H, Ar//), 7.38 (app.  dt, J = 7.5,  1.3 Hz,  1  H, Ar//),
7.21  (ddd, J = 8.0, 7.5, 1.8 Hz, 1  H, Ar//), 5.16 (br t, J = 6.1 Hz,  1  H, N//), 4.50 (br d, J 
= 5.6 Hz,  1   H, NC//), 4.37-4.46 (m, 2 H, SCHC//2), 4.15 (app. td, J = 7.2, 5.2 Hz, 1  H, 
SCH),  3.42-3.55  (m,  2  H,  OC/72CH2N),  3.12  (ddt,  J  =  12.2,  6.1,  4.2  Hz,  1   H, 
OCH2C//HN), 2.87-2.97 (m,  1   H, OCH2CH//N), 2.64 (s, 3 H, NC//3), 2.28 (br s,  1   H, 
0/7); 8C  (75 MHz, CDC13) 135.8 (s), 133.3 (d),  130.3 (d),  130.1 (d), 128.4 (d), 124.8 (s),
72.9  (d), 72.3 (d), 67.2 (t), 61.7 (t), 45.4 (t), 42.5  (q); m/z (El) 366 (M+, 81Br,  12), 364 
(M+, 79Br,  12), 240 (94),  116 (100),  102 (18); HRMS (El):  calcd for Ci2H1779BrN20 4S 
(M+) 364.0092, found 364.0100.
(3S*,  4S*)-3-(2-Fluorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  (2-hydroxy 
ethyl)amide (133e)
HO
General protocol was followed using  108 mg of 130e. The crude residue was purified 
by flash chromatography (starting 99:1  CHCls/MeOH) to give 133e (62 mg, 78%) as a 
yellow solid.
Rf 0.36 (9:1  CHCIj/MeOH); mp  108-111  °C; om ax (neat)/cm'‘ 3247, 2975, 2891,  1586, 
1446, 1317,  1233, 1143,  1038,934, 893, 773; 8„ (300 MHz, CDCI3) 7.46 (t, J = 7.3 Hz, 
1   H, Ar//),  7.29-7.37  (m,  1   H, Ar//), 7.18  (app. dt, J = 7.4,  1.1  Hz,  1   H, Ar/7), 7.09 
(ddd, J = 10.4, 8.2,  1.1  Hz,  1  H, Ar//), 5.59 (br t, /=  5.8 Hz,  1  H, N//), 4.32-4.42 (m, 2 
H, SCHC//2), 4.21  (app.  td, J = 7.0, 4.8 Hz,  1   H, SC//), 4.11  (br s,  1   H, NC//), 3.46- 
3.58  (m,  2  H,  OC//2CH2N),  3.08-3.18  (m,  1   H,  OCH2C//HN),  2.95-3.05  (m,  1   H,
219OCH2CH//N), 2.70 (br s,  1  H, OH), 2.62 (s, 3 H, NC//3); 5C  (75 MHz, CDC13) 160.9 (s, 
7 cf = 248.3 Hz),  130.6 (d, Jcf =  8.8 Hz),  130.0 (d, Jcf = 3.8 Hz),  124.9 (d, Jcf = 3.8 
Hz),  123.5 (s, Jcf = 11.7 Hz),  116.1  (d, Jcf = 22.0 Hz), 71.9 (d), 68.1  (d), 67.1  (t), 61.7 
(t), 45.5  (t), 42.8  (q);  m/z (El)  304  (M+,  8),  228  (20),  178  (100),  135  (39),  109  (27); 
HRMS (El): calcd for C12H17FN2O4S (M+) 304.0893, found 304.0886.
(3S*,  4S*)-3-(4-Methoxyphenyl)-2-methylisoxazolidine-4-sulfonic  acid  (2-hydroxy 
ethyl)amide (133f)
\y/
HO
MeO
General protocol was followed using 138 mg of 130f. The crude residue was purified by 
flash chromatography  (starting 4:1  petroleum ether 40-60°C/EtOAc)  to  give  133f (84 
mg, 83%) as a yellow solid.
Rf0.18  (4:1  EtOAc/petroleum ether 40-60°C); mp  105-108  °C; Umax  (neatVcm1  3503, 
3152, 2966, 1613, 1516, 1456, 1319, 1253, 1148, 1040, 839; 8h (300 MHz, CDC13) 7.36 
(d, J = 8.8 Hz, 2 H, Ar//), 6.89 (d, J = 8.8 Hz, 2 H, Ar//), 5.50 (br t, J = 6.0 Hz,  1  H, 
NH),  4.36  (dd,  J  =  9.9,  4.3  Hz,  1   H,  SCHC//H),  4.31  (dd,  J  =  9.9,  7.4  Hz,  1   H, 
SCHCH//), 4.04  (app.  td, J = 7.4, 4.3  Hz,  1   H, SC//),  3.75-3.81  (m, 4 H,  OC/ / 3  and 
NC//),  3.45-3.58  (m,  2 H,  OC//2CH2N),  3.03-3.13  (m,  1  H,  OCH2C//HN),  2.87-2.97 
(m, 1 H, OCH2CH/7N), 2.69 (br s, 1  H, OH), 2.60 (s, 3 H, NC773); 6C  (75 MHz, CDC13)
159.9  (s),  129.4 (d),  128.4 (s),  114.4 (d), 74.0 (d), 72.9 (d), 66.9 (t), 61.6 (t), 55.3  (q),
45.4  (t), 42.6 (q); m/z (El)  316 (M+,  39),  190 (100),  165  (53),  147  (47);  HRMS  (El): 
calcd for C13H20N2O5S (M+) 316.1093, found 316.1098.
(3S*,  4S*)-2-Methyl-3-(4-nitrophenyl)isoxazolidine-4-sulfonic  acid  (2-hydroxy 
ethyl)amide (133g)
\y/
HO
General protocol was followed using  175 mg of 130g. The crude residue was purified 
by flash chromatography (starting 99:1 CHCl3/MeOH) to give 133g (41  mg, 50%) as a 
yellow solid.
2 2 0Rf 0.26 (9:1  CHCb/MeOH); mp  122-125  °C; Um ax (neat)/cm'‘ 3497, 2926,  1597,  1508, 
1403,  1349,  1307,  1270,  1071, 959;  8h (300 MHz, CD3OD) 8.24 (d, J = 8.8 Hz, 2 H, 
ArH), 7.75 (d, J = 8.8 Hz, 2 H, ArH), 4.23-4.36 (m, 3 H, SCHCW2 and SCH), 4.03 (br d, 
J =  6.4  Hz,  1   H,  NC//),  3.47  (t, J = 5.9  Hz,  2  H,  OC//2CH2N),  2.92-3.13  (m,  2  H, 
OCH2C//2N), 2.63 (s, 3 H, NC//3); 5c (75 MHz, CD3OD) 149.4 (s),  146.9 (s), 130.7 (d),
124.7  (d), 74.5 (d), 74.3 (d), 68.4 (t), 62.3 (t), 46.3 (t), 43.2 (q); m/z (El) 331  (M+,  10), 
205 (100); HRMS (El): calcd for Ci2HnN30 6S (M+) 331.0838, found 331.0829.
(35*,  45*)-3-(4-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic  acid  (2-hydroxy 
ethyl)amide (133h)
\V /
HO
General protocol was followed using  179 mg of 130h. The crude residue was purified 
by flash chromatography (starting 99:1 CHCl3/MeOH) to give 133h (112 mg, 85%) as a 
light yellow solid.
Rf 0.38  (9:1  CHCl3/MeOH);  mp 97-100 °C;  t)m ax  (neat)/cm‘1  3453,  3231,  2874,  1486, 
1433, 1306, 1134,  1039, 935, 841, 816; 5h (300 MHz, CDC13) 7.41 (d, J = 8.6 Hz, 2 H, 
Ar//), 7.33 (d, J = 8.6 Hz, 2 H, Ar//), 5.74 (br s,  1 H, N//), 4.35 (dd, J = 10.0, 4.0 Hz, 1  
H, SCHC//H), 4.29 (dd, J =  10.0, 7.8 Hz,  1   H, SCHCH//), 4.00 (app. td, J = 7.8, 4.0 
Hz,  1  H, SCH), 3.82  (br d, J = 6.6 Hz,  1  H, NC//), 3.50-3.62  (m, 2 H, OC//2CH2N), 
2.96-3.16  (m,  3  H,  OH and OCH2C//2N), 2.61  (s,  3  H, NCZ/3);  Sc (75  MHz, CDC13)
135.6  (s),  134.6 (s),  129.6 (d),  129.2 (d), 73.4 (d), 73.3  (d), 67.0 (t), 61.6 (t), 45.5  (t),
42.7  (q); m/z (El) 322 (M+, 37C1, 7), 320 (M+, 35C1,  17),  194 (100); HRMS (El): calcd 
forC12Hn35ClN20 4S (M+) 320.0598, found 320.0593.
(35*,  45*)-2-Methyl-3-naphthalen-2-yl-isoxazolidine-4-suIfonic  acid  (2-hydroxy 
ethyl)amide (133i)
\y/ HO
2 2 1General protocol was followed using 181 mg of 130i. The crude residue was purified by 
flash chromatography  (starting 99:1  CHCls/MeOH)  to  give  133i  (130 mg,  97%)  as  a 
light brown oil.
RfO.33 (9:1 CHCl3/MeOH); t w  (neat)/cm‘ 3457, 3284,2923,  1509, 1435,  1314,  1144, 
1040, 955; 8H  (300 MHz, CDC13) 7.93 (s, 1  H, ArH), 7.81-7.87 (m, 3 H, Ar//). 7.57 (dd, 
J = 8.6,  1.5 Hz,  1  H, Ar//), 7.49 (app. dt, J = 9.5, 3.6 Hz, 2 H, Ar//), 5.69 (br t, J = 5.8 
Hz,  1  H, N//), 4.43 (dd, J = 10.0,4.0 Hz,  1  H, SCHC//H), 4.38 (dd, J = 10.0, 7.6 Hz,  1  
H, SCHCH//), 4.17 (app. td, J = 7.6, 4.0 Hz,  1   H, SCH), 4.02 (br d, J = 6.6 Hz,  1   H, 
NCH), 3.36-3.49 (m, 2 H, OC//2CH2N), 2.82-3.08 (m, 3 H, OCH2C//2N and OH), 2.65 
(s, 3 H, NCH3); 5c (75 MHz, CDC13)  134.2 (s),  133.4 (s),  133.2 (s),  128.9 (d),  128.0 (2 
x d),  127.8  (d),  126.6 (2 x d),  125.1  (d), 74.5  (d), 73.1  (d), 67.1  (t), 61.5  (t), 45.4 (t),
42.8  (q);  m/z  (El)  336  (M+,  24),  210  (100),  184  (23),  167  (58),  152  (33),  127  (20); 
HRMS (El): calcd for Ci6H2oN20 4S (M+) 336.1144, found 336.1138.
(3S*,  4S*)-3-(3-Bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  (2-hydroxy 
ethyl)amide (133j)
\y/
HO
Br
General protocol was followed using 198 mg of 130j. The crude residue was purified by 
flash  chromatography  (starting 99:1  CHCh/MeOH)  to give  133j  (123  mg,  82%)  as  a 
light brown oil.
Rf0.51 (4:1  CHCl3/MeOH); vm ax (neat)/cm'‘ 3468, 3279, 2924, 1475, 1430, 1317, 1144, 
1039, 936,  882,  787;  SH   (300  MHz,  CDC13)  7.63  (s,  1  H,  Ar//),  7.43-7.48  (m,  1   H, 
Ar//), 7.40 (d, J = 7.8 Hz,  1  H, Ar/7), 7.24 (app. t, J = 7.8 Hz, 1 H, Ar//), 5.67 (br t, J =
5.9  Hz,  1   H, N//), 4.35 (dd, J =  10.0, 4.0 Hz,  1  H, SCHC//H), 4.30 (dd, J =  10.0, 7.5 
Hz,  1  H, SCHCH//), 4.02 (app. td, J = 7.5, 4.0 Hz,  1  H, SCH), 3.82 (br d, J = 6.4 Hz, 1  
H, NCH), 3.52-3.64 (m, 2 H, OC//2CH2N), 3.10-3.20 (m, 1  H, OCH2C//HN), 2.97-3.07 
(m, 1  H, OCH2CH//N), 2.92 (br s,  1  H, OH), 2.63 (s, 3 H, NC//3); 5c (75 MHz, CDC13)
139.6  (s),  131.9 (d),  131.0 (d), 130.5 (d), 127.0 (d),  122.9 (s), 73.3 (d), 67.1 (t), 61.7 (t),
45.5  (t), 42.8 (q)  1   x d not observed; m/z (El) 366 (M+, 81Br, 5), 364 (M+, 79Br, 5), 240 
(32), 120 (70); HRMS (El): calcd for C12Hi779BrN20 4S (M+) 364.0092, found 364.0083.
2 2 2(3S*,  4S*)-3-(3-Chlorophenyl)-2-methylisoxazolidine-4-sulfoiiic  acid  (2-hydroxy
ethyl)amide (133k)
V HO
C l
General protocol was followed using  159 mg of 130k. The crude residue was purified 
by flash chromatography  (starting 2:1  petroleum ether 40-60°C/EtOAc)  to  give  133k 
(83 mg, 70%) as a brown oil.
Rf0.28 (4:1 EtOAc/petroleum ether 40-60°C); a)m ax (neatVcm' 1 3480, 3283, 2877, 1575, 
1433, 1318, 1144,  1040, 935, 882, 788; 8h (300 MHz, CDC13) 7.48 (s, 1 H, Ar//), 7.29- 
7.37 (m, 3 H, Ar//), 5.69 (app. t, J = 5.9 Hz,  1   H, N//), 4.36 (dd, J = 9.8, 4.0 Hz,  1  H, 
SCH  C/m), 4.30 (dd, J = 9.8, 7.7 Hz,  1  H, SCHCH//), 4.02 (app. td, J = 7.7, 4.0 Hz,  1  
H, SCH), 3.83 (br d, /  = 6.7 Hz,  1 H, NC//), 3.52-3.65 (m, 2 H, OC//2CH2N), 3.15 (ddt, 
J =  11.9,  6.2,  4.0  Hz,  1   H,  OCH2C//HN),  3.03  (ddt,  J  =  11.9,  5.6,  4.0  Hz,  1   H, 
OCH2CH//N), 2.89 (br s,  1  H, OH), 2.63  (s, 3 H, NC//3);  6C  (75 MHz, CDC13)  139.3 
(s),  134.8 (s),  130.3 (d),  128.9 (d),  128.1 (d), 126.5 (d), 73.5 (d), 73.3 (d), 67.1 (t), 61.7 
(t), 45.5  (t), 42.8  (q);  m/z (El)  322 (M+,  37C1,  5),  320 (M+,  35C1,  13),  194 (100),  151 
(23); HRMS (El): calcd for Ci2H1735C1N20 4S (M+) 320.0598, found 320.0598.
(3S*, 4S*)-3-(5-Bromofuran-2-yl)-2-methylisoxazolidine-4-sulfonic acid (2-hydroxy 
ethyl)amide (1331)
\y/ HO
General protocol was followed using 29 mg of 1301. The crude residue was purified by 
flash  chromatography  (starting  99:1  CHCE/MeOH)  to  give  1331  (15  mg,  70%)  as  a 
brown oil.
Rf0.32 (9:1 CHCVMeOH); um ax (neat)/cm‘3489, 3281, 2924,  1503, 1457, 1316, 1148, 
1041, 955, 798; 5h (300 MHz, CDC1,) 6.43 (d, J = 3.3 Hz,  1  H, BrCCH), 6.31  (d, J = 
3.3 Hz, 1 H, OCCH), 5.19 (br t, J = 6.0 Hz, 1 H, NH), 4.31-4.38 (m, 3 H, SCHCft and 
NCfl),  3.90  (br  s,  1  H,  SCH),  3.60-3.72  (m,  2  H,  OC//2CH2N),  3.09-3.29  (m,  2  H, 
OCH2C7/2), 2.71  (s, 3 H, N C 2 . 1 2  (br s,  1  H, OH); 8c (75 MHz, CDCI3)  150.8 (s),
223123.9 (s), 112.9 (d), 112.6 (d), 69.2 (d), 67.2 (d), 66.9 (t), 61.7 (t), 45.5 (t), 42.7 (q); m/z
(El) 356 (M+,  81Br, 21), 354 (M+,  79Br, 21), 230 (100), 203 (33),  187 (28); HRMS (El):
calcd for CmH^BrNjOsS (M+) 353.9885, found 353.9889.
(3S*,  4S*)-3-Furan-2-yl-2-methylisoxazolidine-4-sulfonic  acid  (2-hydroxyethyI) 
amide (133m)
HO
General protocol was followed using 97 mg of 130m. The crude residue was purified by 
flash chromatography  (starting 99:1  CHCl3/MeOH)  to  give  133m  (48  mg,  69%)  as a 
brown oil.
Rf0.22 (9:1 CHCl3/MeOH); 0)m ax (neat)/cm_ 1  3459, 3281, 2878,  1505, 1437,  1318, 1145, 
1038, 950;  5H  (300 MHz, CDC13) 7.44 (d, /  =  1.9 Hz,  1  H, OC//CHCH), 6.46 (d, J =
3.2  Hz,  1  H, OCHCHCtf), 6.38 (dd, J = 3.2,  1.9 Hz,  1 H, OCHCtfCH), 5.53 (br s,  1  H, 
NH), 4.27-4.40 (m, 3 H, SCH and SCHCH2), 3.94 (br s,  1  H, NCH), 3.51-3.64 (m, 2 H, 
OCH2CH2N), 3.09-3.21 (m, 1 H, OCH2CHHN), 2.95-3.07 (m,  1 H, OCH2CH//N), 2.82 
(br s,  1  H, OH), 2.70 (s, 3 H, NCtf3); 8C  (75 MHz, CDC13)  148.4 (s),  143.5 (d),  110.9 
(d),  110.4 (d), 69.0 (d), 67.7 (d), 66.8 (t), 61.7 (t), 45.4 (t), 42.8 (q); m/z (El) 276 (M+,
13),  150 (100),  125 (24),  107 (37); HRMS (El): calcd for C10Hi6N2O5S (M+) 276.0780, 
found 276.0785.
(3S*,  4S*)-3-(4-Allyloxyphenyl)-2-methylisoxazolidine-4-sulfonic  acid  (2-hydroxy 
ethyl)amide (133n)
\y/
HO
General protocol was followed using  109 mg of 130n. The crude residue was purified 
by flash chromatography (starting 99:1 CHCl3/MeOH) to give 133n (76 mg, 92%) as a 
yellow oil.
Rf0.38 (9:1 CHCl3/MeOH); um ax (neat)/cm ‘2918, 2850,  1611, 1512,  1463,  1308, 1242, 
1145, 1038, 928; 5H  (300 MHz, CDC13) 7.35 (d, J = 8.8 Hz, 2 H, Ar//), 6.91 (d, J = 8.8 
Hz, 2 H, ArH), 6.04 (ddt, J =  17.3,  10.5, 5.4 Hz,  1   H, C//=CH2), 5.37-5.45  (m,  2 H,
224CH=C//H and N//), 5.28 (app. dq, J = 10.5,  1.4 Hz,  1   H, CH=CH//), 4.52 (app. dt, J = 
5.4,  1.4 Hz, 2 H, OC//2CH=), 4.37 (dd, J = 9.9, 4.0 Hz,  1   H, SCHC7/H), 4.32 (dd, 7 =
9.9,  7.6 Hz,  1  H, SCHCH//), 4.04 (app. td, J = 7.6, 4.0 Hz,  1  H, SCH), 3.76 (br s,  1  H, 
NC//),  3.45-3.58  (m,  2 H,  OC//2CH2N),  3.03-3.13  (m,  1  H,  OCH2C//HN),  2.87-2.96 
(m,  1   H, OCH2CH//N), 2.70 (s,  1  H, OH), 2.60 (s, 3 H, NC//3);  6C  (75 MHz, CDC13)
159.0  (s), 133.0 (d),  129.4 (d), 128.6 (s),  117.9 (t),  115.2 (d), 74.0 (d), 72.9 (d), 68.9 (t),
66.9  (t), 61.6 (t), 45.4 (t), 42.6 (q); m/z (El) 342 (M+, 6), 217 (54), 216 (100),  191  (17), 
173 (14), 150 (19),  118 (23), 91 (52), 86 (62); HRMS (El): calcd for C15H22N20 5S (M+) 
342.1244, found 342.1239.
2254.7. Procedures for isoxazole studies
4-Methoxybenzaldehyde oxime (134)102
/OH
To a stirring suspension of 4-methoxybenzaldehyde  (20.0  g,  0.15  mol) in DCM  (500 
mL) was added to it hydroxylamine hydrochloride (17.9 g, 0.26 mol), and NEt3 (70 mL, 
0.5 mol). The reaction mixture was allowed to stir at RT for 2 hours then quenched with 
sat. NaHCC>3 (200 mL) at 0 °C and extracted with DCM (2 x 200 mL). The combined 
DCM layer was dried (MgSC^), filtered and concentrated in vacuo to yield the crude 
which  was  purified  by  flash  chromatography  (starting  7:1  petroleum  ether  40- 
60°C/EtOAc) to give the desired product (20.8 g, 94%).
Rf 0.48  (2:1  petroleum  ether 40-60°C/EtOAc);  mp  72-74  °C;  \)m ax  (neatycm'1   3174, 
3007, 2839, 1607, 1512, 1441, 1307, 1250, 1168, 1025, 953, 824; 8H  (300 MHz, CDC13)
9.22  (br s,  1 H, OH), 8.13 (s, 1 H, CHN), 7.52 (d, J= 8.7 Hz, 2 H, Ar//), 6.91 (d, J = 8.7 
Hz, 2 H, ArH),  3.82 (s, 3 H, OC//3);  8C  (75 MHz, CDC13)  161.1  (s),  150.0 (d),  128.6 
(d),  124.6  (s),  114.3  (d),  55.4  (q);  m/z  (Cl)  152  (MH+,  100);  HRMS  (Cl):  calcd  for 
C8HioN02 (MH+) 152.0712, found 152.0708.
iV-(4-Methoxybenzyl)-hydroxylamine (135)102,103
4-Methoxybenzaldehyde oxime 134 (9.6 g, 63.5 mmol) was dissolved in 1.25M HC1 in 
MeOH (350 mL) and treated slowly with NaBH3CN (8.0 g,  127.0 mmol). The reaction 
was stirred at RT for 5 days and then solvents were removed in vacuo. The remaining 
solid suspended in H20  was basified to pH >9 using 6M KOH. The aqueous layer was 
then saturated with NaCl and extracted with CHCI3 (4 x 200 mL). The combined CHCI3 
layers  were  dried  with  MgSC>4  from  which  the  solvent  was  evaporated  to  give  the 
product as an off white solid (9.6 g, 99%).
mp 80-82 °C; \)m ax (neatycm' 1  3227, 3004, 2836,  1610,  1510,  1301,  1246,  1175,  1031, 
810;  8h (300 MHz, CDCI3) 7.23  (d, J =  8.6 Hz, 2 H, Ar//),  6.86 (d, J =  8.6 Hz, 2 H, 
Ar//), 6.12 (br s,  1  H, NT/), 3.91  (s, 2 H, C//2NH), 3.78 (s, 3 H, OC//3);  8C  (75 MHz, 
CDCI3)  159.2 (s),  130.5  (d),  128.9 (s),  113.9 (d), 57.6 (t), 55.3 (q); m/z (El)  153  (M+,
22624),  151  (100),  134  (33),  122  (57),  108  (78),  91  (46),  77  (98),  63  (36);  HRMS  (El):
calcd for C8HnN0 2 (M+) 153.0784, found 153.0795.
C-(Phenyl)-A-(4-methoxybenzyl) nitrone (136a)193
OMe
To iV-(4-methoxybenzyl)-hydroxylamine 135 (4.8 g, 31.4 mmol) in dry DCM (50 mL) 
was added benzaldehyde  (2.9 mL,  28.6 mmol)  and NaHC03  (7.2 g,  85.7 mmol). The 
mixture was refluxed at 40 °C overnight, then the resulting suspension was filtered and 
the  remaining  residue  washed  thoroughly  with  DCM  (4  x  50  mL).  The  combined 
organic  fractions  were  concentrated  in  vacuo  to  yield  a  white  solid  that  was 
recrystallised (hexane/EtOAc) to give the title compound as white crystals (6.6 g, 96%). 
Rf 0.13  (2:1  petroleum  ether  40-60°C/EtOAc);  mp  96-99  °C;  um ax  (neatycm1   3051, 
2934,  1610,  1514,  1250,  1146,  1026, 919, 812; 5h (300 MHz, CDC13) 8.18-8.21  (m, 2 
H, Ar//), 7.38-7.42 (m, 5 H, Ar//), 7.33 (s,  1 H, C/7N), 6.93 (d, J = 8.6 Hz, 2 H, Ar//),
4.99  (s, 2 H,  C//2N),  3.82 (s,  3 H,  OC//3);  8C  (75 MHz, CDC13)  160.2 (s),  133.8  (d),
130.9  (d),  130.5 (s),  130.4 (d),  128.6 (d),  128.4 (d),  125.3 (s),  114.4 (d), 70.7 (t), 55.4 
(q);  m/z  (FAB+)  264  (MNa+,  48),  199  (63),  173  (100);  HRMS  (FAB+):  calcd  for 
Ci5Hi5N02Na (MNa+) 264.1000, found 264.1004.
C-(4-Bromophenyl)-iV-(4-methoxybenzyl) nitrone (136b)
11   -I  OMe
Br
To A-(4-methoxybenzyl)-hydroxylamine 135 (2.6 g,  17.0 mmol) in dry DCM (25 mL) 
was added 4-bromobenzaldehyde (2.6 g,  14.2 mmol) and NaHC03 (3.6 g, 42.6 mmol). 
The mixture was refluxed at 40 °C overnight, then the resulting suspension was filtered 
and the remaining residue washed thoroughly with DCM (4 x 30 mL). The combined 
organic fractions were concentrated in vacuo, and the crude product was recrystallised 
(hexane/EtOAc) to give the title compound as a light brown solid (4.0 g, 87%).
Rf 0.14 (2:1  petroleum ether 40-60°C/EtOAc); mp  153-155  °C; \)m ax (neatycm"1  3062, 
2965,  1611,  1512,  1452,  1238,  1142,  1031, 928, 834, 771; 5H  (300 MHz, CDC13) 8.07 
(d, J =  8.6 Hz,  2 H,  Ar//),  7.50 (d, J =  8.6 Hz, 2 H, Ar//),  7.38  (d, J =  8.6 Hz, 2 H, 
Ar//), 7.29 (s,  1   H, C/7N), 6.92 (d, J = 8.6 Hz, 2 H, ArH), 4.96 (s, 2 H, NC//2Ar), 3.81
227(s, 3  H, OCft);  8 c (75 MHz, CDCI3)  160.3 (s),  132.7 (d),  131.7 (d),  131.0 (d),  129.9
(d),  129.3 (s),  124.9 (s),  124.2 (s),  114.4 (d), 70.8 (t), 55.4 (q); m/z (El) 321  (M+,  81Br,
22),  319  (M+,  79Br,  21),  121  (100),  89  (62),  78  (67),  63  (45);  HRMS  (El):  calcd for 
Ci5Hi479BrN0 2 (M+) 319.0202, found 319.0197.
C-(4-.\lethoxyphenyl)-;Y-(4-methoxybeiizyl) nitrone (136c)
To A-(4-methoxybenzyl)-hydroxylamine  135  (3  g,  19.6  mmol)  in dry DCM  (30 mL) 
was  added  4-methoxybenzaldehyde  (2.0  mL,  16.3  mmol)  and  NaHCC>3  (4.1  g,  49.0 
mmol). The mixture was refluxed at 40 °C overnight, then the resulting suspension was 
filtered  and  the  remaining  residue  washed  thoroughly  with  DCM  (4  x  40  mL).  The 
combined  organic  fractions  were  concentrated  in  vacuo,  and  the  crude  product  was 
recrystallised (hexane/EtOAc) to give the title compound as a light yellow solid (4.1 g, 
92%).
R f 0.15  (2:1  petroleum ether 40-60°C/EtOAc); mp  127-129 °C; Dm ax (neatycm'1  3007, 
2839,  1603, 1507,  1455,  1303,  1239, 1143,  1025, 936; 5h (300 MHz, CDC13) 8.18 (d, J 
= 9.1 Hz, 2 H, Ar//), 7.37 (d, J = 8.6 Hz, 2 H, Ar//), 7.25 (s, 1 H, CM ), 6.90 (d, J = 8.6 
Hz, 2 H, Ar//),  6.88  (d, J = 9.1  Hz, 2 H, Ar//), 4.92 (s, 2 H, NC//2Ar),  3.80 (s, 3 H, 
OC//3), 3.79 (s, 3 H, OC//3); 5C  (75 MHz, CDC13) 161.1  (s),  160.1  (s),  133.6 (d), 130.9 
(d),  130.6 (d),  125.5 (s),  123.5 (s),  114.3 (d),  113.7 (d), 70.1  (t), 55.3 (q), 55.2 (q); m/z 
(El) 271  (M+,  12),  121  (100), 91  (31), 77 (53); HRMS (El): calcd for Ci6Hi7N03 (M+) 
271.1203, found 271.1208.
C-(4-ChIorophenyl)-7V-(4-methoxybenzyl) nitrone (136d)
To A-(4-methoxybenzyl)-hydroxylamine  135  (3  g,  19.6  mmol)  in dry DCM  (30 mL) 
was added 4-chlorobenzaldehyde (2.3 g,  16.3 mmol) and NaHC03 (4.1 g, 49.0 mmol). 
The mixture was refluxed at 40 °C overnight, then the resulting suspension was filtered 
and the remaining residue washed thoroughly with DCM (4 x 40 mL). The combined
MeO
OMe
ci
OMe
228organic fractions were concentrated in vacuo, and the crude product was recrystallised 
(hexane/EtOAc) to give the title compound as a light yellow solid (4.0 g, 90%).
Rf 0.17  (2:1  petroleum ether 40-60°C/EtOAc); mp  142-145  °C; X > m & x  (neatycm'1  3006, 
2964,  1612,  1513,  1456,  1238,  1142,  1031, 928, 836, 770; 5H  (300 MHz, CDC13) 8.14 
(d, J =  8.6 Hz, 2 H, Ar//), 7.38  (d, J =  8.6 Hz, 2 H, Ar//), 7.33  (d, J =  8.6 Hz, 2 H, 
Ar//), 7.31  (s,  1  H, CHISI), 6.92 (d, J = 8.6 Hz, 2 H, Ar//), 4.96 (s, 2 H, NC//2Ar), 3.80 
(s, 3 H,  OC//3);  5C  (75  MHz, CDCI3)  160.3  (s),  135.8  (s),  132.7  (d),  131.0 (d),  129.8 
(d),  129.0 (s),  128.7 (d),  125.0 (s),  114.4 (d), 70.7 (t), 55.4 (q); m/z (El) 277 (M+, 37C1, 
4),  275  (M+,  35C1,  12),  121  (100),  89  (41),  78  (47),  63  (19);  HRMS  (El):  calcd  for 
C,5Hi435ClN02 (M+) 275.0708, found 275.0711.
C-(Cyclohexyl)-Af-(4-methoxybenzyl) nitrone (136e)
OMe
To A-(4-methoxybenzyl)-hydroxylamine  135  (2  g,  13.1  mmol)  in dry DCM  (25  mL) 
was  added  cyclohexanecarbaldehyde  (1.3  mL,  10.9  mmol)  and NaHC03  (2.7  g,  32.6 
mmol). The mixture was refluxed at 40 °C overnight, then the resulting suspension was 
filtered  and  the  remaining  residue  washed  thoroughly  with  DCM  (4  x  30  mL).  The 
combined  organic  fractions  were  concentrated  in  vacuo,  and  the  crude  product  was 
recrystallised  (hexane/EtOAc)  to  give  the  title  compound  as  an  orange  solid  (2.6  g, 
95%).
Rf 0.45  (9:1  DCM/MeOH);  mp  92-95  °C;  Dm „  (neat)/cm'‘  3063,  2924,  1612,  1513, 
1448,  1302,  1249,  1172,  1031,  823;  8H  (300 MHz, CDC13) 7.29  (d, J = 8.6 Hz,  2 H, 
ArH),  6.88  (d, J = 8.6 Hz,  2 H, ArH), 6.38 (d, J = 7.2 Hz,  1  H,  CHN), 4.77 (s,  2 H, 
NC//2Ar),  3.79  (s,  3  H,  OCH3),  2.88-3.01  (m,  1   H,  C//CHN),  1.76-1.86  (m,  2  H, 
cyclohexyl-//),  1.58-1.70 (m, 3 H, cyclohexyl-//),  1.01-1.41  (m, 5 H, cyclohexyl-//); 5c 
(75 MHz, CDC13)  160.0 (s),  142.8 (d),  130.7 (d),  125.2 (s),  114.3 (d), 68.7 (t), 55.3 (q),
35.0  (d), 28.8 (t), 25.9 (t), 25.2 (t); m/z (El) 247 (M+, 8), 230 (16),  122 (100), 91  (33); 
HRMS (El): calcd for C15H21NO2 (M+) 247.1567, found 247.1561.
C-(Naphthyl)-A-(4-methoxybenzyl) nitrone (136f)
OMe
229To Af-(4-methoxybenzyl)-hydroxylamine  135  (2  g,  13.1  mmol)  in dry DCM  (25  mL) 
was added 2-naphthaldehyde (1.7 g,  10.9 mmol) and NaHCC>3 (2.7 g, 32.6 mmol). The 
mixture was refluxed at 40 °C overnight, then the resulting suspension was filtered and 
the  remaining  residue  washed  thoroughly  with  DCM  (4  x  30  mL).  The  combined 
organic fractions were concentrated in vacuo, and the crude product was recrystallised 
(hexane/EtOAc) to give the title compound as a cream solid (2.9 g, 92%).
Rf 0.17 (2:1  petroleum ether 40-60°C/EtOAc); mp  155-158  °C; X > m ax (neatycm'1  3053, 
2932,  1610,  1514,  1445,  1305,  1249,  1178,  1028, 945; 6H  (300 MHz, CDC13) 9.22 (s,  1  
H, CHN), 7.78-7.91  (m, 4 H, Ar//), 7.47-7.51  (m, 3 H, Ar//), 7.44 (d, J = 8.6 Hz, 2 H, 
Ar//), 6.95 (d, J = 8.6 Hz, 2 H, Ar//), 5.03 (s, 2 H, NC//2Ar), 3.82 (s, 3 H, OC//3);  6C  
(75 MHz, CDCI3)  160.2 (s),  134.1  (d),  133.9 (s),  133.1  (s),  131.0 (d),  129.2 (d),  128.6 
(d),  127.9 (d),  127.7 (s),  127.5 (d),  127.3 (d),  126.5 (d),  125.9 (d),  125.3 (s),  114.4 (d), 
70.7 (t), 55.4 (q);  m/z (El) 291  (M+,  38),  275  (15),  156  (20),  139  (40),  121  (100), 97 
(44); HRMS (El): calcd for C19H17NO2 (M+) 291.1254, found 291.1260.
(3S*, 4S*)-2-(4-Methoxybenzyl)-3-phenylisoxazoIidine-4-suIfonic acid 
pentafluorophenyl ester (137)
PFPO
PMB
To pentafluorophenyl vinyl sulfonate 100 (0.5 g,  1.8 mmol) in dry toluene (10 mL) was 
added C-(phenyl)-A-(4-methoxybenzyl) nitrone 136a (0.5 g, 2.2 mmol) and the mixture 
was heated to reflux for 9 hours. The reaction was concentrated in vacuo, and the crude 
residue  was  purified  by  flash  chromatography  (starting  8:1  petroleum  ether  40- 
60°C/EtOAc) to give the title compound (850 mg, 85%) as a yellow solid.
Rf 0.60  (2:1  petroleum  ether  40-60°C/EtOAc);  mp  88-92  °C;  Dm ax  (neatycm1   2957, 
1511,  1468,  1392,  1249,  1184,  1020, 993, 786; SH  (300 MHz, CDC13) 7.52-7.56 (m, 2 
H, Ar//), 7.36-7.45 (m, 3 H, Ar//), 7.23 (d, J = 8.6 Hz, 2 H, Ar//), 6.84 (d, J = 8.6 Hz, 2 
H, Ar//), 4.61  (dd, J =  10.4, 2.4 Hz,  1  H, SCHC//H), 4.42-4.49  (m,  1   H, SCHCH//),
4.29-4.36 (m, 2 H, SCH and NCZ0, 3.97 (d, J =  14.2 Hz,  1   H, NCZZHAr), 3.82 (d, J =
14.2 Hz, 1 H, NCHZ/Ar), 3.78 (s, 3 H, OC//3); 5C (75 MHz, CDC13) 159.1 (s), 136.2 (s),
130.2 (d),  129.1  (d),  128.5 (s),  128.1  (2 x d),  113.7 (d), 73.6 (d), 71.4 (d), 66.9 (t), 58.8 
(t),  55.2  (q);  m/z  (FAB+)  516  (MH+,  10),  154  (100);  HRMS  (FAB+):  calcd  for 
C23H19F5NO5S (MH+) 516.0904, found 516.0900.
230(35*, 45*)-3-CycIohexyl-2-(4-methoxybenzyl)isoxazolidine-4-sulfonic acid
pentafluorophenyl ester (138)
PFPO
PMB
To pentafluorophenyl vinyl sulfonate 100 (1.0 g, 3.7 mmol) in dry toluene (20 mL) was 
added  C-(cyclohexyl)-A-PMB  nitrone  136e  (1.4  g,  5.5  mmol)  and  the  mixture  was 
heated to reflux for  17  hours.  The reaction was concentrated  in vacuo,  and the crude 
residue  was  purified  by  flash  chromatography  (starting  10:1  petroleum  ether  40- 
60°C/EtOAc) to give the title compound (1.0 g, 55%) as a yellow solid.
Rf 0.72 (2:1  petroleum ether 40-60°C/EtOAc); mp  120-123  °C; \)m ax (neatycm"1  2917, 
1519,  1378,  1245, 1181,991,817, 731; 5H  (300 MHz, CDC13) 7.31 (d, 7=8.3 Hz, 2 H, 
Ar//), 6.87 (d, 7 = 8.3 Hz, 2 H, ArH), 4.63 (dd, 7 = 9.9, 7.0 Hz,  1  H, SCHC//H), 4.42 
(dd, 7 = 9.9, 8.3 Hz, 1 H, SCHCHH), 4.28 (app. td, 7 = 7.0, 3.8 Hz, 1 H, SCH), 4.11 (d, 
7 = 12.3 Hz, 1  H, NC//HAr), 4.00 (d, 7= 12.3 Hz, 1  H, NCH//Ar), 3.80 (s, 3 H, OCH3), 
3.47 (dd, 7 = 6.7, 3.8 Hz, 1 H, NC/7), 1.58-1.84 (m, 5 H, cyclohexyl-//), 1.36-1.48 (m, 1  
H, cyclohexyl-//),  1.06-1.28 (m, 3 H, cyclohexyl-//), 0.82-1.02 (m, 2 H, cyclohexyl-//); 
6C  (75 MHz, CDC13)  159.2 (s),  130.8 (d),  128.2 (s),  113.8  (d), 70.4 (d),  68.6 (d), 67.0 
(t), 59.5  (t), 55.3  (q), 42.2 (d), 29.5 (t), 29.4 (t), 26.1  (t), 26.0 (t), 25.9 (t); m/z (FAB+) 
522  (MH+,  12),  176 (22),  154  (100); HRMS  (FAB+):  calcd for C23H25F5NO5S  (MH+) 
522.1374, found 522.1337.
(35*, 45*)-3-CycIohexylisoxazolidine-4-sulfonic acid pentafluorophenyl ester (139)
PFPO
PFP ester 138 (100 mg, 0.19 mmol) in MeOH (10 mL) was treated with 10% Pd/C (10 
mg). The round bottom flask was evacuated and cycled with Ar three times, and finally 
flushed with H2. The reaction was heated at reflux for 7 hours then the reaction mixture 
filtered through a pad of Celite®, and the filtrate concentrated in vacuo. The crude was 
purified by flash chromatography (starting 95:5 DCM/MeOH) to yield the product (26 
mg, 34%) as a white solid.
Rf 0.08  (9:1  DCM/MeOH);  mp 287-291  °C; Pm ax  (neatycm' 1  3414,  3097, 2921,  1520, 
1244,  1138,  1041, 892, 722; 8H  (300 MHz, (CD3)2SO) 7.84 (br s,  1  H, N/7), 3.87 (dd, J
231= 12.1, 4.6 Hz,  1  H, SCHC//H), 3.77 (dd, J = 12.1, 5.9 Hz,  1  H, SCHCHH), 3.30 (dd, J 
= 9.9, 2.2 Hz,  1  H, NCH), 2.84 (app. td, J = 5.9, 2.2 Hz,  1  H, SCH),  1.56-1.91 (m, 6 H, 
cyclohexyl-//),  1.08-1.21  (m, 3 H, cyclohexyl-//), 0.78-0.97 (m, 2 H, cyclohexyl-//); 6c 
(75 MHz, (CD3)2SO) 57.5 (d), 57.0 (t), 55.3 (d), 37.1 (d), 29.1 (t), 28.7 (t), 25.5 (t), 25.1 
(t), 25.0 (t).
(3S*,  4S*)-2-(4-Methoxybenzyl)-3-phenylisoxazolidine-4-sulfonic  acid  4-methyl 
benzylamide  (140a)  and  (35*,  4/?*)-2-(4-Methoxybenzyl)-3-phenylisoxazolidine-4- 
sulfonic acid 4-methylbenzylamide (141a)
141a
OMe 140a
OMe
4-Methylbenzylamine  (0.6  mL,  4.66  mmol)  was  added  to  a  stirring  solution  of (35*, 
45*)-2-(4-methoxybenzyl)-3-phenylisoxazolidine-4-sulfonic  acid  pentafluorophenyl 
ester 137 (800 mg,  1.55 mmol) in dry THF (20 mL), followed by DBU (0.4 mL, 2.33 
mmol).  The  mixture  was  refluxed  for  1  hour  then  diluted  with  DCM  (50  mL)  and 
washed with 2M HC1 (2 x 25 mL), sat. NaHC03 (2 x 25 mL), and water (1  x 25 mL). 
The organic phase was separated, dried (MgS0 4), filtered, and the filtrate concentrated 
in  vacuo.  The  crude  residue  was  purified  by  flash  chromatography  (starting  4:1 
petroleum ether 40-60°C/Et20) to give  140a  (516 mg,  74%)  as  a white  solid and the 
141a (150 mg, 21%) as a yellow solid- overall yield (95%, 140a: 141a = 7:2).
Data  for  140a:  R f   0.40  (2:1  Et20/petroleum  ether  40-60°C);  mp  152-154  °C;  t)m ax 
(neatycm' 1 3317, 3284, 2921,  1513,  1420,  1320,  1243,  1156,  1028, 850; 6H  (300 MHz, 
CDC13) 7.38-7.50 (m, 5 H, Ar//), 7.19 (d, J = 8.6 Hz, 2 H, Ar//), 7.07 (d, J = 7.8 Hz, 2 
H, Ar//), 6.96 (d, J = 7.8 Hz, 2 H, ArH), 6.81 (d, J = 8.6 Hz, 2 H, Ar//), 4.46 (app. t, 5.9 
Hz,  1 H, N//), 4.35 (dd, J = 9.9, 4.0 Hz, 1  H, SCHC//H), 4.24 (dd, J = 9.9, 8.3 Hz, 1  H, 
SCHCH//),  4.11  (dd,  J =  13.7,  6.4 Hz,  1   H,  NHCZ/HAr),  4.08  (d, J = 7.2 Hz,  1  H, 
NC//),  3.83-3.98  (m,  3  H,  SCH,  NHCHZ/Ar,  and  NC//HAr),  3.71-3.78  (m,  4  H, 
NCH/ZAr and OC//3), 2.32 (s, 3 H, ArCH3);  6C  (75 MHz, CDC13)  159.0 (s),  137.8 (s),
137.5  (s),  133.4 (s), 130.2 (d), 129.5 (d), 129.0 (d), 128.7 (d), 128.3 (d), 128.0 (d), 113.7 
(d), 73.2 (d), 71.6 (d), 67.0 (t), 58.8 (t), 55.2 (q), 47.1  (t), 21.2 (q),  1   x s not observed; 
m/z  (Cl)  454  (27),  453  (MH+,  100),  345  (75);  HRMS  (Cl):  calcd  for  C25H29N2O4S 
(MH+) 453.1848, found 453.1833.
232Data  for  141a:  Rf 0.30  (2:1  Et20/petroleum  ether  40-60°C);  mp  146-149  °C;  um ax 
(neatVcm'1  3334, 3002, 2926,  1513,  1402,  1326,  1244,  1153,  1026, 809; 6H  (300 MHz, 
CDC13) 7.55 (dd, J = 7.8, 2.1  Hz, 2 H, Ar//), 7.31-7.38 (m, 3 H, Ar#), 7.23 (d, J = 8.6 
Hz, 2 H, Ar#), 7.13 (d, J = 7.8 Hz, 2 H, Ar#), 7.04 (d, J = 7.8 Hz, 2 H, Ar#), 6.86 (d, J 
= 8.6 Hz, 2 H, Ar#), 4.33-4.44 (m, 2 H, SCHC#2), 4.18 (app. q, J = 8.3 Hz, 1  H, SC#), 
3.89-4.08 (m, 4 H, NC#HAr, NHC#2Ar, and NC#), 3.80 (s, 3 H, OC#3), 3.60 (d, J =
14.2  Hz,  1  H, NCH#Ar), 3.29 (br t, J = 5.9 Hz,  1  H, N#), 2.34 (s, 3 H, ArC#3); 8C  (75 
MHz, CDC13)  159.0 (s),  137.9 (s),  133.4 (2 x s),  130.2 (d),  129.6 (d),  129.4 (d),  129.0 
(d),  128.5 (d),  128.4 (s),  128.0 (d),  113.7 (d), 70.8 (d), 68.1  (d), 66.7 (t), 58.8 (t), 55.3 
(q), 46.9 (t), 21.2 (q); m/z (FAB+) 453  (MH+, 5),  154 (100); HRMS  (FAB+):  calcd for 
C25H29N20 4S (MH+) 453.1848, found 453.1836.
3-Phenyl-4,5-dihydroisoxazole-4-sulfonic acid 4-methylbenzylamide (142a)
(35*, 45*)  and (35*, 4R*)-2-(4-Methoxybenzyl)-3-phenylisoxazolidine-4-sulfonic acid 
4-methylbenzylamide  140/141a (139 mg,  0.31  mmol) in toluene  (10 mL)  was treated 
with DDQ (280 mg,  1.23 mmol) and refluxed for 30 hours. Solvents were removed in 
vacuo and residue dissolved in DCM (20 mL). The organic phase was washed with sat. 
NaHC03 (15 mL), and then the aqueous layer further extracted with DCM (3x15 mL). 
The  combined  DCM  layers  were  dried  (MgS04),  and  concentrated  in  vacuo. 
Purification of the crude oil by flash chromatography (starting 4:1  petroleum ether 40- 
60°C/Et2O) yielded the product (20 mg, 20%) as a pink solid.
Rf0.34  (2:1  Et20/petroleum  ether 40-60°C);  mp  129-131  °C;  Dm ax  (neatycm1   3316, 
2920, 3021, 2920,  1515,  1434, 1327, 1129, 1053, 939, 892; 5h (300 MHz, CDC13) 7.86- 
7.89 (m. 2 H, Ar#), 7.41-7.47  (m, 3 H, Ar#), 7.11-7.13  (m, 4 H, Ar#), 5.14 (dd, J =
10.7, 2.7 Hz,  1   H, SCHC/ZH), 5.05 (dd, J = 9.6, 2.7 Hz,  1  H, SCHCH#), 4.63 (dd, J =
10.7, 9.6 Hz, 1 H, SC#), 4.46 (app. t, J = 5.6 Hz,  1  H, N#), 4.13 (dd, 7= 13.6, 5.9 Hz, 1  
H, NC#HAr), 4.06 (dd, J =  13.6, 5.9 Hz,  1  H, NCH#Ar), 2.32 (s, 3 H, ArC#3); 6C  (75 
MHz, CDC13)  153.2 (s),  138.1  (s),  133.3 (s),  131.0 (d),  129.5 (d),  128.9 (d),  128.0 (d),
127.8  (d),  127.3  (s), 73.3  (t), 70.3  (d), 48.0 (t), 21.1  (q); m/z (FAB+) 353 (MNa+, 22), 
329  (20),  176  (100),  154  (42);  HRMS  (FAB+):  calcd  for  C,7Hi8N2Na03S  (MNa+) 
353.0936, found 353.0926.
233(3S*,  45*)  and  (35*,  4R*)-2-(4-Methoxybenzyl)-3-phenylisoxazolidine-4-sulfonic
acid ter/-butylamide (1407141c)
OMe
140/141c
teJt-Butylamine (120 |liL,  1.16 mmol) was added to a stirring solution of (35*, 45*)-2- 
(4-methoxybenzyl)-3-phenylisoxazolidine-4-sulfonic  acid  pentafluorophenyl  ester  137 
(200 mg, 0.39 mmol) in dry THF (6 mL), followed by DBU (90 |iL, 0.58 mmol). The 
mixture was refluxed for 1  hour then diluted with DCM (20 mL) and washed with 2M 
HC1 (2 x 20 mL), sat. NaHC03  (2 x 20 mL), and water (1 x 20 mL). The organic phase 
was separated, dried (MgS0 4), filtered, and the filtrate concentrated in vacuo. The crude 
residue  was  purified  by  flash  chromatography  (starting  3:1  Petroleum  ether  40- 
60°C/Et2O)  to  give  the  product  (134  mg,  85%)  as  an  inseparable  mixture  of 
diastereoisomers (140 and 141c = 2:1 major:minor).
Data for 140/141c:  Rf0.43  (2:1  Et20/petroleum ether 40-60°C);  mp  177-179  °C;  Dm ax 
(neatycm1   3300, 2933,  1513,  1389,  1251,  1143,  1038, 996, 832; 5H  (300 MHz, CDC13) 
7.58-7.63  (m,  2  H min0r,  Ar//),  7.50-7.55  (m,  2  H maj0r,  Ar//),  7.33-7.45  (m,  3  H,  Ar//),
7.22  (d, J = 8.6 Hz, 2 H min0r, Ar//), 7.19 (d, J = 8.6 Hz, 2 H maj0r, Ar//), 6.84 (d, J = 8.6 
Hz, 2 Hminor, Ar//), 6.80 (d, J = 8.6 Hz, 2 Hm ajor, Ar//), 4.49 (s • >   1  Hmajor* NT/), 4.38-4.46
(m, 2 H,  SCHC//H and SCHCH//min0r), 4.31  (dd, J = 9.4,  8.0 Hz,  1  Hmajor, SCHCH//),
4.21  (app.  q, J = 8.3  Hz,  1  Hmin0r,  SC//),  3.96-4.08  (m,  3  H, NCH,  NC//HArminor, and 
SC//maj0r), 3.87 (d, J =  13.9 Hz,  1  Hmajor, NC//HAr), 3.78 (s, 3 Hminor, OC//3), 3.76 (s, 3 
Hm ajor,  O C//3),  3.73-3.79  (m,  1  Hm ajor,  NCHZ/Ar),  3.60  (d,  J  =  14.2  Hz,  1  Hm inor, 
NCH//Ar),  3.08  (br  s,  1  Hminor,  N//),  1.15  (s,  9  Hminor,  C(C//3)3),  1.08  (s,  9  Hm ajor, 
C(CZ/3)3);  8C  (75  MHz,  CDC13)  159.0  (s),  158.9  (s),  137.8  (s),  133.8  (s),  130.3  (d), 
130.1  (d),  129.2 (s),  128.9 (d),  128.8 (d),  128.7 (d),  128.6 (d),  128.3  (s), 75.1  (d), 72.6 
(d), 71.2 (d), 70.8 (d), 67.3 (t), 67.1 (t), 58.9 (t), 58.6 (t), 55.2 (q), 55.0 (s), 54.7 (s), 30.3 
(q), 29.9  (q), 25  out of 30 expected signals observed; m/z (ES+) 468  (35), 427 (MNa+, 
100),  405  (91),  180  (38);  HRMS  (ES+):  calcd for C2iH28N2Na04S  (MNa+)  427.1658, 
found 427.1667.
2343-Phenyl-4,5-dihydroisoxazole-4-sulfonic acid terf-butylamide (142b)
DDQ (300 mg,  1.33 mmol) was added to a stirring suspension of (35*, 45*) and (35*, 
4/?*)-2-(4-methoxybenzyl)-3-phenylisoxazolidine-4-sulfonic  acid  tert-butylamide 
140/141c (134 mg, 0.33 mmol) in benzene (6 mL), and the mixture heated at reflux for 
48 hours. The reaction mixture was concentrated in vacuo and the crude residue purified 
by  flash  chromatography  (starting  4:1  petroleum  ether  40-60°C/Et20)  to  give  the 
product (64 mg, 69%) as a white solid.
Rf 0.25  (2:1  Et20/petroleum  ether  40-60°C);  mp  180-183  °C;  \)m ax  (neatycm1   3301, 
2979,  1513,  1422,  1389,  1240,  1138,  1021, 906; SH  (300 MHz, CDC13) 7.82-7.86 (m, 2 
H, Ar//), 7.41-7.46 (m, 3 H, Ar//), 5.11 (dd, J = 10.7, 3.5 Hz,  1  H, SCHC//H), 5.04 (dd, 
J = 10.2, 3.5 Hz,  1  H, SCHCH//), 4.66 (app. t, J =  10.2 Hz,  1  H, SC//), 4.22 (br s, 1  H, 
N//),  1.29 (s, 9 H, C(C//3)3); 5C  (75 MHz, CDC13)  153.0 (s),  130.7 (d),  128.7 (d),  128.0 
(d),  127.7  (s), 73.0 (t), 71.9 (d), 56.2 (s), 30.2 (q); m/z (Cl) 283  (MH+, 29), 265  (38), 
227 (36),  165  (21),  146 (100),  125 (34),  111  (48), 97 (82), 89 (23); HRMS (Cl): calcd 
for Ci3H19N20 3S (MH+) 283.1116, found 283.1109.
a-Bromo-pentafluorophenyl vinyl sulfonate (143)
Bromine (4.5 mL, 87.5 mmol) in CHC13  (30 mL) was added dropwise over a period of 
10 minutes to a stirring suspension of PFP vinyl sulfonate 100 (12.0 g, 43.8 mmol) and 
AIBN  (0.5  g)  in  CHC13  (150  mL).  After addition,  AIBN  was  added  (0.5  g)  and  the 
reaction mixture heated to reflux for 4 hours, followed by 40 hours at RT. The solvent 
was removed in vacuo and the crude oil remaining re-suspended in DCM (100 mL). To 
this stirring solution was added NEt3 (9.2 mL, 65.7 mmol) and the reaction stirred at RT 
for 3 hrs. The reaction mixture was washed with 2M HC1 (2 x 50 mL), the organic layer 
dried (MgSCL),  filtered and concentrated in vacuo.  The crude residue was purified by 
flash chromatography (starting  10:1  petroleum ether 40-60°C/Et20) to give the desired 
product as a yellow solid (14.0 g, 91%).
235Rf0.52 (5:1  petroleum ether 40-60°C /Et20); mp 36-38 °C; t w  (neat)/cm‘' 3118, 1513, 
1354,  1188, 990, 788, 722; 8H  (300 MHz, CDC13) 7.05 (d, J = 3.5  Hz,  1   H, SCCHH), 
6.54 (d, J = 3.5 Hz,  1  H, SCCH//); 8C (75 MHz, CDC13)  133. 8 (t),  122.0 (s); m/z (El) 
512 (27), 354 (M+, 81Br, 6), 352 (M+, 79Br, 4),  184 (100),  155  (47),  117  (53), 69 (37); 
HRMS (El): calcd for C8H279BrF50 3S (M+) 351.8823, found 351.8827.
4-Bromo-3-(4-bromophenyl)-2-methylisoxazolidine-4-sulfonic  acid  pentafluoro 
phenyl  ester  (145/146),  and  5-Bromo-3-(4-bromophenyl)-2-methylisoxazolidine-5- 
sulfonic acid pentafluorophenyl ester (147)
\\//  Br
\\ //  Br PFPO
Br PFPO
145/146 147
a-Bromo  PFP  vinyl  sulfonate  143  (300  mg,  0.85  mmol)  and  DABCO  (10  mg,  0.08 
mmol) was dissolved in PhMe (5 mL) and stirred at RT for 5 mins, then treated with C- 
(4-bromophenyl)-A/-methyl nitrone 119f (550 mg, 2.55 mmol). The resulting suspension 
was  stirred  at RT for  18 hours.  Solvent was  removed  in vacuo  and the crude residue 
purified by flash chromatography (starting 30:1  petroleum ether 40-60°C/Et20) to give 
145/146  (411  mg,  85%)  as  a mixture of diastereoisomers  and  147  (18  mg,  4%)  as  a 
single  product-  overall  yield  (89%,  145/146:147  =  23:1,  145  and  146  =  5:2 
major: minor).
Data  for  145/146:  Rf 0.67  (2:1  petroleum  ether  40-60°C/Et20);  mp  86-88  °C;  Dm ax 
(neat)/cm-12995, 2879,  1513, 1401, 1194,988, 823,731; Sh (300 MHz, CDC13) 7.55 (d, 
J = 8.6 Hz, 2 Hmajor, Ar//), 7.53  (d, J = 8.6 Hz, 2 Hm inor, Ar//), 7.42 (d, J = 8.6 Hz, 2 
Hm i„or,  Ar//),  7.33  (d,  J =  8.6  Hz,  2  Hm ajor,  Ar//),  5.10  (d,  J =  11.0  Hz,  1   Hm ajor, 
SCBrC//H), 5.08 (d, /  =  11.0 Hz,  1   Hm in0r, SCBrC//H), 4.62 (d, /  =  11.0 Hz,  1   Hm i„0„ 
SCBrCH//), 4.58 (d, /  = 11.0 Hz, 1  Hm ajor, SCBrCH//), 4.42 (s,  1 Hm i„or, NC//), 4.36 (s, 
1  Hm ajor, NC//), 2.76 (s , 3 Hmajor» NCH3), 2.74 (s , 3 Hm inor, NCZ/3); 8c (75 MHz, CDC13)
132.6  (s),  132.5  (s),  131.8 (d),  131.7 (d),  131.6 (d),  131.4 (d),  124.3  (s),  123.9 (s), 83.0 
(s),  80.9 (s), 78.0  (t), 77.2 (t), 77.0 (2 x d), 43.1  (q), 42.9  (q); m/z (FAB+) 570 (MH+, 
81Br81Br,  2),  568  (MH+,  79Br8lBr,  4),  566  (MH+,  79Br79Br,  2),  329  (28),  176  (100); 
HRMS (FAB+): calcd for Ci6Hn79Br2F5N04S (MH+) 565.8696, found 565.8699.
Data  for  147:  Rf 0.21  (2:1  petroleum  ether  40-60°C/Et20);  mp  102-104  °C;  Dm ax 
(neatycm’1  2918,  1518,  1404,  1321,  1230,  1165, 991,  894,  653;  8h (300 MHz, CDC13)
2367.52 (d, J = 8.6 Hz, 2 H, Ar#), 7.30 (d, J = 8.6 Hz, 2 H, Ar#), 4.07 (br dd, J = 11.2, 7.8 
Hz,  1   H, NC#), 3.01  (dd, 7 =  16.9, 7.8 Hz,  1   H, SCBrC#H), 2.93  (dd, 7 =  16.9,  11.2 
Hz,  1   H, SCBrCH#), 2.80 (s, 3  H, NC#3); 8c (75  MHz, CDC13)  172.3  (s),  134.9 (s),
132.3  (d),  129.1  (d),  123.1  (s), 72.6 (d), 44.5 (q), 40.5  (t); m/z (El) 569 (M+, 8lBr8,Br, 
1), 567 (M+, 79Br8lBr, 2), 565 (M+, 79Br79Br,  1), 512 (23), 257 (94),  184 (98),  149 (71), 
102 (100); HRMS (El): calcd for Ci6H,o79Br2F5N0 4S (M+) 564.8612, found 564.8596.
4-Bromo-2-(4-methoxybenzyl)-3-phenylisoxazolidine-4-sulfonic  acid  pentafluoro 
phenyl ester (160/161a), and 5-Bromo-2-(4-methoxybenzyl)-3-phenylisoxazolidine-
5-sulfonic acid pentafluorophenyl ester (162a)
\\ //  Br
PFPO
PMB
\\//  Br
PFPO
160/161 a  162a
a-Bromo-PFP-vinyl  sulfonate  143  (300  mg,  0.85  mmol)  and  DABCO  (10  mg,  0.08 
mmol) was dissolved in PhMe (5 mL) and stirred at RT for 5 mins, then treated with C- 
(phenyl)-/V-(4-methoxybenzyl)  nitrone  136a  (410  mg,  1.70  mmol).  The  resulting 
suspension was stirred at RT for 18 hours. Solvent was removed in vacuo and the crude 
residue purified by flash chromatography (starting 30:1  petroleum ether 40-60°C/Et20) 
to give  160/161a  (410 mg,  81%)  as  a mixture of diastereoisomers  and  162a  (12 mg, 
3%) as a single product- overall yield (84%, 160/161a:162a = 34:1,160 and 161a = 2:1 
major: minor).
Data for 160/161a:  Rf0.72 (2:1  petroleum ether 40-60°C/Et20); \)m ax (neatycm1  2918, 
1514,  1456,  1384,  1246,  1190,  994,  793;  8H   (300  MHz,  CDC13)  7.50-7.56  (m,  2  H, 
Ar//), 7.40-7.47 (m, 3  H ,  Ar//), 7.23 (d, J = 8.8 Hz, 2 H, Ar//), 6.88 (d, J = 8.8 Hz, 2 
Hminor,  Ar//),  6.84  (d,  J  =  8.8  Hz,  2  H maj0r,  Ar//),  5.08  (d,  J  =  11.0  Hz,  1   H major, 
SCBrCZ/H), 5.06 (d, J = 11.0 Hz,  1   H min0r, SCBrC //H ), 4.67 (s,  1   H min0r, NC//), 4.65 (s, 
1   H major,  NC//), 4.55  (d, y =  11.0 Hz,  1  H ,  SCBrCH//), 4.15  (d, J =  14.5 Hz,  1   H minor, 
NCZ/HAr), 4.09 (d, J = 14.5 Hz,  1 H major, NC//HAr), 3.81 (s, 3 H minor, OC//3), 3.79 (d, /  
—   14.5 Hz,  1  H major,  NCHZ/Ar), 3.79 (s , 3 H major, OC//3), 3.71  (d, J =  14.5 Hz,  1   H minor, 
NCHZ/Ar);  8C   (75  MHz,  CDC13)  159.2 (s),  133.8  (s),  130.4 (d),  130.2  (d),  130.1  (d),
130.0  (d),  129.8 (d), 129.6 (d), 129.5 (d), 129.0 (s),  128.5 (d),  127.8 (s),  127.7 (s), 113.8 
(d),  113.7  (d),  83.1  (s),  81.1  (s), 77.9 (t), 77.5  (t), 74.9 (d), 59.0 (t), 58.6 (t), 55.3  (q),
55.2  (q), 24 out of 26 expected signals observed; m/z (FAB+) 618 (MNa+, 81Br, 11), 616
237(MNa+, 79Br,  11), 314 (26),  176 (100); HRMS (FAB+): calcd for C23H,779BrF5NNa05S 
(MNa+) 615.9829, found 615.9817.
Data  for  162a:  Rf  0.31  (2:1  petroleum  ether  40-60°C/Et20);  mp  83-86  °C;  U m ax 
(neaO/cm'1  3009, 2896,  1772,  1612,  1514,  1463,  1364,  1238,  1115,  1028, 803; 6H  (300 
MHz, CDC13) 7.35-7.48 (m, 5 H, ArH), 7.21  (d, J = 8.6 Hz, 2 H, ArH), 6.58 (d, J = 8.6 
Hz, 2 H, ArH), 4.32 (br t, J = 9.6 Hz,  1 H, NCH), 4.12 (d, J = 14.4 Hz,  1 H, NC//HAr), 
3.88  (d, J =  14.4 Hz,  1   H, NCH//Ar), 3.79 (s, 3  H, OC//3),  2.97  (d, J = 9.6 Hz, 2 H, 
SCBrC//2);  5C   (75  MHz,  CDC13)  172.9  (s),  159.3  (s),  136.2  (s),  130.6  (d),  129.2 (d),
129.0  (d),  127.6 (d),  127.2 (s),  113.9 (d), 69.8 (d), 60.2 (t), 55.3  (q), 40.4 (t); m/z (Cl) 
596  (MH+,  81Br,  2),  594  (MH+,  79Br,  2),  567  (51),  404  (32),  284  (66),  226  (45),  176 
(44), 121 (100).
4-Bromo-2-(4-methoxybenzyl)-3-(4-methoxyphenyl)isoxazolidine-4-sulfonic  acid 
pentafluorophenyl  ester  (160/161b),  and  5-Bromo-2-(4-methoxybenzyl)-3-(4- 
methoxyphenyl)isoxazolidine-5-sulfonic acid pentafluorophenyl ester (162b)
\\//  Br
PFPO
PMB
MeO
160/161b
\\//  Br
PFPO OMe
162b
a-Bromo-PFP-vinyl sulfonate 143 (2.0 g, 5.7 mmol) and DABCO (60 mg, 0.6 mmol) 
was dissolved in PhMe (30 mL) and stirred at RT for 5  mins, then treated with C-(4- 
methoxyphenyl)-/V-(4-methoxybenzyl)  nitrone  136c  (2.3  g,  8.5  mmol).  The  resulting 
suspension was stirred at RT for 18 hours. Solvent was removed in vacuo and the crude 
residue purified by flash chromatography (starting 30:1  petroleum ether 40-60°C/Et20) 
to give 160/161b (3.3 g, 93%) as a mixture of diastereoisomers and 162b (0.05 g,  1%) 
as  a  single  product-  overall  yield  (94%,  160/161b:162b  =  65:1,  160  and  161b  = 4:1 
major: minor).
Data for 160/161b:  Rf0.59 (2:1  petroleum ether 40-60°C/Et20); Dm ax (neat)/cm_ 1  2938, 
2839,  1612,  1512,  1467,  1304,  1246,  1190, 993, 830, 730; 5H  (300 MHz, CDC13) 7.47 
(br d, J = 8.6 Hz, 2 H, Ar//), 7.25 (d, J = 8.6 Hz, 2 H, ArH), 6.99 (d, J = 8.6 Hz, 2 H, 
ArH), 6.89 (d, J = 8.6 Hz, 2 Hm inor, ArH), 6.86 (d, J = 8.6 Hz, 2 Hm aj0r, ArH), 5.08 (d, J 
=  11.0 Hz,  1  Hm ajor, SCBrCHH), 5.07 (d, /  =  11.0 Hz,  1   H^nor, SCBrC//H), 4.65 (s,  1  
Hminor, NCH), 4.63 (S ,  1   Hmajor, NCH), 4.57 (d, J =  11.0 Hz,  1  H, SCBrCHH), 4.11 (d, J 
=  14.5  Hz,  1  H, NCHHAr),  3.85  (s,  3  H, OCtf3),  3.83  (s,  3  Hm inor, OCtf3),  3.80 (s,  3
238Hm aj„r, OCHj), 3.79 (d, J =  14.5 Hz,  1   Hm ajor, NCHtfAr), 3.71  (d, J =  14.5 Hz,  1   Hm inor, 
NCH/ZAr);  5c  (75  MHz,  CDCb)  160.8  (s),  160.5  (s),  131.2  (d),  130.4 (d),  130.2  (d),
127.9  (s),  127.8 (s),  125.6 (s),  114.1  (d),  113.9 (d),  113.8 (d),  113.7  (d), 83.6 (s), 81.2
(s), 77.8 (t), 77.3 (t), 74.6 (d), 58.9 (t), 58.5 (t), 55.3 (q), 55.2 (q), 21  out of 28 expected 
signals observed; m/z (FAB+) 648 (MNa+, 81Br, 6), 646 (MNa+, 79Br, 6), 329 (17),  176 
(100);  HRMS  (FAB+):  calcd  for  C24Hi979BrF5NNa06S  (MNa+)  645.9934,  found 
645.9942.
Data for 162b: Rf0.05 (2:1 petroleum ether 40-60°C/Et20); um ax (neatVcm1  2933, 2838, 
1773,  1612,  1512,  1464,  1301,  1241,  1173,  1029, 825; 6H  (300 MHz, CDC13) 7.38 (d, J 
= 8.6 Hz, 2 H, ArH), 7.20 (d, /  = 8.6 Hz, 2 H, ArH), 6.94 (d, J = 8.6 Hz, 2 H, ArH), 
6.85 (d, J = 8.6 Hz, 2 H, ArH), 4.27 (t, J = 9.6 Hz,  1   H, NCH), 4.11  (d, J =  14.7 Hz,  1  
H, NC//HAr), 3.84 (d, J =  14.7 Hz,  1 H, NCHtfAr), 3.83 (s, 3 H, OCH3), 3.79 (s, 3 H, 
OCH3), 2.94 (d, J = 10.4 Hz, 2 H, SCBrCH2)\ 6C  (75 MHz, CDC13)  172.6 (s),  160.1 (s),
159.3  (s),  130.6 (d),  128.9 (d),  127.9 (s),  127.3  (s),  114.5  (d),  113.8 (d), 69.4 (d), 59.9 
(t),  55.4  (q),  55.3  (q),  40.3  (t); m/z (Cl) 626  (MH+,  81Br,  2),  624  (MH+,  79Br, 2), 434 
(27), 390 (51), 314 (50), 269 (64), 206 (59),  179 (70),  121  (100); HRMS (Cl): calcd for 
C2 4H2079BrF5NO6S (MH+) 624.01148, found 624.01234.
4-Bromo-3-(4-chlorophenyl)-2-(4-methoxybenzyl)isoxazolidine-4-sulfonic  acid 
pentafluorophenyl  ester  (160/161c),  and  5-Bromo-3-(4-chlorophenyl)-2-(4- 
methoxybenzyl)isoxazolidine-5-sulfonic acid pentafluorophenyl ester (162c)
a-Bromo PFP vinyl  sulfonate  143 (2.0 g, 5.7 mmol) and DABCO (60 mg, 0.6 mmol) 
was dissolved in PhMe (45 mL) and stirred at RT for 5  mins, then treated with C-(4- 
chlorophenyl)-7V-(4-methoxybenzyl)  nitrone  136d  (2.3  g,  8.5  mmol).  After  24  hours 
stirring  enough  DCM  (10  mL)  was  added  to  aid  dissolution  of the  nitrone  and  the 
resulting  suspension  was  stirred  for  a  further  1  day  at  RT.  Solvent  was  removed  in 
vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  30:1 
petroleum ether 40-60°C/Et20) giving products 160/161c (2.5 g, 70%) as a mixture of 
diastereoisomers  and  162c  (0.14  g,  4%)  as  a  single  product-  overall  yield  (74%, 
160/161c:162c = 18:1,160 and 161c = 3:1 major:minor).
PFPO
PFPO
160/161c
239Data for 160/161c:  Rf0.80 (2:1  petroleum ether 40-60°C/Et20); t)m ax (neat)/cm'' 2936, 
1514,  1386,  1247, 1191, 1092, 993, 826, 723; 8H  (300 MHz, CDC13) 7.38-7.50 (m, 4 H, 
Ar//), 7.21  (d, J = 8.6 Hz, 2 H, ArH), 6.88 (d, J = 8.6 Hz, 2 Hm inor, ArH), 6.84 (d, J =
8.6 Hz, 2 H major,  ArH), 5.07 (d, J =  11.2 Hz,  1   H,  SCBrC/ffl), 4.63 (s,  1   H minor, NCI9), 
4.61  (s,  1   Hm ajor, NCH), 4.55 (d, J=  11.2 Hz,  1   H, SCBrCHH), 4.11  (d, 7=  14.2 Hz,  1  
Hminor,  NC//HAr), 4.08 (d, J =  14.2 Hz,  1   H maj0r,  NC//HAr), 3.82 (s ,  3  H minor,  OC//3), 
3.81 (d, J = 14.2 Hz,  1   H major5  NCH//Ar), 3.79 (s, 3 H major, OC//3), 3.72 (d, J = 14.2 Hz, 
1  Hminor, NCH//Ar); 5C  (75 MHz, CDCI3) 159.3 (s),  135.6 (s), 133.7 (s), 132.3 (s), 131.2 
(d), 130.5 (d), 130.3 (d),  128.8 (d), 127.3 (s), 113.8 (d), 113.7 (d), 83.1 (s), 82.8 (s), 77.8 
(t),  77.2  (t),  74.1  (d),  58.9  (t),  55.2  (q),  18  out of 26  expected  signals  observed;  m/z 
(FAB+)  654  (MNa+,  37Cl81Br,  1),  652  (MNa+,  37Cl79Br  and  35Cl8lBr,  5),  650  (MNa+, 
35Cl79Br,  4),  176  (100);  HRMS  (FAB+):  calcd  for  C23Hi679Br35ClF5NNa05S  (MNa+) 
649.9439, found 649.9441.
Data  for  162c:  Rf 0.26  (2:1  petroleum  ether  40-60°C/Et20);  mp  109-112  °C;  Dm ax 
(neatycm1  3002, 2935,  1773,  1612,  1513,  1420,  1306,  1236,  1149,  1010, 836, 799;  6H  
(500 MHz, CDC13) 7.36-7.41 (m, 4 H, Ar//), 7.19 (d, J = 8.6 Hz, 2 H, ArH), 6.84 (d, J =
8.6 Hz, 2 H, Ar//), 4.30 (br dd, J = 11.8, 7.1 Hz,  1  H, NC//), 4.09 (d, J = 14.3 Hz,  1 H, 
NC/THAr),  3.90 (d, J =  14.3  Hz,  1  H, NCHZ/Ar),  3.79 (s,  3  H, OC//3),  2.97  (dd, J = 
17.0, 7.1  Hz,  1  H, SCBrC/ZH), 2.89 (dd, J =  17.0,  11.8 Hz,  1  H, SCBrCH//); 5C  (125 
MHz, CDCI3)  172.1  (s),  159.4 (s),  134.9 (s),  134.7 (s),  130.6 (d),  129.3 (d),  128.8 (d),
126.8  (s), 113.8 (d), 68.8 (d), 60.2 (t), 55.3 (q), 40.2 (t).
4-Bromo-3-(4-bromophenyI)-2-(4-methoxybenzyl)isoxazolidine-4-sulfonic  acid 
pentafluorophenyl  ester  (160/161d),  and  5-Bromo-3-(4-bromophenyl)-2-(4- 
methoxybenzyl)isoxazolidine-5-su!fonic acid pentafluorophenyl ester (162d)
\\//  Br
PFPO
PMB
Br 160/161 d
\\//  Br
PFPO
162d
a-Bromo PFP vinyl  sulfonate 143 (2.0 g, 5.7 mmol) and DABCO (60 mg, 0.6 mmol) 
was dissolved in PhMe (40 mL) and stirred at RT for 5  mins, then treated with C-(4- 
bromophenyl)-/V-(4-methoxybenzyl)  nitrone  136b  (2.7  g,  8.5  mmol).  After  24  hours 
stirring  enough  DCM  (10  mL)  was  added  to  aid  dissolution  of the  nitrone  and  the 
resulting  suspension  was  stirred  for  a  further  1   day  at  RT.  Solvent  was  removed  in
240vacuo  and  the  crude  residue  was  purified  by  flash  chromatography  (starting  30:1 
petroleum ether 40-60°C/Et20) giving products 160/161d (2.0 g, 52%) as a mixture of 
diastereoisomers  and  162d  (0.18  g,  5%)  as  a  single  product-  overall  yield  (57%, 
160/161d:162d =11:1,160 and 161d = 5:2 major:minor).
Data for 160/161d: Rf0.70 (2:1  petroleum ether 40-60°C/Et20); a)m ax (neatVcm1 2935, 
1589, 1384, 1246, 1190, 1067, 994, 819, 722; 8H  (300 MHz, CDC13) 7.58 (d, 7 = 8.3 Hz, 
2 H, Ar//), 7.40 (d, 7 = 8.3 Hz, 2 H, Ar//), 7.20 (d, 7 = 8.6 Hz, 2 H, ArH), 6.88 (d, 7 =
8.6  Hz, 2 Hminor? Ar//), 6.83 (d, 7 = 8.6 Hz, 2 H maj0r, Ar//), 5.07 (d, 7 = 11.0 Hz,  1  Hm ajor, 
SCBrC//H), 5.03 (d, 7 = 11.0 Hz,  1   H minor, SCBrCHR), 4.61  (s,  1   H min0r, NC//), 4.59 (s, 
1   Hmajor?  NC//), 4.54 (d, 7 =  11.0 Hz,  1  H ,  SCBrCH//), 4.11  (d, 7 =  14.5  Hz,  1  H minor, 
NC//HAr),  4.07  (d, 7 =  14.5  Hz,  1  H major,  NC//HAr),  3.82  (d, 7 =  14.5  Hz,  1   Hmajor, 
NCHZ/Ar),  3.81  (s, 3  H minor,  OC//3), 3.79 (s, 3  H major,  OC//3), 3.71  (d, 7 =   14.5 Hz,  1  
Hminor, NCH//Ar); 6c (75 MHz, CDCI3)  159.3 (s),  132.9 (s),  132.5 (d),  131.8 (d),  131.5 
(d),  131.0 (d),  130.5  (d),  130.3  (d),  127.3  (s),  123.9  (s),  113.8  (d),  113.7 (d),  82.7  (s),
77.8  (t), 74.2 (d), 59.0 (t), 58.7 (t), 55.2 (q),  18 out of 26 expected signals observed; m/z 
(FAB+) 698 (MNa+, 81Br81Br, 1), 696 (MNa+, 79Br81Br, 3), 694 (MNa+, 79Br79Br, 1), 176 
(100);  HRMS  (FAB+):  calcd  for  C23Hi679Br2F5NNa0 5S  (MNa+)  693.8934,  found 
693.8924.
Data  for  162d:  Rf 0.18  (2:1  petroleum  ether  40-60°C/Et20);  mp  116-118  °C;  v max 
(neatycm1  3000, 2840,  1788,  1611,  1511,  1461,  1305,  1236,  1105,  1026, 827;  6H  (300 
MHz, CDCI3) 7.54 (d, 7 = 8.3 Hz, 2 H, ArH), 7.23 (d, J = 8.3 Hz,  1 H, ArH), 7.19 (d, J 
= 8.6 Hz, 2 H, ArH), 6.85 (d, J = 8.6 Hz, 2 H, ArH), 4.29 (br dd, 7 = 11.5, 7.5 Hz, 1 H, 
NC//), 4.09 (d, J = 14.5 Hz,  1 H, NC//HAr), 3.89 (d, J = 14.5 Hz,  1  H, NCHZ/Ar), 3.79 
(s, 3 H, O C//3), 2.98 (dd, 7= 16.9, 7.5 Hz, 1 H, SCBrC//H), 2.88 (dd, 7= 16.9, 11.5 Hz, 
1  H, SCBrCH//);  6C  (75 MHz, CDC13)  172.1  (s),  159.4 (s),  135.5 (s),  132.3 (d),  130.7 
(d), 129.2 (d), 126.8 (s),  122.9 (s), 113.9 (d), 68.9 (d), 60.3 (t), 55.3 (q), 40.2 (t).
4-Bromo-2-(4-methoxybenzyl)-3-naphthalen-2-yl-isoxazolidine-4-suIfonic  acid 
pentafluorophenyl  ester  (160/161e),  and  5-Bromo-2-(4-methoxybenzyl)-3- 
naphthalen-2-yl-isoxazolidine-5-sulfonic acid pentafluorophenyl ester (162e)
\\//  Br
\\ //  Br PFPO O
PFPO
PMB
PMB
160/161 e 162e
241a-Bromo PFP vinyl sulfonate 143 (2.0 g, 5.7 mmol) and DABCO (60 mg, 0.6 mmol) 
was dissolved in PhMe (40 mL) and stirred at RT for 5  mins, then treated with C-(2- 
naphthyl)-Af-(4-methoxybenzyl) nitrone 136f (2.5 g, 8.5  mmol). After 24 hours stirring 
enough  DCM  (10  mL)  was  added  to  aid  dissolution  of the  nitrone  and  the  resulting 
suspension was stirred for a further 1  day at RT. Solvent was removed in vacuo and the 
crude residue was purified by flash chromatography (starting 30:1  petroleum ether 40- 
60°C/Et2O) giving products 160/161e (2.9 g, 81%) as a mixture of diastereoisomers and 
162e (0.15 g, 4%) as a single product- overall yield (85%,  160/161e:162e =  19:1, 160 
and 161e = 2:1 majonminor).
Data for 160/161e:  Rf0.60 (2:1  petroleum ether 40-60°C/Et20); Dm ax (neatycm'1  2936, 
2837,  1514,  1468, 1384,  1246,  1190, 994, 820, 739; 5H  (300 MHz, CDC13) 8.02 (br s,  1  
H, ArH), 7.84-7.97 (m, 3 H, ArH), 7.50-7.69 (m, 3 H, ArH), 7.25  (d, J = 8.6 Hz, 2 H, 
ArH), 6.89 (d, J = 8.6 Hz, 2 H minor, ArH), 6.84 (d, J = 8.6 Hz, 2 H major, ArH), 5.13 (d, J 
= 11.0 Hz,  1   H , SCBrC//H), 4.84 (s,  1  H minor, NCH), 4.83 (s,  1   H maj0r, NCH), 4.66 (d, J 
= 11.0 Hz,  1   H min0r, SCBrCHH), 4.64 (d, /  = 11.0 Hz,  1  H major, SCBrCH//), 4.15 (d, J =
14.2  Hz, 1  H, NC//HAr), 3.86 (d,J  = 14.2 Hz, 1 H, NCHZ/Ar), 3.82 (s, 3 Hm inor, OCH3), 
3.79 (s, 3 Hm ajor, OC//3); 5C  (75 MHz, CDC13)  159.3 (s),  133.9 (s),  133.0 (s),  131.3 (s),
130.5  (d),  130.3  (d),  129.1  (s),  128.4  (d),  128.2  (d),  127.8  (d),  127.7  (d),  127.1  (d),
127.0 (d),  126.5  (d),  113.8 (d),  113.7  (d), 83.0 (s), 77.9 (t), 77.2 (t), 74.9 (d), 59.1  (t),
58.7  (t), 55.2 (q), 23 out of 32 expected signals observed; m/z (FAB+) 668 (MNa+, 81Br, 
9),  666  (MNa+,  79Br,  9),  644  (20),  245  (19),  166  (100);  HRMS  (FAB+):  calcd  for 
C27Hi979BrF5NNa0 5S (MNa+) 665.9985, found 665.9971.
Data for 162e: Rf0.20 (2:1 petroleum ether 40-60°C/Et20); \)m ax (neatycm1 2934, 2836, 
1773,  1612,  1513,  1302,  1242,  1173,  1031, 904, 820, 728; 5h (300 MHz, CDC13) 7.84- 
7.94 (m, 4 H, ArH), 7.61  (dd, J = 8.6, 1.6 Hz,  1 H, ArH), 7.52-7.57 (m, 2 H, ArH), 7.22 
(d, J = 8.6 Hz, 2 H, ArH), 6.85 (d, /  = 8.6 Hz, 2 H, ArH), 4.50 (br dd, J = 11.0, 8.0 Hz, 
1  H, NC//), 4.17 (d, J = 14.2 Hz,  1  H, NC//HAr), 3.94 (d, J = 14.2 Hz,  1  H, NCHZ/Ar), 
3.78 (s, 3 H, OC//3), 3.09 (dd, J =  16.9,  11.0 Hz,  1  H, SCBrC/ZH), 3.02 (dd, J = 16.9,
8.0 Hz,  1  H, SCBrCH//); 5C  (75 MHz, CDC13)  172.5 (s),  159.4 (s),  133.6 (s),  133.5 (s),
133.3  (s),  130.7 (d),  129.2 (d), 127.9 (d), 127.8 (d), 127.3 (d), 127.2 (s),  126.7 (d), 124.4 
(d),  113.9  (d),  69.9  (d),  60.3  (t),  55.3  (q),  40.3  (t),  1   x  d not observed;  m/z (Cl)  646 
(MH+, 81Br,  1), 644 (MH+, 79Br, 1), 410 (31), 334 (48), 290 (70), 199 (74), 121 (100).
2424-Bromo-3-cyclohexyl-2-(4-methoxybenzyI)isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester (160/161f), and 5-Bromo-3-cyclohexyl-2-(4-methoxy 
benzyl)isoxazolidine-5-sulfonic acid pentafluorophenyl ester (162f)
a-Bromo-PFP-vinyl sulfonate 143 (1.4 g, 4.0 mmol) and DABCO (50 mg, 0.4 mmol) 
was  dissolved  in  PhMe  (30  mL)  and  stirred  at  RT  for  5  mins,  then  treated  with  C- 
(cyclohexyl)-A-(4-methoxybenzyl)  nitrone  136e  (1.5  g,  6.1  mmol).  The  resulting 
suspension was stirred at RT for 18 hours. Solvent was removed in vacuo and the crude 
residue purified by flash chromatography (starting 30:1  petroleum ether 40-60°C/Et20) 
to give 160/161f (1.3 g, 54%) and 162f (0.34 g, 14%) as a single products- overall yield 
(68%, 160/161f:162f = 4:1).
Data for 160/161f:  Rf0.72  (2:1  petroleum ether 40-60°C/Et20);  mp  112-114 °C; Dm ax 
(neat)/cm'‘ 2973, 2937,  1613, 1514,  1391,  1257,  1133, 994, 816; 8H  (300 MHz, CDCI3)
7.32  (d, 7=8.6 Hz, 2 H, ArH), 6.88 (d, 7= 8.6 Hz, 2 H, ArH), 5.06 (d, 7= 11.0 Hz, 1  H, 
SCBrCHH),  4.49  (d,  7  =  11.0  Hz,  1   H,  SCBrCHH),  4.11  (d,  7  =  13.7  Hz,  1   H, 
NCHHAr), 4.01  (d, 7 =  13.7 Hz,  1  H, NCHHAr), 3.80 (s, 3 H, OCH3), 3.46 (br d, 7 =
5.6  Hz, 1 H, NC#), 2.15 (app. br d, J = 12.6 Hz, 1 H, cyclohexyl-#), 1.97-2.09 (m, 1 H, 
cyclohexyl-#),  1.91  (app.  br d, J =  12.6 Hz,  1  H,  cyclohexyl-#),  1.66-1.85  (m,  3  H, 
cyclohexyl-#),  1.32  (app.  br t,  /  =  12.6  Hz,  2 H,  cyclohexyl-#),  1.07-1.25  (m,  3  H, 
cyclohexyl-#); 5C  (75 MHz, CDC13)  159.2 (s),  130.2 (d),  128.5 (s),  113.8 (d), 83.4 (s),
77.3 (t), 73.8 (d), 60.5 (t), 55.2 (q), 42.0 (d), 32.4 (t), 29.6 (t), 26.3 (t), 26.2 (t), 26.1 (t); 
m/z (FAB+) 624 (MNa+,  slBr,  12), 622 (MNa+,  79Br,  12), 270 (20),  176 (100); HRMS 
(FAB+): calcd for C23H2379BrF5NNa05S (MNa+) 622.0298, found 622.0301.
Data for 162f: Rf0.27 (2:1 petroleum ether 40-60°C/Et20); t)m ax (neatycm'12926, 2852, 
1772, 1612,  1513,  1450,  1246,  1171,  1032,910, 802; SH  (500 MHz, CDC13) 7.27 (d, 7 =
8.8  Hz, 2H, ArH), 6.88 (d, 7 = 8.8 Hz, 2 H, ArH), 4.11 (d, 7= 13.7 Hz,  1  H, NCHHAr),
4.03 (d, 7 = 13.7 Hz,  1  H, NCHHAr), 3.80 (s, 3 H, OCH3), 3.20 (app. dt, 7 = 7.7,5.9 Hz, 
1  H, NCH), 2.64 (dd, 7 = 17.5, 8.0 Hz,  1  H, SCBrCHH), 2.57 (dd, 7 = 17.5, 8.3 Hz, 1 H, 
SCBrCH#),  1.62-1.78 (m, 5 H, cyclohexyl-#),  1.46-1.53 (m,  1   H, C#CHN),  1.10-1.26 
(m,  3  H,  cyclohexyl-#),  1.01  (ddd, J =  15.6,  12.5,  3.2 Hz,  1   H, cyclohexyl-#), 0.86- 
0.95  (m,  1   H,  cyclohexyl-#);  5C   (125  MHz,  CDC13)  175.6  (s),  159.4  (s),  130.7  (d),
127.1  (s),  113.9 (d), 68.0 (d), 62.4 (t), 55.3 (q), 40.4 (d), 31.9 (t), 29.9 (t), 28.0 (t), 26.3
PFPO
PFPO
162f 160/161 f
243(t), 26.1  (t),  25.8  (t);  m/z (Cl) 602 (MH+,  81Br,  1),  600 (M H\  79Br,  1),  577  (21), 410 
(37), 290 (87), 230 (31), 208 (43),  182 (80),  121 (100).
4-Bromo-3-phenyl-4,5-dihydroisoxazole-4-sulfonic  acid  pentafluorophenyl  ester 
(164)
\\//  Br
PFPO
To a stirring suspension of isoxazolidine 160/161a (100 mg, 0.17 mmol) in benzene (4 
mL) DDQ (150 mg, 0.67 mmol) was added. The reaction was stirred at RT for 10 days. 
Removal of solvent followed by column chromatography (starting  15:1 petroleum ether 
40-60°C/Et20) yielded the desired product 164 (17 mg, 21%) as a yellow solid.
Rf 0.65  (4:1  petroleum  ether  40-60°C/Et20);  mp  105-108  °C;  a)m ax  (neatycm' 1  3063, 
2920,  1519,  1447,  1189,  920,  762;  5h  (300  MHz,  CDC13)  7.94-7.99  (m,  2  H,  ArH), 
7.41-7.54 (m, 3 H, ArH), 5.58 (d, J = 12.3 Hz,  1  H, SCBrCHH), 5.26 (d, J = 12.3 Hz, 1  
H, SCBrCHH); 5C  (75 MHz, CDC13) 152.1 (s), 131.5 (d),  128.7 (d),  128.6 (d),  124.9 (s),
82.9  (t), 75.9 (s); m/z (El) 473 (M+, 81Br,  1), 471  (M+, 79Br,  1), 392 (34), 225 (32), 208 
(67),  184  (64),  144  (100),  89  (63);  HRMS  (El):  calcd  for  C15H779BrF5N0 4S  (M+) 
470.9194, found 470.9203.
2444.8. Procedures from HIV studies
(4-Aminomethylbenzyl)carbamic acid terf-butyl ester (187)178
h2n
NHBoc
/7-Xylyldiamine (3.1 g, 22.9 mmol) in DCM (20 mL) at 0 °C was treated with NEt3 (7.7 
mL,  55.0  mmol).  To  this  ice-cold  suspension  was  added  dropwise  over  3  hours  a 
solution  of  B0C 2O  (2.0  g,  9.2  mmol)  in  DCM  (25  mL)  whilst  maintaining  the 
temperature  at 0  °C.  The  reaction  mixture  was  allowed  to  stir  at  RT  overnight  then 
concentrated  in  vacuo.  The  residue  was  redissolved  in  DCM  (30  mL)  and  washed 
consecutively  with  sat.  NaHCCh,  and  brine.  The  organic  layer  was  dried  (MgSCL), 
filtered,  and concentrated in vacuo to yield the product (2.0 g, 92%)  as a white solid. 
Data agrees with literature.
44.3  (t), 28.4 (q).
[4-(Ethenesulfonylaminomethyl)benzyl]carbamic acid tert-butyl ester (185)
A  premixed  suspension  of  (4-aminomethylbenzyl)carbamic  acid  tert-butyl  ester  187 
(1.9 g, 8.0 mmol) and NEt3 (2.8 mL, 20.1 mmol) in DCM (10 mL) was added dropwise 
to a stirring solution of 2-chloroethane-l-sulfonyl chloride (1.1  g, 6.7 mmol) in DCM
and then warmed to RT. The reaction was diluted with DCM (20 mL) and washed with 
H2O  (1  x  25  mL),  dried  (MgSCL),  and  filtered.  The  filtrate  was  collected  and 
concentrated  in  vacuo to  give the crude which was purified by flash chromatography 
(starting  1:1  petroleum ether 40-60°C/Et20) to furnish the desired product (1.8 g, 84%) 
as white solid.
Rf 0.16 (1:2  petroleum  ether  40-60°C/Et20);  mp  141-142  °C;  \)m ax  (neatycm1   3369, 
3207, 2976,  1687, 1509, 1427, 1330, 1248, 1154, 1051, 960; 8H  (300 MHz, CDC13) 6.48 
(dd, J =  16.6, 9.6 Hz,  1   H, SCH=), 6.25 (d, J = 16.6 Hz,  1  H, SCH=C//H), 5.92 (d, J =
9.6  Hz,  1  H, SCH=CH//), 4.87 (br s, 1  H, BocN//), 4.68 (br s,  1  H, NH), 4.28 (br d, /  =
5.9  Hz, 2 H, BocNHC//2), 4.18 (d, J = 6.2 Hz, 2 H, NHC//2),  1.45 (s, 9 H, C(C//3)3); 5C
mp  146-148 °C;  8H  (300 MHz, CDC13) 7.25 (m, 4 H, Ar//), 4.88 (br s,  1   H, N//), 4.28 
(br d, J = 4.9 Hz, 2 H, C//2NHBoc), 3.84 (s, 2 H, C//2NH2),  1.45 (s, 9 H, C(C//3)3); §c 
(75 MHz, CDCI3)  156.0 (s),  142.2 (s),  137.6 (s),  127.6 (d),  127.2 (d), 79.2 (s), 46.1  (t),
BocHN
O ,  O
(10 mL) at -10 °C. The reaction mixture was stirred for a further  1   hour after addition
245(75 MHz, CDCb)  155.9 (s),  139.0 (s),  136.1  (d),  135.6 (s),  128.2 (d),  127.8 (d),  126.7
(t), 46.7 (t), 44.2 (t), 28.4 (q); m/z (ES+) 365 (38), 349 (MNa+,  100), 293 (19),  180 (40);
HRMS (ES+): calcd for CisH^NaCbS (MNa+) 349.1207, found 349.1198.
(2-Aminoethyl)carbamic acid /c/r-butyl ester (192)1
NHBoc
Ethylenediamine (33.5 mL, 500.0 mmol) in DCM (300 mL) was added dropwise over 3 
hours to a solution of Boc20  (11.5 mL, 50.0 mmol) in DCM (50 mL), whilst stirring at 
0  °C.  After  addition  the  reaction  mixture  was  allowed  to  stir  at  RT  overnight.  The 
suspension  was  washed  with  H20   (3  x  60  mL),  dried  (MgS04),  filtered,  and 
concentrated in vacuo to yield the product (6.2 g, 78%) as a white gel. Data agrees with 
literature.
8h (300 MHz, CDC13) 5.01  (br s,  1 H, NH), 3.12 (app. q, J = 5.9 Hz, 2 H, NCH2), 2.75 
(t, J = 5.9 Hz, 2 H, CH2N),  1.40 (s, 9 H, C(CH3)3); 5C  (75 MHz, CDCI3) 156.2 (s), 79.1 
(s), 43.4 (t), 41.9 (t), 28.4 (q).
[2-(2,3,5,6-Tetrafluoro-4-hydroxybenzoylamino)ethyl]carbamic  acid  tert-butyl 
ester (194)
HOBt (1.3 g, 9.6 mmol) and EDC.HC1 (2.9 g, 15.3 mmol) was added to a suspension of
2,3,5,6-tetrafluoro-4-hydroxybenzoic  acid hydrate  (2.0  g,  8.8  mmol)  in THF (80 mL) 
and left to stir at RT for  10 minutes. (2-Aminoethyl)carbamic acid tert-butyl ester 192 
(1.4 g,  8.8 mmol) was added and stirred overnight at RT. Brine (40 mL) was added and 
the reaction mixture extracted with EtOAc (3 x  80 mL).  The combined EtOAc layers 
was washed with brine, dried (MgS04), filtered, and the filtrate concentrated in vacuo. 
Purification  by  flash  chromatography  (starting  3:1  petroleum  ether  40-60°C/EtOAc) 
furnished the desired product (2.2 g, 71%) as a white solid.
Rf 0.18 (2:1  EtOAc/petroleum ether 40-60°C);  mp  151-154  °C;  \)m ax  (neatycm1  3395, 
3327, 2983, 1652, 1542,  1489, 1329, 1238, 1160, 969, 746; 5H  (300 MHz, CD3OD) 3.43
(75  MHz,  CD3OD)  161.5  (s),  80.3  (s),  41.0  (t),  40.6  (t),  28.7  (q);  m/z  (FAB+)  375 
(MNa+,  31),  297  (28),  154  (100);  HRMS  (FAB+):  calcd for Ci4H16F4N2Na04 (MNa+) 
375.0944, found 375.0950.
NHBoc
F F
(t, J = 6.4 Hz, 2 H, NC//2), 3.24 (t, J = 6.4 Hz, 2 H, NCH2\   1.42 (s, 9 H, C(C//3)3); 5C
246Ethenesulfonic  acid  4-(2-tert-butoxycarbonylaminoethylcarbamoyl)-2,3,5,6-tetra 
fluorophenyl ester (186)
B o c H N ^ /- \n 
H
F
F
A  premixed  suspension  of  [2-(2,3,5,6-tetrafluoro-4-hydroxybenzoylamino)ethyl] 
carbamic  acid tert-butyl ester 194 (1.0 g, 2.8  mmol)  and NEt3 (1.1  mL,  8.1  mmol) in 
DCM (20 mL) was added dropwise to a stirring  solution of 2-chloroethane-l-sulfonyl 
chloride  (440 mg,  2.7  mmol) in DCM  (15  mL)  at -10  °C.  The reaction mixture was 
stirred for a further 1  hour after addition, followed by 3 hours at RT.  The reaction was 
diluted with DCM  (20 mL)  and washed with  H2O  (1  x  25  mL),  dried  (MgSCL),  and 
filtered.  The filtrate was collected and concentrated in vacuo to give a crude product 
which  was  purified  by  flash  chromatography  (starting  2:1  petroleum  ether  40- 
60°C/Et2O) to furnish the desired product (0.6 g, 52%) as a white solid.
Rf 0.13 (2:1  Et20/petroleum  ether  40-60°C);  mp  149-152  °C;  (neatycm' 1   3364, 
3322, 3083, 2949, 1686, 1653, 1427, 1375, 1250,  1177, 986, 709; 5H  (300 MHz, CDC13) 
7.23 (br s,  1 H, NH), 6.80 (dd, J = 16.6, 9.6 Hz,  1  H, SCH=), 6.54 (d, J = 16.6 Hz,  1  H, 
SCH=GHH), 6.33  (d, J = 9.6 Hz,  1   H, SCH=CHH), 4.96 (br t, J = 5.6 Hz,  1   H, NH), 
3.57 (app. q, J = 5.4 Hz, 2 H, NCH2), 3.38 (app q, J = 5.6 Hz, 2 H, NC//2),  1.41 (s, 9 H, 
C(CH3)3); 5c (75 MHz, CD3OD)  159.6 (s),  134.6 (t),  133.3  (d), 80.3 (s), 41.0 (t), 40.6 
(t), 28.7  (q); m/z (ES+) 506 (100), 465  (MNa+,  84),  180 (53);  HRMS  (ES+):  calcd for 
C16Hj8F4N2Na06S (MNa+) 465.0700, found 465.0719.
(3S*,  4S*)-(4-{[3-(2-Fluorophenyl)-2-methylisoxazolidine-4-sulfonylamino]methyl} 
benzyl)carbamic acid tert-butyl ester (188a), (3/?*, 5S*)-(4-{[3-(2-FIuorophenyl)-2- 
methylisoxazolidine-5-sulfonylamino]methyl}benzyI)carbamic  acid tert-butyl  ester 
(189a),  and  (3S*,  5S*)-(4-{[3-(2-Fluorophenyl)-2-methylisoxazolidine-5-sulfonyl 
amino]methyl}benzyl)carbamic acid tert-butyl ester (190a)
F
BocHN BocHN
188a
o  o
BocHN
189a  190a
To  a  solution  of [4-(ethenesulfonylaminomethyl)benzyl] carbamic  acid  tert-butyl  ester
185  (200 mg,  0.6 mmol) in dry toluene (5  mL),  C-(2-fluorophenyl)-A/r -methyl nitrone 
119i  (280  mg,  1.8  mmol)  was  added.  The  reaction  mixture  was  heated  in  a  CEM
247microwave  for  30  minutes  at  140  °C.  When  complete  the  reaction  mixture  was 
concentrated in vacuo and the crude residue purified by flash chromatography (starting 
2:1 petroleum ether 40-60°C/Et20) to give the three products 188a (90 mg, 31%), 189a 
(75  mg,  26%),  and  190a  (32  mg,  11%)  as  light  brown  solids-  overall  yield  (67%, 
188a: 189a: 190a = 3:2:1).
Data  for  190a:  Rf 0.25  (2:1  Et20/petroleum  ether  40-60°C);  mp  122-124  °C;  Dm ax 
(neat)/cm'' 3393, 3291, 2926,  1687, 1513, 1427,  1362, 1299,  1145,  1051, 927, 812,754; 
8h (300 MHz, CDCI3) 7.57 (app. dt, J = 7.8, 1.6 Hz,  1  H, Ar//), 7.34 (d, J = 8.0 Hz, 2 H, 
Ar//), 7.24-7.30 (m, 3 H, Ar//), 7.15 (app. dt. J = 7.8,  1.1  Hz,  1   H, Ar//), 7.02-7.09 (m,
1  H, ArH), 5.05 (dd, J = 8.6, 5.6 Hz,  1 H, SC//), 4.84-4.90 (m, 2 H, SN// and BocN//),
4.44  (d, J = 6.2 Hz,  1 H, SNHC//H), 4.43 (d, J = 5.9 Hz,  1  H, SNHCH//), 4.30 (br d, J 
= 5.6 Hz, 2 H, BocNHC//2), 4.01 (dd, J = 10.2, 7.8 Hz,  1   H, NC//), 3.07 (ddd, J = 13.7,
8.6,  7.8 Hz,  1  H, SCHC//H), 2.85 (ddd, J = 13.7,  10.2, 5.6 Hz,  1  H, SCHCH//), 2.66 (s, 
3 H, NC//3),  1.45 (s, 9 H, C(C//3)3); 8c (75 MHz, CDCI3)  159.6 (s),  155.9 (s), 138.8 (s),
136.3 (s), 129.8 (d, JcF = 8.8 Hz),  128.7 (d, /CF = 3.5 Hz),  128.2 (d),  127.8 (d), 124.9 (d, 
Jc? = 3.8 Hz), 123.5 (s, 7C f = 12.6 Hz), 115.6 (d, Jcf = 22.0 Hz), 89.5 (d), 79.6 (s), 65.2 
(d), 47.5  (t), 44.3  (t), 43.4 (q), 39.6 (t), 28.4 (q); m/z (ES+) 480 (MH+,  100), 424 (25), 
263  (18),  101  (26);  HRMS  (ES+):  calcd  for  C23H31FN3O5S  (MH+)  480.1963,  found 
480.1965.
Data  for  189a:  Rf 0.18  (2:1  Et20/petroleum  ether  40-60°C);  mp  86-88  °C;  t>m ax 
(neatycm' 1  3363, 3239, 2919, 1696, 1512, 1454, 1363,  1248, 1151, 1050, 875, 831,753; 
8h (300 MHz, CDCI3) 7.43 (app. br t, J = 6.7 Hz,  1   H, ArH), 7.32 (d, J = 8.3 Hz, 2 H, 
ArH), 7.25-7.30 (m,  1   H, ArH), 7.24 (d, J = 8.3 Hz, 2 H, ArH), 7.14 (app. br t, J = 7.2 
Hz,  1   H, ArH), 7.02-7.09 (m,  1 H, ArH), 5.12 (br t, 7 = 5.6 Hz,  1  H, BocN//), 4.89-4.96 
(m, 2 H, SNH and SCH), 4.34-4.44 (m, 3 H, NC// and SNHC//2), 4.27 (br d, J = 5.4 Hz,
2 H, BocNHCZ/2), 3.12 (ddd, 7 = 13.4, 6.4, 3.8 Hz,  1 H, SCHC/7H), 2.72-2.81 (m, 4 H, 
NC//3  and  SCHCH//),  1.45  (s,  9  H,  C(C//3)3);  8c  (75  MHz,  CDCI3)  160.8  (s,  JCf =
247.4 Hz),  156.0 (s),  138.9 (s),  136.1  (s),  129.6 (d, 7C F = 8.8 Hz),  128.2 (d),  127.8 (d),
124.6  (d, 7C f = 3.5 Hz),  124.4 (s),  115.7 (d, JCF = 21.7 Hz), 89.7 (d), 79.6 (s), 63.9 (d),
47.5  (t), 44.8 (q), 44.3 (t), 28.4 (q),  1   x d not observed; m/z (ES+) 480 (MH+,  100), 424 
(25), 129 (21),  101  (33); HRMS (ES+): calcd for C23H31FN3O5S (MH+) 480.1963, found 
480.1959.
Data  for  188a:  Rf0.12  (2:1  Et20/petroleum  ether  40-60°C);  mp  107-110  °C;  um ax 
(neatycm' 1  3379, 3181,  2918,  1685,  1537,  1455,  1367,  1281,  1145,  1046, 857, 762; 8H
248(300 MHz, CDCI3) 7.41  (app. br t, 7 = 7.2 Hz,  1  H, ArH), 7.34 (app. dt, 7 = 7.8, 1.9 Hz,
1  H, Ar//), 7.13 (d, 7 = 8.0 Hz, 2 H, Ar//), 7.10-7.21 (m,  1  H, Ar//), 7.03 (d, 7 =8.0 Hz,
2 H, Ar//), 7.01-7.08 (m,  1  H, Ar//), 5.12 (br s,  1   H, SN//), 4.94 (br t, 7 = 5.6 Hz,  1   H, 
BocN//),  4.37  (dd,  7 =  9.9,  3.5  Hz,  1   H,  SCHC//H),  4.15-4.20  (m,  4  H,  SCHCH//, 
NHC//2,  and  BocNHC/ZH),  4.12  (br  d,  7 =  6.4  Hz,  1   H,  NCH),  3.93-4.03  (m,  2  H, 
BocNHCHH and  SCH),  2.60  (s,  3  H,  NC//3),  1.45  (s,  9  H,  C(C//3)3);  5C   (75  MHz, 
CDC13) 161.1 (s,7cf = 248.3 Hz), 156.0 (s), 138.9 (s),  135.4 (s),  130.5 (d, 7CF = 8.8 Hz),
129.9  (d, 7C f = 3.2 Hz),  128.2 (d),  127.8  (d),  125.0 (d, 7CF = 3.5  Hz),  123.7  (s, 7C F =
11.7 Hz),  116.1 (d, 7C f = 22.0 Hz), 79.6 (s), 72.3 (d), 68.0 (d), 67.0 (t), 47.0 (t), 44.2 (t),
42.8 (q), 28.4 (q); m/z (ES+) 518 (37), 502 (MNa+,  100), 454 (20); HRMS (ES+): calcd 
for C23H30FN3NaO5S (MNa+) 502.1795, found 502.1788.
(3S*,  4S*)-(4-{[3-(2-Chlorophenyl)-2-methylisoxazolidine-4-sulfonylamino]methyl} 
benzyl)carbamic acid tert-butyl ester (188b), (3/?*, 5S*)-(4-{[3-(2-Chlorophenyl)-2- 
methylisoxazolidine-5-sulfonylamino]methyl}benzyl)carbamic  acid ter/-butyl  ester 
(189b),  and  (3S*,  5S*)-(4-{[3-(2-Chlorophenyl)-2-methylisoxazolidine-5-suIfonyl 
amino]methyl}benzyl)carbamic acid ter/-butyl ester (190b)
BocHN
O   O O   O
BocHN BocHN
188b  Cl  189b  190b
To  a solution  of [4-(ethenesulfonylaminomethyl)benzyl]carbamic  acid  tert-butyl  ester
185  (250 mg,  0.8  mmol) in dry toluene (5  mL),  C-(2-chlorophenyl)-A-methyl nitrone 
119j  (390  mg,  2.3  mmol)  was  added.  The  reaction  mixture  was  heated  in  a  CEM 
microwave  for  30  minutes  at  140  °C.  When  complete  the  reaction  mixture  was 
concentrated in vacuo and the crude residue purified by flash chromatography (starting 
2:1 petroleum ether 40-60°C/Et20) to give the three products 188b (98 mg, 25%), 189b 
(65 mg, 17%), and 190b (41 mg, 11%)- overall yield (53%, 188b:189b:190b = 5:3:2). 
Data for 190b: Rf0.30 (2:1 Et20/petroleum ether 40-60°C); a)m ax (neatycm1 3312, 2917, 
1689,  1514,  1440,  1366,  1249, 1149,  1051, 861, 755; 8H  (300 MHz, CDC13) 7.64 (dd, 7 
= 7.2, 2.1 Hz,  1  H, ArH), 7.34 (d, 7 = 8.3 Hz, 2 H, ArH), 7.15-7.38 (m, 5 H, ArH), 5.04 
(dd, 7 = 8.8, 5.6 Hz,  1  H, SCH), 4.84-4.96 (m, 2 H, BocN// and SN/7), 4.42 (d, 7 = 5.9 
Hz, 2 H, SNHC//2), 4.29 (br d, 7 = 5.6 Hz, 2 H, BocNHCH2), 4.19 (dd, 7 = 9.9, 7.8 Hz, 
1   H,  NCH),  3.17  (ddd,  7 =  13.7,  8.8,  7.8  Hz,  1   H,  SCHC//H),  2.65-2.74  (m,  4  H, 
SCHCHH and NC/73),  1.45 (s, 9 H, C(C//3)3); 5C  (75 MHz, CDC13) 155.9 (s), 138.9 (s),
136.3  (s),  134.7 (s),  133.7 (s), 129.6 (d), 129.2 (d),  128.4 (d),  128.2 (d),  127.8 (d), 127.7
249(d), 89.4 (d), 79.6 (s), 68.5 (d), 47.5 (t), 44.3 (t), 43.5 (q), 39.6 (t), 28.4 (q); m/z (El) 497
(M+, 37C1, 2), 495 (M \ 35C1,6), 385 (60), 225 (45), 164 (79),  106 (61), 57 (100); HRMS
(El): calcd for C23H3o 35C1N3OsS (M+) 495.1589, found 495.1584.
Data  for  189b:  Rf 0.22  (2:1  Et20/petroleum  ether  40-60°C);  mp  116-119  °C;  \)m ax 
(neatycm"1  3393, 3290, 2925,  1687, 1512, 1428, 1363,  1271,  1145,  1051, 927, 813,750; 
8h (300 MHz, CDC13) 7.53 (dd, J = 7.8,  1.9 Hz,  1   H, Ar//), 7.20-7.38 (m, 7 H, Ar//),
5.04  (app. X,J = 5.6 Hz,  1  H, BocN//), 4.91  (br s,  1   H, SN//), 4.87 (dd, J = 8.3, 4.0 Hz, 
1   H, SC//), 4.58 (br t, /  = 7.2 Hz,  1  H, NCH), 4.37 (d, /  = 5.9 Hz,  1  H, NHC//H), 4.36 
(d, J = 5.9 Hz,  1   H, NHCH/7), 4.27 (br d, J = 5.6 Hz, 2 H, BocNHCH2), 3.26 (ddd, J = 
13.4, 6.7, 4.0 Hz,  1  H, SCHC/ZH), 2.83 (s, 3 H, NCZ/3), 2.55-2.67 (m,  1  H, SCHCH//),
1.45  (s, 9 H, C(CH3)3); Sc (75  MHz, CDCI3)  155.9 (s),  138.9 (s),  136.0 (s),  135.7 (s),
133.5  (s),  129.7 (d),  129.0 (d),  128.2 (d),  127.8 (d),  127.6 (d),  127.4 (d), 89.9 (d), 79.6 
(s), 67.0 (d), 47.5 (t), 45.1 (q), 44.3 (t), 39.0 (t), 28.4 (q); m/z (El) 497 (M+, 37C1, 7), 495 
(M+, 35C1,  17), 385 (72), 225 (42),  154 (87),  106 (75), 57 (100); HRMS (El): calcd for 
C2 3H3035ClN3O5S (M+) 495.1589, found 495.1590.
Data  for  188b:  R f 0.09  (2:1  Et20/petroleum  ether  40-60°C);  mp  138-141  °C;  \)m ax 
(neatycm' 1   3376,  3209,  2919,  1685,  1538,  1439,  1326,  1280,  1144,  1044,  931,  862, 
766;  8h (300 MHz, CDC13) 7.47  (dd, J = 7.0, 2.1  Hz,  1   H, Ar//),  7.29-7.40 (m, 3 H, 
ArH), 7.11  (d, J = 8.0 Hz, 2 H, ArH), 6.97 (d, J = 8.0 Hz, 2 H, ArH), 4.95 (app. t, /  =
5.6  Hz,  1  H, BocNH), 4.90 (br t, 7 = 5.9 Hz, 2 H, SNH), 4.46 (br d, J = 7.0 Hz,  1   H, 
NCH),  4.41  (dd,  J =  9.9,  4.0  Hz,  1  H,  SCHCHH),  4.31  (dd,  J =  9.9,  8.6  Hz,  1   H, 
SCHCHH),  4.24 (br d, J = 5.9 Hz,  2 H,  SNHCH2), 4.13  (dd, J =  13.9, 6.4 Hz,  1   H, 
BocNHCHH), 3.96 (app. td, J = 8.0,4.0 Hz, 1 H, SCH), 3.85 (dd, J = 13.9, 5.0 Hz, 1 H, 
BocNHCHH), 2.60 (s, 3 H, NCH3),  1.45 (s, 9 H, C(CH3)3); 8c (75 MHz, CDC13)  155.9 
(s),  138.9 (s),  135.2 (s),  134.3 (s),  134.2 (s),  130.1  (d),  129.9 (d),  129.8 (d),  128.2 (d),
127.8  (d), 79.6 (s), 72.9 (d), 70.1 (d), 67.1  (t), 47.0 (t), 44.2 (t), 42.7 (q), 28.4 (q),  1  x d 
not observed; m/z (ES+) 498  (ME*,  37C1, 42), 496 (MH+,  35C1,  100), 440 (22); HRMS 
(ES+): calcd for C23H3,35C1N30 5S (MH+) 496.1667, found 496.1664.
250(3S*,  4S*)-(4-{[3-(2-Chlorophenyl)-2-methylisoxazolidine-4-sulfonylamino]methyl} 
benzyl)carbamic  acid  tert-butyl  ester  (188b),  and  (35*,  4/?*)-(4-{[3-(2-Chloro 
phenyl)-2-methylisoxazolidine-4-sulfonylamino]methyl}benzyl)carbamic  acid  tert- 
butyl ester (191)
V
BocHN
191
BocHN
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(35*,45*)-3-(2-Chlorophenyl)-2-methylisoxazolidine-4-sulfonic acid pentafluorophenyl 
ester 103j (200 mg, 0.5 mmol) in THF (5 mL) was treated with (4-aminomethylbenzyl) 
carbamic acid tert-butyl ester 187 (160 mg, 0.7 mmol) followed by NEt3 (0.2 mL,  1.4 
mmol), and the reaction refluxed for 3 hours. The reaction mixture was concentrated in 
vacuo  and  the resulting  crude  residue purified by  flash  chromatography  (starting  8:1 
petroleum ether 40-60°C/EtOAc) to give 188b (144 mg, 64%) and 191 (58 mg, 26%)- 
overall yield (90%, 188b:191 = 5:2).
Data for 188b: Rf0.18 (2:1 petroleum ether 40-60°C/EtOAc); Data as for above.
Data  for  191:  Rf 0.23  (2:1  petroleum  ether  40-60°C/EtOAc);  \)m ax  (neatycm'1   3341, 
2965,  1688,  1515,  1440,  1331,  1256,  1148,  1032, 862, 763; 8H  (300 MHz, CDC13) 7.65 
(dd, J = 7.5, 1.6 Hz,  1 H, ArH), 7.35 (dd, J = 7.5, 1.6 Hz,  1 H, ArH), 7.13-7.31 (m, 6 H, 
ArH), 4.92 (br s,  1 H, SN//), 4.35-4.42 (m, 3 H, SCHC/ / 2 and SC//), 4.26 (br d,J=  5.6 
Hz,  BocNHCH2),  4.13  (d, J = 7.2 Hz,  1   H,  NCH),  4.11  (dd,  J =  14.2,  7.0 Hz,  1   H, 
SNHC//H),  3.99  (dd, J =  14.2, 4.8 Hz,  1  H,  SNHCH//),  3.67  (br t, J = 5.4 Hz,  1  H, 
BocN//), 2.65  (s, 3 H, NC//3),  1.45 (s, 9 H, C(C//3)3); Sc (75 MHz, CDC13)  156.0 (s),
138.9  (s),  135.7 (s),  134.7 (s), 131.2 (s), 130.6 (d), 129.7 (d),  129.1 (d), 128.1 (d), 127.7 
(d),  127.1  (d), 79.7 (s), 70.8 (d), 66.8 (t), 66.5 (d), 46.9 (t), 44.2 (t), 43.3 (q), 28.4 (q); 
m/z (El) 497  (M \  37C1, 4), 495  (M+,  35C1,  10), 235 (27),  154 (53),  134 (100), 91  (23); 
HRMS (El): calcd for C23H3035ClN3O5S (M+) 495.1589, found 495.1597.
251(3S*,  4S*)-(4-{[3-(2-Bromophenyl)-2-methylisoxazolidine-4-sulfonylamino]methyl} 
benzyl)carbamic acid tert-butyl ester (188c), (3R*, 55*)-(4-{[3-(2-Bromophenyl)-2- 
methylisoxazolidine-5-sulfonylamino]methyl}benzyl)carbamic  acid  tert-butyl  ester 
(189c),  and  (35*,  55*)-(4-{[3-(2-Bromophenyl)-2-methylisoxazolidine-5-sulfonyl 
amino]methyl}benzyI)carbamic acid ter/-butyl ester (190c)
BocHN BocHN BocHN
188c  ^ ^ ^ B r   189c  190c
To  a  solution  of [4-(ethenesulfonylaminomethyl)benzyl]carbamic  acid  tert-butyl  ester
185  (250 mg,  0.8  mmol) in dry toluene  (5  mL),  C-(2-bromophenyl)-A^-methyl nitrone 
119k  (490  mg,  2.3  mmol)  was  added.  The  reaction  mixture  was  heated  in  a  CEM 
microwave  for  30  minutes  at  140  °C.  When  complete  the  reaction  mixture  was 
concentrated in vacuo and the crude residue purified by flash chromatography (starting 
2:1 petroleum ether 40-60°C/Et20) to give the three products 188c (105 mg, 25%), 189c 
(45 mg, 11%), and 190c (40 mg, 10%)- overall yield (46%, 188c: 189c: 190c = 5:2:2). 
Data for 190c: Rf0.24 (2:1 Et20/petroleum ether 40-60°C); Dmax (neatycm1  3310, 2964, 
2918,  1688,  1513,  1434,  1327,  1250,  1152,  1021, 860, 755; SH  (300 MHz, CDC13) 7.63 
(dd, J = 7.8,  1.6 Hz,  1 H, ArH), 7.55 (dd, J = 8.0, 1.3 Hz,  1 H, ArH), 7.24-7.36 (m, 5 H, 
ArH), 7.15  (app. dt, J = 7.8,  1.6 Hz,  1   H, ArH), 5.04 (dd, J = 8.6, 5.6 Hz,  1  H, SC//), 
4.83-4.89 (m, 2 H, SNH and BocNH), 4.42 (d, J = 6.2 Hz, 2 H, SNHCH2), 4.30 (br d, J 
= 5.6 Hz, 2 H, BocNHCH2), 4.17 (dd, J = 9.6, 7.5 Hz,  1  H, NCH), 3.19 (ddd, J = 13.6,
8.6,  7.5 Hz,  1  H, SCHC//H), 2.68 (s, 3 H, NC//3), 2.63-2.72 (m,  1   H, SCHCH//),  1.45 
(s, 9 H,  C(C//3)3);  Sc (75 MHz, CDC13)  155.9 (s),  138.9 (s),  136.3  (2 x s),  132.9 (d),
129.6  (d),  128.7  (d),  128.3  (d),  128.2 (d),  127.8  (d),  123.9 (s),  89.4 (d), 79.6 (s), 71.0 
(d), 47.5  (t), 44.3  (t), 43.4 (q), 39.7 (t), 28.4 (q); m/z (FAB+) 564 (MNa+,  81Br, 9), 562 
(MNa+,  79Br,  9),  554  (100),  531  (72), 361  (72),  339  (28),  219  (39),  176 (39);  HRMS 
(FAB+): calcd for C23H3079BrN3NaO5S (MNa+) 562.0987, found 562.0972.
Data for 189c: Rf0.17 (2:1 Et20/petroleum ether 40-60°C); um ax (neatycm'13306, 2918, 
2850,  1687,  1513,  1436,  1330,  1249,  1148,  1022, 861, 754; §h (300 MHz, CDC13) 7.55 
(dd, J = 8.0,  1.3 Hz, 2 H, Ar//), 7.25-7.36 (m, 5 H, ArH), 7.16 (app. dt, J = 7.8,  1.6 Hz, 
1  H, ArH), 4.90 (dd, J = 8.3, 4.0 Hz, 1  H, SCH), 4.83-4.89 (m,  1 H, BocN//), 4.76 (br t, 
J = 5.9 Hz,  1   H,  SN//), 4.57 (br t, J = 7.2 Hz,  1  H, NC//), 4.40 (d, J = 5.6 Hz,  1   H, 
BocNHC/ZH),  4.38  (d, J = 5.6  Hz,  1   H, BocNHCH/7),  4.30  (br d,  J = 5.9  Hz,  2 H, 
SNHC//2), 3.30 (ddd, J = 13.4, 6.4, 4.0 Hz, 1  H, SCHC//H), 2.85 (s, 3 H, NCZ/3), 2.56-2.66  (m,  1   H, SCHCHH),  1.46 (s, 9 H, C(CH3)3); Sc (75 MHz, CDCI3)  155.9 (s),  139.0 
(s),  137.4 (s),  136.0 (s),  133.1  (d),  129.4 (d),  128.2 (d),  128.0 (d),  127.9 (2 x d),  123.6 
(s), 89.9 (d), 79.7 (s), 69.4 (d), 47.5 (t), 45.2 (q), 44.3 (t), 39.1  (t), 28.4 (q); m/z (El) 541 
(M+, 8lBr,  14), 539 (M \ 79Br,  14), 431  (76),  373  (24), 240 (34), 225  (80),  163  (100); 
HRMS (El): calcd for C23H3079BrN3O5S (M+) 539.1084, found 539.1083.
Data  for  188c:  Rf  0.08  (2:1  Et20/petroleum  ether  40-60°C);  mp  83-86  °C;  om ax 
(neatycm' 1  3319, 2971,  1688,  1513,  1433,  1326,  1250,  1146,  1027, 863, 761;  SH  (300 
MHz, CDC13) 7.57 (dd, J = 8.0,  1.1  Hz,  1   H, ArH), 7.46 (br d, J = 7.8 Hz,  1   H, ArH), 
7.34-7.41 (m,  1  H, ArH), 7.20-7.27 (m,  1 H, ArH), 7.11  (d, J = 8.0 Hz, 2 H, ArH), 6.96 
(d, J = 8.0 Hz, 2 H, ArH), 4.97 (app. t, J = 5.6 Hz,  1 H, BocNH), 4.90 (br t, J = 5.9 Hz, 
1   H,  SNH),  4.48  (br  d,  J  =  7.0  Hz,  1   H,  NCH),  4.42  (dd,  J  =  9.9,  3.8  Hz,  1   H, 
SCHCHH), 4.32  (dd,  J = 9.9,  8.3  Hz,  1   H,  SCHCHH),  4.24  (br d, J =  5.9  Hz,  2 H, 
SNHCH2), 4.13 (dd, J = 13.9, 6.7 Hz,  1  H, BocNHCHH), 3.93 (app. td, J = 8.0, 3.8 Hz, 
1   H, SCH), 3.82 (dd, J = 13.9, 5.6 Hz, 1   H, BocNHCHH), 2.61  (s, 3 H, NCH3),  1.45 (s, 
9 H, C(CH3)3); S c   (75 MHz, CDCI3)  155.9 (s),  138.9 (s),  136.0 (s),  135.2 (s), 133.3 (d),
130.2  (d),  130.1  (d),  128.4 (d),  128.2 (d),  127.8 (d),  124.7  (s), 79.6 (s), 73.1  (d), 72.3 
(d), 67.1  (t), 47.1  (t), 44.2 (t), 42.6 (q), 28.4 (q); m/z (ES+) 542 (MH+, 81Br,  100), 540 
(MH+, 79Br, 95),  105  (27); HRMS (ES+): calcd for C23H3179BrN3 05S (MH+) 540.1162, 
found 540.1160.
(35*,  45*)-(4-{[3-(4-Chlorophenyl)-2-methylisoxazolidine-4-sulfonylamino]methyl} 
benzyl)carbamic  acid tert-butyl  ester  (188d),  (3R*,  55*)  and  (35*,  55*)-(4-{[3-(4- 
Chlorophenyl)-2-methylisoxazolidine-5-sulfonylamino]methyl}benzyl)carbamic 
acid tert-butyl ester (189/190d)
BocHN
188d
BocHN  ^   ^
189/190d
To  a  solution  of [4-(ethenesulfonylaminomethyl)benzyl]carbamic  acid  tert-butyl  ester 
185  (100 mg,  0.3  mmol) in dry toluene (5  mL),  C-(4-chlorophenyl)-Af-methyl nitrone 
119e  (160  mg,  0.9  mmol)  was  added.  The  reaction  mixture  was  heated  in  a  CEM 
microwave  for  30  minutes  at  140  °C.  When  complete  the  reaction  mixture  was 
concentrated in vacuo and the crude residue purified by flash chromatography (starting 
2:1  petroleum ether 40-60°C/Et20)  to give 189/190d  (51  mg,  33%)  as a mixture, and
253188d  (70  mg,  46%)-  overall  yield  (79%,  188d:189/190d =  3:2,  189d and  190d = 3:2 
major: minor).
Data for 189/190d:  Rf 0.16 (2:1  Et20/petroleum ether 40-60°C);  mp  109-112  °C; \)m ax 
(neatycm' 1  3364,  3235,  2925,  1694,  1511,  1326,  1248,  1150,  1050,  875,  830;  5H   (500 
MHz, CDC13) 7.26-7.38 (m,  8  H, ArH), 5.00 (dd, J = 8.4, 5.4 Hz,  1 Hmi„0r, SCH), 4.78-
4.96  (m,  3  H,  SC//maj0r, NH and BocNH), 4.13-4.47  (m, 4 H,  NHCH2 and BocNCH2), 
3.99-4.06 (m,  1  Hm ajor, NC//), 3.55 (br dd, J = 9.8, 7.6 Hz,  1  Hm inor, NC//), 3.05 (ddd, J 
=  13.8,  6.2,  2.4  Hz,  1  Hm ajor,  SCHC//H),  3.02  (ddd,  J =  13.8,  8.4,  7.6  Hz,  1  Hm in 0r, 
SCHCHH),  2.85  (ddd, J =  13.8,  9.8,  5.4 Hz,  1  Hmin0r,  SCHCH//),  2.69-2.77  (m, 4 H, 
NC//3maj0r and SCHCH//major), 2.60 (s»  3 Hminor, NC//3),  1.46 (s, 9 H, C(C//3)3); 6C  (125 
MHz, CDCI3)  156.0 (s),  139.1  (s),  139.0 (s),  136.3  (s),  135.9 (s),  134.5  (s),  134.3 (s),
129.6  (d),  129.4 (d),  129.3 (d),  129.2 (2 x d),  129.0 (d),  128.3  (d),  127.9 (d), 89.3 (d),
79.7  (s), 73.6 (d), 72.9 (d), 47.6 (t), 47.2 (t), 44.3 (t), 43.2 (q), 43.2 (t), 28.5 (q), 25 out 
of 34 expected signals observed; m/z (ES+) 498 (MH+, 37C1, 42), 496 (MH+, 35C1,  100), 
271  (20),  101  (19);  HRMS  (ES+):  calcd for C23H3i35C1N30 5S  (MH+) 496.1667, found 
496.1669.
Data  for  188d:  Rf  0.12  (2:1  EtiO/petroleum  ether  40-60°C);  mp  146-149  °C;  Dmax 
(neat)/cm ‘ 3394,  3334, 2926,  1683,  1522,  1312,  1268,  1164,  1061, 859,  828;  8h (300 
MHz, CDCI3) 7.31-7.34 (m, 4 H, ArH), 7.16 (d, J = 8.0 Hz, 2 H, ArH), 7.04 (d, J = 8.0 
Hz, 2 H, ArH), 5.24 (br t, J = 5.4 Hz, 1  H, BocN//), 4.94 (br t, 5.9 Hz,  1 H, SN//), 4.16-
4.32  (m, 4 H, BocNHC/ / 2 and SCHC//2), 4.13  (dd, J =  14.2, 5.9 Hz,  1   H, SNHC//H), 
3.99 (dd, J = 14.2, 5.9 Hz,  1  H, SNHCH/7), 3.76-3.86 (m, 2 H, SCH and NC//), 2.57 (s, 
3 H, NC//3),  1.44 (s, 9 H, C(C//3),); 8c (75 MHz, CDC13) 156.0 (s), 139.1 (s), 135.6 (s),
135.4  (s), 134.6 (s),  129.5 (d), 129.2 (d), 128.2 (d),  127.8 (d), 79.7 (s), 73.6 (d), 66.9 (t),
47.0  (t), 44.2 (t), 42.7 (q), 28.4 (q),  1   x d not observed; m/z (ES+) 498 (MH+, 37C1, 41), 
496  (MH+,  35C1,  100),  440  (24),  105  (22);  HRMS  (ES+):  calcd  for C23H3135C1N305S 
(MH+) 496.1667, found 496.1667.
254(35*,  45*)-(4-{[3-(4-Bromophenyl)-2-methylisoxazoIidine-4-sulfonylamino]methyl} 
benzyl)carbamic  acid ter/-butyl  ester  (188e),  (3/?*,  55*)  and  (35*,  55*)-(4-{[3-(4- 
Bromophenyl)-2-methylisoxazolidine-5-sulfonylamino]methyl}benzyl)carbamic 
acid tert-butyl ester (189/190e)
°x  0
I   H   /°  I I
bochn^ Y \ Y   bochn^ Y ^ Y
188e  189/190e
Br
To  a  solution  of [4-(ethenesulfonylaminomethyl)benzyl]carbamic  acid  tert-butyl  ester 
185  (250 mg, 0.8  mmol) in dry toluene (5  mL),  C-(4-bromophenyl)-/V-methyl nitrone 
119f  (490  mg,  2.3  mmol)  was  added.  The  reaction  mixture  was  heated  in  a  CEM 
microwave  for  30  minutes  at  140  °C.  When  complete  the  reaction  mixture  was 
concentrated in vacuo and the crude residue purified by flash chromatography (starting 
2:1  petroleum ether 40-60°C/Et20)  to give 189/190e  (67  mg,  16%) as a mixture, and 
188e  (213  mg,  51%)-  overall  yield  (67%,  188e:189/190e =  3:1,  189e  and  190e = 3:2 
major: minor).
Data for 189/190e:  Rf 0.20 (2:1  Et2 0/petroleum ether 40-60°C);  (neatycm'1  3287, 
2928,  1690,  1514,  1327,  1249,  1148,  1070, 831, 731; 5H  (500 MHz, CDC13) 7.44-7.49 
(m, 2 H, ArH), 7.21-7.35  (m,  6 H, ArH), 4.86-5.02 (m,  3  H, NH, BocNH, and SCH), 
4.12-4.43 (m, 4 H, NHCH2 and BocNCH2), 3.98-4.04 (m,  1  Hm ajor, NCH), 3.53 (br dd, J 
= 9.3,  7.6 Hz,  1   H minor,  NC//), 2.96-3.07  (m,  1   H ,  SCHCHR),  2.80-2.87  (m,  1   Hm inor, 
SCHCH//), 2.68-2.75 (m, 4 H, SCHCH//m ajor and N C //3minor),  2.59 (s, 3 Hm ajor, NC//3),
1.45 (s, 9 H, C(C//3)3); 5C  (125 MHz, CDC13)  156.0 (s),  139.0 (s),  138.9 (s),  136.3 (s),
136.0  (s),  135.9 (s),  135.6 (s), 132.2 (d), 132.1 (d),  129.9 (d), 129.8 (d), 129.3 (d), 128.2 
(d), 127.9 (d),  122.6 (s),  122.4 (s), 89.3 (d), 79.7 (s), 73.6 (d), 72.9 (d), 47.5 (t), 47.1 (t),
44.3  (t), 43.2 (q), 41.1  (t), 28.5  (q), 26 out of 34 expected signals observed; m/z (ES+) 
542  (MH+,  81Br,  100),  540  (MH+,  79Br,  93),  214  (36);  HRMS  (ES+):  calcd  for 
C23H3i79BrN3 05S (MH+) 540.1162, found 540.1164.
Data  for  188e:  Rf  0.15  (2:1  Et2 0/petroleum  ether  40-60°C);  mp  156-157  °C;  Dm ax 
(neatycm' 1  3215, 2929,  1697,  1534,  1458, 1199,  1031, 860, 697; 8h (400 MHz, CDC13)
7.46 (d, J = 8.5 Hz, 2 H, Ar//), 7.27 (d, J = 8.5 Hz, 2 H, Ar//), 7.15 (d, J = 7.9 Hz, 2 H, 
Ar//), 7.04 (d, J = 7.9 Hz, 2 H, Ar//), 5.39 (app. t, J = 5.4 Hz, 1 H, BocN//), 4.97 (br t, J 
= 5.7 Hz,  1  H, SN//), 4.28 (dd, J = 10.2,3.1 Hz, 1  H, SCHC//H), 4.23 (br d, J = 5.7 Hz, 
2 H, SNHC//2), 4.16 (dd, J = 10.2, 7.8 Hz, 1  H, SCHCH//), 4.11 (dd, J = 14.2, 6.0 Hz, 1  
H, BocNHC//H),  3.98  (dd, J =  14.2, 5.4  Hz,  1   H,  BocNHCH//),  3.75-3.83  (m, 2 H,
255SCH and  NCH),  2.56  (s,  3  H, NC7/3),  1.44  (s,  9  H,  C(Cf/3)3);  8c  (75  MHz,  CDCI3)
155.0  (s), 139.0 (s),  136.2 (s),  135.5 (s), 132.1 (d),  129.9 (d),  128.2 (d),  127.7 (d),  122.7 
(s), 79.7 (s), 73.5 (d), 66.9 (t), 46.9 (t), 44.2 (t), 42.7 (q), 28.4 (q),  1  x d not observed; 
m/z (ES+) 564 (20), 542 (MH+, 81Br, 100), 540 (MH+, 79Br, 90), 279 (27), 217 (31), 199 
(29),  163  (32),  105  (62);  HRMS  (ES+):  calcd  for CasHji^BrNsOjS  (MH+) 540.1162, 
found 540.1157.
(3  S*9   4S*)-3-Furan-2-yl-2-methylisoxazolidine-4-sulfonic  acid  4-(2-terf-butoxy 
carbonylaminoethylcarbamoyl) -2,3,5,6-tetrafluorophenyl ester (195)
\V/
To  a  solution  of  ethenesulfonic  acid  4-(2-terr-butoxycarbonylaminoethylcarbamoyl)-
2,3,5,6-tetrafluorophenyl ester 186 (100 mg, 0.23  mmol) in dry toluene (5 mL),  C-(2- 
furyl)-7V-methyl  nitrone  119n  (80  mg,  0.68  mmol)  was  added.  The reaction  mixture 
was heated in a CEM microwave for 5 minutes at  140 °C. When complete the reaction 
mixture  was  concentrated  in  vacuo  and  the  crude  residue  purified  by  flash 
chromatography  (starting  2:1  petroleum  ether 40-60°C/Et20)  to  give  the  product  (49 
mg, 38%) as a brown oil.
R f 0.13  (2:1  Et2 0/petroleum ether 40-60°C); t)m ax (neatycm' 1  3284,  3073, 2918,  1665, 
1548,  1489,  1383,  1254,  1178,  1099, 924, 748; 5H  (300 MHz, CDC13) 7.46 (d, 7 =  1.6 
Hz,  1   H, OC//CH), 7.35 (br s,  1  H, N//), 6.47 (d, 7 = 3.2 Hz,  1   H, OCHCHC//), 6.37 
(dd, J -  3.2,  1.6 Hz,  1  H, OCHC//), 4.99-5.05 (m, 1  H, SN//), 4.69 (app. td, 7= 8.0, 3.2 
Hz,  1  H, SC//), 4.58 (dd, 7= 10.2, 3.2 Hz, 1  H, SCHC//H), 4.47 (dd, 7= 10.2, 8.0 Hz, 1  
H, SCHCH//), 4.16 (br s,  1  H, NC/7), 3.53 (br q, 7 = 5.4 Hz, 2 H, BocNHC//2), 3.35 (br 
q, 7 = 5.9  Hz,  2 H,  SNC//2),  2.75  (br s,  3  H, NC//3),  1.39  (s,  9 H, C(C//3)3);  5C   (75 
MHz, CDC13) 156.8 (s), 146.7 (s), 144.0 (d), 111.1 (d), 110.8 (d), 80.3 (s), 70.0 (d), 67.5 
(d), 66.7 (t), 42.8 (q), 42.1  (t), 39.6 (t), 28.2 (q); m/z (ES+) 631  (100), 590 (MNa+,  88), 
526  (23),  454  (20),  375  (20),  180  (32);  HRMS  (ES+):  calcd  for  C22H25F4N3Na08S 
(MNa+) 590.1195, found 590.1196.
2562-[5-(2-Oxohexahydrothieno[3,4-*/]imidazol-6-yl)pentanoylamino]-3-phenyl 
propionic acid ethyl ester (196)
Et02C ^ ^ N   2   H
To D-Biotin (200 mg,  1.0 mmol), EDC.HC1 (200 mg,  1.0 mmol), and DMAP (100 mg,
1.0  mmol) in DMF (25  mL) was added L-Phenylalanine ethyl ester.HCl  (200 mg,  1.0 
mmol). This was allowed to stir at RT for 6 hours, then poured onto H2O (15 mL). The 
aqueous suspension was extracted with CHCI3 (2 x 40 mL), and the combined CHCI3 
layers dried (MgSCL), filtered and concentrated in vacuo. The resultant crude material 
was purified by flash chromatography (starting 100% DCM) to give 196 (270 mg, 64%) 
as a white solid.
Rf 0.44 (9:1  DCM/MeOH); mp  127-130 °C; \)m ax (neatycm' 1 3212,  2928,  1731,  1697, 
1645,  1535,  1455,  1265,  1199,  1029,  860;  5H   (500 MHz,  CDC13)  7.18-7.27  (m,  3  H, 
ArH), 7.14 (d, J = 7.2 Hz, 2 H, ArH), 7.10 (d, J = 7.8 Hz,  1 H, NH), 6.89 (s, 1  H, NH), 
6.27 (s,  1   H, NH), 4.80 (dt, J = 7.8, 6.1  Hz,  1  H, PhCH2Ctf), 4.45 (br dd, J = 7.7, 5.0 
Hz,  1 H, biotinyl-CH), 4.25 (br dd, J = 7.7, 4.7 Hz,  1  H, biotinyl-C//), 4.12 (q, /  = 7.1 
Hz, 2 H, CO2CH2CH3), 3.12 (dd, J = 14.0, 6.1  Hz,  1  H, PhC//H), 3.08 (dt, J = 7.2, 4.7 
Hz,  1 H, biotinyl-CH), 3.02 (dd, J = 14.0, 7.8 Hz,  1  H, PhCH//), 2.79 (dd, J = 12.9, 5.0 
Hz,  1  H, biotinyl-Ctf2), 2.55  (d, J =  12.9 Hz,  1  H, biotinyl-CH2),  2.12-2.19  (m, 2 H, 
biotinyl-C//2),  1.52-1.72 (m, 4 H, biotinyl-C//2),  1.32-1.40 (m, 2 H, biotinyl-C/f2),  1.19 
(t, J = 7.1 Hz, 3 H, CO2CH2C//3); 6C  (125 MHz, CDC13)  173.4 (s),  172.9 (s),  164.7 (s),
136.5 (s),  129.3 (d),  128.5 (d),  127.0 (d), 62.0 (d), 61.5 (t), 60.3 (d), 56.1  (d), 53.3 (d),
40.5 (t), 37.8 (t), 35.8 (t), 28.6 (t), 28.0 (t), 25.5 (t),  14.1  (q); m/z (El) 419 (7), 359 (45), 
227  (57),  194 (43),  166 (53),  120 (100), 91  (40); HRMS  (El):  calcd for C 21H 29N3O4S 
(M+) 419.1873, found 419.1878.
5-(2-Oxohexahydrothieno[3,4-</]imidazoI-6-yl)pentanoic  acid  (35*,  45*)-4-{[3-(2- 
chlorophenyl)-2-methylisoxazolidine-4-sulfonylamino]methyl}benzylamide (197)
Boc-isoxazolidine  188b  (139  mg,  0.28  mmol)  was  stirred  in  a  solution  of  1:1 
DCM/TFA  (2 mL)  at RT for 5  hours,  after which PhMe (1  mL)  was  added and then
257volatiles  removed  in  vacuo.  The  resultant  TFA  salt,  D-Biotin  (60  mg,  0.23  mmol), 
HOBt (37 mg, 0.28 mmol), and EDC.HC1 (50 mg, 0.28 mmol) was dissolved in DMF 
(1.5 mL), treated with NEt3 (60 juL, 0.46 mmol), and stirred overnight at RT. DMF was 
removed  in  vacuo and the crude oil purified by flash chromatography  (starting  100% 
DCM) to give the desired product (16 mg, 11%) as a white solid.
Rf 0.39 (9:1 DCM/MeOH); mp  125-128 °C; um ax (neatj/cm'1   3284, 2919,  1699,  1645, 
1539,  1461,  1323,  1144,  1037;  8h (500 MHz, CDCI3) 7.50 (d, J = 7.0 Hz,  1   H, ArH), 
7.40 (d, J = 7.6 Hz, 1 H, ArH), 7.28-7.36 (m, 2 H, ArH), 7.17 (d, J = 7.4 Hz, 2 H, ArH), 
7.05-7.10 (m, 2 H, ArH), 6.55  (br s,  1   H, NH), 6.18 (br s,  1   H, NH), 5.80 (br s,  1   H, 
NH), 5.39 (br s, 1  H, NH), 4.47 (br s,  1 H, NCH), 4.26-4.44 (m, 5 H, SCHCH2, NHCH2, 
and biotinyl-C//), 3.95-4.22 (m, 4 H, SCH, biotinyl-CW, and BocNC//2), 3.07-3.14 (m, 
1  H, biotinyl-CH), 2.87  (dd, J =  12.9, 4.9 Hz,  1   H, biotinyl-C/72), 2.59-2.69 (m, 4 H, 
NC//3 and biotinyl-C//2), 2.19-2.26 (m, 2 H, biotinyl-C//2), 1.56-1.76 (m, 4 H, biotinyl- 
CH2),  1.37-1.45  (m,  2  H,  biotinyl-C//2);  5C   (125  MHz,  CDC13)  173.0  (s),  163.8  (s),
138.4  (s),  135.8 (s),  134.5 (s),  134.3 (s),  130.2 (d),  129.9 (d),  128.2 (d),  127.8 (d), 73.0 
(d), 72.2  (d),  67.4 (t),  61.9  (d),  60.2 (d), 55.6 (d), 47.1  (t), 43.1  (t), 42.8  (q), 40.7  (t),
35.6  (t), 29.8 (t), 27.9 (t), 25.3 (t), 2 x d not observed; m/z (ES+) 624 (MH+, 37C1, 48), 
622  (MH+,  35C1,  100),  149  (43),  119  (55),  91  (48);  HRMS  (ES+):  calcd  for 
C28H3735C1N5 0 5S2 (MH+) 622.1919, found 622.1926.
5-(2-Oxohexahydrothieno[3,4-d]imidazol-6-yl)pentanoic  acid  (35*,  45*)-4-{[3-(2- 
bromophenyl)-2-methylisoxazolidine-4-sulfonylamino]methyl}benzylamide (198)
Boc-isoxazolidine 188c (50 mg, 0.09 mmol) was stirred in 4M HCl/Dioxane (4 mL) for 
1  hour at RT, after which solvents were removed in vacuo. The resultant HC1 salt was 
dissolved in DMF (3 mL) and treated with consecutively D-Biotin (23 mg, 0.09 mmol), 
EDC.HC1 (18 mg, 0.09 mmol), and DMAP (11 mg, 0.09 mmol). Reaction was stirred at 
RT for 5 hours then poured onto H2O (4 mL), and extracted with CHCI3 (2 x  10 mL). 
The CHCI3  layer was  dried  (MgS0 4),  filtered,  and concentrated  in  vacuo to give the 
crude  product  which  was  further  purified  by  flash  chromatography  (starting  95:5 
DCM/MeOH) to give the biotinylated product 198 (25 mg, 42%) as a white solid.
258Rf0.35  (9:1  DCM/MeOH);  mp  136-139 °C; um ax (neat)/cm''  3266, 2920,  1687,  1537, 
1432,  1322,  1144,  1024;  8H   (500 MHz,  CDCI3)  7.59  (app.  dt,  J  =  8.0,  1.3  Hz,  1   H, 
Ar//), 7.48 (br d, J = 7.6 Hz,  1   H, Ar//), 7.35-7.39 (m,  1   H, Ar//), 7.20-7.24 (m,  1  H, 
Ar//), 7.15 (d, J = 7.5 Hz, 2 H, Ar//), 7.07 (br dd, J = 7.7, 4.6 Hz, 2 H, Ar//), 6.74 (br s, 
1   H, N//), 6.27 (br s,  1   H, N//), 6.05 (br s,  1 H, NH), 5.53 (br s,  1  H, N/7), 4.49 (br s,  1  
H, NC//), 4.25-4.43 (m, 5 H, SCHC//2, NHC//2, and biotinyl-C//), 3.83-4.20 (m, 4 H, 
SCH, biotinyl-C//, and BocNC//2), 3.06-3.11  (m,  1  H, biotinyl-C//), 2.85 (dd, 7= 13.0,
5.0 Hz,  1   H, biotinyl-C//2), 2.61-2.67 (m, 4 H, NC//3 and biotinyl-C//2), 2.21  (br t, J =
7.0  Hz,  2  H,  biotinyl-C//2),  1.55-1.75  (m,  4  H,  biotinyl-C//2),  1.35-1.45  (m,  2  H, 
biotinyl-C//2); 8c (125 MHz, CDCI3)  173.2 (s), 164.0 (s),  138.5 (s),  135.9 (s), 135.8 (s),
133.4 (d),  130.3 (2 x d),  128.4 (d),  128.2 (2 x d),  124.9 (s), 73.3 (d), 72.4 (d), 67.4 (t),
61.9  (d), 60.2 (d), 55.7 (d), 47.1 (t), 43.1 (t), 42.7 (q), 40.7 (t), 35.6 (t), 29.8 (t), 28.0 (t),
25.4 (t); m/z (ES+) 668  (MH+,  8lBr, 62), 666 (MH\ ™Br, 56), 241  (27),  148 (56),  119 
(100),  91  (79);  HRMS  (ES+):  calcd  for  C28H3779BrN50 5S2  (MH+)  666.1414,  found 
666.1419.
2-(/ert-Butyldiphenylsilanyloxy)ethanol (203)183
HO^
■ '  OTBDPS
TBDPSC1  (10  mL,  38.4  mmol)  was  added  dropwise  over  5  minutes  to  a  stirring 
suspension of ethylene  glycol  (10.7  mL,  192.0 mmol),  NEt3  (29.5  mL,  211.0 mmol), 
and  DMAP  (0.47  g,  3.8  mmol)  in  DCM  (200  mL)  at  0  °C.  Stirring  was  continued 
overnight at RT.  The reaction mixture was washed with  10%  HC1,  sat.  NaHC0 3,  and 
brine.  Organic layer was dried (MgSCL), filtered, and filtrate concentrated in vacuo to 
give crude which  was purified by flash chromatography  (starting  6:1  petroleum ether 
40-60°C/EtOAc)  to  give  the product (9.9  g,  91%)  as  a white  solid.  Data agrees with 
literature.
Rf 0.54  (2:1  petroleum ether 40-60°C/EtOAc);  mp  42-44  °C;  5h  (300  MHz,  CDCI3) 
7.70-7.75 (m, 4 H, ArH), 7.39-7.49 (m, 6 H, ArH), 3.78-3.82 (m, 2 H, OCH2), 3.70-3.74 
(m,  2 H,  OCH2),  2.32  (br s,  1   H,  OH),  1.12  (s, 9 H,  C(C//3)3);  5C   (75  MHz,  CDC13)
135.6  (d),  133.4 (s),  129.9 (d), 127.8 (d), 65.1 (t), 63.8 (t), 26.9 (q), 19.3 (s).
(terf-Butyldiphenylsilanyloxy)acetaldehyde (204)184
CK  ^
OTBDPS
To 2M oxalyl chloride in DCM (4.2 mL,  8.4 mmol) in DCM (25 mL)  at -78 °C was 
added slowly DMSO (2.4 mL, 33.8 mmol). This was followed by dropwise addition of
2592-(terr-butyldiphenylsilanyloxy)ethanol 203 (2.0 g, 7.0 mmol) in DCM (5 mL) then 20 
minutes  stirring  at  -78  °C.  NEt3  (5  mL)  was  added  carefully  then  the  reaction  was 
allowed  to  warm  slowly  to  RT.  Solvents  were  removed  in  vacuo  and  the  residue 
remaining triturated with 4:1  hexane/EtOAc (100 mL) before filtering through a small 
silica  pad.  The  filtrate  was  concentrated  in  vacuo  and  the  crude  purified  by  flash 
chromatography (starting  12:1 petroleum ether 40-60°C/EtOAc) to give product (1.9 g, 
95%) as a clear oil. Data agrees with literature.
R f  0.18  (12:1  petroleum  ether  40-60°C/EtOAc);  Dm ax  (neatycm'1   3072,  2931,  1738, 
1472,  1105,  822, 739;  5H  (300 MHz, CDC13) 9.74 (s,  1   H,  CHO), 7.66-7.71  (m, 4 H, 
ArH), 7.38-7.49 (m, 6 H, ArH), 4.23 (s, 2 H, C M ),  1.13 (s, 9 H, C(CH3)3); 6C  (75 MHz, 
CDCI3) 201.6 (d),  135.5  (d),  132.6 (s),  130.1  (d),  128.0 (d), 70.0 (t), 26.8 (q),  19.3 (s); 
m/z (ES") 317 (50), 297  (M-H, 28), 265  (48), 255  (100), 225  (28); HRMS (ES'): calcd 
for C18H2i02Si (M-H) 297.1313, found 297.1311.
(teMButyldiphenylsilanyloxy)acetaldehyde oxime (205)185
HO  OTBDPS
(tert-Butyldiphenylsilanyloxy)acetaldehyde  204  (1.5  g,  5.3  mmol)  was  dissolved  in 
EtOH  (18  mL)  and  treated with  hydroxylamine.HCl  (1.2  g,  17.0 mmol)  followed by 
NEt3 (2.5 mL,  17.5  mmol). The suspension was stirred at RT for 4 hours, then diluted 
with H20   (50 mL)  and the reaction mixture extracted  with EtOAc  (3  x  50 mL).  The 
combined organic fractions were dried (MgS0 4), filtered, and the filtrate concentrated 
in vacuo. Hash chromatography (starting  12:1  petroleum ether 40-60°C/EtOAc) of the 
crude material gave the desired product (1.6 g, 95%). Data agrees with literature.
R f  0.40  (12:1  petroleum  ether 40-60°C/EtOAc);  mp  56-58  °C;  t)max  (neatycm1  3203, 
3071, 2857,  1426,  1104, 934, 821, 737; Sr (300 M H z, CDC13) 7.64-7.69 (m, 4 H , ArH), 
7.49 (app. t, J = 5.4 H z,  1   H ,  CHN), 7.36-7.47 (m, 6 H , ArH), 4.55 (d, J = 3.2 H z,  1   H , 
OCMi), 4.26  (d, /  = 5.4  H z ,  1   H ,  OCUH),  1.07  (s, 4.5  H ,  C(Ctf3)3),  1.05  (s, 4.5  H , 
C(CH3)3); 8c (75 M H z , CDC13) 150.2 (d), 135.6 (d), 133.0 (s), 129.9 (d),  127.9 (d), 61.4 
(t), 26.7 (q),  19.2 (s); m/z (FAB+) 314 (M H +,  17), 256 (100), 236 (84),  199 (96); H R M S 
(FAB+): calcd for Ci8H24N02Si (M H +) 314.1576, found 314.1571.
260A-[2-(terf-ButyldiphenylsilanyIoxy)ethyl] hydroxylamine (199)186
/NH
HO  ^   OTBDPS
A solution of (rm-butyldiphenylsilanyloxy)acetaldehyde oxime 205 (5.0 g, 16.0 mmol), 
in  1.25M HC1 in MeOH (100 mL) was treated with NaBtLCN (2.0 g, 31.9 mmol) and 
the reaction stirred at RT for 5  hours.  Solvent was removed in vacuo,  then the white 
residue suspended in H2O (150 mL) and basified to pH >9 with 6N KOH. The aqueous 
layer was then saturated with NaCl and extracted with CHCI3 (4 x 70 mL). The organic 
layer  was  dried  (MgSCL),  filtered,  and  the  filtrate  concentrated  in  vacuo  to  give  the 
product (4.6 g, 92%). Data agrees with literature.
Rf 0.05 (5:1 petroleum ether 40-60°C/EtOAc); \)m ax (neatycm' 1  3071, 2931, 2857,  1471, 
1427,  1111; 5h (300 MHz, CDC13) 7.65-7.75 (m, 4 H, Ar//), 7.34-7.46 (m,  6 H, Ar//), 
4.37-4.45  (br m, 2 H, OH and N//), 3.83 (br t, J = 5.1  Hz, 2 H, OC//2), 3.07 (br t, J =
5.1  Hz, 2 H, NC//2),  1.08 (s, 9 H, C(C//3)3); 5C  (75 MHz, CDC13)  135.5 (d),  133.0 (s),
129.6  (d),  127.9 (d), 60.8 (t), 53.3 (t), 26.6 (q), 19.1 (s).
C-(2-Chlorophenyl)-A/-[2-(tert-Butyldiphenylsilanyloxy)ethyl] nitrone (200a)
/OTBDPS  N   ^
To A-[2-(rm-butyldiphenylsilanyloxy)ethyl]  hydroxylamine  199  (3.0  g,  9.5  mmol)  in 
DCM (30 mL) was added 2-chlorobenzaldehyde (1.0 mL, 8.6 mmol) and NaHCC>3 (2.2 
g,  25.9  mmol).  The  mixture  was  refluxed  at  40  °C  for  40  hours,  then  the  resulting 
suspension was filtered and the residue washed thoroughly with DCM (4 x 40 mL). The 
combined  organic  fractions  were  concentrated  in  vacuo  and  the  product purified  by 
flash  chromatography  (starting  7:1  petroleum  ether 40-60°C/EtOAc)  to  give  the  title 
compound (0.9 g, 25%) as an orange solid.
Rf 0.29  (5:1  petroleum  ether 40-60°C/EtOAc);  mp  89-92  °C;  Dm ax  (neatycm' 1  2964, 
2854,  1568,  1427,  1268,  1103, 941, 821, 751; 5h (300 MHz, CDC13) 9.44 (dd, J = 7.8,
2.1  Hz,  1  H, ArH),  8.01  (s,  1  H, CHN), 7.64-7.68  (m, 4 H, ArH), 7.31-7.45  (m, 9 H, 
ArH), 4.16-4.21  (m, 2 H, OCH2), 4.03-4.08 (m, 2 H, NCH2),  1.03 (s, 9 H, C(C//3)3); 6C  
(75 MHz, CDCI3)  135.5 (d),  133.1  (s),  132.9 (s),  131.4 (d),  131.0 (d),  129.9 (d),  129.4 
(d),  129.2  (d),  128.2 (s),  127.8 (d),  127.1  (d), 70.5  (t), 60.4 (t), 26.8 (q),  19.2 (s); m/z 
(FAB+) 440 (MH+,  37C1, 3), 438 (MH\ 35C1, 9), 329 (18),  176 (86),  154 (100); HRMS 
(FAB+): calcd for C25H2935ClN02Si (MH+) 438.1656, found 438.1661.
261C-(2-Bromophenyl)-N-[2-(ter*-Butyldipheiiylsilanyloxy)ethyl] nitrone (200b)
o OTBDPS N
Br
To A-[2-(terr-butyldiphenylsilanyloxy)ethyl]  hydroxylamine  199  (1.0  g,  3.2  mmol)  in 
DCM (15 mL) was added 2-bromobenzaldehyde (0.3 mL, 2.9 mmol) and NaHC03  (0.7 
g,  8.6  mmol).  The  mixture  was  refluxed  at  40  °C  for  40  hours,  then  the  resulting 
suspension was filtered and the residue washed thoroughly with DCM (4 x 25 mL). The 
combined  organic  fractions  were  concentrated  in  vacuo  and  the  product  purified  by 
flash  chromatography  (starting  7:1  petroleum  ether 40-60°C/EtOAc)  to  give  the  title 
compound (0.7 g, 48%) as a cream solid.
Rf  0.20  (5:1  petroleum  ether  40-60°C/EtOAc);  mp  79-81  °C;  t)m ax  (neatycm"1   3072, 
2855,  1564,  1427,  1269,  1104, 941, 822, 734; 5h (300 MHz, CDC13) 9.40 (dd, J = 8.0,
1.9  Hz,  1   H, Ar//), 7.97  (s,  1  H, C//N), 7.61-7.66 (m,  5  H, Ar//), 7.32-7.44 (m, 7 H, 
Ar//), 7.25  (app. dt, J = 7.8,  1.9 Hz,  1   H, Ar//), 4.15-4.19 (m, 2 H, OC//2), 4.02-4.06 
(m, 2 H, NC//2), 1.01 (s, 9 H, C(C//3)3); 6C  (75 MHz, CDC13) 135.5 (d), 134.1 (s), 133.1 
(s),  132.8 (d),  131.3 (d),  129.9 (d),  129.6 (d),  129.5 (d),  127.8 (d),  127.7 (d),  123.3 (s),
70.5  (t), 60.3 (t), 26.8 (q),  19.2 (s); m/z (FAB+) 506 (MNa+, 81Br, 23), 504 (MNa+, 79Br, 
22),  329  (19),  199  (23),  176  (100);  HRMS  (FAB+):  calcd  for  C25H2879BrNNa02Si 
(MNa+) 504.0970, found 504.0965.
C-(2-Iodophenyl)-A-[2-(ter/-Butyldiphenylsilanyloxy)ethyl] nitrone (200c)
To A-[2-(rm-butyldiphenylsilanyloxy)ethyl]  hydroxylamine  199  (1.8  g,  5.7  mmol)  in 
DCM (25 mL) was added 2-iodobenzaldehyde (1.2 g, 5.2 mmol) and NaHC03 (1.3 g,
15.4  mmol).  The  mixture  was  refluxed  at  40  °C  for  40  hours,  then  the  resulting 
suspension was filtered and the residue washed thoroughly with DCM (4 x 40 mL). The 
combined  organic  fractions  were  concentrated  in  vacuo  and  the  product  purified  by 
flash  chromatography  (starting  7:1  petroleum  ether 40-60°C/EtOAc)  to  give  the  title 
compound (0.8 g, 28%) as a clear oil.
Rf 0.57 (2:1 petroleum ether 40-60°C/EtOAc); 0)m ax (neatycm1  3067, 2930,  1551, 1427, 
1207, 1156,  1105,  1000, 941, 821, 736; 5h (300 MHz, CDC13) 9.34 (dd, /=  8.3, 1.6 Hz,
OTBDPS
2621  H, Ar//), 7.93 (dd, J = 8.0, 1.1 Hz,  1  H, Ar//), 7.85 (s,  1  H, CHN), 7.62-7.68 (m, 4 H, 
Ar//), 7.32-7.48 (m, 7 H, Ar//), 7.09 (app. dt, J = 7.8,  1.6 Hz,  1  H, Ar//), 4.15-4.20 (m,
2 H, OCH2), 4.02-4.06 (m, 2 H, NCH2),  1.03  (s, 9 H, C(C//3)3); 5C  (75 MHz, CDC13)
139.8  (d), 139.0 (d), 135.5 (d), 133.1 (s), 132.4 (s), 131.5 (d),  129.8 (d), 129.3 (d), 128.4 
(d),  127.8 (d), 99.1 (s), 70.4 (t), 60.3 (t), 26.9 (q),  19.3 (s); m/z (FAB+) 552 (MNa+, 52), 
452  (20),  199  (31),  176  (100);  HRMS  (FAB+):  calcd  for  Cis^glNNaOiSi  (MNa+) 
552.0832, found 552.0834.
(35*, 45*)-2-[2-(terf-Butyldiphenylsilanyloxy)ethyl]-3-(2-chlorophenyl) 
isoxazolidine-4-sulfonic acid pentafluorophenyl ester (210a)
\V/
PFPO
OTBDPS
To pentafluorophenyl vinyl sulfonate 100 (430 mg,  1.56 mmol) in dry toluene (10 mL) 
was  added  C-(2-chlorophenyl)-./V-[2-(tert-butyldiphenylsilanyloxy)ethyl]  nitrone  200a 
(819 mg,  1.87 mmol) and the mixture was heated to reflux for 7 hours. The reaction was 
concentrated in vacuo, and the crude residue purified by flash chromatography (starting 
14:1  petroleum  ether 40-60°C/Et20)  to  give the  title  compound  (680  mg,  61%)  as  a 
brown oil.
Rf 0.61  (2:1  Et20/petroleum ether 40-60°C); t)m ax (neatycm'1  2932,  1517,  1473,  1391, 
1112, 993, 823, 737; 8h (300 MHz, CDC13) 7.57-7.69 (m, 5 H, Ar//), 7.30-7.46 (m, 9 H, 
Ar//), 4.87 (d, J = 6.7 Hz,  1   H, NC/7) 4.62 (dd, J = 9.9, 2.9 Hz,  1   H, SCHC/7H), 4.48 
(dd, J = 9.9,  8.0 Hz,  1  H, SCHCH//), 4.41  (app. td, J = 8.0, 2.9 Hz,  1  H, SC//), 3.80-
3.96  (m, 2 H, OC//2), 2.88-3.08 (m, 2 H, NC//2),  1.03 (s, 9 H, C(C//3)3); 6C  (75 MHz, 
CDC13)  135.6 (d),  134.6 (s),  133.7 (s),  133.1  (s),  130.3 (d),  130.2 (d),  130.0 (d),  129.6 
(d),  127.6 (d),  127.5 (d), 72.9 (d), 68.4 (d), 67.1  (t), 61.5 (t), 57.7 (t), 26.8 (q),  19.2 (s); 
m/z (FAB+) 736 (MNa+, 37C1, 25), 734 (MNa+, 35C1, 54), 301  (100), 241  (25),  199 (48); 
HRMS (FAB+): calcd for CsaHji^ClFsNNaOsSSi (MNa+) 734.1199, found 734.1183.
(35*, 45*)-3-(2-BromophenyI)-2-[2-(te/tf-butyldiphenylsilanyloxy)ethyl] 
isoxazoIidine-4-sulfonic acid pentafluorophenyl ester (210b)
PFPO
OTBDPS
263To pentafluorophenyl vinyl sulfonate 100 (1.1 g, 3.9 mmol) in dry toluene (25 mL) was 
added  C-(2-bromophenyl)-iV-[2-(te/T-butyldiphenylsilanyloxy)ethyl]  nitrone  200b  (2.2 
g,  4.6  mmol)  and  the  mixture  was  heated  to  reflux  for  6  hours.  The  reaction  was 
concentrated in vacuo, and the crude residue purified by flash chromatography (starting 
14:1 petroleum ether 40-60°C/Et20) to give the title compound (2.1 g, 73%) as a brown 
oil.
Rf 0.63  (2:1  Et20/petroleum ether 40-60°C); \)m ax (neat)/cm_ 1  2932,  1517,  1472,  1392, 
1185, 994, 823, 737; 8H  (300 MHz, CDC13) 7.56-7.64 (m, 5 H, Ar//), 7.53 (dd, J = 7.8,
1.6  Hz,  1   H, Ar//), 7.30-7.42 (m, 7 H, Ar//), 7.22 (app. dt, J = 7.8,  1.6 Hz,  1   H, Ar//),
4.83  (d, J = 7.0 Hz,  1  H, NCH), 4.58 (dd, J = 10.2, 2.9 Hz,  1 H, SCHC//H), 4.44 (dd, J 
= 10.2, 8.0 Hz, 1  H, SCHCH//), 4.33 (app. td, J= 7.8, 2.9 Hz,  1  H, SC/7), 3.74-3.90 (m, 
2  H,  OC//2),  3.00  (ddd,  J =  13.1,  5.4,  4.0  Hz,  1   H,  NC//HCH2),  2.82-2.92  (m,  1   H, 
NCH//CH2), 0.99 (s, 9 H,  C(C//3)3);  8C  (75  MHz,  CDC13)  135.6 (d),  134.8  (s),  133.7 
(d),  133.6 (s),  130.4 (d),  130.2 (d),  129.6 (d),  128.2 (d),  127.6 (d),  124.8  (s), 73.1  (d),
70.5  (d), 67.2 (t), 61.4 (t), 57.6 (t), 26.8 (q), 19.2 (s); m/z (FAB+) 780 (MNa+, 8lBr, 21), 
778  (MNa+,  79Br,  18),  225  (23),  176  (100);  HRMS  (FAB+):  calcd  for
C33H3,79BrF5NNa0 5SSi (MNa+) 778.0693, found 778.0706.
(3S*,  4S*)-2-[2-(terf-Butyldiphenylsilanyloxy)ethyl]-3-(2-iodophenyl)isoxazolidine- 
4-sulfonic acid pentafluorophenyl ester (210c)
PFPO
OTBDPS
To pentafluorophenyl vinyl sulfonate 100 (350 mg,  1.28 mmol) in dry toluene (8 mL) 
was  added  C-(2-iodophenyl)-./V-[2-(rm-butyldiphenylsilanyloxy)ethyl]  nitrone  200c 
(745 mg, 1.41 mmol) and the mixture was heated to reflux for 7 hours. The reaction was 
concentrated in vacuo, and the crude residue purified by flash chromatography (starting 
14:1  petroleum  ether 40-60°C/Et20)  to  give  the  title  compound  (663  mg,  64%)  as  a 
brown oil.
Rf 0.59  (2:1  Et20/petroleum ether 40-60°C); t)m ax (neatycm1  2932,  1517,  1471,  1392, 
1112, 994, 823, 738; SH  (300 MHz, CDC13) 7.90 (dd, /  = 8.0,  1.3 Hz,  1  H, Ar//), 7.57-
7.66  (m, 4 H, Ar//), 7.48 (dd, J = 7.8,  1.6 Hz,  1  H, Ar//), 7.32-7.44 (m, 7 H, Ar//), 7.07 
(app. dt, J = 8.0,  1.9 Hz,  1   H, Ar//), 4.78 (d, J = 7.2 Hz, NC//), 4.59 (dd, J = 10.2, 3.2 
Hz,  1 H, SCHC/ZH), 4.46 (dd, J = 10.2, 8.0 Hz,  1  H, SCHCHH), 4.30 (app. td, J = 8.0,
2643.2  Hz,  1   H, SC//), 3.77-3.92 (m, 2 H, OC//2), 3.04 (ddd, J =  13.1, 5.1, 4.0 Hz,  1   H, 
NC//HCH2),  2.83-2.92  (m,  1   H,  NCH//CH2),  1.01  (s,  9  H,  C(C//3)3);  5C   (75  MHz, 
CDC13)  140.3 (d),  137.7 (s),  135.6 (d),  133.7 (s),  130.7 (d),  129.8 (d),  129.6 (d),  129.0 
(d),  127.6 (d),  100.7 (s), 74.9 (d), 73.4 (d), 67.2 (t), 61.4 (t), 57.4 (t), 26.8 (q),  19.2 (s); 
m/z  (FAB+)  826  (MNa+,  28),  323  (30),  176  (100);  HRMS  (FAB+):  calcd  for 
C33H3iF5INNa0 5SSi (MNa+) 826.0555, found 826.0533.
(3  S*, 4S*)-2-[2-(terf-Butyldiphenylsilanyloxy)ethyl]-3-(2-chlorophenyl) 
isoxazolidine-4-sulfonic acid 4-methylbenzylamide (206a), and (3S*, 4R*)-2-[2- 
(ter/-Butyldiphenylsilanyloxy)ethyl]-3-(2-chlorophenyl)isoxazolidine-4-sulfonic 
acid 4-methylbenzylamide (207a)
OTBDPS OTBDPS
206a  207a
To a stirring solution of PFP ester 210a (440 mg, 0.62 mmol) in dry THF (10 mL), 4- 
methylbenzylamine (240 pL,  1.85  mmol) was added followed by DBU (140 pL, 0.93 
mmol). The mixture was refluxed for 1  hour and then concentrated in vacuo. The crude 
residue  was  purified  by  flash  chromatography  (starting  8:1  petroleum  ether  40- 
60°C/EtOAc) to yield the two products 206a (243 mg, 60%) and 207a (73 mg,  18%) as 
yellow solids- overall yield (78%, 206a:207a = 10:3).
Data  for  207a:  R f  0.24  (2:1  petroleum  ether  40-60°C/Et20);  mp  135-137  °C;  Dm ax 
(neatycm1  3276,  3049,  2929,  1516,  1426,  1335,  1112,  1084,  955,  805,  760;  5H   (300 
MHz, CDC13) 7.79-7.84 (m,  1   H, Ar//), 7.47-7.76 (m, 4 H, Ar//), 7.34-7.46 (m, 7 H, 
Ar//), 7.23-7.28 (m, 2 H, Ar//), 7.11  (s, 4 H, Ar//), 4.29-4.42 (m, 4 H, SCHC//2, NC//, 
and SC//), 4.13  (dd, J =  13.7, 6.7 Hz,  1   H, NHC/7H), 4.04 (dd, J =  13.7, 4.8 Hz,  1   H, 
NHCH//),  3.96-4.03  (m,  1   H,  OC//HCH2N),  3.87  (ddd,  J =  10.4,  6.2,  4.2  Hz,  1   H, 
OCH//CH2N), 3.48 (dd, J = 6.7, 4.8 Hz, 1 H, N//), 3.05 (ddd, J = 13.4, 7.5, 6.2 Hz, 1  H, 
NC//HCH2), 2.70 (ddd, J =  13.4, 5.1, 4.2 Hz,  1   H, NCH//CH2), 2.33 (s, 3 H, ArC//3),
1.07  (s, 9 H, C(C//3)3); 8C  (75 MHz, CDC13)  137.8 (s),  135.7 (d),  134.8  (s),  133.8 (s),
133.6  (s), 131.5 (s), 131.2 (d), 129.6 (d), 129.4 (d), 129.0 (d), 127.8 (d), 127.7 (d), 127.6 
(d),  127.0 (d), 68.8 (d), 66.9 (d), 66.2 (t), 61.6 (t), 58.5 (t), 47.1  (t), 26.9 (q), 21.1  (q),
19.2  (s); m/z (ESI) 673 (MNa+, 37C1, 17), 671 (MNa+, 35C1, 50), 338 (45), 319 (100), 178 
(19); HRMS (ESI): calcd for C35H4i35ClN2Na04SSi (MNa+) 671.2143, found 671.2139.
265Data  for  206a:  Rf 0.19  (2:1  petroleum  ether  40-60°C/Et20);  mp  127-129  °C;  t w  
(neatycm' 1  3349,  3073,  2855,  1519,  1428,  1316,  1115,  1088,  955,  822,  746;  8H  (300 
MHz, CDCI3) 7.58-7.66 (m, 4 H,  Ar//), 7.51-7.55  (m,  1  H,  Ar//), 7.29-7.44 (m, 9 H, 
Ar//), 7.04 (d, J = 8.0 Hz, 2 H, Ar//), 6.92 (d, J = 8.0 Hz, 2 H, Ar//), 4.74 (dd, J = 6.5,
5.1  Hz,  1   H,  N//),  4.60 (d, J = 7.2  Hz,  1   H,  NC//),  4.40  (dd, J = 9.9,  4.0 Hz,  1   H, 
SCHC//H), 4.27 (dd, J = 9.9, 8.6 Hz,  1   H, SCHCH//), 4.14 (dd, J =  13.7, 6.5 Hz,  1  H, 
NHC//H), 3.93 (dt, J = 8.0,4.1 Hz,  1  H, OC//HCH2N), 3.82 (dd, J = 13.7, 5.1 Hz, 1  H, 
NHCH//), 3.74-3.82 (m, 2 H, SCH and OCH//CH2N), 2.97 (ddd, J =  13.1, 5.6, 4.1  Hz, 
1  H, NC//HCH2), 2.77-2.87 (m,  1  H, NCH//CH2), 2.32 (s,  3 H, ArC//3),  1.01  (s, 9 H, 
C(C//3)3);  5c  (75  MHz,  CDC13)  137.8  (s),  135.5  (d),  134.7  (s),  134.2  (s),  133.8  (s),
133.1  (s),  130.2  (d),  130.0  (d),  129.7  (d),  129.6  (d),  129.5  (d),  129.4  (d),  127.9  (d),
127.8  (d), 127.6 (d), 127.5 (d), 72.7 (d), 68.4 (d), 67.1 (t), 61.6 (t), 57.8 (t), 47.2 (t), 26.8 
(q), 21.1  (q),  19.2 (s); m/z (FAB+) 673 (MNa\ 37C1, 5), 671  (MNa+, 35C1, 12), 329 (20), 
176 (100),  154 (39); HRMS (FAB+): calcd for C35H4i35ClN2Na0 4SSi (MNa+) 671.2143, 
found 671.2126.
(3  5*, 45*)-3-(2-Bromophenyl)-2-[2-(terf-butyldiphenylsilanyloxy)ethyl] 
isoxazolidine-4-sulfonic acid 4-methylbenzylamide (206b) and (35*, 4R*)-3-(2- 
Bromophenyl)-2-[2-(tert-butyldiphenylsilanyloxy)ethyl]isoxazolidine-4-sulfonic 
acid 4-methylbenzylamide (207b)
V
OTBDPS
\y/
OTBDPS
206b  207b
To  a  stirring  solution  of PFP  ester 210b  (1.4  g,  1.9  mmol)  in  dry THF  (30  mL),  4- 
methylbenzylamine  (0.7  mL,  5.6  mmol)  was  added  followed  by  DBU  (0.4  mL,  2.8 
mmol). The mixture was refluxed for 2 hours and then concentrated in vacuo. The crude 
residue remaining was purified by flash chromatography (starting  8:1  petroleum ether 
40-60°C/EtOAc)  to  yield  the  two  products  206b  (625  mg,  48%)  and 207b  (264 mg, 
20%) as yellow solids- overall yield (69%, 206b:207c = 7:3).
Data  for  207b:  R f   0.18  (2:1  petroleum  ether  40-60°C/Et20);  mp  73-75  °C;  \)m ax 
(neatycm' 1  3289,  2928,  1516,  1428,  1332,  1111,  1022, 950,  823,  735;  §h  (500 MHz, 
CDC13) 7.79 (dd, J = 8.0,  1.7 Hz,  1  H, Ar//), 7.71-7.74 (m, 2 H, Ar//), 7.67-7.69 (m, 2 
H, Ar//), 7.55 (dd, J = 8.0,  1.3 Hz,  1 H, Ar//), 7.35-7.44 (m, 6 H, Ar//), 7.27 (app. dt, J 
= 7.8,  1.3 Hz,  1   H, Ar//), 7.17 (app. dt, /=  7.8,  1.7 Hz,  1   H, Ar/Z), 7.10 (s, 4 H, Ar//),
2664.36-4.43  (m, 3 H, SCHC//2 and SC//), 4.26 (d, 7 = 7.4 Hz,  1  H, NC//), 4.12 (dd, 7 =
13.7,  7.0 Hz,  1  H, NHC//H), 4.04 (dd, 7 =  13.7, 4.7 Hz,  1   H, NHCH//), 3.98 (ddd, 7 =
10.6,  7.7, 5.3 Hz,  1 H, OC//HCH2), 3.85 (ddd, 7 =  10.6, 6.2, 3.9 Hz,  1 H, OCH//CH2), 
3.38 (dd, 7 = 7.0, 4.7 Hz, 1  H, N//), 3.03 (ddd, 7 = 13.4, 7.7, 6.2 Hz, 1 H, NC//HCH20), 
2.69 (ddd, 7 = 13.4, 5.3, 3.9 Hz,  1  H, NCH//CH20), 2.32 (s, 3 H, ArC//3),  1.05 (s, 9 H, 
C(C//3)3);  8C   (125  MHz,  CDC13)  137.9  (s),  135.8  (d),  135.7  (d),  133.8  (s),  133.7  (s),
133.1  (s),  132.4  (d),  131.9  (d),  130.1  (d),  129.7  (d),  129.5  (d),  128.0  (d),  127.8  (d),
127.7 (d),  127.6 (d), 125.5 (s), 71.4 (d), 67.0 (d), 66.2 (t), 61.7 (t), 58.5 (t), 47.3 (t), 27.0 
(q), 21.2 (q),  19.3 (s); m/z (ESI) 717 (MNa+, 8IBr,  100), 715 (MNa+, 79Br, 96), 454 (36), 
299  (84);  HRMS  (ESI):  calcd  for  C35H4i79BrN2Na04SSi  (MNa+)  715.1637,  found 
715.1631.
Data  for  206b:  Rf 0.13  (2:1  petroleum  ether  40-60°C/Et20);  mp  131-133  °C;  Um ax 
(neatycm'1  3333,  2929,  1518,  1428,  1314,  1114,  1089,  955,  822,  746;  8H   (500 MHz, 
CDC13) 7.59-7.62 (m, 2 H, Ar//), 7.55-7.58 (m, 3 H, Ar//), 7.50 (dd, J = 7.8,  1.7 Hz,  1  
H, Ar//), 7.36-7.40 (m, 2 H, Ar//), 7.29-7.34 (m, 5 H, Ar//), 7.25 (ddd, J = 8.0, 7.3, 1.7 
Hz,  1  H, Ar//), 7.02 (d, J = 7.8 Hz, 2 H, Ar//), 6.87 (d, J = 7.8 Hz, 2 H, Ar//), 4.71 (dd, 
J = 6.8, 5.0 Hz,  1 H, N//), 4.59 (d, J = 7.3 Hz,  1 H, NC//), 4.40 (dd, J = 9.9, 3.7 Hz,  1  
H, SCHC//H), 4.28 (dd, J = 9.9, 8.5 Hz,  1  H, SCHCH//), 4.13 (dd, J =  13.6, 6.8 Hz,  1  
H, NHC//H), 3.90 (ddd, J = 8.5, 7.3, 3.7 Hz,  1   H, SC//), 3.83 (ddd, 7 =  10.6, 7.7, 5.8 
Hz, 1 H, OC//HCH2N), 3.76 (ddd, 7 = 10.6, 6.6, 4.2 Hz,  1  H, OCH//CH2N), 3.75 (dd, 7 
= 13.6, 5.0 Hz,  1  H, NHCH//), 2.97 (ddd, 7 = 13.2, 5.8, 4.2 Hz,  1  H, NC//HCH2), 2.81 
(ddd,  7 =  13.2,  7.7,  6.6  Hz,  1   H,  NCH//CH2),  2.29  (s,  3  H,  ArC//3),  0.97  (s,  9  H, 
C(C//3)3);  8C   (125  MHz,  CDC13)  137.9  (s),  136.4  (s),  135.7  (d),  135.6  (d),  133.9  (s),
133.8 (s),  133.3 (d), 133.0 (s), 130.5 (d), 130.1 (d), 129.7 (d), 129.6 (d), 129.5 (d), 128.5 
(d),  128.0 (d),  127.7 (d),  127.6 (d),  124.8 (s), 72.9 (d), 70.9 (d), 67.1  (t), 61.6 (t), 57.7 
(t), 47.2 (t), 26.8  (q), 21.1  (q),  19.2 (s); m/z (ESI) 717 (MNa+, 81Br,  100), 715  (MNa+, 
79Br,  96),  504  (28);  HRMS  (ESI):  calcd for C35H4i79BrN2Na04SSi  (MNa+)  715.1637, 
found 715.1642.
267(3S*,  4S*)-2-[2-(ter/-Butyldiphenylsilanyloxy)ethyl]-3-(2-iodophenyl)isoxazolidine- 
4-sulfonic  acid  4-methylbenzylamide  (206c)  and  (35*,  4R*)-2-[2-(tert-
Butyldiphenylsilanyloxy)ethyI]-3-(2-iodophenyl)isoxazolidine-4-sulfonic  acid  4- 
methylbenzylamide (207c)
V
OTBDPS OTBDPS
206c  207c
To a stirring solution of PFP ester 210c (570 mg, 0.72 mmol) in dry THF (10 mL), 4- 
methylbenzylamine (270 pL, 2.15  mmol) was added followed by DBU (160 pL,  1.08 
mmol). The mixture was refluxed for 1 hour and then concentrated in vacuo. The crude 
residue remaining was purified by flash chromatography (starting 8:1  petroleum ether 
40-60°C/Et20) to yield the two products 206c (246 mg, 46%) and 207c (92 mg, 17%) as 
yellow solids- overall yield (63%, 206c:207c = 5:2).
Data  for  207c:  Rf  0.22  (2:1  petroleum  ether  40-60°C/Et20);  mp  86-88  °C;  t)m ax 
(neatycm'1  3323, 2930,  1516,  1428,  1332,  1111, 951, 820, 736; 8h (300 MHz, CDC13)
7.84  (dd, J = 8.0,  1.1 Hz, 1  H, Ar//), 7.68-7.78 (m, 5 H, Ar//), 7.35-7.46 (m, 6 H, Ar//), 
7.31  (app. dt, J = 7.8,  1.1 Hz,  1 H, ArH), 7.11  (s, 4 H, Ar//), 7.03 (app. dt, J = 7.8,  1.6 
Hz,  1  H, Ar//), 4.36-4.45 (m, 3 H, SCHCH2 and SC//), 4.15 (d, J = 7.2 Hz,  1  H, NC//),
4.10 (d, J = 6.7 Hz,  1  H, NHC//H), 4.07 (d, 7 = 5.1 Hz,  1 H, NHCH//), 4.00 (ddd, J =
10.2,  7.5,  5.1  Hz,  1  H,  OC//HCH2N),  3.85  (ddd,  J  =  10.2,  6.4,  4.3  Hz,  1   H, 
OCH//CH2N), 3.47 (dd, J= 6.7, 5.1 Hz, 1  H, N//), 3.03 (ddd, 7= 13.4, 7.5, 6.4 Hz, 1  H, 
NC//HCH2), 2.70 (ddd, J =  13.4, 5.1, 4.3 Hz,  1   H, NCH//CH2), 2.33 (s, 3 H, ArC//3),
1.07  (s, 9 H, C(CZ/3)3); 8c (75 MHz, CDC13)  138.9 (d),  137.8 (s),  136.0 (s),  135.7 (d),
135.6  (d),  133.8 (s), 133.7 (s), 131.8 (d), 130.4 (d), 129.6 (d), 129.4 (d),  128.3 (d), 127.9 
(d),  127.7 (d),  127.6 (d),  101.8 (s), 76.1  (d), 66.9 (d), 66.1  (t), 61.6 (t), 58.3 (t), 47.2 (t),
26.9  (q),  21.1  (q),  19.2  (s);  m/z  (ES+)  764  (44),  763  (MNa+,  100),  741  (17);  HRMS 
(ES+): calcd for C35H4iIN2Na0 4SSi (MNa+) 763.1487, found 763.1499.
Data  for  206c:  Rf 0.15  (2:1  petroleum  ether  40-60°C/Et20);  mp  124-126  °C;  Dm ax 
(neatycm'1  3310, 2929,  1517,  1428,  1311,  1112, 956, 862, 745; 5h (300 MHz, CDC13) 
7.89 (dd, J = 8.0,  1.1 Hz,  1  H, Ar//), 7.59-7.67 (m, 4 H, Ar//), 7.32-7.46 (m, 8 H, Ar//),
7.10 (app. dt, J = 8.0,  1.9 Hz, 1  H, Ar//), 7.04 (d, J = 8.0 Hz, 2 H, Ar//), 6.92 (d, J = 8.0 
Hz, 2 H, Ar//), 4.84 (dd, J = 6.7, 5.4 Hz, 1  H, N//), 4.48 (d, J = 7.2 Hz, 1  H, NC//), 4.41 
(dd, J = 9.9, 3.8 Hz,  1   H, SCHC//H), 4.28 (dd, J = 9.9, 8.6 Hz,  1  H, SCHCH//), 4.15 
(dd, /=  13.7, 6.7 Hz,  1  H, NHC//H), 3.82-3.93 (m, 3 H, SCH and OC//2CH2), 3.80 (dd,
268J =  13.7, 5.4 Hz,  1   H,  NHCH//),  3.02 (ddd, J =  13.1, 5.4, 4.3  Hz,  1   H, NC//HCH2), 
2.78-2.88  (m,  1   H, NCH//CH2), 2.33  (s, 3  H, ArC//3),  1.02 (s, 9 H, C(C//3)3); 5C  (75 
MHz, CDC13)  139.9 (d),  139.3 (s),  137.8 (s),  135.6 (d),  135.5  (d),  133.9 (s),  133.8 (s),
133.0  (s),  130.4  (d),  130.2  (d),  129.6  (d),  129.5  (d),  129.4  (d),  129.2  (d),  128.0  (d),
127.6  (d),  127.5 (d), 101.2 (s), 75.4 (d), 73.1 (d), 67.1 (t), 61.6 (t), 57.5 (t), 47.2 (t), 26.9 
(q), 21.2 (q), 19.2 (s); m/z (ESI) 763 (MNa+, 28), 327 (38), 300 (86), 255 (46), 241 (66), 
185  (53),  173  (100);  HRMS  (ESI):  calcd  for  C35H4iIN2Na0 4SSi  (MNa+)  763.1499, 
found 763.1491.
(3S*,  4S*)-3-(2-Chlorophenyl)-2-(2-hydroxyethyl)isoxazolidine-4-sulfonic  acid  4- 
methylbenzylamide (211a)
,OH
To a stirring solution of 206a (173 mg, 0.27 mmol) in THF (4 mL) at 0 °C was added 
TBAF (1M in THF, 400 |iL, 0.40 mmol). After 2 hours at 0 °C the reaction mixture was 
concentrated in vacuo, and the residue purified by flash chromatography (starting  100% 
CHCI3) to give the product (109 mg, 98%) as a yellow oil.
Rf 0.57 (9:1 CHCl3/MeOH); \)m ax (neatycm'1  3476, 3295, 2923, 1515, 1438, 1323, 1144, 
1038,  807,  752;  5h  (300  MHz,  CDC13)  7.46-7.50  (m,  1  H,  Ar//),  7.38-7.42  (m,  1  H, 
Ar//), 7.31-7.38 (m, 2 H, Ar//), 7.02 (d, /=  7.8 Hz, 2 H, Ar//), 6.89 (d, J = 7.8 Hz, 2 H, 
Ar//), 4.68 (d, J = 1A Hz,  1 H, NC//), 4.58 (app. t, /  = 5.8 Hz,  1 H, N//), 4.48 (dd, J = 
9.9, 3.9 Hz,  1   H, SCHCZZH), 4.36 (dd, J = 9.9, 8.4 Hz,  1  H, SCHCH//), 4.14 (dd, J =
13.7,  6.6 Hz,  1  H, NHCZ/H), 3.96 (ddd, J = 8.4, 7.4, 3.9 Hz,  1  H, SCH), 3.83 (dd, /  =
13.7, 5.1 Hz,  1 H, NHCH//), 3.78 (app. dt, /=  8.3, 2.9 Hz,  1  H, OC//HCH2), 3.62 (app. 
dt,  J  =  11.4,  4.0  Hz,  1  H,  OCH//CH2),  2.99  (ddd,  J  =  13.4,  5.0,  2.9  Hz,  1   H, 
NC//HCH2), 2.80 (ddd, J =  13.4, 8.0, 4.0 Hz,  1   H, NCH//CH2), 2.31  (s, 3 H, ArC//3); 
5C  (75 MHz, CDCI3)  137.8 (s),  134.2 (2 x s),  133.1  (s),  130.2 (d),  130.0 (d),  129.9 (d),
129.4  (d),  127.9 (d), 127.7 (d), 72.2 (d), 68.5 (d), 67.4 (t), 60.5 (t), 57.3 (t), 47.1 (t), 21.1 
(q);  m/z (ESI) 435  (MNa+,  37C1,  35),  433  (MNa+,  35C1,  100),  222  (42);  HRMS  (ESI): 
calcd for Ci9H2335ClN2Na0 4S (MNa+) 433.0965, found 433.0959.
269(3S*,  4S*)-3-(2-Bromophenyl)-2-(2-hydroxyethyl)isoxazolidine-4-sulfonic  acid  4-
methylbenzylamide (211b)
,0H
To a stirring solution of 206b (330 mg, 0.48 mmol) in THF (6 mL) at 0 °C was added 
TBAF (1M in THF, 710 jliL, 0.71 mmol). After 2 hours at 0 °C the reaction mixture was 
concentrated in vacuo, and the residue purified by flash chromatography (starting 100% 
CHCI3) to give the product (204 mg, 93%) as a yellow oil.
Rf 0.61 (9:1 CHCl3/MeOH); t)m ax (neat)/cm'‘ 3498, 3290, 2879,  1515, 1434, 1323, 1203, 
1144,  1044, 806, 751; §h (300 MHz, CDC13) 7.59 (dd, J= 8.0,  1.2 Hz,  1   H, AiH), 7.47 
(dd, J = 7.8,  1.9 Hz, 1  H, Ar//), 7.38 (app. td /  = 7.8,  1.2 Hz, 1  H, Ar//), 7.25 (app. td, J 
= 7.8,  1.9 Hz, 1 H, Ar//), 7.01  (d, J = 8.0 Hz, 2 H, Ar//), 6.88 (d, J = 8.0 Hz, 2 H, Ar//), 
4.69 (d, J = 7.1 Hz,  1  H, NC//), 4.63 (app. t, J = 5.9 Hz,  1  H, N//), 4.49 (dd, J = 9.9, 3.9 
Hz,  1   H, SCHCZZH), 4.37 (dd, J = 9.9, 8.4 Hz,  1   H, SCHCH//), 4.14 (dd, J =  13.5, 6.7 
Hz,  1   H, NHC//H), 3.94 (ddd, J = 8.4, 7.1, 3.9 Hz,  1  H, SC//), 3.81  (dd, J =  13.5, 5.0 
Hz,  1   H, NHCH//), 3.75-3.80 (m,  1  H, OC//HCH2N), 3.62 (dt, J =  11.6, 4.1  Hz,  1  H, 
OCH//CH2N), 3.01  (ddd, J =  13.4, 5.0, 2.8 Hz,  1   H, NC//HCH2), 2.81  (ddd, J =  13.4,
8.0,  4.1  Hz,  1   H, NCH//CH2),  2.30 (s, 3  H,  ArC//3);  §c  (75  MHz,  CDC13)  137.8 (s),
135.8  (s), 133.4 (d), 133.0 (s), 130.2 (d), 129.4 (d), 128.5 (d), 127.9 (d),  127.7 (d), 124.6 
(s),  72.4  (d),  70.8  (d),  67.4  (t),  60.5  (t),  57.3  (t),  47.2  (t),  21.1  (q);  m/z (FAB+) 457 
(MH+, 81Br,  10), 455  (MH+, 79Br,  10), 329 (97), 307 (24),  176 (90),  154 (100); HRMS 
(FAB+): calcd for C,9H2479BrN20 4S (MH+) 455.0640, found 455.0631.
(3  S*,  45*)-2-(2-Hydroxyethyl)-3-(2-iodophenyl)isoxazolidine-4-sulfonic  acid  4- 
methylbenzylamide (211c)
\y/
OH
To a stirring solution of 206c (184 mg, 0.25 mmol) in THF (4 mL) at 0 °C was added 
TBAF (1M in THF, 370 pL, 0.37 mmol). After 2 hours at 0 °C the reaction mixture was 
concentrated in vacuo, and the residue purified by flash chromatography (starting 100% 
CHCI3) to give the product (122 mg, 97%) as a yellow oil.
270Rf 0.61 (9:1 CHCb/MeOH); \)m ax (neatycm1  3531, 3288, 2882,  1516, 1435, 1323, 1144, 
1042, 807, 749; 6H  (300 MHz, CDC13) 7.87 (d, J = 8.0 Hz,  1  H, Ar//), 7.37-7.42 (m, 2 
H, Ar//), 7.05-7.11 (m,  1  H, Ar//), 7.01 (d, J = 8.0 Hz, 2 H, Ar//), 6.89 (d, J = 8.0 Hz, 2 
H, Ar//), 4.76 (app t, J = 5.9 Hz,  1  H, N//), 4.55 (d, J = 7.2 Hz,  1  H, NC//), 4.47 (dd, /  
= 9.9, 3.8 Hz,  1  H, SCHCZ/H), 4.35 (dd, J = 9.9, 8.6 Hz,  1  H, SCHCH//), 4.13 (dd, J =
13.7, 6.4 Hz,  1   H, NHC/ZH), 3.91  (app. td, J = 8.0, 3.8 Hz,  1  H, SCH),  3.81  (dd, J =
13.7, 5.1  Hz,  1  H, NHCH//), 3.73-3.80 (m,  1   H, OC//HCH2N), 3.60 (app. dt, /=  11.8,
4.3  Hz,  1   H,  OCH//CH2N),  3.03  (ddd, J =  13.4,  5.1,  3.2  Hz,  1   H, NC//HCH2),  2.80 
(ddd,  J =  13.4,  8.0,  3.8  Hz,  1  H,  NCHZ/CH2),  2.30  (s,  3  H,  ArC//3);  6C   (75  MHz, 
CDC13)  140.2 (d),  138.8 (s),  137.9 (s),  132.8 (s),  130.6 (d),  129.9 (d),  129.5 (d),  129.3 
(d),  128.0 (d),  100.9 (s), 75.2 (d), 72.7 (d), 67.5 (t), 60.5 (t), 57.2 (t), 47.2 (t), 21.1  (q); 
m/z (FAB+) 503  (MH+,  60),  289  (77),  212  (28),  176  (40),  152  (100);  HRMS  (FAB+): 
calcd for Ci9H24IN20 4S (MH+) 503.0502, found 505.0490.
2714.9. Miscellaneous products
Ethenesulfonic acid allylamide (123a)
A premixed suspension of allylamine (3.9 g, 67.5 mmol) and NEt3 (12.4 g,  122.7 mmol) 
in DCM (25 mL) was added dropwise to a stirring solution of 2-chloroethane-l-sulfonyl 
chloride  (10.0 g,  61.3  mmol)  in DCM  (100 mL)  at -10 °C. The reaction mixture was 
stirred for a further 30 minutes after addition, and then warmed to RT. The reaction was 
diluted with DCM (60 mL) and washed with 2M HC1 (3 x 80 mL), H2O (80 mL), dried 
(MgSCU),  and  filtered.  The  filtrate  was  collected  and  concentrated  in  vacuo  and 
purification  by  flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20) 
furnished the desired product (5.9 g, 65%) as a yellow oil.
R f  0.14 (1:1  petroleum ether 40-60°C/Et20);  X )m ax  (neatycm'1  3288,  3063,  2860,  1645, 
1427,  1393,  1256,  1150,  1065, 928; 5h (300 MHz, CDC13) 6.52 (dd, J = 16.6, 9.9 Hz,  1  
H, SCH), 6.23  (d, J =  16.6 Hz,  1   H, SCHCHR), 5.94 (d, J = 9.9 Hz, SCHCHH), 5.82 
(ddt,  J =  17.1,  10.2,  5.8  Hz,  1  H,  CH2=CH),  5.25  (app.  dq,  J =  17.1,  1.3  Hz,  1   H, 
CH=C//H), 5.17 (app. dq, J = 10.2, 1.3 Hz, 1 H, CH=CH/7), 4.73 (br s, 1  H, NH), 3.61- 
3.67  (m, 2 H, NCH2);  5C  (75 MHz, CDC13)  136.1  (d),  133.2  (d),  126.7  (t),  117.8  (t), 
45.5  (t); m/z (El)  147  (M+,  100), 91  (39),  82 (26); HRMS  (ESI):  calcd for C5H9N02S 
(M+) 147.0354, found 147.0351.
2-Ethenesulfonylamino-3-phenylpropionic acid ethyl ester (123c)
A premixed suspension of phenylalanine ethyl ester (1.3 g, 6.8 mmol) and NEt3 (0.6 g, 
6.1 mmol) in DCM (5 mL) was added dropwise to a stirring solution of 2-chloroethane- 
l-sulfonyl chloride (1.0 g, 6.1 mmol) in DCM (10 mL) at -10 °C. The reaction mixture 
was stirred for a further 30 minutes after addition, and then warmed to RT. The reaction 
was diluted with DCM (20 mL) and washed with 2M HC1 (3 x 80 mL), H2O (80 mL), 
dried (MgSCXO,  and filtered.  The filtrate was collected and concentrated in vacuo and 
purification  by  flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20) 
furnished the desired product (968 mg, 56%) as a white solid.
o
272Rf0.27 (1:1  hexane/Et20); mp 88-90 °C; i)m ax (film)/cm'‘ 3310, 3010, 2870,  1720, 1609,
NHCH),  3.07-3.10 (m,  2 H, PhCH2CH),  1.23  (t, J = 7.2 Hz,  3  H,  CH3CH20);  8c (75
164 (26),  146  (27),  118  (56),  109 (31), 91  (90);  HRMS  (ESI):  calcd for Ci3H17N04S 
(M+) 283.0878, found 283.0879.
Ethenesulfonic acid isopropylamide (123d)
A premixed suspension of isopropyl amine  (6.0 g, 101.2 mmol) and NEt3 (27.9 g, 276.0 
mmol) in DCM (40 mL) was added dropwise to a stirring solution of 2-chloroethane-l- 
sulfonyl chloride (15.0 g, 92.0 mmol) in DCM (150 mL) at -10 °C. The reaction mixture 
was stirred for a further 30 minutes after addition, and then warmed to RT. The reaction 
was diluted with DCM (60 mL) and washed with 2M HC1 (3 x 80 mL), H2O (80 mL), 
dried (MgSC>4),  and filtered. The filtrate was collected and concentrated in vacuo and 
purification  by  flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20) 
furnished the desired product (7.5 g, 55%) as a yellow oil.
R f 0.15  (1:1  petroleum ether 40-60°C/Et20); t)m ax (neatycm'1  3294,  3059, 2880,  1620, 
1464,  1425,  1327,  1134,  1007; 8h (300 MHz, CDC13) 6.53  (dd, J =  16.3, 9.9 Hz,  1   H, 
SCH), 6.22 (d, J =  16.3 Hz,  1 H, SCHC//H), 5.89 (d, J = 9.9 Hz,  1 H, SCHCHH), 4.51 
(br d, J = 6.2 Hz,  1 H, NH), 3.49 (app. octet, J = 6.7 Hz,  1  H, NCi/(CH3)2),  1.19 (d, J =
6.7  Hz,  6 H, CH(C//3)2);  5c (75 MHz, CDC13)  137.1  (d),  125.8  (t), 46.1  (d), 24.0 (q); 
m/z  (Cl)  150  (MH+,  67),  134  (76),  122  (65),  108  (100);  HRMS  (Cl):  calcd  for 
C5H12N02S (MH+) 150.0589, found 150.0586.
Ethenesulfonic acid benzylmethyl amide (123f)
A premixed suspension of A-benzylmethyl amine (12.3 g,  101.2 mmol) and NEt3(27.9 
g, 276.0 mmol) in DCM (40 mL) was added to a stirring solution of 2-chloroethane-l-
1433,  1321,  1263,  1103,  1022;  SH   (300 MHz,  CDC13)  7.15-7.33  (m,  5  H, ArH), 6.28 
(dd, J = 16.5, 9.5 Hz, 1 H, SCH), 6.14 (d, J = 16.5 Hz,  1 H, SCHC//H), 5.78 (d, J = 9.5 
Hz,  1   H, SCHCHH), 5.01  (d, J = 9.1  Hz,  1   H, NH), 4.12-4.22 (m, 3 H, CH3C//20 and
MHz, CDCI3)  171.2 (s),  136.0 (d),  135.2 (s),  129.6 (d),  128.6 (d),  127.4 (d),  126.5 (t),
61.9  (t), 56.7 (d), 39.5 (t), 14.1 (q); m/z (El) 284 (M+, 3), 215 (98), 192 (100), 176 (100),
H
273sulfonyl chloride (15.0 g, 92.0 mmol) in DCM (150 mL) at -10 °C. The reaction mixture 
was stirred for a further 30 minutes after addition, and then warmed to RT. The reaction 
was diluted with DCM (60 mL) and washed with 2M HC1 (3 x 80 mL), H2O (80 mL), 
dried (MgSCXO, and filtered.  The filtrate was collected and concentrated  in vacuo and 
purification  by  flash  chromatography  (starting  5:1  petroleum  ether  40-60°C/Et20) 
furnished the desired product (13.1 g, 67%) as light yellow solid.
Rf 0.24 (1:1 petroleum ether 40-60°C/Et20); mp 23-25 °C; a w  (neaO/cm1  3033, 2918, 
1455,  1334,  1148, 936; 6H  (300 MHz, CDC13) 7.28-7.40 (m, 5  H, Ar//), 6.45  (dd, J = 
16.6, 9.8 Hz, 1 H, SCH), 6.26 (d, J = 16.6 Hz, 1 H, SCH  C/m), 6.01 (d, J = 9.8 Hz, 1  H, 
SCHCH//), 4.25 (s, 2 H, NC//2Ph), 2.60 (s, 3 H, NC//3); 6C  (75 MHz, CDC13) 135.6 (s),
133.3  (d),  128.7 (d),  128.4 (d),  128.0 (d),  127.7 (t), 53.8 (t), 34.1  (q); m/z (El) 211 (M+, 
9),  118  (98),  91  (100),  77  (29),  65  (42),  51  (23);  HRMS  (El):  calcd for C10Hi3NO2S 
(M+) 211.0662, found 211.0657.
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284CHAPTER 6: Supplementary dataThe  following  biological  assays  were  conducted  by  Leiper  et  al.  at  the  Centre  for
Clinical Pharmacology, UCL, Rayne Building, 5 University Street, London WC1E 6JF:
6.1. DDAH activity assay (from Pseudomonas aeruginosa)
1.  Require 12.5 pM working stock of PaDDAH.
2.  Buffer used is 90 mM sodium phosphate ph 7.4.
3.  Take  2  pL  of  working  stock  PaDDAH  and  add  97  pL  of  90mM  sodium 
phosphate buffer ph 7.4, (if adding inhibitors alter amount of buffer accordingly 
to aquire final volume of 100 pL).
4.  Incubate for 5 minutes at 37°C.
5.  Add 1  mM of ADM  A to start the reaction.
6.  Stop the reaction after 10 minutes with 200 pL of colour developer. To make the 
colour developer add  1   part of diacetylmonoxime  (0.2  g diacetylmonoxime in
23.8  mL of H2O and 1.2 mL of acetic acid) to 2 parts of anti-pyrine (125 mg of 
anti-pyrine  in  12.5 mL H2O and  12.5  mL sulphuric acid) prior to stopping the 
reaction.
7.  Heat samples at 94°C for 30 minutes to allow the colour to develop.
8.  Read on a spectrophotometer at wavelength 450 nm.
6.2. ADI activity assay (from Pseudomonas aeruginosa)
1.  Require 1   pM working stock of Pa  ADI.
2.  Buffer  used  is  50  mM  Mes  (2-(Ar-morpholino)ethanesulfonic  acid),  20  mM 
MgCl2 at ph 5.6 (Buffer A).
3.  Take  1   pL  of working  stock  PaADI  and  add  98  pL  of Buffer A,  (if adding 
inhibitors alter amount of buffer accordingly to aquire final volume of 100 pL).
4.  Incubate for 5 minutes at 37°C.
5.  Start the reaction with  1   pL of Buffer B (50 mM Mes, 20 mM MgCh at pH 5.6 
with 100 mM L-Arginine) and mix well with a pipette.
6.  Incubate the reaction for a further 10 minutes at 37°C.
7.  Stop  the  reaction  with  100  pL  of colour developer just before the  end of the 
reaction (to make the colour developer see section 6.1)
8.  Heat samples at 94°C for 30 minutes to allow the colour to develop.
9.  Read on a spectrophotometer at wavelength 450 nm.
2866.3.  NOE data
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